{"atlas_id":"pmmr-mucinous-colon","discovery_summary":{"candidate_target_directness_counts":{"curated-candidate-alias":32,"registry-explicit":97,"unassigned":637},"modality_counts":{"antibody":72,"antibody-drug-conjugate":10,"bispecific-antibody":12,"bispecific-antibody-drug-conjugate":1,"car-nk-cell-therapy":8,"car-t-cell-therapy":25,"cellular-therapy":11,"conventional-cytotoxic-regimen":92,"diagnostic-test":24,"molecular-imaging-agent":34,"other-or-unclear":330,"procedure-or-device":74,"radiation":10,"radioligand-therapy":14,"small-molecule":14,"vaccine":35},"normalized_candidate_count":766,"registry_intervention_entry_count":1335,"source_study_record_count":495,"studies_without_registry_interventions":15,"study_index":[{"brief_title":"A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab","conditions":["Breast Neoplasms","Colonic Neoplasms","Lung Neoplasms","Pancreatic Neoplasms","Stomach Neoplasms"],"intervention_entry_count":1,"nct_id":"NCT00001805","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":54,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Radiation Therapy Before Surgery Compared With Chemotherapy Plus Radiation After Surgery in Treating Patients With Rectal Cancer That Can Be Surgically Removed","conditions":["Colorectal Cancer"],"intervention_entry_count":6,"nct_id":"NCT00003422","overall_status":"COMPLETED","phases":["PHASE3"],"source_record_index":51,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Gene Therapy in Treating Patients With Cancer","conditions":["Cancer"],"intervention_entry_count":1,"nct_id":"NCT00004178","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":46,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy","conditions":["Abdominal Neoplasm","Colonic Neoplasm","Mesothelioma","Peritoneal Neoplasm"],"intervention_entry_count":3,"nct_id":"NCT00004547","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":96,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT00005076","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":83,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":4,"nct_id":"NCT00020917","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":94,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Cetuximab in Treating Patients With Stage IV Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT00020930","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":93,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer","conditions":["Breast Cancer","Colorectal Cancer","Gallbladder Cancer","Gastric Cancer","Head and Neck Cancer","Liver Cancer","Ovarian Cancer","Pancreatic Cancer","Testicular Germ Cell Tumor"],"intervention_entry_count":1,"nct_id":"NCT00027534","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":42,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":6,"nct_id":"NCT00061815","overall_status":"COMPLETED","phases":["PHASE3"],"source_record_index":25,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT00063141","overall_status":"COMPLETED","phases":["PHASE3"],"source_record_index":74,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer","conditions":["Colorectal Cancer","Quality of Life"],"intervention_entry_count":2,"nct_id":"NCT00079066","overall_status":"COMPLETED","phases":["PHASE3"],"source_record_index":83,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors","conditions":["Liver Neoplasms"],"intervention_entry_count":4,"nct_id":"NCT00081848","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":14,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy","conditions":["Colorectal Neoplasms","Metastases","Neoplasm"],"intervention_entry_count":1,"nct_id":"NCT00083720","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":58,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer","conditions":["Adenocarcinoma","Breast Cancer","Colorectal Cancer","Ovarian Cancer"],"intervention_entry_count":3,"nct_id":"NCT00088413","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":68,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer","conditions":["Colon Cancer","Rectal Cancer"],"intervention_entry_count":4,"nct_id":"NCT00101894","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":13,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT00110721","overall_status":"TERMINATED","phases":["PHASE2"],"source_record_index":63,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma","conditions":["Carcinoma","Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT00111774","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":27,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer","conditions":["Colorectal Cancer","Metastases"],"intervention_entry_count":2,"nct_id":"NCT00113763","overall_status":"COMPLETED","phases":["PHASE3"],"source_record_index":1,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)","conditions":["Colorectal Cancer","Neoplasm Metastasis"],"intervention_entry_count":2,"nct_id":"NCT00125034","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":98,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer","conditions":["Breast Cancer","Colorectal Cancer","Lung Cancer","Pancreatic Cancer","Unspecified Adult Solid Tumor, Protocol Specific"],"intervention_entry_count":3,"nct_id":"NCT00128622","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":7,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT00145314","overall_status":"COMPLETED","phases":["PHASE3"],"source_record_index":32,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver","conditions":["Colorectal Cancer","Liver Neoplasms"],"intervention_entry_count":1,"nct_id":"NCT00149396","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":38,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)","conditions":["Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT00154102","overall_status":"COMPLETED","phases":["PHASE3"],"source_record_index":11,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Imaging Colo-rectal Cancer Using a Two Step Antibody Technique in Nuclear Imaging","conditions":["Colonic Neoplasms"],"intervention_entry_count":1,"nct_id":"NCT00185081","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":22,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":4,"nct_id":"NCT00199797","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":34,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer","conditions":["COlorectal Carcinoma","Colorectal Cancer","Colorectal Neoplasms","Colorectal Tumor"],"intervention_entry_count":1,"nct_id":"NCT00199862","overall_status":"COMPLETED","phases":["NA"],"source_record_index":3,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer","conditions":["Colo-rectal Cancer","Rectal Cancer"],"intervention_entry_count":5,"nct_id":"NCT00226941","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"source_record_index":26,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Carcinoembryonic Antigen-loaded Dendritic Cells in Advanced Colorectal Cancer Patients","conditions":["Colorectal Cancer","Liver Metastases"],"intervention_entry_count":1,"nct_id":"NCT00228189","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":34,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Dendritic Cell Vaccination in Patients With Advanced Colorectal Cancer","conditions":["Colorectal Neoplasms"],"intervention_entry_count":1,"nct_id":"NCT00311272","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":12,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment","conditions":["Colorectal Neoplasms"],"intervention_entry_count":1,"nct_id":"NCT00313794","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":11,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT00326495","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":64,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum","conditions":["Neoplasm Metastasis","Rectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT00346099","overall_status":"WITHDRAWN","phases":["PHASE2"],"source_record_index":33,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors","conditions":["Non-colorectal Cancer","Pancreatic Cancer"],"intervention_entry_count":1,"nct_id":"NCT00352131","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":87,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)","conditions":["Neoplasms, Colorectal"],"intervention_entry_count":3,"nct_id":"NCT00387387","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":59,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer","conditions":["Adenocarcinoma of the Colon","Adenocarcinoma of the Rectum","Advanced Adult Primary Liver Cancer","Carcinoma of the Appendix","Gastrointestinal Stromal Tumor","Metastatic Gastrointestinal Carcinoid Tumor","Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Adult Primary Liver Cancer","Recurrent Anal Cancer","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Colon Cancer","Recurrent Esophageal Cancer","Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Recurrent Extrahepatic Bile Duct Cancer","Recurrent Gallbladder Cancer","Recurrent Gastric Cancer","Recurrent Gastrointestinal Carcinoid Tumor","Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Non-small Cell Lung Cancer","Recurrent Pancreatic Cancer","Recurrent Rectal Cancer","Recurrent Salivary Gland Cancer","Recurrent Small Intestine Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Small Intestine Adenocarcinoma","Small Intestine Leiomyosarcoma","Small Intestine Lymphoma","Stage IV Adenoid Cystic Carcinoma of the Oral Cavity","Stage IV Anal Cancer","Stage IV Basal Cell Carcinoma of the Lip","Stage IV Colon Cancer","Stage IV Esophageal Cancer","Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage IV Gastric Cancer","Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage IV Lymphoepithelioma of the Nasopharynx","Stage IV Lymphoepithelioma of the Oropharynx","Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage IV Mucoepidermoid Carcinoma of the Oral Cavity","Stage IV Non-small Cell Lung Cancer","Stage IV Pancreatic Cancer","Stage IV Rectal Cancer","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity","Tongue Cancer","Unresectable Extrahepatic Bile Duct Cancer","Unresectable Gallbladder Cancer"],"intervention_entry_count":3,"nct_id":"NCT00397384","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":98,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT00436072","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":31,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies","conditions":["Carcinoma, Non-Small-Cell Lung","Colorectal Cancer","Malignant Melanoma","Prostate Cancer","Renal Cancer"],"intervention_entry_count":1,"nct_id":"NCT00441337","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":8,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer","conditions":["Colorectal Cancer","Neoplasm Metastasis"],"intervention_entry_count":3,"nct_id":"NCT00444678","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":21,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy","conditions":["Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT00503685","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":73,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments","conditions":["Colorectal Neoplasm"],"intervention_entry_count":1,"nct_id":"NCT00560560","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":58,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer","conditions":["Colorectal, Cancer"],"intervention_entry_count":1,"nct_id":"NCT00569335","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":95,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT00569699","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":97,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT00569790","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":32,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Spectroscopy With Surface Coils and Decoupling","conditions":["Adrenal Cortical Cancer","Brain Cancer","Breast Cancer","CNS Cancer","Colon Cancer","HEENT Cancer","Hodgkin's Disease","Kaposi's Sarcoma","Liver Cancer","Lung Cancer","Non-Hodgkin's Lymphoma","Ovarian Cancer","Pancreatic Cancer","Prostate Cancer","Rectal Cancer","Renal Cancer","Sarcoma","Squamous Cell Carcinoma","Thyroid Cancer"],"intervention_entry_count":2,"nct_id":"NCT00581815","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":74,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":5,"nct_id":"NCT00636610","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":44,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions","conditions":["Advanced Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT00637091","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":24,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Immunoscintigraphy Using Radiolabeled Monoclonal Antibody in Finding Tumor Cells in Patients With Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT00647153","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":12,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery","conditions":["Colorectal Cancer"],"intervention_entry_count":4,"nct_id":"NCT00647530","overall_status":"UNKNOWN","phases":["PHASE2","PHASE3"],"source_record_index":48,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT00660582","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":3,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men","conditions":["Anal Cancer","HIV Infections"],"intervention_entry_count":1,"nct_id":"NCT00666107","overall_status":"UNKNOWN","phases":["NA"],"source_record_index":29,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Trial of Second Generation Designer T Cells in Colorectal Carcinoma","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT00673322","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":7,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT00677924","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"source_record_index":41,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT00719199","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":50,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma","conditions":["Colorectal Carcinoma"],"intervention_entry_count":2,"nct_id":"NCT00725400","overall_status":"WITHDRAWN","phases":["PHASE2"],"source_record_index":97,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Peri-Operative Management of Patients Undergoing Laparoscopic Colorectal Surgery","conditions":["Analgesia","Diverticular Disease","Neoplasm"],"intervention_entry_count":3,"nct_id":"NCT00747292","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"source_record_index":64,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer","conditions":["Anal, Colon, and Rectal Cancers","Colorectal Neoplasms"],"intervention_entry_count":2,"nct_id":"NCT00780988","overall_status":"WITHDRAWN","phases":["PHASE1"],"source_record_index":55,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT00784667","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":63,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":4,"nct_id":"NCT00803647","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":43,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"FOLFIRI and Sunitinib in Metastatic Colorectal Cancer","conditions":["Liver Metastases","Metastatic Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT00806663","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":35,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":4,"nct_id":"NCT00813605","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":41,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors","conditions":["Colorectal Cancer","Locally Advanced","Metastatic Cancer","Non-Small Cell Lung Cancer","Ovarian Cancer","Pancreatic Cancer","Sarcoma","Solid Tumors"],"intervention_entry_count":2,"nct_id":"NCT00819169","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"source_record_index":92,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors","conditions":["Colon Cancer","Colorectal Cancer","Metastatic Colorectal Cancer","Rectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT00819780","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":46,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib","conditions":["Colorectal Cancer","Head and Neck Cancer","Non Small Cell Lung Cancer (NSCLC)"],"intervention_entry_count":1,"nct_id":"NCT00820417","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":40,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab Project","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT00828620","overall_status":"TERMINATED","phases":[],"source_record_index":27,"source_ref":"ctg-page-002","study_type":"OBSERVATIONAL"},{"brief_title":"A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors","conditions":["Colorectal Neoplasms","Head and Neck Neoplasms","Lung Neoplasms","Ovarian Neoplasms","Pancreatic Neoplasms"],"intervention_entry_count":7,"nct_id":"NCT00841191","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":54,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT00842257","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":12,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab","conditions":["Colon Cancer","Rectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT00845039","overall_status":"TERMINATED","phases":["PHASE2"],"source_record_index":78,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"New Individualized Therapy Trial for Metastatic Colorectal Cancer","conditions":["Colorectal Cancer","Colorectal Neoplasm"],"intervention_entry_count":2,"nct_id":"NCT00867334","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":40,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Confocal Probe-based Endoscopic Imaging, Colorectal Cancer, Gastrointestinal (GI) Pathologies","conditions":["Colonic Polyps","Esophageal Diseases"],"intervention_entry_count":0,"nct_id":"NCT00874263","overall_status":"COMPLETED","phases":[],"source_record_index":23,"source_ref":"ctg-page-001","study_type":"OBSERVATIONAL"},{"brief_title":"KRAS Wild-type Metastatic Colorectal Cancer Trial","conditions":["Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT00879385","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":33,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT00891930","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":53,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)","conditions":["Colorectal Cancer"],"intervention_entry_count":4,"nct_id":"NCT00925015","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":38,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT00940316","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":51,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer","conditions":["Colorectal Neoplasms"],"intervention_entry_count":2,"nct_id":"NCT00950820","overall_status":"TERMINATED","phases":["PHASE2"],"source_record_index":17,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Study of Nimotuzumab to Treat Colorectal Cancer","conditions":["Advanced Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT00972465","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":21,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer","conditions":["Metastatic Colorectal Cancer","Metastatic Pancreatic Cancer"],"intervention_entry_count":1,"nct_id":"NCT01040000","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":36,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer","conditions":["Rectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT01043484","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":0,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment","conditions":["Colorectal Neoplasm"],"intervention_entry_count":1,"nct_id":"NCT01074333","overall_status":"TERMINATED","phases":[],"source_record_index":61,"source_ref":"ctg-page-005","study_type":"OBSERVATIONAL"},{"brief_title":"Precision-Based Magnesium Trial","conditions":["Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT01105169","overall_status":"COMPLETED","phases":["NA"],"source_record_index":7,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer","conditions":["Colorectal Neoplasms"],"intervention_entry_count":2,"nct_id":"NCT01152437","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":28,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":11,"nct_id":"NCT01167725","overall_status":"TERMINATED","phases":["PHASE3"],"source_record_index":35,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT01175291","overall_status":"WITHDRAWN","phases":["PHASE2"],"source_record_index":47,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Lapatinib and Cetuximab in Patients With Solid Tumors","conditions":["Colorectal Cancer","Head and Neck Cancer","Lung Cancer"],"intervention_entry_count":1,"nct_id":"NCT01184482","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":14,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer","conditions":["Colon Mucinous Adenocarcinoma","Colon Signet Ring Cell Adenocarcinoma","Rectal Mucinous Adenocarcinoma","Rectal Signet Ring Cell Adenocarcinoma","Recurrent Colon Carcinoma","Recurrent Rectal Carcinoma","Stage IVA Colon Cancer","Stage IVA Rectal Cancer","Stage IVB Colon Cancer","Stage IVB Rectal Cancer"],"intervention_entry_count":4,"nct_id":"NCT01198535","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":11,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","conditions":["Recurrent Colon Cancer","Recurrent Rectal Cancer","Stage IV Colon Cancer","Stage IV Rectal Cancer"],"intervention_entry_count":6,"nct_id":"NCT01205022","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":39,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Prospective Study for Evaluating Colon Polyp Histology With in Vivo Probe Based Confocal Laser Endomicroscopy","conditions":["Adenomatous Polyps","Colon Cancer","Colon Polyps"],"intervention_entry_count":1,"nct_id":"NCT01214031","overall_status":"UNKNOWN","phases":["NA"],"source_record_index":83,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":4,"nct_id":"NCT01225744","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":32,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer","conditions":["Recurrent Colon Carcinoma","Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Laryngeal Verrucous Carcinoma","Recurrent Lip and Oral Cavity Squamous Cell Carcinoma","Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary","Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma","Recurrent Oral Cavity Verrucous Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma","Recurrent Rectal Carcinoma","Recurrent Salivary Gland Carcinoma","Salivary Gland Squamous Cell Carcinoma","Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary","Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7","Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7","Stage IVA Colon Cancer AJCC v7","Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Laryngeal Verrucous Carcinoma AJCC v7","Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVA Major Salivary Gland Cancer AJCC v7","Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7","Stage IVA Oral Cavity Cancer AJCC v6 and v7","Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Rectal Cancer AJCC v7","Stage IVB Colon Cancer AJCC v7","Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVB Laryngeal Verrucous Carcinoma AJCC v7","Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVB Major Salivary Gland Cancer AJCC v7","Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7","Stage IVB Oral Cavity Cancer AJCC v6 and v7","Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVB Rectal Cancer AJCC v7","Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVC Laryngeal Verrucous Carcinoma AJCC v7","Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVC Major Salivary Gland Cancer AJCC v7","Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7","Stage IVC Oral Cavity Cancer AJCC v6 and v7","Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7","Tongue Carcinoma"],"intervention_entry_count":3,"nct_id":"NCT01254617","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":41,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT01273402","overall_status":"WITHDRAWN","phases":["PHASE1"],"source_record_index":62,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT01288339","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":64,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Dendritic Cell Vaccination for Patients with Solid Tumors","conditions":["Breast Cancers","Colorectal Tumors","Glioblastoma","Malignant Mesothelioma","Renal Cell Carcinoma","Sarcomas"],"intervention_entry_count":1,"nct_id":"NCT01291420","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":38,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response","conditions":["Metastatic Colon Cancer"],"intervention_entry_count":1,"nct_id":"NCT01292356","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":36,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema","conditions":["Colorectal Cancer Metastatic"],"intervention_entry_count":1,"nct_id":"NCT01315990","overall_status":"UNKNOWN","phases":["PHASE4"],"source_record_index":57,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)","conditions":["Advanced Solid Tumors","Carcinoid","Colorectal Cancer","Locally Advanced","Lymphoma","Metastatic Cancer","Non-Small Cell Lung Cancer","Sarcoma","Solid Tumors"],"intervention_entry_count":4,"nct_id":"NCT01327612","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":4,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy","conditions":["Bladder Cancer","Breast Cancer","Colon Cancer"],"intervention_entry_count":6,"nct_id":"NCT01339000","overall_status":"TERMINATED","phases":["PHASE2"],"source_record_index":61,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma","conditions":["Colorectal Carcinoma","Hepatic Metastasis"],"intervention_entry_count":1,"nct_id":"NCT01348256","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":75,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Molecular Imaging of Epidermal Growth Factor Receptor in Colorectal Neoplasia Using Confocal Laser Endomicroscopy","conditions":["Colorectal Adenoma","Colorectal Cancer"],"intervention_entry_count":0,"nct_id":"NCT01372189","overall_status":"COMPLETED","phases":[],"source_record_index":57,"source_ref":"ctg-page-005","study_type":"OBSERVATIONAL"},{"brief_title":"Vaccine Therapy in Treating Patients With Metastatic Solid Tumors","conditions":["Breast Cancer","GIST","Malignant Solid Tumour","Malignant Tumor of Colon","Ovarian Cancer"],"intervention_entry_count":2,"nct_id":"NCT01376505","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":18,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment","conditions":["Colorectal Cancer","Skin Toxicities"],"intervention_entry_count":0,"nct_id":"NCT01380262","overall_status":"UNKNOWN","phases":[],"source_record_index":15,"source_ref":"ctg-page-004","study_type":"OBSERVATIONAL"},{"brief_title":"Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer","conditions":["Colorectal Neoplasms"],"intervention_entry_count":2,"nct_id":"NCT01413295","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":21,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"The Usefulness of I-scan in Screening Colonoscopy","conditions":["Colorectal Neoplasm"],"intervention_entry_count":1,"nct_id":"NCT01417611","overall_status":"COMPLETED","phases":["NA"],"source_record_index":6,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases","conditions":["Colorectal Cancer"],"intervention_entry_count":7,"nct_id":"NCT01442935","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":96,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer","conditions":["Breast Cancer","Colon Cancer","Lung Cancer","Prostate Cancer"],"intervention_entry_count":1,"nct_id":"NCT01445054","overall_status":"TERMINATED","phases":["EARLY_PHASE1"],"source_record_index":86,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype","conditions":["Colorectal Neoplasms"],"intervention_entry_count":1,"nct_id":"NCT01450319","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":84,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Feasibility of Check-Cap's P1 Capsule System Screening","conditions":["ColoRectal Cancer","Colonic Polyps"],"intervention_entry_count":1,"nct_id":"NCT01458925","overall_status":"TERMINATED","phases":["NA"],"source_record_index":43,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Spinal Analgesia for Colonic Resection Using an Enhanced Recovery After Surgery (ERAS) Program","conditions":["Colon Cancer","Diverticulitis","Inflammatory Bowel Diseases"],"intervention_entry_count":2,"nct_id":"NCT01477190","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":37,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients","conditions":["Colorectal Cancer","Hepatocellular Cancer","Non-small Cell Lung Cancer","Renal Cell Cancer"],"intervention_entry_count":3,"nct_id":"NCT01507740","overall_status":"TERMINATED","phases":[],"source_record_index":28,"source_ref":"ctg-page-002","study_type":"OBSERVATIONAL"},{"brief_title":"Colorectal Cancer (CRC) Cetuximab Elderly Frail","conditions":["Colorectal Cancer Metastatic"],"intervention_entry_count":3,"nct_id":"NCT01522612","overall_status":"TERMINATED","phases":["PHASE2"],"source_record_index":20,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Positron Emission Tomography/Magnetic Resonance Imaging in Patients","conditions":["Colon Cancer","Head and Neck Cancer","Lung Cancer","Lymphoma","Malignant Neoplasm","Melanoma","Unspecified Adult Solid Tumor, Protocol Specific","Unspecified Childhood Solid Tumor, Protocol Specific"],"intervention_entry_count":1,"nct_id":"NCT01557881","overall_status":"TERMINATED","phases":["NA"],"source_record_index":5,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer","conditions":["Colorectal Neoplasms"],"intervention_entry_count":6,"nct_id":"NCT01588990","overall_status":"COMPLETED","phases":["PHASE4"],"source_record_index":13,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer","conditions":["Colon Cancer","Metastatic Colorectal Cancer","Rectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT01605318","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"source_record_index":45,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"I-Scan Versus High-definition White Light","conditions":["Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT01617278","overall_status":"COMPLETED","phases":["NA"],"source_record_index":39,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Early Biomarker With 18F-FDG PET for Treatment Optimization of Anti-EGFR Therapy in Patients With Metastatic Colorectal Cancer.","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT01691391","overall_status":"COMPLETED","phases":[],"source_record_index":43,"source_ref":"ctg-page-003","study_type":"OBSERVATIONAL"},{"brief_title":"Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)","conditions":["Ovarian Carcinoma","Ovarian Germ Cell Tumor"],"intervention_entry_count":3,"nct_id":"NCT01696994","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"source_record_index":28,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT01719380","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":16,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas","conditions":["Metastatic Cancers"],"intervention_entry_count":1,"nct_id":"NCT01723306","overall_status":"SUSPENDED","phases":["PHASE2"],"source_record_index":15,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Ipilimumab and Local Radiation for Selected Solid Tumors","conditions":["Adult Nasal Type Extranodal NK/T-cell Lymphoma","Anaplastic Large Cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Cutaneous B-cell Non-Hodgkin Lymphoma","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Hepatosplenic T-cell Lymphoma","Intraocular Lymphoma","Nodal Marginal Zone B-cell Lymphoma","Peripheral T-cell Lymphoma","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Immunoblastic Large Cell Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Adult T-cell Leukemia/Lymphoma","Recurrent Colon Cancer","Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Melanoma","Recurrent Mycosis Fungoides/Sezary Syndrome","Recurrent Rectal Cancer","Recurrent Small Lymphocytic Lymphoma","Refractory Hairy Cell Leukemia","Small Intestine Lymphoma","Splenic Marginal Zone Lymphoma","T-cell Large Granular Lymphocyte Leukemia","Testicular Lymphoma","Waldenström Macroglobulinemia"],"intervention_entry_count":2,"nct_id":"NCT01769222","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":38,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)","conditions":["Solid Tumors"],"intervention_entry_count":1,"nct_id":"NCT01772004","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":33,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"An Observational Study of Avastin in Participants With Metastatic Colorectal Cancer (KORALLE)","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT01775644","overall_status":"COMPLETED","phases":[],"source_record_index":49,"source_ref":"ctg-page-002","study_type":"OBSERVATIONAL"},{"brief_title":"Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma","conditions":["Bevacizumab","Capillaroscopy","Glioblastoma","Metastatic Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT01810744","overall_status":"COMPLETED","phases":["NA"],"source_record_index":69,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Non-Invasive Prediction of Colorectal Neoplasia","conditions":["Colonic Polyps","Colorectal Cancer","Polyposis Coli"],"intervention_entry_count":0,"nct_id":"NCT01815463","overall_status":"TERMINATED","phases":[],"source_record_index":8,"source_ref":"ctg-page-002","study_type":"OBSERVATIONAL"},{"brief_title":"TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas","conditions":["Granulosa Cell Ovarian Cancer","Lymphomas","Metastatic Colon Carcinoma","NSCLC","Solid Tumors"],"intervention_entry_count":8,"nct_id":"NCT01851369","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":99,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":4,"nct_id":"NCT01925274","overall_status":"TERMINATED","phases":["PHASE2"],"source_record_index":52,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab","conditions":["Colorectal Cancer Metastatic"],"intervention_entry_count":1,"nct_id":"NCT01943786","overall_status":"UNKNOWN","phases":[],"source_record_index":17,"source_ref":"ctg-page-003","study_type":"OBSERVATIONAL"},{"brief_title":"Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient","conditions":["Colorectal Cancer Metastatic"],"intervention_entry_count":3,"nct_id":"NCT01955629","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"source_record_index":16,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Accuracy of the Optical Diagnosis of Small Colonic Polyps Using the Nice Classification","conditions":["Colon Adenoma","Colorectal Carcinoma","Hyperplastic Polyp"],"intervention_entry_count":1,"nct_id":"NCT02009774","overall_status":"COMPLETED","phases":[],"source_record_index":67,"source_ref":"ctg-page-002","study_type":"OBSERVATIONAL"},{"brief_title":"Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT02015754","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":28,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"I-Scan Vs High Definition White Light (Main Study)","conditions":["Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT02016326","overall_status":"UNKNOWN","phases":["NA"],"source_record_index":10,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Retrospective Evaluation of 5-FU Exposure Optimization in CRC Patients","conditions":["5-FU Containing Therapy Regimens","Adjuvant Colorectal Cancer","Metastatic Colorectal Cancer"],"intervention_entry_count":0,"nct_id":"NCT02055560","overall_status":"COMPLETED","phases":[],"source_record_index":42,"source_ref":"ctg-page-005","study_type":"OBSERVATIONAL"},{"brief_title":"Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":5,"nct_id":"NCT02083653","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":76,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT02118064","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":20,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"ART: Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy","conditions":["Anal Cancer"],"intervention_entry_count":0,"nct_id":"NCT02145416","overall_status":"COMPLETED","phases":[],"source_record_index":20,"source_ref":"ctg-page-001","study_type":"OBSERVATIONAL"},{"brief_title":"S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT02164916","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":72,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"A Phase I/II Study of Active Immunotherapy With Cancer Stem Cells Vaccine for Colorectal Cancer","conditions":["Neoplasms,Colorectal"],"intervention_entry_count":1,"nct_id":"NCT02176746","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":89,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT02211443","overall_status":"UNKNOWN","phases":["PHASE1"],"source_record_index":5,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Resect and Discard Extension to FICE of NIcE Classification","conditions":["Adenomatous Polyps","Hyperplastic Polyps"],"intervention_entry_count":1,"nct_id":"NCT02263144","overall_status":"UNKNOWN","phases":[],"source_record_index":93,"source_ref":"ctg-page-004","study_type":"OBSERVATIONAL"},{"brief_title":"RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).","conditions":["Rectal Cancer"],"intervention_entry_count":16,"nct_id":"NCT02280070","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":62,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy","conditions":["Barrett Esophagus","Biliary Duct Stricture","Colorectal Polyps","Esophageal Neoplasms","Gastric Antrectomy Partial","Head and Neck Neoplasms","Pancreatic Duct Stricture"],"intervention_entry_count":1,"nct_id":"NCT02284802","overall_status":"COMPLETED","phases":["NA"],"source_record_index":75,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)","conditions":["Colorectal Cancer"],"intervention_entry_count":11,"nct_id":"NCT02291289","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":28,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer","conditions":["Breast Cancer","Colon Cancer","Extrahepatic Bile Duct Cancer","Gallbladder Cancer","Gastrointestinal Cancer","Liver and Intrahepatic Biliary Tract Cancer","Lung Cancer","Metastatic Cancer","Pancreatic Cancer","Rectal Cancer","Thyroid Gland Medullary Carcinoma","Unspecified Adult Solid Tumor, Protocol Specific"],"intervention_entry_count":5,"nct_id":"NCT02293954","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"source_record_index":92,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer","conditions":["Clinical Stage IV Cutaneous Melanoma AJCC v8","Metastatic Colorectal Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Melanoma","Metastatic Ovarian Carcinoma","Metastatic Renal Cell Carcinoma","Platinum-Resistant Ovarian Carcinoma","Recurrent Melanoma","Recurrent Renal Cell Carcinoma","Refractory Melanoma","Refractory Renal Cell Carcinoma","Sarcoma","Stage IV Colorectal Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8"],"intervention_entry_count":6,"nct_id":"NCT02298959","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"source_record_index":64,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer","conditions":["Anal Canal Squamous Cell Carcinoma","Metastatic Anal Canal Carcinoma","Stage IV Anal Cancer AJCC v8"],"intervention_entry_count":5,"nct_id":"NCT02314169","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"source_record_index":61,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)","conditions":["Bladder Cancer","Colorectal Cancer","Gastric Cancer","Melanoma","Non-small Cell Lung Carcinoma (NSCLC)","Ovarian Cancer"],"intervention_entry_count":2,"nct_id":"NCT02346955","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":92,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"A Clinical Research of CAR T Cells Targeting CEA Positive Cancer","conditions":["Breast Cancer","Colorectal Cancer","Gastric Cancer","Lung Cancer","Pancreatic Cancer"],"intervention_entry_count":1,"nct_id":"NCT02349724","overall_status":"UNKNOWN","phases":["PHASE1"],"source_record_index":30,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"18F-FES PET/CT in Imaging Patients With Desmoid Tumors","conditions":["Deep Fibromatosis/Desmoid Tumor","Familial Adenomatous Polyposis"],"intervention_entry_count":4,"nct_id":"NCT02374931","overall_status":"TERMINATED","phases":["EARLY_PHASE1"],"source_record_index":63,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors","conditions":["Colon Cancer, Breast Cancer, Cancer of the Head and Neck"],"intervention_entry_count":1,"nct_id":"NCT02391727","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":44,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer","conditions":["BRAF Wildtype","Colorectal Cancer","KRAS Wildtype","NRAS Wildtype"],"intervention_entry_count":2,"nct_id":"NCT02399943","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":86,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","conditions":["Advanced Malignant Solid Neoplasm","Anal Carcinoma","HIV Infection","HIV-associated Cancers","Kaposi Sarcoma","Lung Carcinoma","Metastatic Malignant Solid Neoplasm","Recurrent Classic Hodgkin Lymphoma","Refractory Classic Hodgkin Lymphoma","Unresectable Solid Neoplasm"],"intervention_entry_count":6,"nct_id":"NCT02408861","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":50,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Intensive Versus Minimal Surveillance of Patients With Resected Dukes B2-C Colorectal Carcinoma","conditions":["Colorectal Cancer","Surveillance"],"intervention_entry_count":1,"nct_id":"NCT02409472","overall_status":"COMPLETED","phases":["NA"],"source_record_index":74,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases","conditions":["Liver Metastases"],"intervention_entry_count":2,"nct_id":"NCT02416466","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":55,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy","conditions":["Adult Solid Neoplasm","Bladder Carcinoma","Colon Carcinoma","Estrogen Receptor Negative","HER2/Neu Negative","Head and Neck Squamous Cell Carcinoma","Hepatocellular Carcinoma","Melanoma","Non-Small Cell Lung Carcinoma","Pancreatic Carcinoma","Progesterone Receptor Negative","Rectal Carcinoma","Renal Cell Carcinoma","Soft Tissue Sarcoma","TP53 Gene Mutation","Triple-Negative Breast Carcinoma","Unresectable Solid Neoplasm"],"intervention_entry_count":3,"nct_id":"NCT02432963","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"source_record_index":85,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.","conditions":["Solid Tumors"],"intervention_entry_count":2,"nct_id":"NCT02503774","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":23,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer","conditions":["Recurrent Colorectal Carcinoma","Stage IVA Colorectal Cancer","Stage IVB Colorectal Cancer"],"intervention_entry_count":5,"nct_id":"NCT02508077","overall_status":"TERMINATED","phases":["PHASE2"],"source_record_index":53,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133","conditions":["Acute Myeloid and Lymphoid Leukemias","Brain Tumor","Breast Cancer","Colorectal Cancer","Liver Cancer","Ovarian Tumor","Pancreatic Cancer"],"intervention_entry_count":1,"nct_id":"NCT02541370","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":39,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Prognostic Value of the Lymphocytic Infiltrate in Colon Cancers","conditions":["Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT02557061","overall_status":"COMPLETED","phases":["NA"],"source_record_index":37,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)","conditions":["Colorectal Carcinoma"],"intervention_entry_count":5,"nct_id":"NCT02563002","overall_status":"COMPLETED","phases":["PHASE3"],"source_record_index":90,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT02568046","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"source_record_index":40,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer","conditions":["Metastatic Colorectal Adenocarcinoma","Metastatic Pancreatic Ductal Adenocarcinoma","Stage IV Colorectal Cancer AJCC v7","Stage IV Pancreatic Cancer AJCC v6 and v7","Stage IVA Colorectal Cancer AJCC v7","Stage IVB Colorectal Cancer AJCC v7"],"intervention_entry_count":6,"nct_id":"NCT02600949","overall_status":"ENROLLING_BY_INVITATION","phases":["PHASE1"],"source_record_index":89,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases","conditions":["Colon Cancer","Liver Metastases","Rectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT02602327","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":98,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor","conditions":["Colorectal Carcinoma","Gastric Carcinoma","Malignant Glioma of Brain"],"intervention_entry_count":1,"nct_id":"NCT02617134","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"source_record_index":13,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT02623621","overall_status":"COMPLETED","phases":[],"source_record_index":86,"source_ref":"ctg-page-003","study_type":"OBSERVATIONAL"},{"brief_title":"TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors","conditions":["Colorectal Adenocarcinoma","Metastatic Pancreatic Adenocarcinoma","Recurrent Breast Carcinoma","Recurrent Colorectal Carcinoma","Recurrent Melanoma of the Skin","Recurrent Non-Small Cell Lung Carcinoma","Recurrent Pancreatic Carcinoma","Recurrent Renal Cell Carcinoma","Solid Neoplasm","Stage IV Breast Cancer","Stage IV Non-Small Cell Lung Cancer","Stage IV Renal Cell Cancer","Stage IV Skin Melanoma","Stage IVA Colorectal Cancer","Stage IVA Pancreatic Cancer","Stage IVB Colorectal Cancer","Stage IVB Pancreatic Cancer"],"intervention_entry_count":5,"nct_id":"NCT02650635","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":79,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors","conditions":["Advanced Solid Tumors"],"intervention_entry_count":5,"nct_id":"NCT02671435","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":66,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer","conditions":["Rectal Adenocarcinoma"],"intervention_entry_count":4,"nct_id":"NCT02688712","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"source_record_index":71,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery","conditions":["Recurrent Colorectal Carcinoma","Stage IVA Colorectal Cancer","Stage IVB Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT02713373","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":80,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer","conditions":["Breast Cancer","Colorectal Cancer","Gastric Cancer","Glioma","Lung Cancer","Ovarian Cancer","Pancreatic Cancer"],"intervention_entry_count":1,"nct_id":"NCT02713984","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"source_record_index":23,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","conditions":["Advanced Solid Malignancies","Colorectal Carcinoma (CRC)","Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)","Non-Small Cell Lung Cancer (NSCLC)"],"intervention_entry_count":6,"nct_id":"NCT02740985","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":72,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors","conditions":["Colorectal Adenocarcinoma","Metastatic Cholangiocarcinoma","Metastatic Colorectal Carcinoma","Metastatic Digestive System Carcinoma","Metastatic Esophageal Carcinoma","Metastatic Gastric Carcinoma","Metastatic Pancreatic Adenocarcinoma","Stage IV Colorectal Cancer AJCC v7","Stage IV Esophageal Cancer AJCC v7","Stage IV Gastric Cancer AJCC v7","Stage IV Pancreatic Cancer AJCC v6 and v7","Stage IVA Colorectal Cancer AJCC v7","Stage IVB Colorectal Cancer AJCC v7"],"intervention_entry_count":5,"nct_id":"NCT02757391","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":42,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status","conditions":["Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT02831842","overall_status":"COMPLETED","phases":[],"source_record_index":4,"source_ref":"ctg-page-001","study_type":"OBSERVATIONAL"},{"brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","conditions":["Acinar Cell Carcinoma","Adenoid Cystic Carcinoma","Adrenal Cortical Carcinoma","Adrenal Gland Pheochromocytoma","Anal Canal Neuroendocrine Carcinoma","Anal Canal Undifferentiated Carcinoma","Angiosarcoma","Apocrine Neoplasm","Appendix Mucinous Adenocarcinoma","Bartholin Gland Transitional Cell Carcinoma","Basal Cell Carcinoma","Bladder Adenocarcinoma","Breast Metaplastic Carcinoma","Cervical Adenocarcinoma","Cholangiocarcinoma","Chordoma","Colorectal Squamous Cell Carcinoma","Desmoid Fibromatosis","Endometrial Transitional Cell Carcinoma","Endometrioid Adenocarcinoma","Esophageal Neuroendocrine Carcinoma","Esophageal Undifferentiated Carcinoma","Extrahepatic Bile Duct Carcinoma","Extramammary Paget Disease","Fallopian Tube Adenocarcinoma","Fallopian Tube Transitional Cell Carcinoma","Fibromyxoid Tumor","Gallbladder Carcinoma","Gastric Neuroendocrine Carcinoma","Gastric Squamous Cell Carcinoma","Gastric Undifferentiated Carcinoma","Gastrointestinal Stromal Tumor","Gestational Trophoblastic Tumor","Giant Cell Carcinoma","Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type","Intestinal Neuroendocrine Carcinoma","Intrahepatic Cholangiocarcinoma","Lung Neuroendocrine Tumor","Lung Sarcomatoid Carcinoma","Major Salivary Gland Carcinoma","Malignant Neoplasm of Unknown Primary","Malignant Odontogenic Neoplasm","Malignant Peripheral Nerve Sheath Tumor","Malignant Solid Neoplasm","Malignant Testicular Sex Cord-Stromal Tumor","Metastatic Pituitary Neuroendocrine Tumor","Minimally Invasive Lung Adenocarcinoma","Mixed Mesodermal (Mullerian) Tumor","Mucinous Adenocarcinoma","Mucinous Cystadenocarcinoma","Nasal Cavity Adenocarcinoma","Nasal Cavity Carcinoma","Nasopharyngeal Carcinoma","Nasopharyngeal Low Grade Papillary Adenocarcinoma","Nasopharyngeal Undifferentiated Carcinoma","Oral Cavity Carcinoma","Oropharyngeal Undifferentiated Carcinoma","Ovarian Adenocarcinoma","Ovarian Germ Cell Tumor","Ovarian Mucinous Adenocarcinoma","Ovarian Squamous Cell Carcinoma","Ovarian Transitional Cell Carcinoma","PEComa","Pancreatic Acinar Cell Carcinoma","Pancreatic Neuroendocrine Carcinoma","Paraganglioma","Paranasal Sinus Adenocarcinoma","Paranasal Sinus Carcinoma","Parathyroid Gland Carcinoma","Penile Squamous Cell Carcinoma","Peritoneal Mesothelial Neoplasm","Placental Choriocarcinoma","Primary Peritoneal High Grade Serous Adenocarcinoma","Pseudomyxoma Peritonei","Rare Disorder","Scrotal Squamous Cell Carcinoma","Seminal Vesicle Adenocarcinoma","Seminoma","Serous Cystadenocarcinoma","Small Intestinal Adenocarcinoma","Small Intestinal Squamous Cell Carcinoma","Spindle Cell Neoplasm","Teratoma With Somatic-Type Malignancy","Testicular Non-Seminomatous Germ Cell Tumor","Thyroid Gland Carcinoma","Tracheal Carcinoma","Transitional Cell Carcinoma","Ureter Adenocarcinoma","Ureter Squamous Cell Carcinoma","Urethral Adenocarcinoma","Urethral Squamous Cell Carcinoma","Vaginal Adenocarcinoma","Vaginal Squamous Cell Carcinoma, Not Otherwise Specified","Vulvar Carcinoma"],"intervention_entry_count":6,"nct_id":"NCT02834013","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"source_record_index":44,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors","conditions":["Cervical Carcinoma","Colorectal Adenocarcinoma","Non-squamous Non-small Cell Lung Cancer","Platinum-refractory Ovarian Carcinoma","Renal Cell Carcinoma"],"intervention_entry_count":2,"nct_id":"NCT02835833","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":1,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor","conditions":["Colorectal Carcinoma","Gastric Carcinoma","Hepatocellular Carcinoma","Malignant Glioma of Brain","Non-small Cell Lung Cancer","Pancreatic Carcinoma","Triple-Negative Invasive Breast Carcinoma"],"intervention_entry_count":1,"nct_id":"NCT02839954","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"source_record_index":85,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":4,"nct_id":"NCT02848443","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":40,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer","conditions":["Liver Metastases"],"intervention_entry_count":1,"nct_id":"NCT02850536","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":48,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC","conditions":["Refractory Metastatic Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT02860546","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":65,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803","conditions":["Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Adenocarcinoma of Rectum","Chronic Lymphocytic Leukemia","Chronic Myeloid Leukemia","Colon Carcinoma","Ewing's Sarcoma","Hodgkin Lymphoma","Myelodysplastic Syndrome","Myeloproliferative Syndromes","Non Hodgkin Lymphoma","Plasma Cell Myeloma","Rhabdomyosarcoma","Soft Tissue Sarcoma"],"intervention_entry_count":2,"nct_id":"NCT02890758","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":85,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)","conditions":["Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma"],"intervention_entry_count":5,"nct_id":"NCT02900664","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":26,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.","conditions":["Curative Resection","Stage IV Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT02919644","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":83,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy","conditions":["Carcinoma, Hepatocellular","Colorectal Cancer Metastatic","Pancreatic Cancer Metastatic"],"intervention_entry_count":1,"nct_id":"NCT02959151","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"source_record_index":66,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT02965417","overall_status":"WITHDRAWN","phases":["PHASE2"],"source_record_index":22,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas","conditions":["Colon Cancer","Metastatic Colorectal Cancer","Pancreas Cancer","Rectum Cancer","Recurrent Colorectal Carcinoma"],"intervention_entry_count":1,"nct_id":"NCT02973672","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":69,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","conditions":["Anaplastic Large Cell Lymphoma, ALK-Negative","Anaplastic Large Cell Lymphoma, ALK-Positive","Apocrine Carcinoma","Carcinoma Arising From Cylindroma","Carcinoma Arising From Spiradenoma","Digital Papillary Adenocarcinoma","Endocrine Mucin-Producing Sweat Gland Carcinoma","Extramammary Paget Disease","Extraocular Sebaceous Carcinoma","Hidradenocarcinoma","Malignant Sweat Gland Neoplasm","Merkel Cell Carcinoma","Microcystic Adnexal Carcinoma","NK-Cell Lymphoma, Unclassifiable","Papillary Adenocarcinoma","Porocarcinoma","Primary Cutaneous Mucinous Carcinoma","Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Recurrent T-Cell Non-Hodgkin Lymphoma","Refractory Anaplastic Large Cell Lymphoma","Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Refractory Merkel Cell Carcinoma","Refractory Mycosis Fungoides","Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Refractory Skin Squamous Cell Carcinoma","Refractory T-Cell Non-Hodgkin Lymphoma","Sezary Syndrome","Signet Ring Cell Adenocarcinoma","Skin Adenoid Cystic Carcinoma","Skin Adnexal Carcinoma","Skin Basal Cell Carcinoma","Skin Basosquamous Cell Carcinoma","Skin Keratoacanthoma","Skin Squamous Cell Carcinoma","Squamoid Eccrine Ductal Carcinoma","Squamous Cell Carcinoma of Unknown Primary","Sweat Gland Carcinoma","Trichilemmal Carcinoma","Vulvar Squamous Cell Carcinoma"],"intervention_entry_count":7,"nct_id":"NCT02978625","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"source_record_index":93,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Impact of HLA-E Overexpression by Tumor Cells on the Biology of TIL in Colorectal Cancer","conditions":["ColoRectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT02980146","overall_status":"COMPLETED","phases":[],"source_record_index":88,"source_ref":"ctg-page-003","study_type":"OBSERVATIONAL"},{"brief_title":"PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT02994888","overall_status":"COMPLETED","phases":[],"source_record_index":59,"source_ref":"ctg-page-002","study_type":"OBSERVATIONAL"},{"brief_title":"A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer","conditions":["Colon Cancer","Esophageal Carcinoma","Gastric Cancer","Hepatic Carcinoma","Pancreatic Cancer","Prostate Cancer"],"intervention_entry_count":1,"nct_id":"NCT03013712","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"source_record_index":27,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT03017807","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":56,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6","conditions":["Bile Duct Cancer","Breast Cancer","Chordoma of Sacrum","Colon Cancer","Head and Neck Cancer","Liver Cancer","Lung Cancer","Lymphoma","Pancreatic Cancer","Sarcoma","Squamous Cell Carcinoma"],"intervention_entry_count":3,"nct_id":"NCT03058289","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":58,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies","conditions":["Advanced Solid Tumors","Cancer","Hematologic Malignancies"],"intervention_entry_count":4,"nct_id":"NCT03082209","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":70,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer","conditions":["Rectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT03085992","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":32,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies","conditions":["Advanced Malignancies","Metastatic Cancer"],"intervention_entry_count":3,"nct_id":"NCT03126110","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":89,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Optical Polyp Testing for In Vivo Classification","conditions":["Colon Hyperplastic Polyp","Colonic Adenocarcinoma","Colonic Adenoma","Colonic Cancer","Colonic Carcinoma","Colonic Diseases","Colonic Dysplasia","Colonic Neoplasms","Colonic Polyp"],"intervention_entry_count":1,"nct_id":"NCT03139942","overall_status":"COMPLETED","phases":["NA"],"source_record_index":48,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG)","conditions":["Metastatic Colorectal Cancer","Metastatic Head and Neck Cancer"],"intervention_entry_count":1,"nct_id":"NCT03146338","overall_status":"UNKNOWN","phases":["NA"],"source_record_index":72,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Preoperative Radiotherapy and E7046 in Rectum Cancer","conditions":["Neoadjuvant Therapy in Rectal Cancer"],"intervention_entry_count":5,"nct_id":"NCT03152370","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":18,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"RetroviewTM Colonoscope and Lesion Detection Rate","conditions":["Colonic Neoplasms"],"intervention_entry_count":1,"nct_id":"NCT03155165","overall_status":"COMPLETED","phases":[],"source_record_index":91,"source_ref":"ctg-page-004","study_type":"OBSERVATIONAL"},{"brief_title":"First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide","conditions":["Breast Carcinoma","Colorectal Carcinoma","Lung Carcinoma","Metastatic Malignant Neoplasm in the Breast","Metastatic Malignant Neoplasm in the Colon","Metastatic Malignant Neoplasm in the Lung","Metastatic Malignant Neoplasm in the Rectum","Pancreatic Carcinoma"],"intervention_entry_count":1,"nct_id":"NCT03164486","overall_status":"ACTIVE_NOT_RECRUITING","phases":["EARLY_PHASE1"],"source_record_index":65,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Panitumumab Skin Toxicity Prevention Trial","conditions":["Colorectal Cancer Metastatic","Skin Toxicity"],"intervention_entry_count":2,"nct_id":"NCT03167268","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":13,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC","conditions":["Colorectal Cancer"],"intervention_entry_count":22,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"source_record_index":17,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System","conditions":["Biliary Tract Cancer","Colorectal Cancer","Esophageal Squamous Cell Carcinoma","HER2","Targeted Therapy"],"intervention_entry_count":4,"nct_id":"NCT03185988","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":29,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","conditions":["MSI","Metastatic Colorectal Cancer"],"intervention_entry_count":7,"nct_id":"NCT03186326","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":60,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","conditions":["Colon Cancer","Gastric Cancer","Gastrointestinal Cancer","Pancreatic Cancer","Rectal Cancer"],"intervention_entry_count":4,"nct_id":"NCT03190941","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":60,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer","conditions":["Colorectal Adenocarcinoma","Colorectal Cancer","Colorectal Carcinoma","Colorectal Neoplasms","Refractory Cancer"],"intervention_entry_count":4,"nct_id":"NCT03206073","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":56,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":4,"nct_id":"NCT03206151","overall_status":"COMPLETED","phases":["PHASE3"],"source_record_index":82,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors","conditions":["Neoplasms"],"intervention_entry_count":5,"nct_id":"NCT03250832","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":77,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation","conditions":["MSS","RAS-mutant Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT03271047","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":77,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)","conditions":["Colorectal Neoplasms","Digestive System Neoplasms","Gastrointestinal Neoplasms","Intestinal Neoplasms"],"intervention_entry_count":2,"nct_id":"NCT03271255","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":43,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas","conditions":["Pancreas Cancer"],"intervention_entry_count":1,"nct_id":"NCT03277209","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":94,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies","conditions":["Carcinoma, Hepatocellular","Metastatic Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT03291379","overall_status":"COMPLETED","phases":["EARLY_PHASE1"],"source_record_index":94,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer","conditions":["Advanced Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT03311750","overall_status":"TERMINATED","phases":["PHASE2"],"source_record_index":26,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors","conditions":["Advanced Solid Tumors","Colorectal Cancer","EGFR Positive Solid Tumor","HER2 Positive Gastric Cancer","HER2-positive Breast Cancer","Head and Neck Squamous Cell Carcinoma","Hepatocellular Carcinoma","Melanoma","Non Small Cell Lung Cancer","Pancreatic Cancer","Renal Cell Carcinoma"],"intervention_entry_count":3,"nct_id":"NCT03319459","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":56,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT03356158","overall_status":"UNKNOWN","phases":["PHASE1"],"source_record_index":12,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"EMI-137 in Laparoscopic Colonic Resections","conditions":["Colonic Cancer","Metastasis to Lymph Node"],"intervention_entry_count":1,"nct_id":"NCT03360461","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":1,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer","conditions":["Colon Carcinoma Metastatic in the Liver","Colorectal Adenocarcinoma","Pancreatic Adenocarcinoma","Resectable Pancreatic Carcinoma","Stage I Pancreatic Cancer","Stage IA Pancreatic Cancer","Stage IB Pancreatic Cancer","Stage II Pancreatic Cancer","Stage IIA Pancreatic Cancer","Stage IIB Pancreatic Cancer","Stage III Pancreatic Cancer","Stage IV Colorectal Cancer","Stage IVA Colorectal Cancer","Stage IVB Colorectal Cancer"],"intervention_entry_count":4,"nct_id":"NCT03373188","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":14,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT03380689","overall_status":"WITHDRAWN","phases":["PHASE1"],"source_record_index":95,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)","conditions":["Colorectal Neoplasm"],"intervention_entry_count":1,"nct_id":"NCT03384940","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":58,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Prophylactic HIPEC for Colorectal Cancers at High Risk of Developing Peritoneal Metastases","conditions":["Colorectal Cancer","Peritoneal Metastases"],"intervention_entry_count":1,"nct_id":"NCT03422432","overall_status":"COMPLETED","phases":["NA"],"source_record_index":17,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care","conditions":["Stomach Neoplasms"],"intervention_entry_count":1,"nct_id":"NCT03425773","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":15,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT03426371","overall_status":"TERMINATED","phases":["PHASE3"],"source_record_index":31,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers","conditions":["Bladder Cancer","Cervical Cancer","Colorectal Cancer","Endometrial Cancer","Metastatic Castration Resistant Prostate Cancer","Non-Small Cell Lung Cancer","Non-hodgkin Lymphoma","Ovarian Cancer","Pancreatic Cancer","Renal Cell Cancer","Sarcoma","Squamous Cell Carcinoma of the Head and Neck","Triple Negative Breast Cancer"],"intervention_entry_count":6,"nct_id":"NCT03454451","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":81,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Assessment and Prediction of Cetuximab-Induced Hypersensitivity Reactions Using Cetuximab Specific IgE Detection","conditions":["Head & Neck Squamous Cell Carcinoma","Tumor Disease Including Colorectal Cancer"],"intervention_entry_count":0,"nct_id":"NCT03485638","overall_status":"UNKNOWN","phases":[],"source_record_index":30,"source_ref":"ctg-page-004","study_type":"OBSERVATIONAL"},{"brief_title":"A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC","conditions":["Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT03491709","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":21,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)","conditions":["Colorectal Neoplasms","Head and Neck Neoplasms","Neoplasms"],"intervention_entry_count":1,"nct_id":"NCT03515824","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":66,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Sym004 Versus Futuximab or Modotuximab in Patients With mCRC","conditions":["Carcinoma","Colorectal Cancer Metastatic","Metastatic Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT03549338","overall_status":"TERMINATED","phases":["PHASE2"],"source_record_index":71,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)","conditions":["Metastases, Neoplasm","Neoplasm Seeding","Neoplasm, Stomach"],"intervention_entry_count":2,"nct_id":"NCT03563326","overall_status":"UNKNOWN","phases":["PHASE1"],"source_record_index":90,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","conditions":["Bile Duct Cancer","Bladder Cancer","Breast Neoplasm Malignant Primary","Cervical Cancer","Cholangiocarcinoma","Colo-rectal Cancer","HER-2 Gene Amplification","HER2 Gene Mutation","HER2 Positive Gastric Cancer","HER2-positive Breast Cancer","Head and Neck Cancer","Head and Neck Carcinoma","Larynx Cancer","Lip Cancer Stage I","Liver Cancer","Lung Cancer","Mouth Cancer","Mucinous Adenocarcinoma Gastric","Mucinous Breast Cancer Recurrent","Mucoepidermoid Carcinoma","Palate Cancer","Pancreatic Cancer","Primary Peritoneal Carcinoma","Prostate Cancer","Rare Diseases","Rectal Cancer","Rectal Cancer Stage I","Rectal Cancer Stage II","Rectal Cancer Stage III","Recurrent Breast Cancer","Recurrent Colon Cancer","Recurrent Gastric Cancer","Recurrent Ovarian Carcinoma","Recurrent Prostate Cancer","Recurrent Renal Cell Cancer","Salivary Gland Cancer","Salivary Gland Carcinoma","Salivary Gland Neoplasms","Salivary Gland Tumor","Skin Cancer","Solid Tumor","Tongue Cancer","Tonsil Cancer","Urologic Cancer"],"intervention_entry_count":1,"nct_id":"NCT03602079","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":35,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies","conditions":["Cancer of Colon","Cancer of Liver","Cancer of Pancreas","Cancer of Rectum","Cancer, Gall Bladder","Glioblastoma Multiforme","Myeloma Multiple"],"intervention_entry_count":9,"nct_id":"NCT03607643","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"source_record_index":59,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies","conditions":["B-cell Acute Lymphoblastic Leukemia","Colorectal Cancer","Esophagus Cancer","Gastric Cancer","Glioma","Hepatoma","Lung Cancer","Lymphoma","Melanoma","Mesothelioma","Multiple Myeloma","Myeloid Leukemia","Ovarian Cancer","Pancreatic Cancer","Renal Carcinoma","Synovial Sarcoma"],"intervention_entry_count":1,"nct_id":"NCT03638206","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"source_record_index":88,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer","conditions":["Colorectal Neoplasms"],"intervention_entry_count":1,"nct_id":"NCT03659448","overall_status":"RECRUITING","phases":["PHASE3"],"source_record_index":79,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Endogenous Mechanisms of Inactivation of the Endothelium Tumor","conditions":["Breast Cancer","Colon Cancer"],"intervention_entry_count":0,"nct_id":"NCT03667612","overall_status":"UNKNOWN","phases":[],"source_record_index":3,"source_ref":"ctg-page-003","study_type":"OBSERVATIONAL"},{"brief_title":"COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.","conditions":["Advanced Cancer","Breast Cancer","Colo-rectal Cancer","Endometrial Cancer","Lung Cancer","Lung Neoplasm","Neoplasm Malignant","Ovarian Cancer","Ovarian Neoplasm","Triple Negative Breast Cancer"],"intervention_entry_count":2,"nct_id":"NCT03667716","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":66,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"NBI Versus White Light Endoscopy for Optical Characterization of Neoplastic Polyps in the Colorectum","conditions":["Colon Adenoma","Colorectal Carcinoma","Hyperplastic Polyp","Serrated Adenoma"],"intervention_entry_count":1,"nct_id":"NCT03679429","overall_status":"UNKNOWN","phases":[],"source_record_index":3,"source_ref":"ctg-page-004","study_type":"OBSERVATIONAL"},{"brief_title":"CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)","conditions":["Breast Cancer","Carcinoembryonic Antigen","Colorectal Cancer","Gastric Cancer","Pancreas Cancer","Peritoneal Carcinomatosis","Peritoneal Metastases"],"intervention_entry_count":1,"nct_id":"NCT03682744","overall_status":"WITHDRAWN","phases":["PHASE1"],"source_record_index":20,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells","conditions":["Unresectable Metastatic Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT03692429","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":79,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.","conditions":["Adenocarcinoma"],"intervention_entry_count":2,"nct_id":"NCT03695835","overall_status":"COMPLETED","phases":[],"source_record_index":92,"source_ref":"ctg-page-003","study_type":"OBSERVATIONAL"},{"brief_title":"Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas","conditions":["Colorectal Adenocarcinoma","Ewing Sarcoma"],"intervention_entry_count":9,"nct_id":"NCT03715933","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":9,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)","conditions":["Breast Cancer","Colorectal Cancer","Non Small Cell Lung Cancer","Prostate Cancer","Small Cell Lung Cancer"],"intervention_entry_count":1,"nct_id":"NCT03724253","overall_status":"TERMINATED","phases":["PHASE2"],"source_record_index":84,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors","conditions":["Bladder Cancer","Breast Cancer","Cancer of the Salivary Gland","Colorectal Cancer","Esophageal Cancer","Gastric Cancer","Head and Neck Squamous Cell Carcinoma","Lung Cancer","Pancreatic Adenocarcinoma","Solid Tumor"],"intervention_entry_count":1,"nct_id":"NCT03740256","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":57,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)","conditions":["Colorectal Neoplasms"],"intervention_entry_count":2,"nct_id":"NCT03743428","overall_status":"SUSPENDED","phases":["NA"],"source_record_index":80,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients","conditions":["Colon Cancer","Gastric Cancer","Gastrointestinal Cancer","Pancreatic Cancer","Rectal Cancer"],"intervention_entry_count":10,"nct_id":"NCT03745326","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"source_record_index":63,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -","conditions":["BRAF Gene Mutation","Circulating Tumor DNA","Colorectal Cancer Metastatic","Epidermal Growth Factor Receptor Inhibitor","KRAS Gene Mutation","NRAS Gene Mutation"],"intervention_entry_count":1,"nct_id":"NCT03750175","overall_status":"COMPLETED","phases":[],"source_record_index":51,"source_ref":"ctg-page-002","study_type":"OBSERVATIONAL"},{"brief_title":"Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal","conditions":["Colorectal Cancer Metastatic"],"intervention_entry_count":4,"nct_id":"NCT03751176","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":2,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)","conditions":["Advanced Solid Tumors","Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative","Cervical Carcinoma","Colorectal Carcinoma","Endometrial Carcinoma","Gastric or Gastroesophageal Junction Adenocarcinoma","Hepatocellular Carcinoma","Melanoma (Excluding Uveal Melanoma)","Nasopharyngeal Carcinoma","Non-small Cell Lung Carcinoma","Pancreatic Carcinoma","Renal Cell Carcinoma","Small Cell Lung Cancer","Squamous Cell Carcinoma of the Head and Neck","Undifferentiated Pleomorphic Sarcoma","Urothelial Carcinoma"],"intervention_entry_count":2,"nct_id":"NCT03752398","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":85,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors","conditions":["Breast Cancer","Cervical Cancer","Colo-rectal Cancer","Head and Neck Cancer","Hepatocarcinoma","Lung Cancer","Melanoma","Ovarian Cancer","Pancreas Cancer","Renal Cancer"],"intervention_entry_count":1,"nct_id":"NCT03755739","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"source_record_index":75,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"MGD019 DART® Protein in Unresectable/Metastatic Cancer","conditions":["Advanced Cancer","Colorectal Cancer","Cutaneous Melanoma","Prostate Cancer Metastatic","Solid Tumor, Adult","Squamous Cell Non Small Cell Lung Cancer"],"intervention_entry_count":1,"nct_id":"NCT03761017","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":78,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)","conditions":["Advanced Solid Tumors","Biliary Tract Cancers","Colorectal Cancer","Gastric Cancer","Glioblastoma","Ovarian Cancer","Pancreatic Cancer","Triple Negative Breast Cancer"],"intervention_entry_count":2,"nct_id":"NCT03797326","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":73,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers","conditions":["Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT03799731","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":87,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer","conditions":["Colorectal Adenocarcinoma","Colorectal Cancer Metastatic","Metastatic Microsatellite Stable Colorectal Carcinoma","Refractory Colorectal Carcinoma","Stage IV Colorectal Cancer","Stage IVA Colorectal Cancer","Stage IVB Colorectal Cancer","Stage IVC Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT03800602","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":76,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers","conditions":["Cholangiocarcinoma","Colon Cancer","Liver Metastasis","Metastatic Colon Carcinoma","Pancreatic Cancer"],"intervention_entry_count":2,"nct_id":"NCT03801915","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":77,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer","conditions":["Microsatellite Instability","POLE Exonuclease Mutant Colon Cancer","Stage III Colon Cancer"],"intervention_entry_count":1,"nct_id":"NCT03827044","overall_status":"TERMINATED","phases":["PHASE3"],"source_record_index":82,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers","conditions":["Cholangiocarcinoma","Colorectal Cancer","GastroEsophageal Cancer","Hepatocellular Carcinoma","Metastatic Castration Resistant Prostate Cancer","Non-small Cell Lung Cancer","Pancreatic Cancer","Renal Cell Carcinoma","Sarcoma","Squamous Cell Carcinoma of Head and Neck","Triple-Negative Breast Cancer","Urothelial Carcinoma"],"intervention_entry_count":4,"nct_id":"NCT03829436","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":77,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors","conditions":["Leiomyosarcoma","Mismatch Repair Proficient Colorectal Cancer","Pancreatic Adenocarcinoma"],"intervention_entry_count":3,"nct_id":"NCT03851614","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"source_record_index":11,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer","conditions":["Advanced Cancer","Angiosarcoma","Colorectal Cancer Without Liver Metastases","Endometrial Cancer","Fibrolamellar Carcinoma","Non-small-cell Lung Cancer","Ovarian Cancer","Prostate Cancer"],"intervention_entry_count":2,"nct_id":"NCT03860272","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"source_record_index":39,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma","conditions":["Colorectal Cancer"],"intervention_entry_count":4,"nct_id":"NCT03866239","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":65,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients","conditions":["ADCC","Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT03874026","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":37,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Combined Forward and Retroflexion Withdrawal in the Detection of Polyps and Adenoma During Colonoscopy","conditions":["Colonic Adenoma","Colonic Neoplasms","Colonic Polyp"],"intervention_entry_count":2,"nct_id":"NCT03901651","overall_status":"COMPLETED","phases":["NA"],"source_record_index":25,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors","conditions":["Solid Tumor"],"intervention_entry_count":3,"nct_id":"NCT03970382","overall_status":"SUSPENDED","phases":["PHASE1"],"source_record_index":81,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor","conditions":["Cervical Cancer","Colorectal Cancer","Gall Bladder Cancer","Gastric Cancer","Pancreatic Cancer","Tumor, Solid"],"intervention_entry_count":1,"nct_id":"NCT03985072","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":9,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer","conditions":["Colorectal Cancer Stage IV"],"intervention_entry_count":1,"nct_id":"NCT03986541","overall_status":"COMPLETED","phases":[],"source_record_index":30,"source_ref":"ctg-page-001","study_type":"OBSERVATIONAL"},{"brief_title":"An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer","conditions":["Colorectal Carcinoma Metastatic in the Liver","Metastatic Colorectal Carcinoma","Stage IV Colorectal Cancer AJCC v8","Stage IVA Colorectal Cancer AJCC v8","Stage IVB Colorectal Cancer AJCC v8","Stage IVC Colorectal Cancer AJCC v8"],"intervention_entry_count":2,"nct_id":"NCT03993327","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":55,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Prevention of Obesity-related Cancers: Setting up of a Multi-Cancer Education and Prevention Program in Hong Kong","conditions":["Breast Cancer","Colorectal Cancer","Obesity","Prostate Cancer"],"intervention_entry_count":3,"nct_id":"NCT04034953","overall_status":"UNKNOWN","phases":["NA"],"source_record_index":90,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors","conditions":["Breast Cancer","Colorectal Cancer","Esophageal Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma","Non-small Cell Lung Cancer","Other Solid Tumors","Pancreatic Ductal Carcinoma"],"intervention_entry_count":1,"nct_id":"NCT04045496","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":52,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus","conditions":["Anal Cancer Stage III A","Anal Cancer Stage III B"],"intervention_entry_count":1,"nct_id":"NCT04046133","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"source_record_index":69,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour","conditions":["Colorectal Cancer","Gastric Cancer","Nasopharyngeal Carcinoma","Prostate Cancer","Sarcoma","Triple Negative Breast Cancer"],"intervention_entry_count":1,"nct_id":"NCT04107142","overall_status":"UNKNOWN","phases":["PHASE1"],"source_record_index":14,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma","conditions":["Clinical Stage II Gastric Cancer AJCC v8","Clinical Stage IIA Gastric Cancer AJCC v8","Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8","Clinical Stage IIB Gastric Cancer AJCC v8","Clinical Stage III Esophageal Adenocarcinoma AJCC v8","Clinical Stage III Gastric Cancer AJCC v8","Colorectal Adenocarcinoma","Gastric Adenocarcinoma","Malignant Digestive System Neoplasm","Malignant Solid Neoplasm","Pancreatic Ductal Adenocarcinoma","Pathologic Stage II Gastric Cancer AJCC v8","Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IIB Gastric Cancer AJCC v8","Pathologic Stage III Esophageal Adenocarcinoma AJCC v8","Pathologic Stage III Gastric Cancer AJCC v8","Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IIIA Gastric Cancer AJCC v8","Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IIIB Gastric Cancer AJCC v8","Pathologic Stage IIIC Gastric Cancer AJCC v8","Small Intestinal Adenocarcinoma","Stage I Pancreatic Cancer AJCC v8","Stage IA Pancreatic Cancer AJCC v8","Stage IB Pancreatic Cancer AJCC v8","Stage II Pancreatic Cancer AJCC v8","Stage IIA Pancreatic Cancer AJCC v8","Stage IIB Pancreatic Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","Stage III Small Intestinal Adenocarcinoma AJCC v8","Stage IIIA Colorectal Cancer AJCC v8","Stage IIIA Small Intestinal Adenocarcinoma AJCC v8","Stage IIIB Colorectal Cancer AJCC v8","Stage IIIC Colorectal Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Stage IVA Colorectal Cancer AJCC v8","Stage IVB Colorectal Cancer AJCC v8"],"intervention_entry_count":1,"nct_id":"NCT04111172","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"source_record_index":81,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China","conditions":["Breast Cancer","Colorectal Cancer","Esophageal Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma","Non-small Cell Lung Cancer","Other Solid Tumors","Pancreatic Ductal Carcinoma"],"intervention_entry_count":1,"nct_id":"NCT04121286","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":0,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues","conditions":["Breast Carcinoma","Colon Carcinoma","Esophageal Carcinoma","Gastric Carcinoma","Head and Neck Carcinoma","Kidney Carcinoma","Lung Carcinoma","Ovarian Carcinoma","Pancreatic Carcinoma","Solid Neoplasm","Uterine Corpus Cancer"],"intervention_entry_count":5,"nct_id":"NCT04147494","overall_status":"ACTIVE_NOT_RECRUITING","phases":["EARLY_PHASE1"],"source_record_index":41,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy","conditions":["Colorectal Neoplasms"],"intervention_entry_count":3,"nct_id":"NCT04192929","overall_status":"WITHDRAWN","phases":["NA"],"source_record_index":91,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer","Microsatellite Stable","RAS Mutation"],"intervention_entry_count":1,"nct_id":"NCT04194359","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":96,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors","conditions":["Anal Cancer","Biliary Tract Cancer","Bladder Cancer","Cervical Cancer","Gastric Cancer","Head and Neck Squamous Cell Carcinoma","Hepatocellular Carcinoma","Melanoma","Merkel Cell Carcinoma","Mesothelioma","Microsatellite Instability High","Non Small Cell Lung Cancer","Ovarian Cancer","Renal Cell Carcinoma","Skin Squamous Cell Carcinoma","Small-cell Lung Cancer","Thymic Cancer","Thyroid Cancer","Triple Negative Breast Cancer"],"intervention_entry_count":2,"nct_id":"NCT04234113","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":74,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)","conditions":["Colorectal Cancer","Lung Cancer"],"intervention_entry_count":2,"nct_id":"NCT04235114","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":75,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies","conditions":["Acral Lentiginous Melanoma","Breast Cancer","Colorectal Cancer","DMMR Colorectal Cancer","Esophageal Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma","Hepatocellular Carcinoma","MSI-H Colorectal Cancer","Melanoma","Non-Small Cell Lung Cancer","Ovarian Cancer","Platinum-Resistant Epithelial Ovarian Cancer","Platinum-Resistant Fallopian Tube Carcinoma","Platinum-Resistant Primary Peritoneal Carcinoma","Triple Negative Breast Cancer","Urothelial Carcinoma"],"intervention_entry_count":3,"nct_id":"NCT04244552","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":70,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate","conditions":["Colorectal Cancer Metastatic","High Immune Infiltrate","Microsatellite Stable"],"intervention_entry_count":4,"nct_id":"NCT04262687","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":65,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"National Cancer Institute \"Cancer Moonshot Biobank\"","conditions":["Acute Myeloid Leukemia","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Clinical Stage IV Esophageal Adenocarcinoma AJCC v8","Clinical Stage IV Gastric Cancer AJCC v8","Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Esophageal Carcinoma","Fallopian Tube Carcinoma","Gastric Carcinoma","Hormone Receptor-Positive Breast Carcinoma","Invasive Breast Carcinoma","Lung Non-Small Cell Carcinoma","Lung Small Cell Carcinoma","Malignant Solid Neoplasm","Melanoma","Metastatic Prostate Carcinoma","Multiple Myeloma","Ovarian Carcinoma","Ovarian High Grade Serous Adenocarcinoma","Primary Peritoneal Carcinoma","Stage III Fallopian Tube Cancer AJCC v8","Stage III Lung Cancer AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Stage IV Fallopian Tube Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8","Triple-Negative Breast Carcinoma"],"intervention_entry_count":6,"nct_id":"NCT04314401","overall_status":"ACTIVE_NOT_RECRUITING","phases":[],"source_record_index":47,"source_ref":"ctg-page-002","study_type":"OBSERVATIONAL"},{"brief_title":"Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors","conditions":["Advanced Solid Tumor","Breast Cancer","Cancer","Colorectal Carcinoma","Liver Metastases","Melanoma","Non-melanoma Skin Cancer","Solid Tumor","Squamous Cell Carcinoma of Head and Neck","Triple Negative Breast Cancer"],"intervention_entry_count":2,"nct_id":"NCT04348916","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":25,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer","conditions":["Advanced Colon Adenocarcinoma","Metastatic Colon Adenocarcinoma","Metastatic Colorectal Adenocarcinoma","Metastatic Colorectal Carcinoma","Metastatic Rectal Adenocarcinoma","Stage III Colon Cancer AJCC v8","Stage III Rectal Cancer AJCC v8","Stage IIIA Colon Cancer AJCC v8","Stage IIIA Rectal Cancer AJCC v8","Stage IIIB Colon Cancer AJCC v8","Stage IIIB Rectal Cancer AJCC v8","Stage IIIC Colon Cancer AJCC v8","Stage IIIC Rectal Cancer AJCC v8","Stage IV Colon Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Stage IV Rectal Cancer AJCC v8","Stage IVA Colon Cancer AJCC v8","Stage IVA Colorectal Cancer AJCC v8","Stage IVA Rectal Cancer AJCC v8","Stage IVB Colon Cancer AJCC v8","Stage IVB Colorectal Cancer AJCC v8","Stage IVB Rectal Cancer AJCC v8","Stage IVC Colon Cancer AJCC v8","Stage IVC Colorectal Cancer AJCC v8","Stage IVC Rectal Cancer AJCC v8"],"intervention_entry_count":3,"nct_id":"NCT04362839","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":11,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers","conditions":["Advanced Solid Tumor","Bladder Cancer","Cervical Cancer","Colorectal Cancer","EGF-R Positive Non-Small Cell Lung Cancer","Endometrium Cancer","Esophageal Cancer","HER-2 Protein Overexpression","HER2-positive Breast Cancer","HER2-positive Gastric Cancer","Head and Neck Squamous Cell Carcinoma","Metastatic Cancer","Non Small Cell Lung Cancer","Ovarian Cancer","Pancreatic Cancer","Sarcoma","Triple Negative Breast Cancer"],"intervention_entry_count":3,"nct_id":"NCT04464967","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"source_record_index":52,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"The Molecular Mechanism of RAS Wild-type mCRC Resistance to Anti-EGFR-antibody","conditions":["Colorectal Cancer"],"intervention_entry_count":0,"nct_id":"NCT04466267","overall_status":"COMPLETED","phases":[],"source_record_index":67,"source_ref":"ctg-page-003","study_type":"OBSERVATIONAL"},{"brief_title":"A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT04479436","overall_status":"TERMINATED","phases":["PHASE2"],"source_record_index":87,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers","conditions":["Cancer"],"intervention_entry_count":7,"nct_id":"NCT04485013","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":46,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers","conditions":["Colorectal Cancers","Small Bowel Cancers"],"intervention_entry_count":4,"nct_id":"NCT04491955","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":62,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study","conditions":["Constitutional Mismatch Repair Deficiency Syndrome","Hematopoietic and Lymphoid Cell Neoplasm","Lynch Syndrome","Recurrent Lymphoma","Recurrent Malignant Solid Neoplasm","Recurrent Neuroblastoma","Recurrent Primary Central Nervous System Neoplasm","Refractory Lymphoma","Refractory Malignant Solid Neoplasm","Refractory Neuroblastoma","Refractory Primary Central Nervous System Neoplasm","Xeroderma Pigmentosum"],"intervention_entry_count":3,"nct_id":"NCT04500548","overall_status":"WITHDRAWN","phases":["PHASE1"],"source_record_index":51,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors","conditions":["Colorectal Cancer","Ovarian Cancer"],"intervention_entry_count":1,"nct_id":"NCT04503980","overall_status":"UNKNOWN","phases":["EARLY_PHASE1"],"source_record_index":74,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"A Clinical Research of CAR T Cells Targeting CEA Positive Colorectal Cancer (CRC)","conditions":["Colorectal Cancer Liver Metastasis","Stage III Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT04513431","overall_status":"UNKNOWN","phases":["EARLY_PHASE1"],"source_record_index":72,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)","conditions":["Colorectal Neoplasms"],"intervention_entry_count":2,"nct_id":"NCT04515394","overall_status":"TERMINATED","phases":["PHASE2"],"source_record_index":16,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer","conditions":["MSS","Refractory Metastatic Colorectal Cancer","pMMR"],"intervention_entry_count":2,"nct_id":"NCT04527068","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":75,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations","conditions":["Biliary Tract Neoplasms","Carcinoma, Non-Small-Cell Lung","HER2 Mutations Breast Neoplasms","Urologic Neoplasms","Uterine Cervical Neoplasms","Uterine Neoplasms"],"intervention_entry_count":3,"nct_id":"NCT04579380","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"source_record_index":45,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":5,"nct_id":"NCT04587128","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"source_record_index":81,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)","conditions":["Locally Advanced Gastrointestinal Stromal Tumor","Locally Advanced Sarcoma","Metastatic Gastrointestinal Stromal Tumor","Metastatic Sarcoma","Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8","Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8","Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8","Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8"],"intervention_entry_count":6,"nct_id":"NCT04595747","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"source_record_index":49,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Retrospective Study on the Use of Immunotherapy in Patients With MSI-H Metastatic Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT04612309","overall_status":"ACTIVE_NOT_RECRUITING","phases":[],"source_record_index":14,"source_ref":"ctg-page-003","study_type":"OBSERVATIONAL"},{"brief_title":"Advanced Therapies for Liver Metastases","conditions":["Colorectal Cancer (CRC)","IPMN, Pancreatic","Liver Metastasis","Pancreatic Ductal Adenocarcinoma (PDAC)"],"intervention_entry_count":0,"nct_id":"NCT04622423","overall_status":"RECRUITING","phases":[],"source_record_index":19,"source_ref":"ctg-page-004","study_type":"OBSERVATIONAL"},{"brief_title":"Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors","conditions":["Breast Cancer","Colorectal Cancer","Gastric Cancer","Head and Neck Cancer","Ovarian Cancer","Pancreas Cancer","Small-cell Lung Cancer"],"intervention_entry_count":1,"nct_id":"NCT04640480","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":44,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"SGM-101 in Locally Advanced and Recurrent Rectal Cancer","conditions":["Rectal Cancer","Recurrent Rectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT04642924","overall_status":"UNKNOWN","phases":["PHASE2","PHASE3"],"source_record_index":10,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":6,"nct_id":"NCT04660812","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":78,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors","conditions":["Adenocarcinoma","Bile Duct Cancer","Biliary Tract Cancer","Bladder Cancer","Breast Cancer","Breast Neoplasm","Cancer","Carcinoma, Ductal","Carcinoma, Hepatocellular","Carcinoma, Ovarian Epithelial","Carcinoma, Small Cell","Carcinoma, Squamous","Carcinoma, Transitional Cell","Colorectal Cancer","Endometrial Cancer","Esophagogastric Junction Neoplasms","HER-2 Gene Amplification","HER-2 Protein Overexpression","HER2-positive","HER2-positive Breast Cancer","HER2-positive Gastric Cancer","HER2-positive Solid Tumors","Head and Neck Cancer","Inflammatory Breast Cancer","Lung Cancer, Non-Small-Cell","Lung Cancer, Small Cell","Malignant Neoplasms","Ovarian Neoplasms","Pancreatic Cancer","Prostate Cancer","Stomach Neoplasms"],"intervention_entry_count":2,"nct_id":"NCT04660929","overall_status":"UNKNOWN","phases":["PHASE1"],"source_record_index":24,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of PY314 in Subjects With Advanced Solid Tumors","conditions":["Advanced Solid Tumor","Breast Cancer","Colorectal Cancer","Gynecologic Cancer","Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer","Lung Adenocarcinoma","Ovarian Cancer","Renal Cell Carcinoma","Triple Negative Breast Cancer"],"intervention_entry_count":2,"nct_id":"NCT04691375","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":4,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"SGM-101 in Colorectal Lung Metastases","conditions":["Colorectal Cancer","Metastatic Colon Cancer"],"intervention_entry_count":1,"nct_id":"NCT04737213","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":45,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer","conditions":["Advanced Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT04744831","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":76,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)","conditions":["Sintilimab, Cetuximab, Regorafenib,Combine,mCRC"],"intervention_entry_count":2,"nct_id":"NCT04745130","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":94,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer","conditions":["Locally Advanced Rectal Adenocarcinoma","Stage II Rectal Cancer AJCC v8","Stage III Rectal Cancer AJCC v8"],"intervention_entry_count":7,"nct_id":"NCT04751370","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"source_record_index":31,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"SGM-101 in Colorectal Brain Metastases.","conditions":["Brain Cancer","Brain Diseases","Brain Metastases","Brain Neoplasms","Brain Tumor","Colorectal Neoplasms","Gastrointestinal Cancer","Gastrointestinal Disease","Gastrointestinal Neoplasms","Intestinal Disease","Intestinal Neoplasms","Rectal Neoplasms","Rectum Cancer"],"intervention_entry_count":1,"nct_id":"NCT04755920","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":73,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.","conditions":["Colon Cancer"],"intervention_entry_count":1,"nct_id":"NCT04775862","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":7,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"PF-07284892 in Participants With Advanced Solid Tumors","conditions":["Solid Tumor"],"intervention_entry_count":5,"nct_id":"NCT04800822","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":15,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"VASCular Impact of Angiogenic Treatment in Patients With Advanced Colorectal Cancer","conditions":["Oncology"],"intervention_entry_count":1,"nct_id":"NCT04813913","overall_status":"COMPLETED","phases":["PHASE4"],"source_record_index":26,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT04853043","overall_status":"TERMINATED","phases":["PHASE2"],"source_record_index":80,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination","conditions":["Colorectal Cancer","Esophageal Squamous Cell Carcinoma","Gastric Cancer","Head and Neck Squamous Cell Carcinoma","Non-Small Cell Lung Cancer Metastatic"],"intervention_entry_count":3,"nct_id":"NCT04868877","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":70,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer","conditions":["Colorectal Carcinoma","Lung Adenocarcinoma","Malignant Solid Neoplasm","Pancreatic Carcinoma"],"intervention_entry_count":3,"nct_id":"NCT04870034","overall_status":"WITHDRAWN","phases":["EARLY_PHASE1"],"source_record_index":1,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Artificial Intelligence System Based on Raman Spectroscopy in Inflammatory Bowel Disease","conditions":["Inflammatory Bowel Diseases"],"intervention_entry_count":1,"nct_id":"NCT04888299","overall_status":"UNKNOWN","phases":["NA"],"source_record_index":73,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer","conditions":["Lynch Syndrome","Metastatic Endometrial Cancer","Mismatch Repair Deficiency","Recurrent Endometrial Cancer","Recurrent Endometrial Carcinoma","Recurrent Endometrial Clear Cell Adenocarcinoma","Recurrent Uterine Corpus Carcinosarcoma"],"intervention_entry_count":4,"nct_id":"NCT04906382","overall_status":"TERMINATED","phases":["EARLY_PHASE1"],"source_record_index":84,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.","conditions":["Colorectal Neoplasms"],"intervention_entry_count":1,"nct_id":"NCT04911517","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":9,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Relapse Markers for Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":0,"nct_id":"NCT04920955","overall_status":"COMPLETED","phases":[],"source_record_index":53,"source_ref":"ctg-page-004","study_type":"OBSERVATIONAL"},{"brief_title":"A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":10,"nct_id":"NCT04929223","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":64,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer","conditions":["Colon Adenocarcinoma","Colon Cancer","Colorectal Adenocarcinoma","Colorectal Cancer","Rectal Adenocarcinoma","Rectal Cancer","Rectum Cancer"],"intervention_entry_count":2,"nct_id":"NCT04963283","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"source_record_index":19,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing","conditions":["CRC","Cancer","Colorectal Cancer","Head and Neck Squamous Cell Carcinoma HNSCC","Mesothelioma","Mesothelioma, Malignant","Mesothelioma; Lung","NSCLC","Non Small Cell Lung Cancer","Ovarian Cancer","Ovarian Carcinoma","Ovarian Neoplasms","Pancreas Cancer","Pancreatic Cancer","Renal Cell Carcinoma (Kidney Cancer)","Solid Tumor, Adult","Triple Negative Breast Cancer (TNBC)"],"intervention_entry_count":3,"nct_id":"NCT04981119","overall_status":"RECRUITING","phases":[],"source_record_index":63,"source_ref":"ctg-page-005","study_type":"OBSERVATIONAL"},{"brief_title":"A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors","conditions":["Neoplasms"],"intervention_entry_count":1,"nct_id":"NCT04991740","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":91,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer","conditions":["Unresectable Metastatic Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT04991948","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":71,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"AB122 Platform Study","conditions":["Advanced or Metastatic Solid Tumor","Alveolar Soft Part Sarcoma","Biliary Tract Cancer","Colorectal Cancer","Esophageal Cancer","Gastric Cancer","Head and Neck Cancer","Non-small Cell Lung Cancer","Pancreatic Ductal Adenocarcinoma"],"intervention_entry_count":21,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":50,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT05007132","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":86,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"IMC001 for Clinical Research on Advanced Digestive System Malignancies","conditions":["Advanced Colorectal Cancer","Advanced Gastric Cancer","Advanced Hepatocellular Carcinoma","Advanced Pancreatic Cancer"],"intervention_entry_count":1,"nct_id":"NCT05028933","overall_status":"UNKNOWN","phases":["PHASE1"],"source_record_index":49,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Role of Circulating Tumour DNA Testing in Assessing for Alterations of Primary Anti-EGFR Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients","conditions":["Colorectal Cancer"],"intervention_entry_count":0,"nct_id":"NCT05051592","overall_status":"UNKNOWN","phases":[],"source_record_index":5,"source_ref":"ctg-page-004","study_type":"OBSERVATIONAL"},{"brief_title":"A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours","conditions":["Bladder Cancer","Castration-resistant Prostate Cancer","Cervical Cancer","Endometrial Cancer","Gastric Cancer","Hepatocellular Carcinoma (HCC)","Melanoma","Non-small Cell Lung Cancer (NSCLC)","Oesophageal Cancer","Ovarian Cancer","Pancreatic Cancer","RAS Wild Type Colorectal Cancer","Squamous Cell Cancer of the Head and Neck","Triple Negative Breast Cancer"],"intervention_entry_count":2,"nct_id":"NCT05057013","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":99,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)","conditions":["Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT05064059","overall_status":"COMPLETED","phases":["PHASE3"],"source_record_index":27,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT05089266","overall_status":"UNKNOWN","phases":["PHASE1"],"source_record_index":13,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Comparison Between Tailored Surgery Versus Total Mesorectal Excision in ycT2-3N0M0","conditions":["Rectal Cancer, Adenocarcinoma"],"intervention_entry_count":2,"nct_id":"NCT05164315","overall_status":"TERMINATED","phases":["NA"],"source_record_index":97,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Primary Tumour Response to Induction Chemotherapy in Synchronously Metastasized Colorectal Cancer","conditions":["Gastrointestinal Neoplasm"],"intervention_entry_count":0,"nct_id":"NCT05172635","overall_status":"COMPLETED","phases":[],"source_record_index":15,"source_ref":"ctg-page-001","study_type":"OBSERVATIONAL"},{"brief_title":"Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors","conditions":["Clear Cell Renal Cell Carcinoma (ccRCC)","Colorectal Cancer (CRC)","Drug-Drug Interaction (DDI)","Head and Neck Squamous Cell Carcinoma (HNSCC)","Hepatocellular Carcinoma (HCC)","Metastatic Castration-Resistant Prostate Cancer (mCRPC)","Non-Clear Cell Renal Cell Carcinoma (nccRCC)","Non-small Cell Lung Cancer (NSCLC)","Renal Cell Carcinoma (RCC)","Solid Tumor","Urothelial Carcinoma (UC)"],"intervention_entry_count":9,"nct_id":"NCT05176483","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":71,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Endoscopic Optical Coherence Tomography for Screening and Diagnosis of Colorectal Precancerous and Malignant Polyps","conditions":["Cancer of the Colon","Cancer of the Rectum","Colon Cancer","Malignant Polyp","Precancerous Polyp","Rectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT05179837","overall_status":"TERMINATED","phases":["NA"],"source_record_index":34,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"A Clinical Trial of TAA06 Injection in Advanced Solid Tumors","conditions":["Malignant Melanoma, Lung Cancer, or Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT05190185","overall_status":"UNKNOWN","phases":["PHASE1"],"source_record_index":42,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"The Accuracy of Human Endoscopic Detection of Submucosal Invasive Cancer in Colorectal Polyps","conditions":["Colorectal Polyp"],"intervention_entry_count":0,"nct_id":"NCT05191095","overall_status":"COMPLETED","phases":[],"source_record_index":16,"source_ref":"ctg-page-002","study_type":"OBSERVATIONAL"},{"brief_title":"NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer","conditions":["Refractory Metastatic Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT05213195","overall_status":"UNKNOWN","phases":["PHASE1"],"source_record_index":84,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases","conditions":["Colorectal Cancer","Metastatic Liver Cancer"],"intervention_entry_count":1,"nct_id":"NCT05240950","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":67,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.","conditions":["Colorectal Cancer Metastatic"],"intervention_entry_count":2,"nct_id":"NCT05243862","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":54,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer","conditions":["Locally Advanced Rectal Carcinoma","Stage III Rectal Cancer AJCC v8","Stage IIIA Rectal Cancer AJCC v8","Stage IIIB Rectal Cancer AJCC v8","Stage IIIC Rectal Cancer AJCC v8"],"intervention_entry_count":2,"nct_id":"NCT05245786","overall_status":"ACTIVE_NOT_RECRUITING","phases":["EARLY_PHASE1"],"source_record_index":2,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer","conditions":["Refractory Metastatic Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT05248048","overall_status":"UNKNOWN","phases":["EARLY_PHASE1"],"source_record_index":22,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors","conditions":["Castration-resistant Prostate Cancer","Colorectal Cancer","Cutaneous Squamous Cell Carcinoma","Hepatocellular Carcinoma","Non-Small Cell Lung Cancer","Ovarian Cancer"],"intervention_entry_count":2,"nct_id":"NCT05256381","overall_status":"TERMINATED","phases":["PHASE2"],"source_record_index":25,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT05278728","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":34,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Safety and Tolerability of 212Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors","conditions":["Breast Cancer","Cervical Cancer","Colon Cancer","Glioblastoma","NSCLC","Nonsmall Cell Lung Cancer","mCRPC (Metastatic Castration-resistant Prostate Cancer)"],"intervention_entry_count":1,"nct_id":"NCT05283330","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":22,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms","conditions":["Advanced Solid Tumors","Colorectal (Colon or Rectal) Cancer","Digestive System Neoplasms","Pancreatic Cancer Resectable"],"intervention_entry_count":1,"nct_id":"NCT05287165","overall_status":"UNKNOWN","phases":["EARLY_PHASE1"],"source_record_index":62,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC","conditions":["Rectal Neoplasms"],"intervention_entry_count":4,"nct_id":"NCT05307198","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":95,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT05310643","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":24,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"LYL273 for Patients With Relapsed or Refractory mCRC","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT05319314","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":36,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT05350501","overall_status":"TERMINATED","phases":["PHASE2"],"source_record_index":33,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study","conditions":["Metastatic Colon Adenocarcinoma","Metastatic Colorectal Adenocarcinoma","Metastatic Rectal Adenocarcinoma","Stage IV Colon Cancer AJCC V8","Stage IV Colorectal Cancer AJCC V8","Stage IV Rectal Cancer AJCC V8"],"intervention_entry_count":3,"nct_id":"NCT05356897","overall_status":"WITHDRAWN","phases":["PHASE2"],"source_record_index":12,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours","conditions":["Advanced Solid Tumor","Bladder Carcinoma","Breast Cancer","Colorectal Cancer","FGFR3","FGFR3 Overexpression","FGFR3 Protein Overexpression","FGFR3 Receptor","Gastric Cancer","Head and Neck Squamous Cell Carcinoma","Liver Cancer","Lung Cancer","Ovarian Cancer","Susceptible FGFR3 Genetic Alterations"],"intervention_entry_count":3,"nct_id":"NCT05363605","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"source_record_index":87,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors","conditions":["Breast Cancer","Colorectal Cancer","GastroEsophageal Cancer","Head and Neck Cancer","Non Small Cell Lung Cancer","Ovarian Cancer","Pancreatic Cancer"],"intervention_entry_count":12,"nct_id":"NCT05395052","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":52,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Tailoring Treatment in Colorectal Cancer","conditions":["Colorectal Neoplasms"],"intervention_entry_count":1,"nct_id":"NCT05401318","overall_status":"RECRUITING","phases":[],"source_record_index":93,"source_ref":"ctg-page-005","study_type":"OBSERVATIONAL"},{"brief_title":"Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome","conditions":["Colorectal Carcinoma","Colorectal Neoplasm","Lynch Syndrome"],"intervention_entry_count":7,"nct_id":"NCT05419011","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"source_record_index":85,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer","conditions":["Cholangiocarcinoma","Colorectal Cancer","Colorectal Neoplasms","Mesothelioma","Mesothelioma Peritoneum","Mesothelioma, Malignant","Mesotheliomas Pleural","Non Small Cell Lung Cancer","Ovarian Adenocarcinoma","Ovarian Cancer","Ovarian Neoplasms","Ovarian Serous Adenocarcinoma","Pancreatic Adenocarcinoma","Pancreatic Cancer","Pancreatic Neoplasms","TNBC - Triple-Negative Breast Cancer","Triple Negative Breast Cancer"],"intervention_entry_count":3,"nct_id":"NCT05451849","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"source_record_index":73,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"A Phase I Clinical Trial of Bevacizumab Injection","conditions":["Cervical Cancer","Glioblastoma","Lung Cancer","Ovarian Cancer","Rectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT05476341","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":46,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Evaluating Novel Therapies in ctDNA Positive GI Cancers","conditions":["Adenocarcinoma of Biliary Tract","Colon Adenocarcinoma","Gallbladder Adenocarcinoma","Gastric Adenocarcinoma","Hepatocellular Carcinoma","Pancreatic Adenocarcinoma","Rectal Adenocarcinoma"],"intervention_entry_count":2,"nct_id":"NCT05482516","overall_status":"RECRUITING","phases":["PHASE3"],"source_record_index":60,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","conditions":["Biliary Tract Cancer","Colorectal Cancer","Endometrial Cancer","Gastric Cancer","Metastatic Castration-resistant Prostate Cancer","Ovarian Cancer","Urothelial Cancer"],"intervention_entry_count":9,"nct_id":"NCT05489211","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":76,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer","conditions":["Colorectal Cancer","Melanoma (Skin)","Myxoid Liposarcoma","Non-Small Cell Lung Cancer","Osteosarcoma","Sarcoma","Synovial Sarcoma","Triple-Negative Breast Cancer"],"intervention_entry_count":3,"nct_id":"NCT05492682","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":99,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Application of ICG in Lymph Node Dissection During Radical Resection of Rectal Cancer With Preserved Autonomic Nerves Around LCA and IMA","conditions":["Indocyanine Green"],"intervention_entry_count":2,"nct_id":"NCT05517681","overall_status":"COMPLETED","phases":["NA"],"source_record_index":3,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer","conditions":["Adaptive Treatment","Locally Advanced Rectal Carcinoma","Neoadjuvant Treatment","Radiotherapy"],"intervention_entry_count":2,"nct_id":"NCT05524012","overall_status":"ACTIVE_NOT_RECRUITING","phases":[],"source_record_index":54,"source_ref":"ctg-page-002","study_type":"OBSERVATIONAL"},{"brief_title":"Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors","conditions":["Colon Cancer","Esophageal Cancer","Gastric Cancer","Pancreatic Cancer","Rectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT05538195","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"source_record_index":5,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors","conditions":["Anal Cancer","Anal Neoplasm","Androgen-Independent Prostatic Cancer","Androgen-Insensitive Prostatic Cancer","Androgen-Resistant Prostatic Cancer","Carcinoma, Squamous Cell of Head and Neck","Castration-Resistant Prostatic Cancer","Head and Neck Squamous Cell Carcinoma","Hormone Refractory Prostatic Cancer","Laryngeal Squamous Cell Carcinoma","Malignant Melanoma","Melanoma","Non-small Cell Carcinoma","Non-small Cell Lung Cancer","Oral Squamous Cell Carcinoma","Small Cell Carcinoma","Small-cell Lung Cancer"],"intervention_entry_count":5,"nct_id":"NCT05551117","overall_status":"TERMINATED","phases":["PHASE2"],"source_record_index":69,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas","conditions":["Burkitt Lymphoma","Colorectal Cancer","Cutaneous Squamous Cell Carcinoma","Diffuse Large B Cell Lymphoma","Esophageal Cancer","Follicular Lymphoma","Head and Neck Squamous Cell Carcinoma","Hodgkin Lymphoma","Hormone Receptor Positive Breast Carcinoma","Non Small Cell Lung Cancer","Small Bowel Cancer","Triple Negative Breast Cancer"],"intervention_entry_count":2,"nct_id":"NCT05565417","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":62,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors","conditions":["Abdominal Neoplasm","Advanced Solid Tumors","Carcinoma","Colorectal Cancer","Epstein-Barr Virus Infections","Genital Neoplasm, Female","Lung Neoplasm","NSCLC (Non-small Cell Lung Cancer)","Neoplasms","Neoplasms by Site","Papillomavirus Infection","Urogenital Neoplasms","Vulvar Diseases","Vulvar Neoplasms"],"intervention_entry_count":3,"nct_id":"NCT05592626","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":90,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study","conditions":["Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT05600309","overall_status":"COMPLETED","phases":["PHASE3"],"source_record_index":30,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours","conditions":["Colorectal Cancer","Ewing Sarcoma","Gastric Cancer","NTSR1 Expressing Solid Tumours","Neuroendocrine Differentiated (NED) Prostate Cancer","Pancreatic Ductal Adenocarcinoma (PDAC)","Squamous Cell Carcinoma of Head and Neck"],"intervention_entry_count":2,"nct_id":"NCT05605522","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":6,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT05608044","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"source_record_index":45,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers","conditions":["Anal Cancer","Cervical Cancer","HPV Positive Oropharyngeal Squamous Cell Carcinoma","HPV-Associated Cervical Carcinoma","HPV-Related Adenocarcinoma","HPV-Related Adenosquamous Carcinoma","HPV-Related Anal Squamous Cell Carcinoma","HPV-Related Carcinoma","HPV-Related Endocervical Adenocarcinoma","HPV-Related Malignancy","HPV-Related Penile Squamous Cell Carcinoma","HPV-Related Squamous Cell Carcinoma","HPV-Related Vulvar Squamous Cell Carcinoma","Oropharynx Cancer","Penile Cancer","Vaginal Cancer","Vulvar Cancer"],"intervention_entry_count":2,"nct_id":"NCT05639972","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":22,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors","conditions":["CRC (Colorectal Cancer)","HCC - Hepatocellular Carcinoma","MSI-H Cancer","NSCLC Non-small Cell Lung Cancer","Pancreatic Adenocarcinoma","Solid Tumor, Adult","Squamous Cell Cancer of the Head and Neck","UC (Urothelial Cancer)"],"intervention_entry_count":2,"nct_id":"NCT05651022","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":10,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy","conditions":["Advanced Colorectal Adenocarcinoma","Advanced Microsatellite Stable Colorectal Carcinoma","Metastatic Colorectal Adenocarcinoma","Metastatic Microsatellite Stable Colorectal Carcinoma","Stage III Colorectal Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8"],"intervention_entry_count":5,"nct_id":"NCT05672316","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":24,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine","conditions":["Human Papillomavirus Infection"],"intervention_entry_count":2,"nct_id":"NCT05680454","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":17,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers","conditions":["Anal Cancer","Cervical Cancer","HPV Positive Oropharyngeal Squamous Cell Carcinoma","HPV Positive Rectal Squamous Cell Carcinoma","HPV-Associated Vaginal Adenocarcinoma","HPV-Related Adenocarcinoma","HPV-Related Adenosquamous Carcinoma","HPV-Related Anal Squamous Cell Carcinoma","HPV-Related Carcinoma","HPV-Related Cervical Carcinoma","HPV-Related Endocervical Adenocarcinoma","HPV-Related Malignancy","HPV-Related Penile Squamous Cell Carcinoma","HPV-Related Squamous Cell Carcinoma","HPV-Related Vulvar Squamous Cell Carcinoma","Metastatic Cancer","Oropharynx Cancer","Penile Cancer","Throat Cancer","Vaginal Cancer","Vulva Cancer"],"intervention_entry_count":2,"nct_id":"NCT05686226","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":38,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine","conditions":["Human Papilloma Virus Infection"],"intervention_entry_count":2,"nct_id":"NCT05694728","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":92,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT05694936","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"source_record_index":66,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of ASP1002 in Adults for Treatment of Solid Tumors","conditions":["Advanced Solid Tumors"],"intervention_entry_count":12,"nct_id":"NCT05719558","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":80,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection","conditions":["Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer"],"intervention_entry_count":7,"nct_id":"NCT05720559","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":49,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors","conditions":["Colorectal Cancer","KRAS G12A","KRAS G12C","KRAS G12D","KRAS G12R","KRAS G12S","KRAS G12V","KRAS G13D","NRAS G12C","NRAS G12D","NRAS G12R","NRAS G12S","NRAS G12V","Pancreatic Ductal Adenocarcinoma"],"intervention_entry_count":1,"nct_id":"NCT05726864","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":76,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer","conditions":["CCR5","Colorectal Cancer","Metastatic","Microsatellite Stable"],"intervention_entry_count":4,"nct_id":"NCT05730673","overall_status":"WITHDRAWN","phases":["PHASE2"],"source_record_index":45,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Immunotherapy in Patients With Early dMMR Rectal Cancer","conditions":["Cancer of Rectum"],"intervention_entry_count":2,"nct_id":"NCT05732389","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":84,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression","conditions":["CRC","Cancer","Colorectal Adenocarcinoma","Colorectal Cancer","Colorectal Cancer Metastatic","Colorectal Neoplasms","NSCLC","NSCLC, Recurrent","Non Small Cell Lung Cancer","Non Small Cell Lung Cancer Recurrent","Non-Small Cell Squamous Lung Cancer","Pancreas Cancer","Pancreatic Cancer","Pancreatic Neoplasms","Solid Tumor","Solid Tumor, Adult"],"intervention_entry_count":2,"nct_id":"NCT05736731","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":10,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer","conditions":["Colorectal Cancer Metastatic"],"intervention_entry_count":6,"nct_id":"NCT05759728","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":90,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Study of RO7515629 in Participants With HLA-G Positive Solid Tumors","conditions":["Colorectal Cancer","Non-small Cell Lung Cancer","Ovarian Neoplasms","Pancreatic Adenocarcinoma","Renal Cell Carcinoma"],"intervention_entry_count":2,"nct_id":"NCT05769959","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":25,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases","conditions":["For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method"],"intervention_entry_count":6,"nct_id":"NCT05774964","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":8,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases","conditions":["Colorectal Cancer","Liver Metastasis Colon Cancer"],"intervention_entry_count":1,"nct_id":"NCT05775146","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":56,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations","conditions":["Colorectal Neoplasms","Gallbladder Neoplasms","Haematological Malignancy","Lung Neoplasm","Ovarian Neoplasms","Pancreatic Neoplasm","Prostatic Neoplasm","Salivary Gland Neoplasm","Skin Neoplasm","Solid Tumour","Urinary Bladder Neoplasm"],"intervention_entry_count":2,"nct_id":"NCT05786716","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"source_record_index":20,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC(AK104-IIT-13)","conditions":["Locally Advanced Rectal Cancer"],"intervention_entry_count":4,"nct_id":"NCT05794750","overall_status":"NOT_YET_RECRUITING","phases":["PHASE2"],"source_record_index":19,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers","conditions":["Colo-rectal Cancer","Gastric Cancer","Non-small Cell Lung Cancer"],"intervention_entry_count":2,"nct_id":"NCT05800418","overall_status":"COMPLETED","phases":["PHASE1"],"source_record_index":39,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers","conditions":["Metastatic Colorectal Carcinoma","Metastatic Malignant Solid Neoplasm","Stage IV Colorectal Cancer AJCC v8","Unresectable Colorectal Carcinoma","Unresectable Malignant Solid Neoplasm"],"intervention_entry_count":7,"nct_id":"NCT05803382","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":53,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"PRE-ISPY Phase I/II Oncology Platform Program","conditions":["Adenocarcinoma","Adenocarcinoma of Colon","Colo-rectal Cancer","Colon Cancer","Colonic Neoplasms","Colorectal Neoplasms","ER Positive Breast Cancer","Estrogen Receptor Positive Tumor","HER-2 Protein Overexpression","HER2 Low Breast Cancer","HER2 Low Breast Carcinoma","HER2 Mutation-Related Tumors","HER2-negative Breast Cancer","HER2-positive Breast Cancer","HER2-positive Metastatic Breast Cancer","HR Positive","Hormone Receptor Negative Breast Carcinoma","Hormone Receptor-positive Breast Cancer","Metastatic","Metastatic Breast Cancer","Metastatic Cancer","Minimal Residual Disease","Neoplasm, Residual","PR-positive Breast Cancer","Progesterone Receptor-positive Breast Cancer","Rectal Cancer","Rectal Neoplasms","Solid Carcinoma","Solid Tumor","Solid Tumor, Adult","Triple Negative Breast Cancer","ctDNA Monitoring"],"intervention_entry_count":5,"nct_id":"NCT05868226","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":50,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"XKDCT080 in GCC-positive Recurrent or Refractory Solid Tumors With Single Center, Single Arm, and Dose Escalation","conditions":["Colon Cancer"],"intervention_entry_count":1,"nct_id":"NCT05875402","overall_status":"UNKNOWN","phases":["NA"],"source_record_index":8,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Circulating Tumor DNA Methylation Guided Postoperative Follow-up Strategy for Non-metastatic Colorectal Cancer","conditions":["Circulating Tumor DNA Methylation","Non-metastatic Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT05904665","overall_status":"RECRUITING","phases":["NA"],"source_record_index":5,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer","conditions":["Colon Neoplasm"],"intervention_entry_count":5,"nct_id":"NCT05914389","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":51,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Study of OB-002 in Patients With Refractory Metastatic Cancer","conditions":["Metastatic Breast Cancer","Metastatic Cancer","Metastatic Colorectal Cancer","Metastatic Gastric Cancer","Metastatic Pancreatic Cancer","Metastatic Urothelial Carcinoma"],"intervention_entry_count":1,"nct_id":"NCT05940844","overall_status":"WITHDRAWN","phases":["PHASE1"],"source_record_index":37,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Adenocarcinoma"],"intervention_entry_count":1,"nct_id":"NCT05942768","overall_status":"COMPLETED","phases":[],"source_record_index":69,"source_ref":"ctg-page-002","study_type":"OBSERVATIONAL"},{"brief_title":"Test of CD47-SIRPα Inhibitors on the Immune Microenvironment Colon Cancer","conditions":["Cancer of the Colon"],"intervention_entry_count":1,"nct_id":"NCT05955196","overall_status":"RECRUITING","phases":[],"source_record_index":89,"source_ref":"ctg-page-003","study_type":"OBSERVATIONAL"},{"brief_title":"A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7","conditions":["Metastatic Malignant Neoplasm"],"intervention_entry_count":1,"nct_id":"NCT05958199","overall_status":"SUSPENDED","phases":["PHASE1"],"source_record_index":4,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab","conditions":["Colorectal Cancer","Peritoneal Metastases"],"intervention_entry_count":3,"nct_id":"NCT06003998","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":6,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors","conditions":["Breast Cancer","Colon Cancer","Esophageal Cancer","Gastric Cancer","Lung Cancer","Pancreas Cancer","Rectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT06006390","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"source_record_index":88,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.","conditions":["Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT06010901","overall_status":"UNKNOWN","phases":["PHASE1"],"source_record_index":19,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT06011330","overall_status":"COMPLETED","phases":[],"source_record_index":18,"source_ref":"ctg-page-002","study_type":"OBSERVATIONAL"},{"brief_title":"LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients","conditions":["Metastatic Microsatellite-stable Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT06012734","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":7,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors","conditions":["Bile Duct Cancer","Breast Cancer","Colorectal Cancer","Esophagus Cancer","Gastric Cancer","Non-small Cell Lung Cancer","Pancreas Cancer"],"intervention_entry_count":1,"nct_id":"NCT06043466","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":23,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","conditions":["Brain Metastases, Adult","Cervical Cancer","Colorectal Cancer","Diffuse Astrocytoma, IDH-Mutant","Esophageal Cancer","Esophageal Squamous Cell Carcinoma","Gastric Cancer","Gastroesophageal Junction Adenocarcinoma","Glioblastoma, IDH-wildtype","Head and Neck Squamous Cell Carcinoma","Melanoma","Merkel Cell Carcinoma","Microsatellite Instability-High Colorectal Cancer","Microsatellite Instability-High Solid Malignant Tumor","Mismatch Repair Deficient Colorectal Cancer","Mismatch Repair Deficient Solid Malignant Tumor","Non-small Cell Lung Cancer","Renal Cell Carcinoma","Small Cell Lung Cancer","Squamous Cell Carcinoma","Urothelial Carcinoma"],"intervention_entry_count":9,"nct_id":"NCT06047379","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":79,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy","conditions":["Colorectal Cancer","Gastric Cancer","Neuroendocrine Tumors"],"intervention_entry_count":1,"nct_id":"NCT06055439","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":9,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent","conditions":["Advanced Solid Tumor","Gastric Cancer","Hepatocellular Carcinoma","Metastatic Colorectal Cancer","Solid Tumor","Solid Tumor, Adult"],"intervention_entry_count":1,"nct_id":"NCT06075849","overall_status":"UNKNOWN","phases":["PHASE1"],"source_record_index":36,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Crisaborole Ointment for Skin Toxicity Induced by Cetuximab","conditions":["Cetuximab","Metastatic Colorectal Cancer","Skin Toxicity"],"intervention_entry_count":2,"nct_id":"NCT06118047","overall_status":"UNKNOWN","phases":["PHASE2"],"source_record_index":47,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors","conditions":["Breast Cancer","Cholangiocarcinoma","Colon Cancer","Esophagus Cancer","Gastric Cancer","Lung Cancer","Pancreas Cancer","Rectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT06126406","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":42,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer","conditions":["Breast Carcinoma","Colorectal Carcinoma"],"intervention_entry_count":8,"nct_id":"NCT06130826","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":89,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)","conditions":["Malignant Solid Neoplasm"],"intervention_entry_count":6,"nct_id":"NCT06136897","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"source_record_index":41,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours","conditions":["Advanced Solid Tumor","Gastric Cancer","Head and Neck Squamous Cell Carcinoma","Metastatic Colorectal Carcinoma","Non-small Cell Lung Cancer","Pancreatic Ductal Adenocarcinoma","Renal Cell Carcinoma"],"intervention_entry_count":3,"nct_id":"NCT06147037","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"source_record_index":24,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer","conditions":["MSI","dMMR Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT06152523","overall_status":"WITHDRAWN","phases":["PHASE2"],"source_record_index":43,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors","conditions":["Biliary Tract Cancer","Breast Cancer","Cervical Cancer","Colon Cancer","Endometrial Cancer","Esophageal Cancer","Gastric Cancer","GastroEsophageal Cancer","Head and Neck Cancer","Hepatocellular Cancer","Non-small Cell Lung Cancer","Pancreatic Cancer","Prostate Cancer","Rectal Cancer","Renal Cancer","Thyroid Cancer"],"intervention_entry_count":1,"nct_id":"NCT06239194","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":83,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer","conditions":["Locally Advanced Colorectal Carcinoma","Recurrent Colorectal Carcinoma","Stage III Colorectal Cancer"],"intervention_entry_count":7,"nct_id":"NCT06307548","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":91,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Diagnostic Value of Endocytoscopy for Colorectal Lesions","conditions":["Colorectal Neoplasms"],"intervention_entry_count":1,"nct_id":"NCT06324097","overall_status":"COMPLETED","phases":[],"source_record_index":68,"source_ref":"ctg-page-002","study_type":"OBSERVATIONAL"},{"brief_title":"Real-time Artificial Intelligence-based Endocytoscopic Diagnosis of Colorectal Neoplasms","conditions":["Colorectal Neoplasms"],"intervention_entry_count":1,"nct_id":"NCT06335654","overall_status":"COMPLETED","phases":[],"source_record_index":53,"source_ref":"ctg-page-002","study_type":"OBSERVATIONAL"},{"brief_title":"A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer","conditions":["Advanced Solid Tumours","Carcinoma, Non-Small-Cell Lung","Carcinoma, Renal Cell (Clear Cell Only)","Colorectal Neoplasms","Esophageal Neoplasms","Ovarian Neoplasms","Pancreatic Neoplasms","Squamous Cell Carcinoma of Head and Neck","Stomach Neoplasms (Excluding Gastrointestinal Stromal Tumors)","Triple Negative Breast Neoplasms","Uterine Cervical Neoplasms"],"intervention_entry_count":1,"nct_id":"NCT06380816","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":78,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Gender Differences in Robotic Surgery for Rectal Cancer: a Retrospective Study","conditions":["Complication,Postoperative","Gender","Rectal Cancer","Surgery-Complications"],"intervention_entry_count":1,"nct_id":"NCT06391060","overall_status":"COMPLETED","phases":[],"source_record_index":48,"source_ref":"ctg-page-005","study_type":"OBSERVATIONAL"},{"brief_title":"Multimodal Imaging in Rectal Cancer & Pancreatic Cancer","conditions":["Pancreatic Cancer","Rectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT06395337","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"source_record_index":4,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Clinical Trial of TB511 in Advanced Solid Tumors","conditions":["Colorectal Cancer","Hepatocellular Carcinoma","NSCLC","Prostate Cancer"],"intervention_entry_count":2,"nct_id":"NCT06400160","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":27,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of Sofe-M in Participants With Selected Advanced Solid Tumors","conditions":["Carcinoma, Non-Small-Cell Lung","Colorectal Neoplasms","Endometrial Neoplasms","Ovarian Neoplasms","Pancreatic Neoplasm","Triple Negative Breast Neoplasms","Uterine Cervical Neoplasms"],"intervention_entry_count":5,"nct_id":"NCT06400472","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":48,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Study and Modulation of Immune Responses in Primary and Metastatic Colon Cancers","conditions":["Colon Cancer","Peritoneal Carcinoma"],"intervention_entry_count":1,"nct_id":"NCT06435689","overall_status":"NOT_YET_RECRUITING","phases":[],"source_record_index":67,"source_ref":"ctg-page-001","study_type":"OBSERVATIONAL"},{"brief_title":"Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA","conditions":["Colorectal Cancer Metastatic"],"intervention_entry_count":1,"nct_id":"NCT06440902","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":61,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination","conditions":["Advanced or Metastatic Solid Tumors","Colorectal Cancer","Melanoma","Non-Small Cell Lung Cancer","Urothelial Cancer"],"intervention_entry_count":3,"nct_id":"NCT06448364","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":54,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Immunologic Changes and Recovery-related Factors in Elderly Colon Cancer Patients","conditions":["Aged","Cancer of Colon","Interleukins"],"intervention_entry_count":1,"nct_id":"NCT06454071","overall_status":"COMPLETED","phases":["PHASE2"],"source_record_index":56,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of PHN-010 in Patients With Advanced Solid Tumors","conditions":["Advanced Cancer","Advanced Solid Tumor","Cervical Cancer","Colon Cancer","Endometrial Cancer","Lung Cancer","Ovarian Cancer"],"intervention_entry_count":1,"nct_id":"NCT06457997","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":29,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males","conditions":["AIN1","AIN2","AIN3","Anal Cancer","Genital Wart","HPV-Related Carcinoma","PIN-1","PIN2","PIN3","Penile Cancer"],"intervention_entry_count":2,"nct_id":"NCT06465914","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"source_record_index":50,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations","conditions":["Colorectal Cancer","Pancreatic Cancer"],"intervention_entry_count":1,"nct_id":"NCT06487377","overall_status":"WITHDRAWN","phases":["PHASE1"],"source_record_index":2,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"The Sagittarius Trial","conditions":["Colon Cancer Stage II","Colon Cancer Stage III"],"intervention_entry_count":11,"nct_id":"NCT06490536","overall_status":"RECRUITING","phases":["PHASE3"],"source_record_index":6,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Immunosurveillance for Metastatic Colorectal Cancer","conditions":["Monitoring, Immunologic"],"intervention_entry_count":3,"nct_id":"NCT06509880","overall_status":"COMPLETED","phases":["PHASE2","PHASE3"],"source_record_index":30,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer","conditions":["Colon Cancer","Colorectal Cancer","Rectum Cancer"],"intervention_entry_count":5,"nct_id":"NCT06530303","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":8,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.","conditions":["Colorectal Carcinoma","Neoplasms","Non-small-cell Lung Cancer","Ovarian Carcinoma","Renal Cell Carcinoma","Squamous Cell Carcinoma of the Head and Neck"],"intervention_entry_count":3,"nct_id":"NCT06546553","overall_status":"TERMINATED","phases":["PHASE1"],"source_record_index":67,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer","conditions":["Locally Advanced Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT06550453","overall_status":"UNKNOWN","phases":["PHASE4"],"source_record_index":82,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Multi-mode Ablation and Molecular Imaging Multi-omics Study for Digestive-Origin Malignant Liver Tumors","conditions":["Colorectal Cancer Liver Metastases","Primary Liver Cancer"],"intervention_entry_count":2,"nct_id":"NCT06588569","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"source_record_index":47,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM","conditions":["Colorectal Cancer Liver Metastasis"],"intervention_entry_count":2,"nct_id":"NCT06590259","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":59,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study","conditions":["Colon Cancer","Colon Cancer (Stage II &Amp;Amp;Amp; III)"],"intervention_entry_count":2,"nct_id":"NCT06609551","overall_status":"RECRUITING","phases":["PHASE3"],"source_record_index":19,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer","conditions":["Metastatic Microsatellite Stable Colorectal Carcinoma","Refractory Microsatellite Stable Colorectal Carcinoma","Stage IV Colorectal Cancer AJCC v8"],"intervention_entry_count":5,"nct_id":"NCT06654037","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":55,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"To Explore the Effect of Huaier Granule on the Negative Conversion Rate After the CEA Level Increases Again After Colorectal Cancer Surgery","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT06665334","overall_status":"NOT_YET_RECRUITING","phases":["PHASE4"],"source_record_index":18,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors","conditions":["Breast Cancer","Colorectal Cancer","Endometrial Cancer","Esophageal Cancer","Gastric Cancer","Gastroesophageal Cancer","HER-2 Protein Overexpression","Non-small Cell Lung Cancer","Ovarian Cancer","Pancreatic Cancer","Salivary Gland Cancer","Urothelial Carcinoma"],"intervention_entry_count":1,"nct_id":"NCT06695845","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":81,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Adenocarcinoma","Stage III Colorectal Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Unresectable Colorectal Adenocarcinoma"],"intervention_entry_count":10,"nct_id":"NCT06696768","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":70,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER)","conditions":["Metastatic Colorectal Cancer (mCRC)"],"intervention_entry_count":2,"nct_id":"NCT06699836","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"source_record_index":71,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Target-specific immunoPET Imaging of Digestive System Carcinoma","conditions":["Appendix Cancer","Bile Duct Carcinoma","Colon Cancer","Digestive Cancer","Digestive System Cancer","Digestive System Carcinoma","Digestive System Neoplasm","Esophagus Cancer","Gallbladder Carcinoma","Liver Cancer","Malignancy","Pancreatic Cancer","Rectum Cancer","Small Intestine Cancer","Stomach Cancer"],"intervention_entry_count":10,"nct_id":"NCT06715839","overall_status":"RECRUITING","phases":["NA"],"source_record_index":32,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","conditions":["Advanced Solid Tumors","HER2 Mutation"],"intervention_entry_count":1,"nct_id":"NCT06760819","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":72,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Ga-68-FAPI-46 PET for CRC Recurrence Detection in Elevated CEA","conditions":["Colorectal Cancer Recurrent"],"intervention_entry_count":1,"nct_id":"NCT06769828","overall_status":"RECRUITING","phases":["NA"],"source_record_index":55,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT06776757","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":93,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer","conditions":["Colorectal Cancer Stage IV","Metastatic Colorectal Cancer (CRC)","Microsatellite Stable (MSS) Colorectal Cancer (CRC)"],"intervention_entry_count":5,"nct_id":"NCT06784947","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"source_record_index":9,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Real-time AI-assisted Endocyroscopy for the Diagnosis of Colorectal Lesions","conditions":["Colorectal Neoplasms","Colorectal Polyp"],"intervention_entry_count":1,"nct_id":"NCT06791395","overall_status":"COMPLETED","phases":[],"source_record_index":6,"source_ref":"ctg-page-005","study_type":"OBSERVATIONAL"},{"brief_title":"Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors","conditions":["Colorectal Cancer","Metastatic Cancer","Pancreatic Cancer","Stomach Cancer"],"intervention_entry_count":1,"nct_id":"NCT06821048","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":44,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":4,"nct_id":"NCT06856837","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":31,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"Efficacy and Safety of Trifluridine/Tipiracil (TAS-102) Combined With Bevacizumab and Serplulimab in Patients With Metastatic Colorectal Cancer Undergoing Cytoreductive Surgery: A Single-Arm, Single-Center Clinical Study","conditions":["Colorectal Cancer (CRC)"],"intervention_entry_count":1,"nct_id":"NCT06882915","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1"],"source_record_index":60,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Diagnosis, Treatment, and Prevention of Colorectal Cancer Amid Abnormal Lipid Metabolism","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT06886022","overall_status":"ACTIVE_NOT_RECRUITING","phases":[],"source_record_index":36,"source_ref":"ctg-page-005","study_type":"OBSERVATIONAL"},{"brief_title":"5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer (CRC)"],"intervention_entry_count":4,"nct_id":"NCT06887218","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":29,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors","conditions":["Biliary Tract Cancer","Colorectal Carcinoma","Gastric Cancer, Metastatic","Multiple Cancer","Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)"],"intervention_entry_count":2,"nct_id":"NCT06937567","overall_status":"RECRUITING","phases":["EARLY_PHASE1"],"source_record_index":88,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Exploratory Clinical Study of Claudin18.2-Targeted CAR-DC and CAR-T Therapy in Advanced Colorectal Cancer","conditions":["Colorectal Neoplasia"],"intervention_entry_count":2,"nct_id":"NCT06946615","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":78,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated With IBI363 Combination Therapy","conditions":["Immunotherapy"],"intervention_entry_count":1,"nct_id":"NCT06946745","overall_status":"RECRUITING","phases":[],"source_record_index":88,"source_ref":"ctg-page-004","study_type":"OBSERVATIONAL"},{"brief_title":"To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors","conditions":["Breast Cancer","Colorectal Cancer","Lung Cancer"],"intervention_entry_count":1,"nct_id":"NCT06948539","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1"],"source_record_index":68,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer","conditions":["Colorectal Cancer Metastatic","Colorectal Cancer Recurrent"],"intervention_entry_count":2,"nct_id":"NCT06992648","overall_status":"RECRUITING","phases":["PHASE3"],"source_record_index":94,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Improving Uptake of Surveillance in Colorectal Cancer Survivors Through Navigation and Web Education","conditions":["Stage I Colorectal Cancer AJCC v8","Stage II Colorectal Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8"],"intervention_entry_count":5,"nct_id":"NCT06995924","overall_status":"RECRUITING","phases":["NA"],"source_record_index":29,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"ctDNA Monitoring in Patients With HCC and mCRC","conditions":["Colorectal Cancer Metastatic","HCC - Hepatocellular Carcinoma"],"intervention_entry_count":3,"nct_id":"NCT07001085","overall_status":"RECRUITING","phases":["NA"],"source_record_index":34,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies)","conditions":["Colorectal Cancer Metastatic"],"intervention_entry_count":3,"nct_id":"NCT07007767","overall_status":"NOT_YET_RECRUITING","phases":["PHASE2"],"source_record_index":79,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors","conditions":["Cervical Adenocarcinoma","Colorectal Adenocarcinoma","Head and Neck Cancer","Hormone Receptor Positive Breast Adenocarcinoma","Non Small Cell Lung Cancer","Triple Negative Breast Cancer (TNBC)","Urothelial Carcinoma Bladder"],"intervention_entry_count":2,"nct_id":"NCT07020117","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":47,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","conditions":["Colorectal Cancer","G12D Mutated KRAS","Non Small Cell Lung Cancer","Pancreatic Ductal Adenocarcinoma","Solid Tumor, Adult"],"intervention_entry_count":5,"nct_id":"NCT07020221","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":57,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Colorectal Cancers :A Retrospective Study","conditions":["Colorectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT07024225","overall_status":"RECRUITING","phases":[],"source_record_index":60,"source_ref":"ctg-page-002","study_type":"OBSERVATIONAL"},{"brief_title":"Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer","conditions":["Lung Cancer","Lung Cancer Metastatic","Lung Diseases","Lung Inflammation","Lung Neoplasms"],"intervention_entry_count":6,"nct_id":"NCT07026110","overall_status":"RECRUITING","phases":["NA"],"source_record_index":98,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer","conditions":["RAS/BRAF Wild Type Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT07044908","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":65,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)","conditions":["Colo-rectal Cancer"],"intervention_entry_count":4,"nct_id":"NCT07058012","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":40,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Virtual Versus Dye-based Chromoendoscopy in Inflammatory Bowel Disease Surveillance Colonoscopy","conditions":["Colorectal Neoplasms","Crohns Disease","Inflammatory Bowel Disease (IBD)","Ulcerative Colitis (Disorder)"],"intervention_entry_count":2,"nct_id":"NCT07089771","overall_status":"NOT_YET_RECRUITING","phases":["NA"],"source_record_index":58,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of LY4257496 in Participants With Cancer (OMNIRAY)","conditions":["Breast Neoplasms","Colorectal Neoplasms","Endometrial Neoplasms","Esophageal Neoplasms","Neoplasm Metastasis","Prostate Neoplasm","Stomach Neoplasms"],"intervention_entry_count":3,"nct_id":"NCT07114601","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":2,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer","conditions":["Locally Advanced Rectal Cancer (LARC)","Mismatch Repair-Proficient (pMMR) Rectal Cancer","Non-metastatic Rectal Cancer"],"intervention_entry_count":1,"nct_id":"NCT07175636","overall_status":"NOT_YET_RECRUITING","phases":["PHASE2"],"source_record_index":10,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors","conditions":["Colon Cancer","Esophageal Cancer","Gastric Cancer","Lung Cancer","Pancreas Cancer","Rectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT07179692","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":57,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","conditions":["Castration-Resistant Prostate Cancer (CRPC)","Cervical Cancer","Colorectal Cancer","Endometrial Cancer","Esophageal Squamous Cell Carcinoma (ESCC)","Head &Amp; Neck Squamous Cell Carcinoma (HNSCC)","NSCLC (Non-small Cell Lung Cancer)","Ovarian Cancer","Small Cell Lung Cancer (SCLC )","TNBC, Triple Negative Breast Cancer"],"intervention_entry_count":1,"nct_id":"NCT07189871","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":1,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer","conditions":["Colon Cancer"],"intervention_entry_count":1,"nct_id":"NCT07224022","overall_status":"NOT_YET_RECRUITING","phases":["PHASE2"],"source_record_index":37,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors","conditions":["Neoplasms"],"intervention_entry_count":5,"nct_id":"NCT07277270","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":23,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors","conditions":["Advanced Breast Cancer","Colorectal Cancer","Metastatic Breast Cancer (HR+/ HER2-)","Metastatic Colorectal Adenocarcinoma","Triple Negative Breast Cancer"],"intervention_entry_count":7,"nct_id":"NCT07318805","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":61,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"COLONYVAQTM, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer","conditions":["Colorectal Cancer Metastatic","Colorectal Cancer Stage III","Colorectal Cancer Stage IV"],"intervention_entry_count":1,"nct_id":"NCT07328087","overall_status":"RECRUITING","phases":["EARLY_PHASE1"],"source_record_index":96,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors","conditions":["HER2-Expressing Solid Tumors"],"intervention_entry_count":2,"nct_id":"NCT07334119","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":77,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"ProLARS Trial: Prospective Longitudinal Follow-up of Low Anterior Resection Syndrome (LARS) and COREFO Score After Rectum Surgery in Patients Undergoing Upfront Surgery or Different Neo-adjuvant Treatment Regimens","conditions":["LARS - Low Anterior Resection Syndrome","Low Anterior Resection","Rectal Adenocarcinoma","Rectal Resection","Total Mesorectal Excision"],"intervention_entry_count":1,"nct_id":"NCT07339904","overall_status":"RECRUITING","phases":["NA"],"source_record_index":91,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"AI-Based Prediction of Liver Metastasis in Colorectal Cancer (A Retrospective Study)","conditions":["Colorectal Cancer Liver Metastases (CRLM)"],"intervention_entry_count":1,"nct_id":"NCT07399236","overall_status":"RECRUITING","phases":[],"source_record_index":21,"source_ref":"ctg-page-002","study_type":"OBSERVATIONAL"},{"brief_title":"Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment","conditions":["Colon Carcinoma","Colorectal Carcinoma","Rectal Carcinoma","Stage I Colon Cancer AJCC v8","Stage I Colorectal Cancer AJCC v8","Stage I Rectal Cancer AJCC v8","Stage II Colon Cancer AJCC v8","Stage II Colorectal Cancer AJCC v8","Stage II Rectal Cancer AJCC v8","Stage III Colon Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8","Stage III Rectal Cancer AJCC v8"],"intervention_entry_count":12,"nct_id":"NCT07405476","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":97,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Yttrium-90 Radioembolization Neoadjuvant Therapy With Immune Marker Profiling and Dosimetry for Potentially Resectable Patients With Colorectal Liver Metastases","conditions":["Colorectal Liver Metastases (CRCLM)","Unresectable Colorectal Liver Metastases"],"intervention_entry_count":1,"nct_id":"NCT07406126","overall_status":"NOT_YET_RECRUITING","phases":[],"source_record_index":87,"source_ref":"ctg-page-005","study_type":"OBSERVATIONAL"},{"brief_title":"Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.","conditions":["Colon Cancer Adenocarcinoma","Colon Cancer Metastatic","Colorectal Adenocarcinoma","Colorectal Cancer","Rectal Adenocarcinoma","Rectal Cancer, Adenocarcinoma","Rectal Cancer, Metastatic"],"intervention_entry_count":3,"nct_id":"NCT07407465","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":86,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","conditions":["Acute Myeloid Leukemia (AML)","Breast Cancer","Cancer","Colorectal Cancer (Locally Advanced or Metastatic)","Glioblastoma","Liver Cancer","Melanoma (Skin Cancer)","Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","Non Hodgkin Lymphoma","Non-Small Cell Lung Cancer (NSCLC)","Ovarian Cancer","Pancreatic Ductal Adenocarcinoma (PDAC)","Prostate Cancer - Recurrent"],"intervention_entry_count":2,"nct_id":"NCT07410494","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":82,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial (\"Chip-CRC Trial\")","conditions":["Carcinomatosis","Colorectal Cancer","Peritoneal Metastases"],"intervention_entry_count":4,"nct_id":"NCT07411599","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":99,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT07416552","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":2,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.","conditions":["Colon Cancer","Mesothelioma","Ovarian Cancer"],"intervention_entry_count":1,"nct_id":"NCT07420010","overall_status":"NOT_YET_RECRUITING","phases":["EARLY_PHASE1"],"source_record_index":82,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer","conditions":["Adenocarcinoma of Colon","Colorectal Cancer Metastatic"],"intervention_entry_count":1,"nct_id":"NCT07462650","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":35,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Structured TXI-RDI Integration for Endoscopic Resection","conditions":["Endoscopic Mucosal Resection","Polyp Colorectal"],"intervention_entry_count":2,"nct_id":"NCT07474844","overall_status":"WITHDRAWN","phases":["NA"],"source_record_index":0,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs","conditions":["HER2 IHC3+ Advanced Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT07483684","overall_status":"NOT_YET_RECRUITING","phases":["PHASE3"],"source_record_index":68,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"JS212 Combination Therapies in Metastatic Colorectal Cancer","conditions":["Metastatic Colorectal Cancer"],"intervention_entry_count":5,"nct_id":"NCT07503756","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":49,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria","conditions":["Rectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT07505472","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"source_record_index":70,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"FL-261 Imaging for Cancer Diagnosis and Staging","conditions":["Advanced Solid Tumors","Colorectal Cancer","Head & Neck Cancer","Non-Small Cell Lung Cancer"],"intervention_entry_count":1,"nct_id":"NCT07510321","overall_status":"RECRUITING","phases":[],"source_record_index":46,"source_ref":"ctg-page-002","study_type":"OBSERVATIONAL"},{"brief_title":"A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers","conditions":["Colorectal Cancer","Esophageal Adenocarcinoma","Gastric Adenocarcinoma","Gastroesophageal Adenocarcinoma"],"intervention_entry_count":1,"nct_id":"NCT07544589","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":26,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Histidine and Immunotherapy Response in Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT07586293","overall_status":"NOT_YET_RECRUITING","phases":[],"source_record_index":95,"source_ref":"ctg-page-001","study_type":"OBSERVATIONAL"},{"brief_title":"Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors","conditions":["Colorectal Cancer","Head and Neck Squamous Cell Carcinoma","Non-small Cell Lung Cancer","Pancreatic Ductal Adenocarcinoma","Solid Tumor"],"intervention_entry_count":1,"nct_id":"NCT07589205","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":0,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer","conditions":["Colorectal Cancer","Metastatic Colorectal Adenocarcinoma","Unresectable Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT07589517","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":33,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer","conditions":["Metastatic Colorectal Neoplasms","Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT07591597","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":0,"source_ref":"ctg-page-002","study_type":"INTERVENTIONAL"},{"brief_title":"Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial","conditions":["Rectal Cancer"],"intervention_entry_count":3,"nct_id":"NCT07594925","overall_status":"RECRUITING","phases":["PHASE2"],"source_record_index":16,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"YMN-A02 for Advanced pMMR Colorectal Cancer With Liver Metastases","conditions":["Colorectal Cancer With Liver Metastatic"],"intervention_entry_count":4,"nct_id":"NCT07610707","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1"],"source_record_index":80,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer","conditions":["Unresectable/Metastatic Colorectal Cancer"],"intervention_entry_count":5,"nct_id":"NCT07649655","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1"],"source_record_index":52,"source_ref":"ctg-page-004","study_type":"INTERVENTIONAL"},{"brief_title":"Cell Membrane Potential Regulates Spatial-Specific Mechanoptosis Resistance and Metastasis in Colorectal Cancer Via Mechanotransduction and the PVR/CD96 Axis","conditions":["Colorectal Cancer"],"intervention_entry_count":0,"nct_id":"NCT07650786","overall_status":"COMPLETED","phases":[],"source_record_index":31,"source_ref":"ctg-page-004","study_type":"OBSERVATIONAL"},{"brief_title":"A Clinical Study of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in the Treatment of Advanced Colorectal Cancer","conditions":["Colorectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT07653685","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1","PHASE2"],"source_record_index":68,"source_ref":"ctg-page-005","study_type":"INTERVENTIONAL"},{"brief_title":"A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors","conditions":["Breast Cancer","Colorectal Cancer","GRPR-positive Solid Tumors","Prostate Cancer"],"intervention_entry_count":4,"nct_id":"NCT07661641","overall_status":"RECRUITING","phases":["PHASE1"],"source_record_index":18,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"},{"brief_title":"Active Surveillance vs Adjuvant Chemoradiotherapy for Locally Resected Intermediate-Risk T1 Rectal Cancer","conditions":["Rectal Cancer"],"intervention_entry_count":2,"nct_id":"NCT07669298","overall_status":"RECRUITING","phases":["NA"],"source_record_index":35,"source_ref":"ctg-page-003","study_type":"INTERVENTIONAL"},{"brief_title":"IKS04 Regimen in Advanced Solid Tumors That Express CA242","conditions":["Biliary Tract Cancer (BTC)","Cholangiocarcinoma","Colorectal Cancer","GEJ Adenocarcinoma","Gall Bladder Cancer","Gastric Cancer (GC)","Gastro Esophageal Junctional Cancer","PDAC - Pancreatic Ductal Adenocarcinoma"],"intervention_entry_count":1,"nct_id":"NCT07738939","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1"],"source_record_index":59,"source_ref":"ctg-page-001","study_type":"INTERVENTIONAL"}],"target_assignment_count":140,"unique_nct_id_count":495},"normalization_rule_set":{"bytes":20700,"filename":"clinicaltrials-target-rules.json","schema_version":"codex-surface-clinicaltrials-target-rules/v0.1","sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"},"records":[{"action":null,"action_evidence":[],"actions":[],"aliases":["(Early) Imaging of response with [18F-]-FDG PET-CT and kinase activity profiles"],"intervention_id":"I-CTG-early-imaging-of-response-with-18f-fdg-pet-4fdfa2a180","intervention_name":"(Early) Imaging of response with [18F-]-FDG PET-CT and kinase activity profiles","intervention_type":"BEHAVIORAL","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["18F"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BEHAVIORAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01691391","overall_status":"COMPLETED","phases":[],"registered_name":"(Early) Imaging of response with [18F-]-FDG PET-CT and kinase activity profiles","registry_intervention_type":"BEHAVIORAL","source_record_index":43,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01691391"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["1 mg 89Zr-DFO-Nimotuzumab"],"intervention_id":"I-CTG-1-mg-89zr-dfo-nimotuzumab-ad74941ac3","intervention_name":"1 mg 89Zr-DFO-Nimotuzumab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT04235114","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"1 mg 89Zr-DFO-Nimotuzumab","registry_intervention_type":"DRUG","source_record_index":75,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT04235114"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["111Indium CHX-A"],"intervention_id":"I-CTG-111indium-chx-a-65ae89ac97","intervention_name":"111Indium CHX-A","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1","phases":["EARLY_PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01445054","overall_status":"TERMINATED","phases":["EARLY_PHASE1"],"registered_name":"111Indium CHX-A","registry_intervention_type":"DRUG","source_record_index":86,"source_ref":"ctg-page-002"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT01445054"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["120mg Regorafenib at week2"],"intervention_id":"I-CTG-120mg-regorafenib-at-week2-4113c8b27c","intervention_name":"120mg Regorafenib at week2","intervention_type":"DRUG","modality":"small-molecule","modality_distribution":[{"modality":"small-molecule","registry_occurrence_count":1}],"modality_support":{"matched_cues":["small-molecule"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT05730673","overall_status":"WITHDRAWN","phases":["PHASE2"],"registered_name":"120mg Regorafenib at week2","registry_intervention_type":"DRUG","source_record_index":45,"source_ref":"ctg-page-005"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT05730673"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["160 mg Regorafenib at week 3"],"intervention_id":"I-CTG-160-mg-regorafenib-at-week-3-cd13ed6b64","intervention_name":"160 mg Regorafenib at week 3","intervention_type":"DRUG","modality":"small-molecule","modality_distribution":[{"modality":"small-molecule","registry_occurrence_count":1}],"modality_support":{"matched_cues":["small-molecule"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT05730673","overall_status":"WITHDRAWN","phases":["PHASE2"],"registered_name":"160 mg Regorafenib at week 3","registry_intervention_type":"DRUG","source_record_index":45,"source_ref":"ctg-page-005"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT05730673"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["177Lu-BetaBart"],"intervention_id":"I-CTG-177lu-betabart-fb338b61db","intervention_name":"177Lu-BetaBart","intervention_type":"DRUG","modality":"radioligand-therapy","modality_distribution":[{"modality":"radioligand-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["177Lu"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07189871","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"177Lu-BetaBart","registry_intervention_type":"DRUG","source_record_index":1,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07189871"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["18F-FDG"],"intervention_id":"I-CTG-18f-fdg-8a2b994805","intervention_name":"18F-FDG","intervention_type":"RADIATION","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["18F"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1","phases":["EARLY_PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["RADIATION"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT04147494","overall_status":"ACTIVE_NOT_RECRUITING","phases":["EARLY_PHASE1"],"registered_name":"18F-FDG","registry_intervention_type":"RADIATION","source_record_index":41,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT04147494"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["18F-αvβ6-BP"],"intervention_id":"I-CTG-18f-v-6-bp-08e45d3cef","intervention_name":"18F-αvβ6-BP","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["18F"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1","phases":["EARLY_PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03164486","overall_status":"ACTIVE_NOT_RECRUITING","phases":["EARLY_PHASE1"],"registered_name":"18F-αvβ6-BP","registry_intervention_type":"DRUG","source_record_index":65,"source_ref":"ctg-page-003"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT03164486"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["1H Spectroscopy at 1.5T and 3T"],"intervention_id":"I-CTG-1h-spectroscopy-at-1-5t-and-3t-d2b75d3f74","intervention_name":"1H Spectroscopy at 1.5T and 3T","intervention_type":"DEVICE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00581815","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"1H Spectroscopy at 1.5T and 3T","registry_intervention_type":"DEVICE","source_record_index":74,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00581815"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["203Pb-DOTAM"],"intervention_id":"I-CTG-203pb-dotam-965dd78c82","intervention_name":"203Pb-DOTAM","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07416552","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"203Pb-DOTAM","registry_intervention_type":"DRUG","source_record_index":2,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07416552"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["212Pb-DOTAM"],"intervention_id":"I-CTG-212pb-dotam-a9d2afc7be","intervention_name":"212Pb-DOTAM","intervention_type":"DRUG","modality":"radioligand-therapy","modality_distribution":[{"modality":"radioligand-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["212Pb"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT07416552","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"212Pb-DOTAM","registry_intervention_type":"DRUG","source_record_index":2,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07416552"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"antagonist; radionuclide-delivery","action_evidence":[{"action":"antagonist","evidence_type":"registry-field","excerpt":"…metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.","matched_text":"antagonist","nct_id":"NCT05283330"},{"action":"radionuclide-delivery","evidence_type":"registry-field","excerpt":"212Pb-DOTAM-GRPR1 is a radioimmunoconjugate comprised of 212Pb, the metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.","matched_text":"radioimmunoconjugate","nct_id":"NCT05283330"}],"actions":["antagonist","radionuclide-delivery"],"aliases":["212Pb-DOTAM-GRPR1"],"intervention_id":"I-CTG-212pb-dotam-grpr1-28e4663353","intervention_name":"212Pb-DOTAM-GRPR1","intervention_type":"DRUG","modality":"radioligand-therapy","modality_distribution":[{"modality":"radioligand-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["212Pb"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05283330","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"212Pb-DOTAM-GRPR1","registry_intervention_type":"DRUG","source_record_index":22,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05283330"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"…of 212Pb, the metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.","matched_alias":"GRPR","nct_id":"NCT05283330","relation":"targeted"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:GRPR","target_name":"gastrin-releasing peptide receptor","target_symbol":"GRPR"}],"target_directness":"registry-explicit","target_ids":["symbol:GRPR"],"target_names":["gastrin-releasing peptide receptor"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["350 mg leronlimab"],"intervention_id":"I-CTG-350-mg-leronlimab-788ba15886","intervention_name":"350 mg leronlimab","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06699836","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"350 mg leronlimab","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT06699836"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["5-fluorouracil","5-Fluorouracil"],"intervention_id":"I-CTG-5-fluorouracil-54c81ae48b","intervention_name":"5-Fluorouracil","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":6}],"modality_support":{"matched_cues":["fluorouracil","Fluorouracil"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3","phases":["PHASE1","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":6,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT00061815","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"5-fluorouracil","registry_intervention_type":"DRUG","source_record_index":25,"source_ref":"ctg-page-003"},{"intervention_index":4,"nct_id":"NCT00061815","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"5-fluorouracil","registry_intervention_type":"DRUG","source_record_index":25,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT00199797","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"5-Fluorouracil","registry_intervention_type":"DRUG","source_record_index":34,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT01522612","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"5-fluorouracil","registry_intervention_type":"DRUG","source_record_index":20,"source_ref":"ctg-page-005"},{"intervention_index":3,"nct_id":"NCT03206151","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"5-fluorouracil","registry_intervention_type":"DRUG","source_record_index":82,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT05489211","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"5-Fluorouracil","registry_intervention_type":"DRUG","source_record_index":76,"source_ref":"ctg-page-003"}],"status":"COMPLETED / RECRUITING / TERMINATED","statuses":["COMPLETED","RECRUITING","TERMINATED"],"study_count":5,"study_ids":["NCT00061815","NCT00199797","NCT01522612","NCT03206151","NCT05489211"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["5-Fluorouracil (5-FU)"],"intervention_id":"I-CTG-5-fluorouracil-5-fu-70024f00b0","intervention_name":"5-Fluorouracil (5-FU)","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Fluorouracil"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"5-Fluorouracil (5-FU)","registry_intervention_type":"DRUG","source_record_index":17,"source_ref":"ctg-page-001"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT03169777"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["5-Fluouracil"],"intervention_id":"I-CTG-5-fluouracil-02062800ef","intervention_name":"5-Fluouracil","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE4","phases":["PHASE4"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT01588990","overall_status":"COMPLETED","phases":["PHASE4"],"registered_name":"5-Fluouracil","registry_intervention_type":"DRUG","source_record_index":13,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01588990"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["5-FU"],"intervention_id":"I-CTG-5-fu-e38b30c404","intervention_name":"5-FU","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":4},{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":5,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00803647","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"5-FU","registry_intervention_type":"DRUG","source_record_index":43,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT01442935","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"5-FU","registry_intervention_type":"DRUG","source_record_index":96,"source_ref":"ctg-page-002"},{"intervention_index":15,"nct_id":"NCT02280070","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"5-FU","registry_intervention_type":"DRUG","source_record_index":62,"source_ref":"ctg-page-003"},{"intervention_index":3,"nct_id":"NCT03607643","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"5-FU","registry_intervention_type":"DRUG","source_record_index":59,"source_ref":"ctg-page-003"},{"intervention_index":3,"nct_id":"NCT03751176","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"5-FU","registry_intervention_type":"DRUG","source_record_index":2,"source_ref":"ctg-page-004"}],"status":"COMPLETED / UNKNOWN","statuses":["COMPLETED","UNKNOWN"],"study_count":5,"study_ids":["NCT00803647","NCT01442935","NCT02280070","NCT03607643","NCT03751176"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["5-FU/LV"],"intervention_id":"I-CTG-5-fu-lv-7780ef39f8","intervention_name":"5-FU/LV","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":9,"nct_id":"NCT02291289","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"5-FU/LV","registry_intervention_type":"DRUG","source_record_index":28,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02291289"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"antagonist","action_evidence":[{"action":"antagonist","evidence_type":"registry-field","excerpt":"If a participant develops nausea/vomiting, an anti-emetic such as 5-HT3 antagonist may be given.","matched_text":"antagonist","nct_id":"NCT01851369"},{"action":"antagonist","evidence_type":"registry-field","excerpt":"5-HT3 antagonist","matched_text":"antagonist","nct_id":"NCT01851369"}],"actions":["antagonist"],"aliases":["5-HT3 antagonist"],"intervention_id":"I-CTG-5-ht3-antagonist-70ee71046f","intervention_name":"5-HT3 antagonist","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT01851369","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"5-HT3 antagonist","registry_intervention_type":"OTHER","source_record_index":99,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01851369"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["50 mg 89Zr-DFO-Nimotuzumab"],"intervention_id":"I-CTG-50-mg-89zr-dfo-nimotuzumab-97671e4dcf","intervention_name":"50 mg 89Zr-DFO-Nimotuzumab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04235114","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"50 mg 89Zr-DFO-Nimotuzumab","registry_intervention_type":"DRUG","source_record_index":75,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT04235114"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["5FU/LV"],"intervention_id":"I-CTG-5fu-lv-6f078c1a90","intervention_name":"5FU/LV","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT06887218","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"5FU/LV","registry_intervention_type":"DRUG","source_record_index":29,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06887218"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["6-month adjuvant chemotherapy with 5-FU monotherapy"],"intervention_id":"I-CTG-6-month-adjuvant-chemotherapy-with-5-fu-mo-10b1416de5","intervention_name":"6-month adjuvant chemotherapy with 5-FU monotherapy","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06609551","overall_status":"RECRUITING","phases":["PHASE3"],"registered_name":"6-month adjuvant chemotherapy with 5-FU monotherapy","registry_intervention_type":"DRUG","source_record_index":19,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06609551"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["700 mg leronlimab"],"intervention_id":"I-CTG-700-mg-leronlimab-38a4c1ed26","intervention_name":"700 mg leronlimab","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT06699836","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"700 mg leronlimab","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT06699836"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["700mg leronlimab weekly dose"],"intervention_id":"I-CTG-700mg-leronlimab-weekly-dose-cda1c365e6","intervention_name":"700mg leronlimab weekly dose","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05730673","overall_status":"WITHDRAWN","phases":["PHASE2"],"registered_name":"700mg leronlimab weekly dose","registry_intervention_type":"DRUG","source_record_index":45,"source_ref":"ctg-page-005"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT05730673"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["80mg Regorafenib at week 1"],"intervention_id":"I-CTG-80mg-regorafenib-at-week-1-ad37cdaf9e","intervention_name":"80mg Regorafenib at week 1","intervention_type":"DRUG","modality":"small-molecule","modality_distribution":[{"modality":"small-molecule","registry_occurrence_count":1}],"modality_support":{"matched_cues":["small-molecule"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05730673","overall_status":"WITHDRAWN","phases":["PHASE2"],"registered_name":"80mg Regorafenib at week 1","registry_intervention_type":"DRUG","source_record_index":45,"source_ref":"ctg-page-005"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT05730673"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)"],"intervention_id":"I-CTG-9-valent-human-papillomavirus-types-6-11-1-25b4049687","intervention_name":"9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06465914","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"registered_name":"9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)","registry_intervention_type":"BIOLOGICAL","source_record_index":50,"source_ref":"ctg-page-005"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT06465914"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["[111In]-FPI-1967"],"intervention_id":"I-CTG-111in-fpi-1967-89b7f5ed6d","intervention_name":"[111In]-FPI-1967","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":2}],"modality_support":{"matched_cues":["imaging agent","indium-111"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05363605","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"[111In]-FPI-1967","registry_intervention_type":"DRUG","source_record_index":87,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT05363605"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"[111In]-FPI-1967","rationale":"Exact registered FPI-1967 name; the registry identifies vofatamab as its targeting component.","rule_id":"candidate-fpi1967","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:FGFR3","target_name":"fibroblast growth factor receptor 3","target_symbol":"FGFR3"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:FGFR3"],"target_names":["fibroblast growth factor receptor 3"]},{"action":"molecular-imaging","action_evidence":[{"action":"molecular-imaging","evidence_type":"registry-field","excerpt":"\\[111In\\]-FPI-2058 is an imaging agent that consists of an NTSR1-targeting small molecule linked to In-111.Participants will receive \\[111In\\]-FPI-2058 by IV Injection for imaging once during screening period. The dose i…","matched_text":"imaging agent","nct_id":"NCT05605522"}],"actions":["molecular-imaging"],"aliases":["[111In]-FPI-2058"],"intervention_id":"I-CTG-111in-fpi-2058-acfaea1b28","intervention_name":"[111In]-FPI-2058","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["111In","imaging agent"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05605522","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"[111In]-FPI-2058","registry_intervention_type":"DRUG","source_record_index":6,"source_ref":"ctg-page-001"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT05605522"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"\\[111In\\]-FPI-2058 is an imaging agent that consists of an NTSR1-targeting small molecule linked to In-111.Participants will receive \\[111In\\]-FPI-2058 by IV Injection for imaging once during screening period. The dose i…","matched_alias":"NTSR1","nct_id":"NCT05605522","relation":"targeting"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:NTSR1","target_name":"neurotensin receptor 1","target_symbol":"NTSR1"}],"target_directness":"registry-explicit","target_ids":["symbol:NTSR1"],"target_names":["neurotensin receptor 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["[111In]-FPI-2107"],"intervention_id":"I-CTG-111in-fpi-2107-37ea0ec994","intervention_name":"[111In]-FPI-2107","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":2}],"modality_support":{"matched_cues":["imaging agent","indium-111"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT06147037","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"registered_name":"[111In]-FPI-2107","registry_intervention_type":"DRUG","source_record_index":24,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT06147037"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"[111In]-FPI-2107","rationale":"Exact registered FPI-2107 name; the registry identifies the EGFR/c-MET bispecific FPI-2053 as its targeting component.","rule_id":"candidate-fpi2107","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:EGFR","target_name":"epidermal growth factor receptor","target_symbol":"EGFR"},{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"[111In]-FPI-2107","rationale":"Exact registered FPI-2107 name; the registry identifies the EGFR/c-MET bispecific FPI-2053 as its targeting component.","rule_id":"candidate-fpi2107","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:MET","target_name":"hepatocyte growth factor receptor","target_symbol":"MET"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:EGFR","symbol:MET"],"target_names":["epidermal growth factor receptor","hepatocyte growth factor receptor"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["[111In]In-DOTA-ANTI-CEA antibody injection"],"intervention_id":"I-CTG-111in-in-dota-anti-cea-antibody-injection-db4657027f","intervention_name":"[111In]In-DOTA-ANTI-CEA antibody injection","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["111In","tracer injection"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06395337","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"[111In]In-DOTA-ANTI-CEA antibody injection","registry_intervention_type":"DRUG","source_record_index":4,"source_ref":"ctg-page-004"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT06395337"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"[111In]In-DOTA-ANTI-CEA antibody injection","matched_alias":"CEA","nct_id":"NCT06395337","relation":"ANTI-CEA"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CEACAM5","target_name":"carcinoembryonic antigen-related cell adhesion molecule 5","target_symbol":"CEACAM5"}],"target_directness":"registry-explicit","target_ids":["symbol:CEACAM5"],"target_names":["carcinoembryonic antigen-related cell adhesion molecule 5"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["[177Lu]Lu-A9-0631"],"intervention_id":"I-CTG-177lu-lu-a9-0631-66f6221fe7","intervention_name":"[177Lu]Lu-A9-0631","intervention_type":"DRUG","modality":"radioligand-therapy","modality_distribution":[{"modality":"radioligand-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["177Lu"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT07661641","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"[177Lu]Lu-A9-0631","registry_intervention_type":"DRUG","source_record_index":18,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07661641"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["[18F]F-RESCA-EPCD6"],"intervention_id":"I-CTG-18f-f-resca-epcd6-8dea9211d8","intervention_name":"[18F]F-RESCA-EPCD6","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["18F","ImmunoPET"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT07026110","overall_status":"RECRUITING","phases":["NA"],"registered_name":"[18F]F-RESCA-EPCD6","registry_intervention_type":"DRUG","source_record_index":98,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07026110"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"molecular-imaging","action_evidence":[{"action":"molecular-imaging","evidence_type":"registry-field","excerpt":"…ose with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\\[18F\\]F-RESCA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-G5 injection.","matched_text":"ImmunoPET","nct_id":"NCT06715839"}],"actions":["molecular-imaging"],"aliases":["[18F]F-RESCA-G5"],"intervention_id":"I-CTG-18f-f-resca-g5-733d72e44e","intervention_name":"[18F]F-RESCA-G5","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["18F","ImmunoPET"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT06715839","overall_status":"RECRUITING","phases":["NA"],"registered_name":"[18F]F-RESCA-G5","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06715839"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\\[18F\\]F-RESCA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-G5 injection.","matched_alias":"GPC3","nct_id":"NCT06715839","relation":"targeted"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:GPC3","target_name":"glypican-3","target_symbol":"GPC3"}],"target_directness":"registry-explicit","target_ids":["symbol:GPC3"],"target_names":["glypican-3"]},{"action":"molecular-imaging","action_evidence":[{"action":"molecular-imaging","evidence_type":"registry-field","excerpt":"…ially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\\[18F\\]F-RESCA-RB14). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-RB14 injection.","matched_text":"ImmunoPET","nct_id":"NCT06715839"}],"actions":["molecular-imaging"],"aliases":["[18F]F-RESCA-RB14"],"intervention_id":"I-CTG-18f-f-resca-rb14-b3e631ee50","intervention_name":"[18F]F-RESCA-RB14","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["18F","ImmunoPET"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT06715839","overall_status":"RECRUITING","phases":["NA"],"registered_name":"[18F]F-RESCA-RB14","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06715839"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\\[18F\\]F-RESCA-RB14). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-RB14 injection.","matched_alias":"HER2","nct_id":"NCT06715839","relation":"targeted"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:ERBB2","target_name":"receptor tyrosine-protein kinase erbB-2","target_symbol":"ERBB2"}],"target_directness":"registry-explicit","target_ids":["symbol:ERBB2"],"target_names":["receptor tyrosine-protein kinase erbB-2"]},{"action":"molecular-imaging","action_evidence":[{"action":"molecular-imaging","evidence_type":"registry-field","excerpt":"Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\\[18F\\]F-RESCA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-RND20 injection.","matched_text":"ImmunoPET","nct_id":"NCT06715839"}],"actions":["molecular-imaging"],"aliases":["[18F]F-RESCA-RND20"],"intervention_id":"I-CTG-18f-f-resca-rnd20-5136376ed7","intervention_name":"[18F]F-RESCA-RND20","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["18F","ImmunoPET"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":9,"nct_id":"NCT06715839","overall_status":"RECRUITING","phases":["NA"],"registered_name":"[18F]F-RESCA-RND20","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06715839"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\\[18F\\]F-RESCA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-RND20 injection.","matched_alias":"Nectin-4","nct_id":"NCT06715839","relation":"targeted"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:NECTIN4","target_name":"nectin cell adhesion molecule 4","target_symbol":"NECTIN4"}],"target_directness":"registry-explicit","target_ids":["symbol:NECTIN4"],"target_names":["nectin cell adhesion molecule 4"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["[18F]F-RESCA-RT4"],"intervention_id":"I-CTG-18f-f-resca-rt4-052aca8d82","intervention_name":"[18F]F-RESCA-RT4","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["18F","ImmunoPET"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT07026110","overall_status":"RECRUITING","phases":["NA"],"registered_name":"[18F]F-RESCA-RT4","registry_intervention_type":"DRUG","source_record_index":98,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07026110"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"molecular-imaging","action_evidence":[{"action":"molecular-imaging","evidence_type":"registry-field","excerpt":"…gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\\[18F\\]F-RESCA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-T4 injection.","matched_text":"ImmunoPET","nct_id":"NCT06715839"}],"actions":["molecular-imaging"],"aliases":["[18F]F-RESCA-T4"],"intervention_id":"I-CTG-18f-f-resca-t4-35b147630c","intervention_name":"[18F]F-RESCA-T4","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":2}],"modality_support":{"matched_cues":["18F","ImmunoPET"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT06715839","overall_status":"RECRUITING","phases":["NA"],"registered_name":"[18F]F-RESCA-T4","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT07026110","overall_status":"RECRUITING","phases":["NA"],"registered_name":"[18F]F-RESCA-T4","registry_intervention_type":"DRUG","source_record_index":98,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":2,"study_ids":["NCT06715839","NCT07026110"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Enrolled patients (especially those with gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\\[18F\\]F-RESCA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-T4 injection.","matched_alias":"Trop2","nct_id":"NCT06715839","relation":"targeted"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:TACSTD2","target_name":"tumor-associated calcium signal transducer 2","target_symbol":"TACSTD2"}],"target_directness":"registry-explicit","target_ids":["symbol:TACSTD2"],"target_names":["tumor-associated calcium signal transducer 2"]},{"action":"molecular-imaging","action_evidence":[{"action":"molecular-imaging","evidence_type":"registry-field","excerpt":"…those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\\[18F\\]F-RESCA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-WWH347 injection.","matched_text":"ImmunoPET","nct_id":"NCT06715839"}],"actions":["molecular-imaging"],"aliases":["[18F]F-RESCA-WWH347"],"intervention_id":"I-CTG-18f-f-resca-wwh347-2c82aa5ec4","intervention_name":"[18F]F-RESCA-WWH347","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["18F","ImmunoPET"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":7,"nct_id":"NCT06715839","overall_status":"RECRUITING","phases":["NA"],"registered_name":"[18F]F-RESCA-WWH347","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06715839"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\\[18F\\]F-RESCA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-WWH347 inje…","matched_alias":"GPA33","nct_id":"NCT06715839","relation":"targeted"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:GPA33","target_name":"cell surface A33 antigen","target_symbol":"GPA33"}],"target_directness":"registry-explicit","target_ids":["symbol:GPA33"],"target_names":["cell surface A33 antigen"]},{"action":"radionuclide-delivery","action_evidence":[{"action":"radionuclide-delivery","evidence_type":"registry-field","excerpt":"\\[225Ac\\]-FPI-2059 is a targeted alpha therapeutic that consists of an NTSR1-targeting small molecule that is linked to Ac-225, an alpha particle emitting radionuclide. Participants will be dosed through IV administratio…","matched_text":"targeted alpha therapeutic","nct_id":"NCT05605522"}],"actions":["radionuclide-delivery"],"aliases":["[225]-FPI-2059"],"intervention_id":"I-CTG-225-fpi-2059-cbaa866dc3","intervention_name":"[225]-FPI-2059","intervention_type":"DRUG","modality":"radioligand-therapy","modality_distribution":[{"modality":"radioligand-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["225Ac"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05605522","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"[225]-FPI-2059","registry_intervention_type":"DRUG","source_record_index":6,"source_ref":"ctg-page-001"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT05605522"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"\\[225Ac\\]-FPI-2059 is a targeted alpha therapeutic that consists of an NTSR1-targeting small molecule that is linked to Ac-225, an alpha particle emitting radionuclide. Participants will be dosed through IV administratio…","matched_alias":"NTSR1","nct_id":"NCT05605522","relation":"targeting"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:NTSR1","target_name":"neurotensin receptor 1","target_symbol":"NTSR1"}],"target_directness":"registry-explicit","target_ids":["symbol:NTSR1"],"target_names":["neurotensin receptor 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["[225Ac]-FPI-1966"],"intervention_id":"I-CTG-225ac-fpi-1966-e299fbd736","intervention_name":"[225Ac]-FPI-1966","intervention_type":"DRUG","modality":"radioligand-therapy","modality_distribution":[{"modality":"radioligand-therapy","registry_occurrence_count":2}],"modality_support":{"matched_cues":["actinium-225"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05363605","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"[225Ac]-FPI-1966","registry_intervention_type":"DRUG","source_record_index":87,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT05363605"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"[225Ac]-FPI-1966","rationale":"Exact registered FPI-1966 name; the registry identifies vofatamab as its targeting component.","rule_id":"candidate-fpi1966","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:FGFR3","target_name":"fibroblast growth factor receptor 3","target_symbol":"FGFR3"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:FGFR3"],"target_names":["fibroblast growth factor receptor 3"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["[225Ac]-FPI-2068"],"intervention_id":"I-CTG-225ac-fpi-2068-86d75ffcc8","intervention_name":"[225Ac]-FPI-2068","intervention_type":"DRUG","modality":"radioligand-therapy","modality_distribution":[{"modality":"radioligand-therapy","registry_occurrence_count":2}],"modality_support":{"matched_cues":["actinium-225"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT06147037","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"registered_name":"[225Ac]-FPI-2068","registry_intervention_type":"DRUG","source_record_index":24,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT06147037"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"[225Ac]-FPI-2068","rationale":"Exact registered FPI-2068 name; the registry identifies the EGFR/c-MET bispecific FPI-2053 as its targeting component.","rule_id":"candidate-fpi2068","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:EGFR","target_name":"epidermal growth factor receptor","target_symbol":"EGFR"},{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"[225Ac]-FPI-2068","rationale":"Exact registered FPI-2068 name; the registry identifies the EGFR/c-MET bispecific FPI-2053 as its targeting component.","rule_id":"candidate-fpi2068","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:MET","target_name":"hepatocyte growth factor receptor","target_symbol":"MET"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:EGFR","symbol:MET"],"target_names":["epidermal growth factor receptor","hepatocyte growth factor receptor"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["[225Ac]Ac-A9-0642"],"intervention_id":"I-CTG-225ac-ac-a9-0642-acd879c5d4","intervention_name":"[225Ac]Ac-A9-0642","intervention_type":"DRUG","modality":"radioligand-therapy","modality_distribution":[{"modality":"radioligand-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["225Ac"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT07661641","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"[225Ac]Ac-A9-0642","registry_intervention_type":"DRUG","source_record_index":18,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07661641"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["[225Ac]Ac-AKY-1189 (therapeutic)"],"intervention_id":"I-CTG-225ac-ac-aky-1189-therapeutic-e092f13cd1","intervention_name":"[225Ac]Ac-AKY-1189 (therapeutic)","intervention_type":"DRUG","modality":"radioligand-therapy","modality_distribution":[{"modality":"radioligand-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["225Ac"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07020117","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"[225Ac]Ac-AKY-1189 (therapeutic)","registry_intervention_type":"DRUG","source_record_index":47,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07020117"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["[64Cu]Cu-AKY-1189 (imaging)"],"intervention_id":"I-CTG-64cu-cu-aky-1189-imaging-45a8ab64f4","intervention_name":"[64Cu]Cu-AKY-1189 (imaging)","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["64Cu"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07020117","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"[64Cu]Cu-AKY-1189 (imaging)","registry_intervention_type":"DRUG","source_record_index":47,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07020117"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["[68Ga]-NeoBOMB1"],"intervention_id":"I-CTG-68ga-neobomb1-9353e21018","intervention_name":"[68Ga]-NeoBOMB1","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["68Ga"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03724253","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"[68Ga]-NeoBOMB1","registry_intervention_type":"DRUG","source_record_index":84,"source_ref":"ctg-page-001"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT03724253"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"\\[68Ga\\]-radiolabeled bombesin peptide targeting Gastrin Releasing Peptide Receptors","matched_alias":"Gastrin Releasing Peptide Receptors","nct_id":"NCT03724253","relation":"targeting Gastrin Releasing Peptide Receptors"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:GRPR","target_name":"gastrin-releasing peptide receptor","target_symbol":"GRPR"}],"target_directness":"registry-explicit","target_ids":["symbol:GRPR"],"target_names":["gastrin-releasing peptide receptor"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["[68Ga]Ga-A9-6217"],"intervention_id":"I-CTG-68ga-ga-a9-6217-28ce6e0997","intervention_name":"[68Ga]Ga-A9-6217","intervention_type":"DIAGNOSTIC_TEST","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["68Ga"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07661641","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"[68Ga]Ga-A9-6217","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":18,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07661641"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"molecular-imaging","action_evidence":[{"action":"molecular-imaging","evidence_type":"registry-field","excerpt":"…ally those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\\[68Ga\\]Ga-DOTA-H2D3). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-DOTA-H2D3 injection.","matched_text":"ImmunoPET","nct_id":"NCT06715839"}],"actions":["molecular-imaging"],"aliases":["[68Ga]Ga-DOTA-H2D3"],"intervention_id":"I-CTG-68ga-ga-dota-h2d3-c90970f5a7","intervention_name":"[68Ga]Ga-DOTA-H2D3","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["68Ga","ImmunoPET"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06715839","overall_status":"RECRUITING","phases":["NA"],"registered_name":"[68Ga]Ga-DOTA-H2D3","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06715839"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\\[68Ga\\]Ga-DOTA-H2D3). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-DOTA-H2D3 injection.","matched_alias":"HER2","nct_id":"NCT06715839","relation":"targeted"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:ERBB2","target_name":"receptor tyrosine-protein kinase erbB-2","target_symbol":"ERBB2"}],"target_directness":"registry-explicit","target_ids":["symbol:ERBB2"],"target_names":["receptor tyrosine-protein kinase erbB-2"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["[68Ga]Ga-FL-261 PET Imaging / [111In]In-FL-261 SPECT Imaging"],"intervention_id":"I-CTG-68ga-ga-fl-261-pet-imaging-111in-in-fl-261-1cd979f4ad","intervention_name":"[68Ga]Ga-FL-261 PET Imaging / [111In]In-FL-261 SPECT Imaging","intervention_type":"DIAGNOSTIC_TEST","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["68Ga"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07510321","overall_status":"RECRUITING","phases":[],"registered_name":"[68Ga]Ga-FL-261 PET Imaging / [111In]In-FL-261 SPECT Imaging","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":46,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07510321"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"This diagnostic study evaluates c-MET-targeted imaging using \\[68Ga\\]Ga-FL-261 PET or \\[111In\\]In-FL-261 SPECT in patients with suspected or confirmed malignancies (e.g., non-small cell lung cancer, colorectal cancer, he…","matched_alias":"c-MET","nct_id":"NCT07510321","relation":"targeted"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:MET","target_name":"hepatocyte growth factor receptor","target_symbol":"MET"}],"target_directness":"registry-explicit","target_ids":["symbol:MET"],"target_names":["hepatocyte growth factor receptor"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["[68Ga]Ga-NOTA-EPCD6"],"intervention_id":"I-CTG-68ga-ga-nota-epcd6-c3b6b40e63","intervention_name":"[68Ga]Ga-NOTA-EPCD6","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["68Ga","ImmunoPET"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT07026110","overall_status":"RECRUITING","phases":["NA"],"registered_name":"[68Ga]Ga-NOTA-EPCD6","registry_intervention_type":"DRUG","source_record_index":98,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07026110"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"molecular-imaging","action_evidence":[{"action":"molecular-imaging","evidence_type":"registry-field","excerpt":"…se with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\\[68Ga\\]Ga-NOTA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-NOTA-G5 injection.","matched_text":"ImmunoPET","nct_id":"NCT06715839"}],"actions":["molecular-imaging"],"aliases":["[68Ga]Ga-NOTA-G5"],"intervention_id":"I-CTG-68ga-ga-nota-g5-6d44b3e9a5","intervention_name":"[68Ga]Ga-NOTA-G5","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["68Ga","ImmunoPET"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT06715839","overall_status":"RECRUITING","phases":["NA"],"registered_name":"[68Ga]Ga-NOTA-G5","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06715839"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\\[68Ga\\]Ga-NOTA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-NOTA-G5 injectio…","matched_alias":"GPC3","nct_id":"NCT06715839","relation":"targeted"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:GPC3","target_name":"glypican-3","target_symbol":"GPC3"}],"target_directness":"registry-explicit","target_ids":["symbol:GPC3"],"target_names":["glypican-3"]},{"action":"molecular-imaging","action_evidence":[{"action":"molecular-imaging","evidence_type":"registry-field","excerpt":"Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\\[68Ga\\]Ga-NOTA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-NOTA-RND20 injection.","matched_text":"ImmunoPET","nct_id":"NCT06715839"}],"actions":["molecular-imaging"],"aliases":["[68Ga]Ga-NOTA-RND20"],"intervention_id":"I-CTG-68ga-ga-nota-rnd20-882a3bd082","intervention_name":"[68Ga]Ga-NOTA-RND20","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["68Ga","ImmunoPET"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":8,"nct_id":"NCT06715839","overall_status":"RECRUITING","phases":["NA"],"registered_name":"[68Ga]Ga-NOTA-RND20","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06715839"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\\[68Ga\\]Ga-NOTA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-NOTA-RND20 injection.","matched_alias":"Nectin-4","nct_id":"NCT06715839","relation":"targeted"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:NECTIN4","target_name":"nectin cell adhesion molecule 4","target_symbol":"NECTIN4"}],"target_directness":"registry-explicit","target_ids":["symbol:NECTIN4"],"target_names":["nectin cell adhesion molecule 4"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["[68Ga]Ga-NOTA-RT4"],"intervention_id":"I-CTG-68ga-ga-nota-rt4-fdc302ba89","intervention_name":"[68Ga]Ga-NOTA-RT4","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["68Ga","ImmunoPET"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07026110","overall_status":"RECRUITING","phases":["NA"],"registered_name":"[68Ga]Ga-NOTA-RT4","registry_intervention_type":"DRUG","source_record_index":98,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07026110"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"molecular-imaging","action_evidence":[{"action":"molecular-imaging","evidence_type":"registry-field","excerpt":"…astric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\\[68Ga\\]Ga-NOTA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-NOTA-T4 injection.","matched_text":"ImmunoPET","nct_id":"NCT06715839"}],"actions":["molecular-imaging"],"aliases":["[68Ga]Ga-NOTA-T4"],"intervention_id":"I-CTG-68ga-ga-nota-t4-9e339e2328","intervention_name":"[68Ga]Ga-NOTA-T4","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":2}],"modality_support":{"matched_cues":["68Ga","ImmunoPET"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT06715839","overall_status":"RECRUITING","phases":["NA"],"registered_name":"[68Ga]Ga-NOTA-T4","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT07026110","overall_status":"RECRUITING","phases":["NA"],"registered_name":"[68Ga]Ga-NOTA-T4","registry_intervention_type":"DRUG","source_record_index":98,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":2,"study_ids":["NCT06715839","NCT07026110"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Enrolled patients (especially those with gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\\[68Ga\\]Ga-NOTA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-NOTA-T4 injectio…","matched_alias":"Trop2","nct_id":"NCT06715839","relation":"targeted"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:TACSTD2","target_name":"tumor-associated calcium signal transducer 2","target_symbol":"TACSTD2"}],"target_directness":"registry-explicit","target_ids":["symbol:TACSTD2"],"target_names":["tumor-associated calcium signal transducer 2"]},{"action":"molecular-imaging","action_evidence":[{"action":"molecular-imaging","evidence_type":"registry-field","excerpt":"…hose with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\\[68Ga\\]Ga-NOTA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-NOTA-WWH347 injection.","matched_text":"ImmunoPET","nct_id":"NCT06715839"}],"actions":["molecular-imaging"],"aliases":["[68Ga]Ga-NOTA-WWH347"],"intervention_id":"I-CTG-68ga-ga-nota-wwh347-6c428e5c54","intervention_name":"[68Ga]Ga-NOTA-WWH347","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["68Ga","ImmunoPET"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":6,"nct_id":"NCT06715839","overall_status":"RECRUITING","phases":["NA"],"registered_name":"[68Ga]Ga-NOTA-WWH347","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06715839"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\\[68Ga\\]Ga-NOTA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-NOTA-WWH347 in…","matched_alias":"GPA33","nct_id":"NCT06715839","relation":"targeted"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:GPA33","target_name":"cell surface A33 antigen","target_symbol":"GPA33"}],"target_directness":"registry-explicit","target_ids":["symbol:GPA33"],"target_names":["cell surface A33 antigen"]},{"action":"cytotoxic-payload-delivery","action_evidence":[{"action":"cytotoxic-payload-delivery","evidence_type":"registry-field","excerpt":"A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.","matched_text":"Antibody Drug Conjugate","nct_id":"NCT03602079"}],"actions":["cytotoxic-payload-delivery"],"aliases":["A166"],"intervention_id":"I-CTG-a166-64561330f1","intervention_name":"A166","intervention_type":"DRUG","modality":"antibody-drug-conjugate","modality_distribution":[{"modality":"antibody-drug-conjugate","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Antibody Drug Conjugate"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03602079","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"A166","registry_intervention_type":"DRUG","source_record_index":35,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03602079"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.","matched_alias":"HER2","nct_id":"NCT03602079","relation":"targeting HER2"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:ERBB2","target_name":"receptor tyrosine-protein kinase erbB-2","target_symbol":"ERBB2"}],"target_directness":"registry-explicit","target_ids":["symbol:ERBB2"],"target_names":["receptor tyrosine-protein kinase erbB-2"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["A2B530"],"intervention_id":"I-CTG-a2b530-dd25994920","intervention_name":"A2B530","intervention_type":"BIOLOGICAL","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR T"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05736731","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"A2B530","registry_intervention_type":"BIOLOGICAL","source_record_index":10,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT05736731"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["AB122"],"intervention_id":"I-CTG-ab122-90ee1bf613","intervention_name":"AB122","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"AB122","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"AB122","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT04999761"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["AB154"],"intervention_id":"I-CTG-ab154-b162427726","intervention_name":"AB154","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":11,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"AB154","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT04999761"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"inhibitor","action_evidence":[{"action":"inhibitor","evidence_type":"registry-field","excerpt":"AB680 is a cluster of differentiated CD73 Inhibitor","matched_text":"Inhibitor","nct_id":"NCT04660812"}],"actions":["inhibitor"],"aliases":["AB680"],"intervention_id":"I-CTG-ab680-d446c5ca53","intervention_name":"AB680","intervention_type":"DRUG","modality":"small-molecule","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1},{"modality":"small-molecule","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04660812","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"AB680","registry_intervention_type":"DRUG","source_record_index":78,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT04660812"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"AB680 is a cluster of differentiated CD73 Inhibitor","matched_alias":"CD73","nct_id":"NCT04660812","relation":"Inhibitor"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"AB680","rationale":"Exact intervention-name alias for the CD73-directed small-molecule inhibitor.","rule_id":"candidate-ab680","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:NT5E","target_name":"ecto-5-prime-nucleotidase","target_symbol":"NT5E"}],"target_directness":"registry-explicit","target_ids":["symbol:NT5E"],"target_names":["ecto-5-prime-nucleotidase"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ABBV-621"],"intervention_id":"I-CTG-abbv-621-145a5a1d8e","intervention_name":"ABBV-621","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03082209","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"ABBV-621","registry_intervention_type":"DRUG","source_record_index":70,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03082209"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Abemaciclib"],"intervention_id":"I-CTG-abemaciclib-1354cf6146","intervention_name":"Abemaciclib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06654037","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Abemaciclib","registry_intervention_type":"DRUG","source_record_index":55,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06654037"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Abiraterone"],"intervention_id":"I-CTG-abiraterone-6f8c767b5d","intervention_name":"Abiraterone","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT05551117","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Abiraterone","registry_intervention_type":"DRUG","source_record_index":69,"source_ref":"ctg-page-001"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT05551117"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Abiraterone Acetate"],"intervention_id":"I-CTG-abiraterone-acetate-be32af7aa2","intervention_name":"Abiraterone Acetate","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT02740985","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Abiraterone Acetate","registry_intervention_type":"DRUG","source_record_index":72,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02740985"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Ablation"],"intervention_id":"I-CTG-ablation-d5288a34c4","intervention_name":"Ablation","intervention_type":"DEVICE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03695835","overall_status":"COMPLETED","phases":[],"registered_name":"Ablation","registry_intervention_type":"DEVICE","source_record_index":92,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03695835"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ABX-EGF"],"intervention_id":"I-CTG-abx-egf-dc1ceaee75","intervention_name":"ABX-EGF","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00111774","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"ABX-EGF","registry_intervention_type":"DRUG","source_record_index":27,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00111774"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Active surveillance"],"intervention_id":"I-CTG-active-surveillance-4d63f5a6e2","intervention_name":"Active surveillance","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07669298","overall_status":"RECRUITING","phases":["NA"],"registered_name":"Active surveillance","registry_intervention_type":"OTHER","source_record_index":35,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07669298"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ACZ885"],"intervention_id":"I-CTG-acz885-94eb7288a5","intervention_name":"ACZ885","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT02900664","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"ACZ885","registry_intervention_type":"BIOLOGICAL","source_record_index":26,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02900664"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Adenorine"],"intervention_id":"I-CTG-adenorine-b88c9ce4cd","intervention_name":"Adenorine","intervention_type":"DIETARY_SUPPLEMENT","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2 / PHASE3","phases":["PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIETARY_SUPPLEMENT"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06509880","overall_status":"COMPLETED","phases":["PHASE2","PHASE3"],"registered_name":"Adenorine","registry_intervention_type":"DIETARY_SUPPLEMENT","source_record_index":30,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT06509880"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5"],"intervention_id":"I-CTG-adenovirus-5-cea-muc1-brachyury-vaccine-tr-871a711d3a","intervention_name":"Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05419011","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5","registry_intervention_type":"BIOLOGICAL","source_record_index":85,"source_ref":"ctg-page-001"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT05419011"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE"],"intervention_id":"I-CTG-adenovirus-5-f35-human-guanylyl-cyclase-c--cfef342113","intervention_name":"Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04111172","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE","registry_intervention_type":"BIOLOGICAL","source_record_index":81,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT04111172"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Adjuvant chemoradiotherapy"],"intervention_id":"I-CTG-adjuvant-chemoradiotherapy-4f2ba517df","intervention_name":"Adjuvant chemoradiotherapy","intervention_type":"RADIATION","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["fluorouracil"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["RADIATION"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07669298","overall_status":"RECRUITING","phases":["NA"],"registered_name":"Adjuvant chemoradiotherapy","registry_intervention_type":"RADIATION","source_record_index":35,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07669298"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["adjuvant therapy"],"intervention_id":"I-CTG-adjuvant-therapy-fa8e84690a","intervention_name":"adjuvant therapy","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT00003422","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"adjuvant therapy","registry_intervention_type":"PROCEDURE","source_record_index":51,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00003422"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell"],"intervention_id":"I-CTG-adoptive-cell-transfer-of-nkg2dl-targettin-a7524f38de","intervention_name":"Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell","intervention_type":"BIOLOGICAL","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Chimeric Antigen Receptor-grafted Gamma Delta T cell"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04107142","overall_status":"UNKNOWN","phases":["PHASE1"],"registered_name":"Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell","registry_intervention_type":"BIOLOGICAL","source_record_index":14,"source_ref":"ctg-page-005"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT04107142"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Adoptive Immunotherapy"],"intervention_id":"I-CTG-adoptive-immunotherapy-f363a01a06","intervention_name":"Adoptive Immunotherapy","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02757391","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Adoptive Immunotherapy","registry_intervention_type":"BIOLOGICAL","source_record_index":42,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT02757391"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Adverse event"],"intervention_id":"I-CTG-adverse-event-0176fffe25","intervention_name":"Adverse event","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":7,"nct_id":"NCT02280070","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Adverse event","registry_intervention_type":"OTHER","source_record_index":62,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02280070"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Aflibercept"],"intervention_id":"I-CTG-aflibercept-0ebf41ec93","intervention_name":"Aflibercept","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":6,"nct_id":"NCT03186326","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Aflibercept","registry_intervention_type":"DRUG","source_record_index":60,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03186326"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Aflibercept AVE0005"],"intervention_id":"I-CTG-aflibercept-ave0005-bd9bb07c15","intervention_name":"Aflibercept AVE0005","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01955629","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"Aflibercept AVE0005","registry_intervention_type":"DRUG","source_record_index":16,"source_ref":"ctg-page-003"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT01955629"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["AK104 injection"],"intervention_id":"I-CTG-ak104-injection-212be18ed8","intervention_name":"AK104 injection","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05794750","overall_status":"NOT_YET_RECRUITING","phases":["PHASE2"],"registered_name":"AK104 injection","registry_intervention_type":"DRUG","source_record_index":19,"source_ref":"ctg-page-001"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT05794750"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Aldesleukin"],"intervention_id":"I-CTG-aldesleukin-953b24ad52","intervention_name":"Aldesleukin","intervention_type":"multiple","modality":"cellular-therapy","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":3},{"modality":"cellular-therapy","registry_occurrence_count":2}],"modality_support":{"matched_cues":["TCR-T"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","DRUG"],"registry_occurrence_count":5,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT02757391","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Aldesleukin","registry_intervention_type":"BIOLOGICAL","source_record_index":42,"source_ref":"ctg-page-004"},{"intervention_index":3,"nct_id":"NCT03190941","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Aldesleukin","registry_intervention_type":"DRUG","source_record_index":60,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT03745326","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"Aldesleukin","registry_intervention_type":"DRUG","source_record_index":63,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT05639972","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Aldesleukin","registry_intervention_type":"DRUG","source_record_index":22,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT05686226","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Aldesleukin","registry_intervention_type":"DRUG","source_record_index":38,"source_ref":"ctg-page-001"}],"status":"RECRUITING / TERMINATED","statuses":["RECRUITING","TERMINATED"],"study_count":5,"study_ids":["NCT02757391","NCT03190941","NCT03745326","NCT05639972","NCT05686226"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ALT-803"],"intervention_id":"I-CTG-alt-803-14dbe0617e","intervention_name":"ALT-803","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":13,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"ALT-803","registry_intervention_type":"BIOLOGICAL","source_record_index":17,"source_ref":"ctg-page-001"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT03169777"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ALT803"],"intervention_id":"I-CTG-alt803-664ec51b87","intervention_name":"ALT803","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT02890758","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"ALT803","registry_intervention_type":"BIOLOGICAL","source_record_index":85,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02890758"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ALX148"],"intervention_id":"I-CTG-alx148-e9f16593fa","intervention_name":"ALX148","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05868226","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"ALX148","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05868226"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"binder","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1","matched_text":"binds","nct_id":"NCT00813605"},{"action":"binder","evidence_type":"registry-field","excerpt":"AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.","matched_text":"binds","nct_id":"NCT00819169"}],"actions":["binder"],"aliases":["AMG 479"],"intervention_id":"I-CTG-amg-479-f079f70775","intervention_name":"AMG 479","intervention_type":"BIOLOGICAL","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":3}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT00813605","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"AMG 479","registry_intervention_type":"BIOLOGICAL","source_record_index":41,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT00819169","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"AMG 479","registry_intervention_type":"BIOLOGICAL","source_record_index":92,"source_ref":"ctg-page-001"}],"status":"COMPLETED / TERMINATED","statuses":["COMPLETED","TERMINATED"],"study_count":2,"study_ids":["NCT00813605","NCT00819169"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1","matched_alias":"Insulin-like growth factor receptor type 1","nct_id":"NCT00813605","relation":"binds with Insulin-like growth factor receptor type 1"},{"evidence_type":"registry-field","excerpt":"AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.","matched_alias":"Insulin-like growth factor receptor type 1","nct_id":"NCT00819169","relation":"binds with Insulin-like growth factor receptor type 1"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"AMG 479","rationale":"Exact intervention-name aliases for IGF1R-directed antibodies.","rule_id":"candidate-ganitumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:IGF1R","target_name":"insulin-like growth factor 1 receptor","target_symbol":"IGF1R"}],"target_directness":"registry-explicit","target_ids":["symbol:IGF1R"],"target_names":["insulin-like growth factor 1 receptor"]},{"action":"binder","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"AMG 655 is an investigational, fully human, monoclonal antibody that selectively binds to Death Receptor-5 (DR-5)","matched_text":"binds","nct_id":"NCT00813605"},{"action":"binder","evidence_type":"registry-field","excerpt":"AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.","matched_text":"binds","nct_id":"NCT00819169"}],"actions":["binder"],"aliases":["AMG 655"],"intervention_id":"I-CTG-amg-655-488f67c71e","intervention_name":"AMG 655","intervention_type":"BIOLOGICAL","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":3}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00813605","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"AMG 655","registry_intervention_type":"BIOLOGICAL","source_record_index":41,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT00819169","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"AMG 655","registry_intervention_type":"BIOLOGICAL","source_record_index":92,"source_ref":"ctg-page-001"}],"status":"COMPLETED / TERMINATED","statuses":["COMPLETED","TERMINATED"],"study_count":2,"study_ids":["NCT00813605","NCT00819169"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"AMG 655 is an investigational, fully human, monoclonal antibody that selectively binds to Death Receptor-5 (DR-5)","matched_alias":"Death Receptor-5","nct_id":"NCT00813605","relation":"binds to Death Receptor-5"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"AMG 655","rationale":"Exact intervention-name alias for the DR5-directed antibody.","rule_id":"candidate-amg655","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:TNFRSF10B","target_name":"tumor necrosis factor receptor superfamily member 10B","target_symbol":"TNFRSF10B"}],"target_directness":"registry-explicit","target_ids":["symbol:TNFRSF10B"],"target_names":["tumor necrosis factor receptor superfamily member 10B"]},{"action":"inhibitor","action_evidence":[{"action":"inhibitor","evidence_type":"registry-field","excerpt":"…l organic molecule that has been shown in preclinical pharmacology studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively inhibiting all known VEGF receptors, PDG…","matched_text":"inhibitor","nct_id":"NCT00101894"}],"actions":["inhibitor"],"aliases":["AMG 706"],"intervention_id":"I-CTG-amg-706-402c244e95","intervention_name":"AMG 706","intervention_type":"DRUG","modality":"small-molecule","modality_distribution":[{"modality":"small-molecule","registry_occurrence_count":1}],"modality_support":{"matched_cues":["kinase inhibitor"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00101894","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"AMG 706","registry_intervention_type":"DRUG","source_record_index":13,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00101894"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Aminolevulinic Acid"],"intervention_id":"I-CTG-aminolevulinic-acid-26266e8895","intervention_name":"Aminolevulinic Acid","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06307548","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Aminolevulinic Acid","registry_intervention_type":"DRUG","source_record_index":91,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06307548"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Amivantamab"],"intervention_id":"I-CTG-amivantamab-3efdc81039","intervention_name":"Amivantamab","intervention_type":"COMBINATION_PRODUCT","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["COMBINATION_PRODUCT"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":10,"nct_id":"NCT05395052","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Amivantamab","registry_intervention_type":"COMBINATION_PRODUCT","source_record_index":52,"source_ref":"ctg-page-005"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT05395052"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Andes-1537 for Injection"],"intervention_id":"I-CTG-andes-1537-for-injection-95f88580f3","intervention_name":"Andes-1537 for Injection","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03985072","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Andes-1537 for Injection","registry_intervention_type":"DRUG","source_record_index":9,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03985072"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Anlotinib hydrochloride capsules"],"intervention_id":"I-CTG-anlotinib-hydrochloride-capsules-8604440201","intervention_name":"Anlotinib hydrochloride capsules","intervention_type":"DRUG","modality":"small-molecule","modality_distribution":[{"modality":"small-molecule","registry_occurrence_count":1}],"modality_support":{"matched_cues":["tyrosine kinase inhibitor"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT06010901","overall_status":"UNKNOWN","phases":["PHASE1"],"registered_name":"Anlotinib hydrochloride capsules","registry_intervention_type":"DRUG","source_record_index":19,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT06010901"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["anti-CD133-CAR vector-transduced T cells"],"intervention_id":"I-CTG-anti-cd133-car-vector-transduced-t-cells-71f6e37e6a","intervention_name":"anti-CD133-CAR vector-transduced T cells","intervention_type":"BIOLOGICAL","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR vector-transduced T cells"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02541370","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"anti-CD133-CAR vector-transduced T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":39,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02541370"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"anti-CD133-CAR vector-transduced T cells","matched_alias":"CD133","nct_id":"NCT02541370","relation":"anti-CD133"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PROM1","target_name":"prominin-1","target_symbol":"PROM1"}],"target_directness":"registry-explicit","target_ids":["symbol:PROM1"],"target_names":["prominin-1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["anti-CEA CAR-T cells","Anti-CEA CAR-T Cells"],"intervention_id":"I-CTG-anti-cea-car-t-cells-a8afa7bb5a","intervention_name":"anti-CEA CAR-T cells","intervention_type":"multiple","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":4}],"modality_support":{"matched_cues":["CAR-T cells","CAR-T Cells"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","DRUG"],"registry_occurrence_count":4,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02416466","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"anti-CEA CAR-T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":55,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT02850536","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"anti-CEA CAR-T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":48,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT03682744","overall_status":"WITHDRAWN","phases":["PHASE1"],"registered_name":"anti-CEA CAR-T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":20,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT05240950","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Anti-CEA CAR-T Cells","registry_intervention_type":"DRUG","source_record_index":67,"source_ref":"ctg-page-005"}],"status":"COMPLETED / RECRUITING / WITHDRAWN","statuses":["COMPLETED","RECRUITING","WITHDRAWN"],"study_count":4,"study_ids":["NCT02416466","NCT02850536","NCT03682744","NCT05240950"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"anti-CEA CAR-T cells","matched_alias":"CEA","nct_id":"NCT02416466","relation":"anti-CEA"},{"evidence_type":"registry-field","excerpt":"anti-CEA CAR-T cells","matched_alias":"CEA","nct_id":"NCT02850536","relation":"anti-CEA"},{"evidence_type":"registry-field","excerpt":"Intraperitoneal delivery of anti-CEA CAR-T cells","matched_alias":"CEA","nct_id":"NCT03682744","relation":"anti-CEA"},{"evidence_type":"registry-field","excerpt":"anti-CEA CAR-T cells","matched_alias":"CEA","nct_id":"NCT03682744","relation":"anti-CEA"},{"evidence_type":"registry-field","excerpt":"The study will evaluate the safety of intravenous infusion of anti-CEA CAR-T (+) cells in humans at doses of 1×10\\^6/kg, 3×10\\^6/kg, and 6×10\\^6/kg using a standard \"3+3\" design and preliminarily observe the efficacy.","matched_alias":"CEA","nct_id":"NCT05240950","relation":"anti-CEA"},{"evidence_type":"registry-field","excerpt":"Anti-CEA CAR-T Cells","matched_alias":"CEA","nct_id":"NCT05240950","relation":"Anti-CEA"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CEACAM5","target_name":"carcinoembryonic antigen-related cell adhesion molecule 5","target_symbol":"CEACAM5"}],"target_directness":"registry-explicit","target_ids":["symbol:CEACAM5"],"target_names":["carcinoembryonic antigen-related cell adhesion molecule 5"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Anti-CEA-CAR T"],"intervention_id":"I-CTG-anti-cea-car-t-7a15bcb339","intervention_name":"Anti-CEA-CAR T","intervention_type":"BIOLOGICAL","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":2}],"modality_support":{"matched_cues":["CAR T"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1 / PHASE1","phases":["EARLY_PHASE1","PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02349724","overall_status":"UNKNOWN","phases":["PHASE1"],"registered_name":"Anti-CEA-CAR T","registry_intervention_type":"BIOLOGICAL","source_record_index":30,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT04513431","overall_status":"UNKNOWN","phases":["EARLY_PHASE1"],"registered_name":"Anti-CEA-CAR T","registry_intervention_type":"BIOLOGICAL","source_record_index":72,"source_ref":"ctg-page-004"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":2,"study_ids":["NCT02349724","NCT04513431"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"T cells modified with CEA targeted chimeric antigen receptor.","matched_alias":"CEA","nct_id":"NCT02349724","relation":"targeted"},{"evidence_type":"registry-field","excerpt":"Anti-CEA-CAR T","matched_alias":"CEA","nct_id":"NCT02349724","relation":"Anti-CEA"},{"evidence_type":"registry-field","excerpt":"T cells modified with CEA targeted chimeric antigen receptor.","matched_alias":"CEA","nct_id":"NCT04513431","relation":"targeted"},{"evidence_type":"registry-field","excerpt":"Anti-CEA-CAR T","matched_alias":"CEA","nct_id":"NCT04513431","relation":"Anti-CEA"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CEACAM5","target_name":"carcinoembryonic antigen-related cell adhesion molecule 5","target_symbol":"CEACAM5"}],"target_directness":"registry-explicit","target_ids":["symbol:CEACAM5"],"target_names":["carcinoembryonic antigen-related cell adhesion molecule 5"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["anti-CTLA-4 antibody"],"intervention_id":"I-CTG-anti-ctla-4-antibody-d6dc4b60f3","intervention_name":"anti-CTLA-4 antibody","intervention_type":"BIOLOGICAL","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["anti-CTLA-4 antibody The anti-CTLA-4 antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT03058289","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"anti-CTLA-4 antibody","registry_intervention_type":"BIOLOGICAL","source_record_index":58,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03058289"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC","matched_alias":"CTLA-4","nct_id":"NCT03058289","relation":"anti-CTLA-4"},{"evidence_type":"registry-field","excerpt":"anti-CTLA-4 antibody","matched_alias":"CTLA-4","nct_id":"NCT03058289","relation":"anti-CTLA-4"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CTLA4","target_name":"cytotoxic T-lymphocyte protein 4","target_symbol":"CTLA4"}],"target_directness":"registry-explicit","target_ids":["symbol:CTLA4"],"target_names":["cytotoxic T-lymphocyte protein 4"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["anti-EGFR monoclonal antibody"],"intervention_id":"I-CTG-anti-egfr-monoclonal-antibody-11294839cd","intervention_name":"anti-EGFR monoclonal antibody","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03491709","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"anti-EGFR monoclonal antibody","registry_intervention_type":"DRUG","source_record_index":21,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03491709"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection","matched_alias":"EGFR","nct_id":"NCT03491709","relation":"anti-EGFR"},{"evidence_type":"registry-field","excerpt":"anti-EGFR monoclonal antibody","matched_alias":"EGFR","nct_id":"NCT03491709","relation":"anti-EGFR"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:EGFR","target_name":"epidermal growth factor receptor","target_symbol":"EGFR"}],"target_directness":"registry-explicit","target_ids":["symbol:EGFR"],"target_names":["epidermal growth factor receptor"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Anti-EGFR-Containing Regimen"],"intervention_id":"I-CTG-anti-egfr-containing-regimen-079e0c7097","intervention_name":"Anti-EGFR-Containing Regimen","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02831842","overall_status":"COMPLETED","phases":[],"registered_name":"Anti-EGFR-Containing Regimen","registry_intervention_type":"DRUG","source_record_index":4,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02831842"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Anti-EGFR-Containing Regimen","matched_alias":"EGFR","nct_id":"NCT02831842","relation":"Anti-EGFR"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:EGFR","target_name":"epidermal growth factor receptor","target_symbol":"EGFR"}],"target_directness":"registry-explicit","target_ids":["symbol:EGFR"],"target_names":["epidermal growth factor receptor"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Anti-HER2 CAR-T"],"intervention_id":"I-CTG-anti-her2-car-t-c75d83eaec","intervention_name":"Anti-HER2 CAR-T","intervention_type":"BIOLOGICAL","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR-T"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02713984","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"Anti-HER2 CAR-T","registry_intervention_type":"BIOLOGICAL","source_record_index":23,"source_ref":"ctg-page-004"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT02713984"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"HER-2-targeting CAR-T cells infusion in HER2 positive cancers","matched_alias":"HER-2","nct_id":"NCT02713984","relation":"targeting"},{"evidence_type":"registry-field","excerpt":"Anti-HER2 CAR-T","matched_alias":"HER2","nct_id":"NCT02713984","relation":"Anti-HER2"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:ERBB2","target_name":"receptor tyrosine-protein kinase erbB-2","target_symbol":"ERBB2"}],"target_directness":"registry-explicit","target_ids":["symbol:ERBB2"],"target_names":["receptor tyrosine-protein kinase erbB-2"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL)"],"intervention_id":"I-CTG-anti-kirsten-rat-sarcoma-virus-kras-glycin-147f0492e0","intervention_name":"anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL)","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT03745326","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL)","registry_intervention_type":"BIOLOGICAL","source_record_index":63,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT03745326"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Anti-KRAS G12V mTCR PBL"],"intervention_id":"I-CTG-anti-kras-g12v-mtcr-pbl-93878ef2b4","intervention_name":"Anti-KRAS G12V mTCR PBL","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT03190941","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Anti-KRAS G12V mTCR PBL","registry_intervention_type":"BIOLOGICAL","source_record_index":60,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT03190941"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["anti-MUC1 CAR-pNK cells"],"intervention_id":"I-CTG-anti-muc1-car-pnk-cells-ec10721779","intervention_name":"anti-MUC1 CAR-pNK cells","intervention_type":"BIOLOGICAL","modality":"car-nk-cell-therapy","modality_distribution":[{"modality":"car-nk-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR-pNK"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02839954","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"anti-MUC1 CAR-pNK cells","registry_intervention_type":"BIOLOGICAL","source_record_index":85,"source_ref":"ctg-page-002"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02839954"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"anti-MUC1 CAR-pNK cells","matched_alias":"MUC1","nct_id":"NCT02839954","relation":"anti-MUC1"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:MUC1","target_name":"mucin-1","target_symbol":"MUC1"}],"target_directness":"registry-explicit","target_ids":["symbol:MUC1"],"target_names":["mucin-1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["anti-MUC1 CAR-T cells"],"intervention_id":"I-CTG-anti-muc1-car-t-cells-7dae37eda8","intervention_name":"anti-MUC1 CAR-T cells","intervention_type":"BIOLOGICAL","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR-T cells"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02617134","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"anti-MUC1 CAR-T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":13,"source_ref":"ctg-page-005"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02617134"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"anti-MUC1 CAR-T cells","matched_alias":"MUC1","nct_id":"NCT02617134","relation":"anti-MUC1"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:MUC1","target_name":"mucin-1","target_symbol":"MUC1"}],"target_directness":"registry-explicit","target_ids":["symbol:MUC1"],"target_names":["mucin-1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["anti-PD-1 antibody"],"intervention_id":"I-CTG-anti-pd-1-antibody-0f75f0b392","intervention_name":"anti-PD-1 antibody","intervention_type":"BIOLOGICAL","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["anti-PD-1 antibody The anti-PD-1 antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03058289","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"anti-PD-1 antibody","registry_intervention_type":"BIOLOGICAL","source_record_index":58,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03058289"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"The anti-PD-1 antibody will be added concomitantly with INT230-6 as noted in cohort DEC and DEC2","matched_alias":"PD-1","nct_id":"NCT03058289","relation":"anti-PD-1"},{"evidence_type":"registry-field","excerpt":"anti-PD-1 antibody","matched_alias":"PD-1","nct_id":"NCT03058289","relation":"anti-PD-1"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"registry-explicit","target_ids":["symbol:PDCD1"],"target_names":["programmed cell death protein 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Anti-PD-1 monoclonal antibody"],"intervention_id":"I-CTG-anti-pd-1-monoclonal-antibody-83ef48eab2","intervention_name":"Anti-PD-1 monoclonal antibody","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT05307198","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Anti-PD-1 monoclonal antibody","registry_intervention_type":"DRUG","source_record_index":95,"source_ref":"ctg-page-004"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT05307198"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Anti-PD-1 monoclonal antibody","matched_alias":"PD-1","nct_id":"NCT05307198","relation":"Anti-PD-1"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"registry-explicit","target_ids":["symbol:PDCD1"],"target_names":["programmed cell death protein 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Anti-PD-L1 Monoclonal Antibody"],"intervention_id":"I-CTG-anti-pd-l1-monoclonal-antibody-b15c504477","intervention_name":"Anti-PD-L1 Monoclonal Antibody","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Monoclonal Antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT05914389","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Anti-PD-L1 Monoclonal Antibody","registry_intervention_type":"DRUG","source_record_index":51,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05914389"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"The incidence of adverse events with Anti-PD-L1 Monoclonal Antibodies is relatively low. Based on phase I clinical trial data of Envafolimab, a dose reduction design was conducted to minimize the incidence of adverse eve…","matched_alias":"PD-L1","nct_id":"NCT05914389","relation":"Anti-PD-L1"},{"evidence_type":"registry-field","excerpt":"Anti-PD-L1 Monoclonal Antibody","matched_alias":"PD-L1","nct_id":"NCT05914389","relation":"Anti-PD-L1"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CD274","target_name":"programmed death-ligand 1","target_symbol":"CD274"}],"target_directness":"registry-explicit","target_ids":["symbol:CD274"],"target_names":["programmed death-ligand 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Anti-SEMA4D Monoclonal Antibody VX15/2503"],"intervention_id":"I-CTG-anti-sema4d-monoclonal-antibody-vx15-2503-7692562550","intervention_name":"Anti-SEMA4D Monoclonal Antibody VX15/2503","intervention_type":"BIOLOGICAL","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Monoclonal Antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03373188","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Anti-SEMA4D Monoclonal Antibody VX15/2503","registry_intervention_type":"BIOLOGICAL","source_record_index":14,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03373188"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Anti-SEMA4D Monoclonal Antibody VX15/2503","matched_alias":"SEMA4D","nct_id":"NCT03373188","relation":"Anti-SEMA4D"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:SEMA4D","target_name":"semaphorin-4D","target_symbol":"SEMA4D"}],"target_directness":"registry-explicit","target_ids":["symbol:SEMA4D"],"target_names":["semaphorin-4D"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Apatinib Mesylate Tablets"],"intervention_id":"I-CTG-apatinib-mesylate-tablets-4e0201acc6","intervention_name":"Apatinib Mesylate Tablets","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":2}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA / PHASE2","phases":["NA","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03271255","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Apatinib Mesylate Tablets","registry_intervention_type":"DRUG","source_record_index":43,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT03743428","overall_status":"SUSPENDED","phases":["NA"],"registered_name":"Apatinib Mesylate Tablets","registry_intervention_type":"DRUG","source_record_index":80,"source_ref":"ctg-page-005"}],"status":"SUSPENDED / UNKNOWN","statuses":["SUSPENDED","UNKNOWN"],"study_count":2,"study_ids":["NCT03271255","NCT03743428"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Apheresis"],"intervention_id":"I-CTG-apheresis-ed41b65a76","intervention_name":"Apheresis","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04981119","overall_status":"RECRUITING","phases":[],"registered_name":"Apheresis","registry_intervention_type":"OTHER","source_record_index":63,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT04981119"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Aprepitant"],"intervention_id":"I-CTG-aprepitant-787ff3ff6c","intervention_name":"Aprepitant","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":6,"nct_id":"NCT01851369","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Aprepitant","registry_intervention_type":"OTHER","source_record_index":99,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01851369"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["artificial intelligence system"],"intervention_id":"I-CTG-artificial-intelligence-system-9c12a4b349","intervention_name":"artificial intelligence system","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06335654","overall_status":"COMPLETED","phases":[],"registered_name":"artificial intelligence system","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":53,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT06335654"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ASP1002"],"intervention_id":"I-CTG-asp1002-6134c9a134","intervention_name":"ASP1002","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05719558","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"ASP1002","registry_intervention_type":"DRUG","source_record_index":80,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05719558"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"binder; blocker; inhibitor","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"Atezolizumab is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway,","matched_text":"bind","nct_id":"NCT05482516"},{"action":"binder","evidence_type":"registry-field","excerpt":"…ype of targeted therapy drug called an immune checkpoint inhibitor. It is a monoclonal antibody that works by binding to the protein PD-L1 (programmed death) on the surface of some cancer cells, which keeps cancer cells from su…","matched_text":"binding","nct_id":"NCT06784947"},{"action":"blocker","evidence_type":"registry-field","excerpt":"…gs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway,","matched_text":"blocking","nct_id":"NCT05482516"},{"action":"inhibitor","evidence_type":"registry-field","excerpt":"Atezolizumab is a type of targeted therapy drug called an immune checkpoint inhibitor. It is a monoclonal antibody that works by binding to the protein PD-L1 (programmed death) on the surface of some cancer cells, which …","matched_text":"inhibitor","nct_id":"NCT06784947"}],"actions":["binder","blocker","inhibitor"],"aliases":["Atezolizumab"],"intervention_id":"I-CTG-atezolizumab-5dd1e8658b","intervention_name":"Atezolizumab","intervention_type":"multiple","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":5},{"modality":"other-or-unclear","registry_occurrence_count":4}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3","phases":["PHASE1","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["COMBINATION_PRODUCT","DRUG"],"registry_occurrence_count":8,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT02291289","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Atezolizumab","registry_intervention_type":"DRUG","source_record_index":28,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT03866239","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Atezolizumab","registry_intervention_type":"DRUG","source_record_index":65,"source_ref":"ctg-page-002"},{"intervention_index":3,"nct_id":"NCT04929223","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Atezolizumab","registry_intervention_type":"DRUG","source_record_index":64,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT05243862","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Atezolizumab","registry_intervention_type":"DRUG","source_record_index":54,"source_ref":"ctg-page-003"},{"intervention_index":7,"nct_id":"NCT05395052","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Atezolizumab","registry_intervention_type":"COMBINATION_PRODUCT","source_record_index":52,"source_ref":"ctg-page-005"},{"intervention_index":0,"nct_id":"NCT05482516","overall_status":"RECRUITING","phases":["PHASE3"],"registered_name":"Atezolizumab","registry_intervention_type":"DRUG","source_record_index":60,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT06012734","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Atezolizumab","registry_intervention_type":"DRUG","source_record_index":7,"source_ref":"ctg-page-005"},{"intervention_index":3,"nct_id":"NCT06784947","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Atezolizumab","registry_intervention_type":"DRUG","source_record_index":9,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / RECRUITING / TERMINATED","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","RECRUITING","TERMINATED"],"study_count":8,"study_ids":["NCT02291289","NCT03866239","NCT04929223","NCT05243862","NCT05395052","NCT05482516","NCT06012734","NCT06784947"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"atezolizumab","rationale":"Exact intervention-name aliases for PD-L1-directed antibodies.","rule_id":"candidate-pdl1-antibodies","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CD274","target_name":"programmed death-ligand 1","target_symbol":"CD274"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:CD274"],"target_names":["programmed death-ligand 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ATRC-101"],"intervention_id":"I-CTG-atrc-101-68cdc8775f","intervention_name":"ATRC-101","intervention_type":"BIOLOGICAL","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["IgG1"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04244552","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"ATRC-101","registry_intervention_type":"BIOLOGICAL","source_record_index":70,"source_ref":"ctg-page-005"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT04244552"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["autologous dendritic cell vaccination"],"intervention_id":"I-CTG-autologous-dendritic-cell-vaccination-078253425d","intervention_name":"autologous dendritic cell vaccination","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccination"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01291420","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"autologous dendritic cell vaccination","registry_intervention_type":"BIOLOGICAL","source_record_index":38,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01291420"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["autologous dendritic cells loaded with autologous tumour homogenate"],"intervention_id":"I-CTG-autologous-dendritic-cells-loaded-with-aut-0ac8911b52","intervention_name":"autologous dendritic cells loaded with autologous tumour homogenate","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02919644","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"autologous dendritic cells loaded with autologous tumour homogenate","registry_intervention_type":"BIOLOGICAL","source_record_index":83,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT02919644"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Autologous hematopoietic and immune cell rescue (transplantation)"],"intervention_id":"I-CTG-autologous-hematopoietic-and-immune-cell-r-2ddcee3f25","intervention_name":"Autologous hematopoietic and immune cell rescue (transplantation)","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00780988","overall_status":"WITHDRAWN","phases":["PHASE1"],"registered_name":"Autologous hematopoietic and immune cell rescue (transplantation)","registry_intervention_type":"PROCEDURE","source_record_index":55,"source_ref":"ctg-page-005"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT00780988"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Autologous tumor cell + CpG vaccine"],"intervention_id":"I-CTG-autologous-tumor-cell-cpg-vaccine-75a426cf64","intervention_name":"Autologous tumor cell + CpG vaccine","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00780988","overall_status":"WITHDRAWN","phases":["PHASE1"],"registered_name":"Autologous tumor cell + CpG vaccine","registry_intervention_type":"BIOLOGICAL","source_record_index":55,"source_ref":"ctg-page-005"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT00780988"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Avastin"],"intervention_id":"I-CTG-avastin-f9a8fcc9c3","intervention_name":"Avastin","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1},{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01507740","overall_status":"TERMINATED","phases":[],"registered_name":"Avastin","registry_intervention_type":"DRUG","source_record_index":28,"source_ref":"ctg-page-002"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT01507740"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"Avastin","rationale":"Exact intervention-name aliases for the VEGF-A-directed antibody.","rule_id":"candidate-bevacizumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"secreted-ligand","target_id":"symbol:VEGFA","target_name":"vascular endothelial growth factor A","target_symbol":"VEGFA"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:VEGFA"],"target_names":["vascular endothelial growth factor A"]},{"action":"binder; blocker","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"…elumab is a fully human monoclonal antibody (MoAb) of the immunoglobulin G (IgG) 1 subtype which specifically binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.","matched_text":"binds","nct_id":"NCT03827044"},{"action":"blocker","evidence_type":"registry-field","excerpt":"… (MoAb) of the immunoglobulin G (IgG) 1 subtype which specifically binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.","matched_text":"blocks","nct_id":"NCT03827044"}],"actions":["binder","blocker"],"aliases":["Avelumab","avelumab"],"intervention_id":"I-CTG-avelumab-b59aea15d3","intervention_name":"avelumab","intervention_type":"multiple","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":4},{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":["Monoclonal antibody","monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3","phases":["PHASE1","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","COMBINATION_PRODUCT","DRUG"],"registry_occurrence_count":5,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01772004","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Avelumab","registry_intervention_type":"DRUG","source_record_index":33,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"avelumab","registry_intervention_type":"BIOLOGICAL","source_record_index":17,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT03186326","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Avelumab","registry_intervention_type":"DRUG","source_record_index":60,"source_ref":"ctg-page-005"},{"intervention_index":0,"nct_id":"NCT03827044","overall_status":"TERMINATED","phases":["PHASE3"],"registered_name":"Avelumab","registry_intervention_type":"DRUG","source_record_index":82,"source_ref":"ctg-page-005"},{"intervention_index":4,"nct_id":"NCT05395052","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Avelumab","registry_intervention_type":"COMBINATION_PRODUCT","source_record_index":52,"source_ref":"ctg-page-005"}],"status":"COMPLETED / TERMINATED / WITHDRAWN","statuses":["COMPLETED","TERMINATED","WITHDRAWN"],"study_count":5,"study_ids":["NCT01772004","NCT03169777","NCT03186326","NCT03827044","NCT05395052"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Fully human anti-programmed death-ligand 1 (PD-L1) immunoglobulin (Ig)G1 lambda monoclonal antibody","matched_alias":"programmed death-ligand 1","nct_id":"NCT03169777","relation":"anti-programmed death-ligand 1"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"avelumab","rationale":"Exact intervention-name aliases for PD-L1-directed antibodies.","rule_id":"candidate-pdl1-antibodies","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CD274","target_name":"programmed death-ligand 1","target_symbol":"CD274"}],"target_directness":"registry-explicit","target_ids":["symbol:CD274"],"target_names":["programmed death-ligand 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["AZD4635"],"intervention_id":"I-CTG-azd4635-ee309fd293","intervention_name":"AZD4635","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02740985","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"AZD4635","registry_intervention_type":"DRUG","source_record_index":72,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02740985"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Balstilimab"],"intervention_id":"I-CTG-balstilimab-5a47b9bd23","intervention_name":"Balstilimab","intervention_type":"multiple","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":3},{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":["anti-PD-1 antibody","monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","DRUG"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03860272","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"registered_name":"Balstilimab","registry_intervention_type":"DRUG","source_record_index":39,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT05608044","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Balstilimab","registry_intervention_type":"DRUG","source_record_index":45,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT05672316","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Balstilimab","registry_intervention_type":"BIOLOGICAL","source_record_index":24,"source_ref":"ctg-page-001"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":3,"study_ids":["NCT03860272","NCT05608044","NCT05672316"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"A fully human monoclonal anti-PD-1 antibody","matched_alias":"PD-1","nct_id":"NCT03860272","relation":"anti-PD-1"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"balstilimab","rationale":"Exact intervention-name aliases for PD-1-directed antibodies.","rule_id":"candidate-other-pd1-antibodies","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"registry-explicit","target_ids":["symbol:PDCD1"],"target_names":["programmed cell death protein 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["BAY 43-9006"],"intervention_id":"I-CTG-bay-43-9006-32706741de","intervention_name":"BAY 43-9006","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00326495","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"BAY 43-9006","registry_intervention_type":"DRUG","source_record_index":64,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00326495"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["BAY2927088"],"intervention_id":"I-CTG-bay2927088-10eedb2ea7","intervention_name":"BAY2927088","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06760819","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"BAY2927088","registry_intervention_type":"DRUG","source_record_index":72,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06760819"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Best supportive care"],"intervention_id":"I-CTG-best-supportive-care-8f032e0c75","intervention_name":"Best supportive care","intervention_type":"OTHER","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00113763","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"Best supportive care","registry_intervention_type":"OTHER","source_record_index":1,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00113763"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Best Supportive Care (BSC)"],"intervention_id":"I-CTG-best-supportive-care-bsc-e0cd284b91","intervention_name":"Best Supportive Care (BSC)","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT02083653","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Best Supportive Care (BSC)","registry_intervention_type":"OTHER","source_record_index":76,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02083653"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"inhibitor","action_evidence":[{"action":"inhibitor","evidence_type":"registry-field","excerpt":"BET Bromodomain Inhibitor ZEN-3694","matched_text":"Inhibitor","nct_id":"NCT05803382"}],"actions":["inhibitor"],"aliases":["BET Bromodomain Inhibitor ZEN-3694"],"intervention_id":"I-CTG-bet-bromodomain-inhibitor-zen-3694-3b8be26ce3","intervention_name":"BET Bromodomain Inhibitor ZEN-3694","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05803382","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"BET Bromodomain Inhibitor ZEN-3694","registry_intervention_type":"DRUG","source_record_index":53,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05803382"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"blocker; inhibitor","action_evidence":[{"action":"blocker","evidence_type":"registry-field","excerpt":"Bevacizumab is a tumor-starving (anti-angiogenic) therapy. Avastin is designed to block a protein called vascular endothelial growth factor, or VEGF.","matched_text":"block","nct_id":"NCT05482516"},{"action":"blocker","evidence_type":"registry-field","excerpt":"Bevacizumab works by blocking a protein called Vascular Endothelial Growth Factor (VEGF), which some cancer cells produce in large amounts. Blocking VEGF may prevent the growth of new blood vessels that tumors need to gr…","matched_text":"blocking","nct_id":"NCT06784947"},{"action":"inhibitor","evidence_type":"registry-field","excerpt":"…vacizumab is a humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF)-A to inhibit angiogenesis.","matched_text":"inhibit","nct_id":"NCT03250832"},{"action":"inhibitor","evidence_type":"registry-field","excerpt":"…lp improve the immune response in the tumor. Bevacizumab is a type of targeted therapy called an angiogenesis inhibitor.","matched_text":"inhibitor","nct_id":"NCT06784947"}],"actions":["blocker","inhibitor"],"aliases":["Bevacizumab","bevacizumab"],"intervention_id":"I-CTG-bevacizumab-8446a83051","intervention_name":"Bevacizumab","intervention_type":"multiple","modality":"antibody","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":32},{"modality":"antibody","registry_occurrence_count":8},{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":3}],"modality_support":{"matched_cues":["chemotherapy","FOLFIRI","IgG1","Monoclonal antibody","monoclonal antibody","oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3 / PHASE4","phases":["PHASE1","PHASE2","PHASE3","PHASE4"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","DRUG"],"registry_occurrence_count":42,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT00636610","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":44,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT00819780","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":46,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT01167725","overall_status":"TERMINATED","phases":["PHASE3"],"registered_name":"bevacizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":35,"source_ref":"ctg-page-004"},{"intervention_index":3,"nct_id":"NCT01205022","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"bevacizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":39,"source_ref":"ctg-page-004"},{"intervention_index":3,"nct_id":"NCT01327612","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":4,"source_ref":"ctg-page-005"},{"intervention_index":5,"nct_id":"NCT01442935","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":96,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT01588990","overall_status":"COMPLETED","phases":["PHASE4"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":13,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT01775644","overall_status":"COMPLETED","phases":[],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":49,"source_ref":"ctg-page-002"},{"intervention_index":5,"nct_id":"NCT02291289","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":28,"source_ref":"ctg-page-005"},{"intervention_index":3,"nct_id":"NCT02563002","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"Bevacizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":90,"source_ref":"ctg-page-004"},{"intervention_index":4,"nct_id":"NCT02671435","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":66,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT02835833","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":1,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT02848443","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":40,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT03082209","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":70,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"bevacizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":17,"source_ref":"ctg-page-001"},{"intervention_index":5,"nct_id":"NCT03186326","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":60,"source_ref":"ctg-page-005"},{"intervention_index":4,"nct_id":"NCT03250832","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":77,"source_ref":"ctg-page-005"},{"intervention_index":2,"nct_id":"NCT03380689","overall_status":"WITHDRAWN","phases":["PHASE1"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":95,"source_ref":"ctg-page-003"},{"intervention_index":5,"nct_id":"NCT03607643","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":59,"source_ref":"ctg-page-003"},{"intervention_index":7,"nct_id":"NCT03715933","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":9,"source_ref":"ctg-page-005"},{"intervention_index":2,"nct_id":"NCT04262687","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":65,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT04527068","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":75,"source_ref":"ctg-page-004"},{"intervention_index":4,"nct_id":"NCT04587128","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":81,"source_ref":"ctg-page-005"},{"intervention_index":3,"nct_id":"NCT04660812","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":78,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT04929223","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":64,"source_ref":"ctg-page-003"},{"intervention_index":8,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT05007132","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":86,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT05482516","overall_status":"RECRUITING","phases":["PHASE3"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":60,"source_ref":"ctg-page-004"},{"intervention_index":5,"nct_id":"NCT05489211","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":76,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT05719558","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":80,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT06003998","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":6,"source_ref":"ctg-page-003"},{"intervention_index":8,"nct_id":"NCT06047379","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":79,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT06400472","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"bevacizumab","registry_intervention_type":"DRUG","source_record_index":48,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT06448364","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"bevacizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":54,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT06696768","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Bevacizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":70,"source_ref":"ctg-page-002"},{"intervention_index":4,"nct_id":"NCT06784947","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":9,"source_ref":"ctg-page-002"},{"intervention_index":3,"nct_id":"NCT06856837","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":31,"source_ref":"ctg-page-005"},{"intervention_index":2,"nct_id":"NCT06887218","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":29,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT07277270","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":23,"source_ref":"ctg-page-002"},{"intervention_index":6,"nct_id":"NCT07318805","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":61,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT07407465","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":86,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT07503756","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Bevacizumab","registry_intervention_type":"DRUG","source_record_index":49,"source_ref":"ctg-page-001"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / RECRUITING / TERMINATED / UNKNOWN / WITHDRAWN","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","RECRUITING","TERMINATED","UNKNOWN","WITHDRAWN"],"study_count":42,"study_ids":["NCT00636610","NCT00819780","NCT01167725","NCT01205022","NCT01327612","NCT01442935","NCT01588990","NCT01775644","NCT02291289","NCT02563002","NCT02671435","NCT02835833","NCT02848443","NCT03082209","NCT03169777","NCT03186326","NCT03250832","NCT03380689","NCT03607643","NCT03715933","NCT04262687","NCT04527068","NCT04587128","NCT04660812","NCT04929223","NCT04999761","NCT05007132","NCT05482516","NCT05489211","NCT05719558","NCT06003998","NCT06047379","NCT06400472","NCT06448364","NCT06696768","NCT06784947","NCT06856837","NCT06887218","NCT07277270","NCT07318805","NCT07407465","NCT07503756"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"bevacizumab","rationale":"Exact intervention-name aliases for the VEGF-A-directed antibody.","rule_id":"candidate-bevacizumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"secreted-ligand","target_id":"symbol:VEGFA","target_name":"vascular endothelial growth factor A","target_symbol":"VEGFA"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:VEGFA"],"target_names":["vascular endothelial growth factor A"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Bevacizumab + Capecitabine + Radiotherapy"],"intervention_id":"I-CTG-bevacizumab-capecitabine-radiotherapy-6e5e021cd4","intervention_name":"Bevacizumab + Capecitabine + Radiotherapy","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Capecitabine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01043484","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Bevacizumab + Capecitabine + Radiotherapy","registry_intervention_type":"DRUG","source_record_index":0,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01043484"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Bevacizumab Biosimilar"],"intervention_id":"I-CTG-bevacizumab-biosimilar-a36da74e4d","intervention_name":"Bevacizumab Biosimilar","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":2}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07007767","overall_status":"NOT_YET_RECRUITING","phases":["PHASE2"],"registered_name":"Bevacizumab Biosimilar","registry_intervention_type":"DRUG","source_record_index":79,"source_ref":"ctg-page-002"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07007767"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"bevacizumab biosimilar","rationale":"Exact intervention-name aliases for the VEGF-A-directed antibody.","rule_id":"candidate-bevacizumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"secreted-ligand","target_id":"symbol:VEGFA","target_name":"vascular endothelial growth factor A","target_symbol":"VEGFA"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:VEGFA"],"target_names":["vascular endothelial growth factor A"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Bevacizumab in combination with chemotherapy based on fluoropyrimidine IV"],"intervention_id":"I-CTG-bevacizumab-in-combination-with-chemothera-9b51bb8bfe","intervention_name":"Bevacizumab in combination with chemotherapy based on fluoropyrimidine IV","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE4","phases":["PHASE4"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04813913","overall_status":"COMPLETED","phases":["PHASE4"],"registered_name":"Bevacizumab in combination with chemotherapy based on fluoropyrimidine IV","registry_intervention_type":"DRUG","source_record_index":26,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT04813913"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Bevacizumab Injection","Bevacizumab injection"],"intervention_id":"I-CTG-bevacizumab-injection-b001eba9fa","intervention_name":"Bevacizumab Injection","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":2},{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":2}],"modality_support":{"matched_cues":["chemotherapy","monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA / PHASE1 / PHASE2","phases":["NA","PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03271255","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Bevacizumab Injection","registry_intervention_type":"DRUG","source_record_index":43,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT03743428","overall_status":"SUSPENDED","phases":["NA"],"registered_name":"Bevacizumab Injection","registry_intervention_type":"DRUG","source_record_index":80,"source_ref":"ctg-page-005"},{"intervention_index":0,"nct_id":"NCT05476341","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Bevacizumab injection","registry_intervention_type":"DRUG","source_record_index":46,"source_ref":"ctg-page-005"}],"status":"COMPLETED / SUSPENDED / UNKNOWN","statuses":["COMPLETED","SUSPENDED","UNKNOWN"],"study_count":3,"study_ids":["NCT03271255","NCT03743428","NCT05476341"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"bevacizumab injection","rationale":"Exact intervention-name aliases for the VEGF-A-directed antibody.","rule_id":"candidate-bevacizumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"secreted-ligand","target_id":"symbol:VEGFA","target_name":"vascular endothelial growth factor A","target_symbol":"VEGFA"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:VEGFA"],"target_names":["vascular endothelial growth factor A"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Bevacizumab injection(Avastin)"],"intervention_id":"I-CTG-bevacizumab-injection-avastin-cb4c34f227","intervention_name":"Bevacizumab injection(Avastin)","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05476341","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Bevacizumab injection(Avastin)","registry_intervention_type":"DRUG","source_record_index":46,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT05476341"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Bevacizumab-containing regimen"],"intervention_id":"I-CTG-bevacizumab-containing-regimen-3d791f39a9","intervention_name":"Bevacizumab-containing regimen","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT02831842","overall_status":"COMPLETED","phases":[],"registered_name":"Bevacizumab-containing regimen","registry_intervention_type":"DRUG","source_record_index":4,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02831842"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["BIBW 2992"],"intervention_id":"I-CTG-bibw-2992-4416ed0aea","intervention_name":"BIBW 2992","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01152437","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"BIBW 2992","registry_intervention_type":"DRUG","source_record_index":28,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01152437"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["binimetinib","Binimetinib"],"intervention_id":"I-CTG-binimetinib-fc88a18a7b","intervention_name":"binimetinib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":3}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1 / PHASE1 / PHASE2","phases":["EARLY_PHASE1","PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03271047","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"binimetinib","registry_intervention_type":"DRUG","source_record_index":77,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT04800822","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"binimetinib","registry_intervention_type":"DRUG","source_record_index":15,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT04870034","overall_status":"WITHDRAWN","phases":["EARLY_PHASE1"],"registered_name":"Binimetinib","registry_intervention_type":"DRUG","source_record_index":1,"source_ref":"ctg-page-003"}],"status":"COMPLETED / TERMINATED / WITHDRAWN","statuses":["COMPLETED","TERMINATED","WITHDRAWN"],"study_count":3,"study_ids":["NCT03271047","NCT04800822","NCT04870034"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Biomarker"],"intervention_id":"I-CTG-biomarker-78a06ba58b","intervention_name":"Biomarker","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT02280070","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Biomarker","registry_intervention_type":"OTHER","source_record_index":62,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02280070"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Biopsy"],"intervention_id":"I-CTG-biopsy-9621fbc743","intervention_name":"Biopsy","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":3}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1 / PHASE1 / PHASE2","phases":["EARLY_PHASE1","PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":7,"nct_id":"NCT01851369","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Biopsy","registry_intervention_type":"PROCEDURE","source_record_index":99,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT04906382","overall_status":"TERMINATED","phases":["EARLY_PHASE1"],"registered_name":"Biopsy","registry_intervention_type":"PROCEDURE","source_record_index":84,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT06130826","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Biopsy","registry_intervention_type":"PROCEDURE","source_record_index":89,"source_ref":"ctg-page-004"}],"status":"COMPLETED / RECRUITING / TERMINATED","statuses":["COMPLETED","RECRUITING","TERMINATED"],"study_count":3,"study_ids":["NCT01851369","NCT04906382","NCT06130826"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Biopsy Procedure"],"intervention_id":"I-CTG-biopsy-procedure-426e7eb4e9","intervention_name":"Biopsy Procedure","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":9}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":9,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02298959","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"registered_name":"Biopsy Procedure","registry_intervention_type":"PROCEDURE","source_record_index":64,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT02978625","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Biopsy Procedure","registry_intervention_type":"PROCEDURE","source_record_index":93,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT04595747","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Biopsy Procedure","registry_intervention_type":"PROCEDURE","source_record_index":49,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT05419011","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Biopsy Procedure","registry_intervention_type":"PROCEDURE","source_record_index":85,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT05803382","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Biopsy Procedure","registry_intervention_type":"PROCEDURE","source_record_index":53,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT06136897","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Biopsy Procedure","registry_intervention_type":"PROCEDURE","source_record_index":41,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT06654037","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Biopsy Procedure","registry_intervention_type":"PROCEDURE","source_record_index":55,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT06696768","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Biopsy Procedure","registry_intervention_type":"PROCEDURE","source_record_index":70,"source_ref":"ctg-page-002"},{"intervention_index":9,"nct_id":"NCT07405476","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Biopsy Procedure","registry_intervention_type":"PROCEDURE","source_record_index":97,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING / RECRUITING","statuses":["ACTIVE_NOT_RECRUITING","RECRUITING"],"study_count":9,"study_ids":["NCT02298959","NCT02978625","NCT04595747","NCT05419011","NCT05803382","NCT06136897","NCT06654037","NCT06696768","NCT07405476"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Biospecimen Collection"],"intervention_id":"I-CTG-biospecimen-collection-4197a4ebc7","intervention_name":"Biospecimen Collection","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":17}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":17,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT02298959","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"registered_name":"Biospecimen Collection","registry_intervention_type":"PROCEDURE","source_record_index":64,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT02314169","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Biospecimen Collection","registry_intervention_type":"PROCEDURE","source_record_index":61,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT02408861","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Biospecimen Collection","registry_intervention_type":"PROCEDURE","source_record_index":50,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT02834013","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Biospecimen Collection","registry_intervention_type":"PROCEDURE","source_record_index":44,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT02978625","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Biospecimen Collection","registry_intervention_type":"PROCEDURE","source_record_index":93,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT04314401","overall_status":"ACTIVE_NOT_RECRUITING","phases":[],"registered_name":"Biospecimen Collection","registry_intervention_type":"PROCEDURE","source_record_index":47,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT04500548","overall_status":"WITHDRAWN","phases":["PHASE1"],"registered_name":"Biospecimen Collection","registry_intervention_type":"PROCEDURE","source_record_index":51,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT04595747","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Biospecimen Collection","registry_intervention_type":"PROCEDURE","source_record_index":49,"source_ref":"ctg-page-004"},{"intervention_index":2,"nct_id":"NCT05419011","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Biospecimen Collection","registry_intervention_type":"PROCEDURE","source_record_index":85,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT05672316","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Biospecimen Collection","registry_intervention_type":"PROCEDURE","source_record_index":24,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT05803382","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Biospecimen Collection","registry_intervention_type":"PROCEDURE","source_record_index":53,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT06130826","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Biospecimen Collection","registry_intervention_type":"PROCEDURE","source_record_index":89,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT06136897","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Biospecimen Collection","registry_intervention_type":"PROCEDURE","source_record_index":41,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT06307548","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Biospecimen Collection","registry_intervention_type":"PROCEDURE","source_record_index":91,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT06654037","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Biospecimen Collection","registry_intervention_type":"PROCEDURE","source_record_index":55,"source_ref":"ctg-page-004"},{"intervention_index":2,"nct_id":"NCT06696768","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Biospecimen Collection","registry_intervention_type":"PROCEDURE","source_record_index":70,"source_ref":"ctg-page-002"},{"intervention_index":8,"nct_id":"NCT07405476","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Biospecimen Collection","registry_intervention_type":"PROCEDURE","source_record_index":97,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING / RECRUITING / TERMINATED / WITHDRAWN","statuses":["ACTIVE_NOT_RECRUITING","RECRUITING","TERMINATED","WITHDRAWN"],"study_count":17,"study_ids":["NCT02298959","NCT02314169","NCT02408861","NCT02834013","NCT02978625","NCT04314401","NCT04500548","NCT04595747","NCT05419011","NCT05672316","NCT05803382","NCT06130826","NCT06136897","NCT06307548","NCT06654037","NCT06696768","NCT07405476"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["BLOOD AND TUMOR"],"intervention_id":"I-CTG-blood-and-tumor-10e5261d4d","intervention_name":"BLOOD AND TUMOR","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05955196","overall_status":"RECRUITING","phases":[],"registered_name":"BLOOD AND TUMOR","registry_intervention_type":"PROCEDURE","source_record_index":89,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05955196"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Blood Collection for Plasma ctDNA"],"intervention_id":"I-CTG-blood-collection-for-plasma-ctdna-c06f923009","intervention_name":"Blood Collection for Plasma ctDNA","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07001085","overall_status":"RECRUITING","phases":["NA"],"registered_name":"Blood Collection for Plasma ctDNA","registry_intervention_type":"OTHER","source_record_index":34,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07001085"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["blood pressure measurement"],"intervention_id":"I-CTG-blood-pressure-measurement-e479a7af1e","intervention_name":"blood pressure measurement","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT01810744","overall_status":"COMPLETED","phases":["NA"],"registered_name":"blood pressure measurement","registry_intervention_type":"OTHER","source_record_index":69,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01810744"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Blood sample"],"intervention_id":"I-CTG-blood-sample-c4e8a6bf03","intervention_name":"Blood sample","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05524012","overall_status":"ACTIVE_NOT_RECRUITING","phases":[],"registered_name":"Blood sample","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":54,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT05524012"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Blood sampling"],"intervention_id":"I-CTG-blood-sampling-8397318160","intervention_name":"Blood sampling","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT02557061","overall_status":"COMPLETED","phases":["NA"],"registered_name":"Blood sampling","registry_intervention_type":"BIOLOGICAL","source_record_index":37,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02557061"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Blood test"],"intervention_id":"I-CTG-blood-test-b2571e0e22","intervention_name":"Blood test","intervention_type":"OTHER","modality":"cellular-therapy","modality_distribution":[{"modality":"cellular-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["NK cells"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06454071","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Blood test","registry_intervention_type":"OTHER","source_record_index":56,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT06454071"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Bone Marrow Biopsy"],"intervention_id":"I-CTG-bone-marrow-biopsy-d361d304aa","intervention_name":"Bone Marrow Biopsy","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT02408861","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Bone Marrow Biopsy","registry_intervention_type":"PROCEDURE","source_record_index":50,"source_ref":"ctg-page-003"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT02408861"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Bone Scan"],"intervention_id":"I-CTG-bone-scan-76e68ecb1f","intervention_name":"Bone Scan","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT06130826","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Bone Scan","registry_intervention_type":"PROCEDURE","source_record_index":89,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06130826"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Bortezomib"],"intervention_id":"I-CTG-bortezomib-080fc3cced","intervention_name":"Bortezomib","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03607643","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"Bortezomib","registry_intervention_type":"DRUG","source_record_index":59,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT03607643"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Botensilimab"],"intervention_id":"I-CTG-botensilimab-fc49d21f07","intervention_name":"Botensilimab","intervention_type":"multiple","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":3},{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","DRUG"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03860272","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"registered_name":"Botensilimab","registry_intervention_type":"DRUG","source_record_index":39,"source_ref":"ctg-page-005"},{"intervention_index":0,"nct_id":"NCT05608044","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Botensilimab","registry_intervention_type":"DRUG","source_record_index":45,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT05672316","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Botensilimab","registry_intervention_type":"BIOLOGICAL","source_record_index":24,"source_ref":"ctg-page-001"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":3,"study_ids":["NCT03860272","NCT05608044","NCT05672316"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"An Fc-engineered anti-CTLA-4 monoclonal antibody","matched_alias":"CTLA-4","nct_id":"NCT03860272","relation":"anti-CTLA-4"},{"evidence_type":"registry-field","excerpt":"An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.","matched_alias":"CTLA-4","nct_id":"NCT05608044","relation":"monoclonal antibody"},{"evidence_type":"registry-field","excerpt":"An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.","matched_alias":"cytotoxic T-lymphocyte antigen 4","nct_id":"NCT05608044","relation":"anti-cytotoxic T-lymphocyte antigen 4"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"botensilimab","rationale":"Exact intervention-name alias for the CTLA-4-directed antibody.","rule_id":"candidate-botensilimab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CTLA4","target_name":"cytotoxic T-lymphocyte protein 4","target_symbol":"CTLA4"}],"target_directness":"registry-explicit","target_ids":["symbol:CTLA4"],"target_names":["cytotoxic T-lymphocyte protein 4"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["BTG-002814"],"intervention_id":"I-CTG-btg-002814-7ade8f054d","intervention_name":"BTG-002814","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1","phases":["EARLY_PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03291379","overall_status":"COMPLETED","phases":["EARLY_PHASE1"],"registered_name":"BTG-002814","registry_intervention_type":"DRUG","source_record_index":94,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03291379"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["BVAC-B"],"intervention_id":"I-CTG-bvac-b-af1d5fe703","intervention_name":"BVAC-B","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03425773","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"BVAC-B","registry_intervention_type":"BIOLOGICAL","source_record_index":15,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03425773"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["BW and height"],"intervention_id":"I-CTG-bw-and-height-f41a2fad6d","intervention_name":"BW and height","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT02280070","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"BW and height","registry_intervention_type":"OTHER","source_record_index":62,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02280070"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["BYL719"],"intervention_id":"I-CTG-byl719-94ba9da64b","intervention_name":"BYL719","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT01719380","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"BYL719","registry_intervention_type":"DRUG","source_record_index":16,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01719380"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"binder; inhibitor","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"…ely related RTKs KIT and FLT-3. The mode of action for cabozantinib is similar to other drugs targeting RTKs: binding in a fully reversible manner to a region of the kinase domain (including the ATP-binding site) which forces t…","matched_text":"binding","nct_id":"NCT04963283"},{"action":"inhibitor","evidence_type":"registry-field","excerpt":"Cabozantinib is a multi-targeted inhibitor of RTKs. The targets of cabozantinib include several RTKs known to play important roles in tumor cell proliferation and/or tumor neovascularization, namely MET, VEGFR2 (also kno…","matched_text":"inhibitor","nct_id":"NCT04963283"}],"actions":["binder","inhibitor"],"aliases":["Cabozantinib"],"intervention_id":"I-CTG-cabozantinib-c1202a0fd8","intervention_name":"Cabozantinib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04963283","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Cabozantinib","registry_intervention_type":"DRUG","source_record_index":19,"source_ref":"ctg-page-005"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT04963283"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CAdVEC"],"intervention_id":"I-CTG-cadvec-b1e763cb1d","intervention_name":"CAdVEC","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03740256","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"CAdVEC","registry_intervention_type":"BIOLOGICAL","source_record_index":57,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT03740256"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["cancer stem cell vaccine"],"intervention_id":"I-CTG-cancer-stem-cell-vaccine-c02a83eda3","intervention_name":"cancer stem cell vaccine","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02176746","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"cancer stem cell vaccine","registry_intervention_type":"BIOLOGICAL","source_record_index":89,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02176746"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Cannabidiol"],"intervention_id":"I-CTG-cannabidiol-763c603576","intervention_name":"Cannabidiol","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03607643","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"Cannabidiol","registry_intervention_type":"DRUG","source_record_index":59,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT03607643"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["capecitabine","Capecitabine"],"intervention_id":"I-CTG-capecitabine-c72c76a9c0","intervention_name":"capecitabine","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":21}],"modality_support":{"matched_cues":["capecitabine","Capecitabine","oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3 / PHASE4","phases":["PHASE1","PHASE2","PHASE3","PHASE4"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":21,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT00226941","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"Capecitabine","registry_intervention_type":"DRUG","source_record_index":26,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT00444678","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Capecitabine","registry_intervention_type":"DRUG","source_record_index":21,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT00647530","overall_status":"UNKNOWN","phases":["PHASE2","PHASE3"],"registered_name":"capecitabine","registry_intervention_type":"DRUG","source_record_index":48,"source_ref":"ctg-page-001"},{"intervention_index":4,"nct_id":"NCT01167725","overall_status":"TERMINATED","phases":["PHASE3"],"registered_name":"capecitabine","registry_intervention_type":"DRUG","source_record_index":35,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT01588990","overall_status":"COMPLETED","phases":["PHASE4"],"registered_name":"Capecitabine","registry_intervention_type":"DRUG","source_record_index":13,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT01955629","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"Capecitabine","registry_intervention_type":"DRUG","source_record_index":16,"source_ref":"ctg-page-003"},{"intervention_index":4,"nct_id":"NCT02083653","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Capecitabine","registry_intervention_type":"DRUG","source_record_index":76,"source_ref":"ctg-page-002"},{"intervention_index":10,"nct_id":"NCT02291289","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Capecitabine","registry_intervention_type":"DRUG","source_record_index":28,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT02688712","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Capecitabine","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-003"},{"intervention_index":3,"nct_id":"NCT03152370","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"capecitabine","registry_intervention_type":"DRUG","source_record_index":18,"source_ref":"ctg-page-005"},{"intervention_index":2,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"capecitabine","registry_intervention_type":"DRUG","source_record_index":17,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT04262687","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Capecitabine","registry_intervention_type":"DRUG","source_record_index":65,"source_ref":"ctg-page-004"},{"intervention_index":2,"nct_id":"NCT05307198","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Capecitabine","registry_intervention_type":"DRUG","source_record_index":95,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT05489211","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Capecitabine","registry_intervention_type":"DRUG","source_record_index":76,"source_ref":"ctg-page-003"},{"intervention_index":6,"nct_id":"NCT05720559","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Capecitabine","registry_intervention_type":"DRUG","source_record_index":49,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT05794750","overall_status":"NOT_YET_RECRUITING","phases":["PHASE2"],"registered_name":"Capecitabine","registry_intervention_type":"DRUG","source_record_index":19,"source_ref":"ctg-page-001"},{"intervention_index":3,"nct_id":"NCT05803382","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Capecitabine","registry_intervention_type":"DRUG","source_record_index":53,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT05914389","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Capecitabine","registry_intervention_type":"DRUG","source_record_index":51,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT06490536","overall_status":"RECRUITING","phases":["PHASE3"],"registered_name":"Capecitabine","registry_intervention_type":"DRUG","source_record_index":6,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT07407465","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Capecitabine","registry_intervention_type":"DRUG","source_record_index":86,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT07503756","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Capecitabine","registry_intervention_type":"DRUG","source_record_index":49,"source_ref":"ctg-page-001"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / NOT_YET_RECRUITING / RECRUITING / TERMINATED / UNKNOWN / WITHDRAWN","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","NOT_YET_RECRUITING","RECRUITING","TERMINATED","UNKNOWN","WITHDRAWN"],"study_count":21,"study_ids":["NCT00226941","NCT00444678","NCT00647530","NCT01167725","NCT01588990","NCT01955629","NCT02083653","NCT02291289","NCT02688712","NCT03152370","NCT03169777","NCT04262687","NCT05307198","NCT05489211","NCT05720559","NCT05794750","NCT05803382","NCT05914389","NCT06490536","NCT07407465","NCT07503756"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Capecitabine + Radiotherapy"],"intervention_id":"I-CTG-capecitabine-radiotherapy-b30419b255","intervention_name":"Capecitabine + Radiotherapy","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Capecitabine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT01043484","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Capecitabine + Radiotherapy","registry_intervention_type":"DRUG","source_record_index":0,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01043484"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CapeOx"],"intervention_id":"I-CTG-capeox-aa8e491416","intervention_name":"CapeOx","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT00387387","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"CapeOx","registry_intervention_type":"DRUG","source_record_index":59,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00387387"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["capillaroscopy"],"intervention_id":"I-CTG-capillaroscopy-2022d7eaf9","intervention_name":"capillaroscopy","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01810744","overall_status":"COMPLETED","phases":["NA"],"registered_name":"capillaroscopy","registry_intervention_type":"OTHER","source_record_index":69,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01810744"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CAR T cells"],"intervention_id":"I-CTG-car-t-cells-c5bd1845e7","intervention_name":"CAR T cells","intervention_type":"DRUG","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR T cells"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05089266","overall_status":"UNKNOWN","phases":["PHASE1"],"registered_name":"CAR T cells","registry_intervention_type":"DRUG","source_record_index":13,"source_ref":"ctg-page-004"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT05089266"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"αPD1-MSLN-CAR T Cells","matched_alias":"MSLN","nct_id":"NCT05089266","relation":"CAR"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:MSLN","target_name":"mesothelin","target_symbol":"MSLN"}],"target_directness":"registry-explicit","target_ids":["symbol:MSLN"],"target_names":["mesothelin"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CAR-T cell"],"intervention_id":"I-CTG-car-t-cell-14e8e8d819","intervention_name":"CAR-T cell","intervention_type":"DRUG","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR-T cell"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02959151","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"CAR-T cell","registry_intervention_type":"DRUG","source_record_index":66,"source_ref":"ctg-page-004"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02959151"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CAR-T cell immunotherapy"],"intervention_id":"I-CTG-car-t-cell-immunotherapy-1ef738f219","intervention_name":"CAR-T cell immunotherapy","intervention_type":"BIOLOGICAL","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":2}],"modality_support":{"matched_cues":["CAR-T cell"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03013712","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"CAR-T cell immunotherapy","registry_intervention_type":"BIOLOGICAL","source_record_index":27,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT03638206","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"CAR-T cell immunotherapy","registry_intervention_type":"BIOLOGICAL","source_record_index":88,"source_ref":"ctg-page-005"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":2,"study_ids":["NCT03013712","NCT03638206"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen.","matched_alias":"EpCAM","nct_id":"NCT03013712","relation":"aiming at EpCAM"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:EPCAM","target_name":"epithelial cell adhesion molecule","target_symbol":"EPCAM"}],"target_directness":"registry-explicit","target_ids":["symbol:EPCAM"],"target_names":["epithelial cell adhesion molecule"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CAR-T cells targeting EpCAM"],"intervention_id":"I-CTG-car-t-cells-targeting-epcam-552a0c6e28","intervention_name":"CAR-T cells targeting EpCAM","intervention_type":"BIOLOGICAL","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR-T cells"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03563326","overall_status":"UNKNOWN","phases":["PHASE1"],"registered_name":"CAR-T cells targeting EpCAM","registry_intervention_type":"BIOLOGICAL","source_record_index":90,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT03563326"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Biological: CAR-T cells targeting EpCAM","matched_alias":"EpCAM","nct_id":"NCT03563326","relation":"targeting EpCAM"},{"evidence_type":"registry-field","excerpt":"CAR-T cells targeting EpCAM","matched_alias":"EpCAM","nct_id":"NCT03563326","relation":"targeting EpCAM"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:EPCAM","target_name":"epithelial cell adhesion molecule","target_symbol":"EPCAM"}],"target_directness":"registry-explicit","target_ids":["symbol:EPCAM"],"target_names":["epithelial cell adhesion molecule"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CAR-T infusion"],"intervention_id":"I-CTG-car-t-infusion-933023072e","intervention_name":"CAR-T infusion","intervention_type":"BIOLOGICAL","modality":"car-nk-cell-therapy","modality_distribution":[{"modality":"car-nk-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR-NK"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1","phases":["EARLY_PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05248048","overall_status":"UNKNOWN","phases":["EARLY_PHASE1"],"registered_name":"CAR-T infusion","registry_intervention_type":"BIOLOGICAL","source_record_index":22,"source_ref":"ctg-page-001"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT05248048"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer","matched_alias":"NKG2D","nct_id":"NCT05248048","relation":"CAR"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:KLRK1","target_name":"NKG2-D type II integral membrane protein","target_symbol":"KLRK1"}],"target_directness":"registry-explicit","target_ids":["symbol:KLRK1"],"target_names":["NKG2-D type II integral membrane protein"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["carboplatin","Carboplatin"],"intervention_id":"I-CTG-carboplatin-fcaf0e1c36","intervention_name":"Carboplatin","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":6},{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":2}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1 / PHASE1 / PHASE2","phases":["EARLY_PHASE1","PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":8,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT03715933","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"carboplatin","registry_intervention_type":"DRUG","source_record_index":9,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT04906382","overall_status":"TERMINATED","phases":["EARLY_PHASE1"],"registered_name":"Carboplatin","registry_intervention_type":"DRUG","source_record_index":84,"source_ref":"ctg-page-002"},{"intervention_index":13,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Carboplatin","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"},{"intervention_index":15,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Carboplatin","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"},{"intervention_index":4,"nct_id":"NCT05489211","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Carboplatin","registry_intervention_type":"DRUG","source_record_index":76,"source_ref":"ctg-page-003"},{"intervention_index":9,"nct_id":"NCT05719558","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Carboplatin","registry_intervention_type":"DRUG","source_record_index":80,"source_ref":"ctg-page-001"},{"intervention_index":5,"nct_id":"NCT06047379","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Carboplatin","registry_intervention_type":"DRUG","source_record_index":79,"source_ref":"ctg-page-004"},{"intervention_index":2,"nct_id":"NCT06400472","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"carboplatin","registry_intervention_type":"DRUG","source_record_index":48,"source_ref":"ctg-page-002"}],"status":"RECRUITING / TERMINATED","statuses":["RECRUITING","TERMINATED"],"study_count":7,"study_ids":["NCT03715933","NCT04906382","NCT04999761","NCT05489211","NCT05719558","NCT06047379","NCT06400472"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Carboplatin + Pemetrexed + Pembrolizumab"],"intervention_id":"I-CTG-carboplatin-pemetrexed-pembrolizumab-bfcbee9719","intervention_name":"Carboplatin + Pemetrexed + Pembrolizumab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT07020221","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Carboplatin + Pemetrexed + Pembrolizumab","registry_intervention_type":"DRUG","source_record_index":57,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07020221"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CDH17 CAR-T"],"intervention_id":"I-CTG-cdh17-car-t-5fafb7c24d","intervention_name":"CDH17 CAR-T","intervention_type":"BIOLOGICAL","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR-T"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1","phases":["EARLY_PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06937567","overall_status":"RECRUITING","phases":["EARLY_PHASE1"],"registered_name":"CDH17 CAR-T","registry_intervention_type":"BIOLOGICAL","source_record_index":88,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06937567"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"CDH17 CAR-T","matched_alias":"CDH17","nct_id":"NCT06937567","relation":"CAR"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CDH17","target_name":"cadherin-17","target_symbol":"CDH17"}],"target_directness":"registry-explicit","target_ids":["symbol:CDH17"],"target_names":["cadherin-17"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CEA-loaded dendritic cell vaccine"],"intervention_id":"I-CTG-cea-loaded-dendritic-cell-vaccine-88a88d2400","intervention_name":"CEA-loaded dendritic cell vaccine","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00228189","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"CEA-loaded dendritic cell vaccine","registry_intervention_type":"BIOLOGICAL","source_record_index":34,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00228189"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CEA-targeted CAR-T cells"],"intervention_id":"I-CTG-cea-targeted-car-t-cells-716275dc4a","intervention_name":"CEA-targeted CAR-T cells","intervention_type":"BIOLOGICAL","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":10}],"modality_support":{"matched_cues":["CAR-T cells"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":10,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05538195","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"CEA-targeted CAR-T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":5,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT05538195","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"CEA-targeted CAR-T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":5,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT06006390","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"CEA-targeted CAR-T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":88,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT06006390","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"CEA-targeted CAR-T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":88,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT06043466","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"CEA-targeted CAR-T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":23,"source_ref":"ctg-page-005"},{"intervention_index":0,"nct_id":"NCT06126406","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"CEA-targeted CAR-T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":42,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT06126406","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"CEA-targeted CAR-T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":42,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT07179692","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"CEA-targeted CAR-T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":57,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT07179692","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"CEA-targeted CAR-T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":57,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT07179692","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"CEA-targeted CAR-T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":57,"source_ref":"ctg-page-003"}],"status":"COMPLETED / RECRUITING / UNKNOWN","statuses":["COMPLETED","RECRUITING","UNKNOWN"],"study_count":5,"study_ids":["NCT05538195","NCT06006390","NCT06043466","NCT06126406","NCT07179692"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"CEA-targeted CAR-T cells","matched_alias":"CEA","nct_id":"NCT05538195","relation":"targeted"},{"evidence_type":"registry-field","excerpt":"CEA-targeted CAR-T cells","matched_alias":"CEA","nct_id":"NCT05538195","relation":"targeted"},{"evidence_type":"registry-field","excerpt":"CEA-targeted CAR-T cells","matched_alias":"CEA","nct_id":"NCT06006390","relation":"targeted"},{"evidence_type":"registry-field","excerpt":"CEA-targeted CAR-T cells","matched_alias":"CEA","nct_id":"NCT06006390","relation":"targeted"},{"evidence_type":"registry-field","excerpt":"CEA-targeted CAR-T cells","matched_alias":"CEA","nct_id":"NCT06043466","relation":"targeted"},{"evidence_type":"registry-field","excerpt":"CEA-targeted CAR-T cells","matched_alias":"CEA","nct_id":"NCT06126406","relation":"targeted"},{"evidence_type":"registry-field","excerpt":"CEA-targeted CAR-T cells","matched_alias":"CEA","nct_id":"NCT06126406","relation":"targeted"},{"evidence_type":"registry-field","excerpt":"CEA-targeted CAR-T cells","matched_alias":"CEA","nct_id":"NCT07179692","relation":"targeted"},{"evidence_type":"registry-field","excerpt":"CEA-targeted CAR-T cells","matched_alias":"CEA","nct_id":"NCT07179692","relation":"targeted"},{"evidence_type":"registry-field","excerpt":"CEA-targeted CAR-T cells","matched_alias":"CEA","nct_id":"NCT07179692","relation":"targeted"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CEACAM5","target_name":"carcinoembryonic antigen-related cell adhesion molecule 5","target_symbol":"CEACAM5"}],"target_directness":"registry-explicit","target_ids":["symbol:CEACAM5"],"target_names":["carcinoembryonic antigen-related cell adhesion molecule 5"]},{"action":"binder; inhibitor","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"… receptor tyrosine kinases. Cediranib exerts its anti-angiogenic property by competitively inhibiting the ATP binding site on the VEGF receptors.","matched_text":"binding","nct_id":"NCT03851614"},{"action":"inhibitor","evidence_type":"registry-field","excerpt":"… (AZD2171) is a potent oral small molecule Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinase inhibitor, specifically inhibiting all three VEGF receptors (VEGFR-1, -2 and -3). It has additional inhibitory activity…","matched_text":"inhibitor","nct_id":"NCT03851614"}],"actions":["binder","inhibitor"],"aliases":["Cediranib"],"intervention_id":"I-CTG-cediranib-2c3f197078","intervention_name":"Cediranib","intervention_type":"DRUG","modality":"small-molecule","modality_distribution":[{"modality":"small-molecule","registry_occurrence_count":1}],"modality_support":{"matched_cues":["small molecule"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT03851614","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Cediranib","registry_intervention_type":"DRUG","source_record_index":11,"source_ref":"ctg-page-005"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT03851614"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Celecoxib"],"intervention_id":"I-CTG-celecoxib-de59c17075","intervention_name":"Celecoxib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT00081848","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Celecoxib","registry_intervention_type":"DRUG","source_record_index":14,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00081848"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Cemiplimab"],"intervention_id":"I-CTG-cemiplimab-21fb1ce506","intervention_name":"Cemiplimab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07058012","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Cemiplimab","registry_intervention_type":"DRUG","source_record_index":40,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07058012"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]"],"intervention_id":"I-CTG-cemiplimab-fianlimab-fixed-dose-combinatio-2883943204","intervention_name":"Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07224022","overall_status":"NOT_YET_RECRUITING","phases":["PHASE2"],"registered_name":"Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]","registry_intervention_type":"DRUG","source_record_index":37,"source_ref":"ctg-page-005"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07224022"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Immune checkpoint inhibition with antibodies directed against PD-1 and CTLA-4 receptors have demonstrated significant and durable efficacy in several advanced malignancies. LAG-3 is classified as an immune checkpoint pro…","matched_alias":"CTLA-4","nct_id":"NCT07224022","relation":"co-listed-target"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CTLA4","target_name":"cytotoxic T-lymphocyte protein 4","target_symbol":"CTLA4"},{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Immune checkpoint inhibition with antibodies directed against PD-1 and CTLA-4 receptors have demonstrated significant and durable efficacy in several advanced malignancies. LAG-3 is classified as an immune checkpoint pro…","matched_alias":"PD-1","nct_id":"NCT07224022","relation":"directed against PD-1"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"registry-explicit","target_ids":["symbol:CTLA4","symbol:PDCD1"],"target_names":["cytotoxic T-lymphocyte protein 4","programmed cell death protein 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["cemiplimab + REGN7075"],"intervention_id":"I-CTG-cemiplimab-regn7075-229dd94a54","intervention_name":"cemiplimab + REGN7075","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT07058012","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"cemiplimab + REGN7075","registry_intervention_type":"DRUG","source_record_index":40,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07058012"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["cemiplimab plus fianlimab"],"intervention_id":"I-CTG-cemiplimab-plus-fianlimab-273c96b045","intervention_name":"cemiplimab plus fianlimab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07058012","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"cemiplimab plus fianlimab","registry_intervention_type":"DRUG","source_record_index":40,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07058012"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"antagonist; binder; inhibitor","action_evidence":[{"action":"antagonist","evidence_type":"registry-field","excerpt":"Following pre-treatment with a histamine-receptor antagonist, Cetuximab was administered with an initial intravenous infusion of 400 mg/m\\^2, followed by subsequent once weekly intravenous infusions of 250 mg/m\\^2","matched_text":"antagonist","nct_id":"NCT00925015"},{"action":"antagonist","evidence_type":"registry-field","excerpt":"EGFR antagonist, chimeric immunoglobulin G subclass 1 (IgG1) monoclonal antibody","matched_text":"antagonist","nct_id":"NCT04464967"},{"action":"binder","evidence_type":"registry-field","excerpt":"Cetuximab is a recombinant human/mouse chimeric monoclonal antibody which binds specifically to the extracellular domain of the epidermal growth factor receptor (epidermal growth factor receptor (EGFR), human epidermal g…","matched_text":"binds","nct_id":"NCT00326495"},{"action":"inhibitor","evidence_type":"registry-field","excerpt":"…(EGFR), human epidermal growth factor receptor 1 (HER1), c-ErbB) in normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.","matched_text":"inhibits","nct_id":"NCT00326495"},{"action":"inhibitor","evidence_type":"registry-field","excerpt":"Epidermal growth factor receptor inhibitor antineoplastic agent","matched_text":"inhibitor","nct_id":"NCT03319459"},{"action":"inhibitor","evidence_type":"registry-field","excerpt":"Epidermal growth factor receptor inhibitor, anti-neoplastic","matched_text":"inhibitor","nct_id":"NCT04587128"},{"action":"inhibitor","evidence_type":"registry-field","excerpt":"Monoclonal antibody (EGFR inhibitor)","matched_text":"inhibitor","nct_id":"NCT07318805"}],"actions":["antagonist","binder","inhibitor"],"aliases":["cetuximab","Cetuximab"],"intervention_id":"I-CTG-cetuximab-22d728a3c3","intervention_name":"Cetuximab","intervention_type":"multiple","modality":"antibody","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":48},{"modality":"antibody","registry_occurrence_count":8},{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":5}],"modality_support":{"matched_cues":["chemotherapy","Fluorouracil","Monoclonal antibody","monoclonal antibody","oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3","phases":["PHASE1","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","COMBINATION_PRODUCT","DRUG"],"registry_occurrence_count":60,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00005076","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":83,"source_ref":"ctg-page-005"},{"intervention_index":0,"nct_id":"NCT00020917","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":94,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT00020930","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":93,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT00061815","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":25,"source_ref":"ctg-page-003"},{"intervention_index":5,"nct_id":"NCT00061815","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":25,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT00063141","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"cetuximab","registry_intervention_type":"DRUG","source_record_index":74,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT00079066","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":83,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT00083720","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":58,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT00125034","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":98,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT00154102","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":11,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT00226941","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":26,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT00326495","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":64,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT00397384","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"cetuximab","registry_intervention_type":"DRUG","source_record_index":98,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT00436072","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":31,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT00444678","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":21,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT00503685","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":73,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT00719199","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT00784667","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":63,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT00803647","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":43,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT00845039","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":78,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT00925015","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":38,"source_ref":"ctg-page-005"},{"intervention_index":0,"nct_id":"NCT01074333","overall_status":"TERMINATED","phases":[],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":61,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT01152437","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":28,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT01167725","overall_status":"TERMINATED","phases":["PHASE3"],"registered_name":"cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":35,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT01198535","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":11,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT01225744","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT01254617","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":41,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT01292356","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"cetuximab","registry_intervention_type":"DRUG","source_record_index":36,"source_ref":"ctg-page-004"},{"intervention_index":6,"nct_id":"NCT01442935","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":96,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT01450319","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":84,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT01522612","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":20,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT01719380","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":16,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT01925274","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":52,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT02164916","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":72,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT02291289","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":28,"source_ref":"ctg-page-005"},{"intervention_index":4,"nct_id":"NCT02563002","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"Cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":90,"source_ref":"ctg-page-004"},{"intervention_index":2,"nct_id":"NCT02671435","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":66,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT02713373","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":80,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT02994888","overall_status":"COMPLETED","phases":[],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":59,"source_ref":"ctg-page-002"},{"intervention_index":3,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":17,"source_ref":"ctg-page-001"},{"intervention_index":4,"nct_id":"NCT03186326","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":60,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT03319459","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":56,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT03356158","overall_status":"UNKNOWN","phases":["PHASE1"],"registered_name":"Cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":12,"source_ref":"ctg-page-004"},{"intervention_index":2,"nct_id":"NCT04464967","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":52,"source_ref":"ctg-page-002"},{"intervention_index":3,"nct_id":"NCT04485013","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"cetuximab","registry_intervention_type":"DRUG","source_record_index":46,"source_ref":"ctg-page-004"},{"intervention_index":5,"nct_id":"NCT04485013","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"cetuximab","registry_intervention_type":"DRUG","source_record_index":46,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT04515394","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":16,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT04587128","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":81,"source_ref":"ctg-page-005"},{"intervention_index":3,"nct_id":"NCT04800822","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"cetuximab","registry_intervention_type":"BIOLOGICAL","source_record_index":15,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT04853043","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":80,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT04929223","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":64,"source_ref":"ctg-page-003"},{"intervention_index":9,"nct_id":"NCT05395052","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Cetuximab","registry_intervention_type":"COMBINATION_PRODUCT","source_record_index":52,"source_ref":"ctg-page-005"},{"intervention_index":2,"nct_id":"NCT05694936","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":66,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT05720559","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":49,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT05774964","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":8,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT06118047","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":47,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT06440902","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":61,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT07020221","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":57,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT07318805","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":61,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT07411599","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Cetuximab","registry_intervention_type":"DRUG","source_record_index":99,"source_ref":"ctg-page-003"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / RECRUITING / TERMINATED / UNKNOWN / WITHDRAWN","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","RECRUITING","TERMINATED","UNKNOWN","WITHDRAWN"],"study_count":58,"study_ids":["NCT00005076","NCT00020917","NCT00020930","NCT00061815","NCT00063141","NCT00079066","NCT00083720","NCT00125034","NCT00154102","NCT00226941","NCT00326495","NCT00397384","NCT00436072","NCT00444678","NCT00503685","NCT00719199","NCT00784667","NCT00803647","NCT00845039","NCT00925015","NCT01074333","NCT01152437","NCT01167725","NCT01198535","NCT01225744","NCT01254617","NCT01292356","NCT01442935","NCT01450319","NCT01522612","NCT01719380","NCT01925274","NCT02164916","NCT02291289","NCT02563002","NCT02671435","NCT02713373","NCT02994888","NCT03169777","NCT03186326","NCT03319459","NCT03356158","NCT04464967","NCT04485013","NCT04515394","NCT04587128","NCT04800822","NCT04853043","NCT04929223","NCT05395052","NCT05694936","NCT05720559","NCT05774964","NCT06118047","NCT06440902","NCT07020221","NCT07318805","NCT07411599"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Cetuximab is a chimeric anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody, administered via a intravenous (IV) infusion at 400 mg/m2 (initial loading dose) or 250 mg/m2 (weekly dose). Dosage is based …","matched_alias":"EGFR","nct_id":"NCT00226941","relation":"anti-EGFR"},{"evidence_type":"registry-field","excerpt":"Cetuximab is a chimeric anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody, administered via a intravenous (IV) infusion at 400 mg/m2 (initial loading dose) or 250 mg/m2 (weekly dose). Dosage is based …","matched_alias":"epidermal growth factor receptor","nct_id":"NCT00226941","relation":"anti-epidermal growth factor receptor"},{"evidence_type":"registry-field","excerpt":"Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody","matched_alias":"epidermal growth factor receptor","nct_id":"NCT03169777","relation":"anti-epidermal growth factor receptor"},{"evidence_type":"registry-field","excerpt":"Epidermal growth factor receptor inhibitor antineoplastic agent","matched_alias":"Epidermal growth factor receptor","nct_id":"NCT03319459","relation":"inhibitor"},{"evidence_type":"registry-field","excerpt":"EGFR antagonist, chimeric immunoglobulin G subclass 1 (IgG1) monoclonal antibody","matched_alias":"EGFR","nct_id":"NCT04464967","relation":"antagonist"},{"evidence_type":"registry-field","excerpt":"Epidermal growth factor receptor inhibitor, anti-neoplastic","matched_alias":"Epidermal growth factor receptor","nct_id":"NCT04587128","relation":"inhibitor"},{"evidence_type":"registry-field","excerpt":"Monoclonal antibody (EGFR inhibitor)","matched_alias":"EGFR","nct_id":"NCT07318805","relation":"inhibitor"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"cetuximab","rationale":"Exact intervention-name alias for the EGFR-directed antibody.","rule_id":"candidate-cetuximab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:EGFR","target_name":"epidermal growth factor receptor","target_symbol":"EGFR"}],"target_directness":"registry-explicit","target_ids":["symbol:EGFR"],"target_names":["epidermal growth factor receptor"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Cetuximab (Erbitux)"],"intervention_id":"I-CTG-cetuximab-erbitux-a5910d5bf7","intervention_name":"Cetuximab (Erbitux)","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00660582","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Cetuximab (Erbitux)","registry_intervention_type":"DRUG","source_record_index":3,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00660582"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["cetuximab and lapatinib"],"intervention_id":"I-CTG-cetuximab-and-lapatinib-92aa5f1a93","intervention_name":"cetuximab and lapatinib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01184482","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"cetuximab and lapatinib","registry_intervention_type":"DRUG","source_record_index":14,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01184482"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Cetuximab and Radiation Therapy"],"intervention_id":"I-CTG-cetuximab-and-radiation-therapy-2fd470462b","intervention_name":"Cetuximab and Radiation Therapy","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00725400","overall_status":"WITHDRAWN","phases":["PHASE2"],"registered_name":"Cetuximab and Radiation Therapy","registry_intervention_type":"OTHER","source_record_index":97,"source_ref":"ctg-page-003"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT00725400"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Cetuximab injection"],"intervention_id":"I-CTG-cetuximab-injection-49d9830a2d","intervention_name":"Cetuximab injection","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03491709","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Cetuximab injection","registry_intervention_type":"DRUG","source_record_index":21,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03491709"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Cetuximab, irinotecan"],"intervention_id":"I-CTG-cetuximab-irinotecan-3bb2b8cb08","intervention_name":"Cetuximab, irinotecan","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["irinotecan"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00637091","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Cetuximab, irinotecan","registry_intervention_type":"DRUG","source_record_index":24,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00637091"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Cetuximab/Gefitinib combination and/or monotherapy"],"intervention_id":"I-CTG-cetuximab-gefitinib-combination-and-or-mon-c7431b06f0","intervention_name":"Cetuximab/Gefitinib combination and/or monotherapy","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00820417","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Cetuximab/Gefitinib combination and/or monotherapy","registry_intervention_type":"DRUG","source_record_index":40,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00820417"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"inhibitor","action_evidence":[{"action":"inhibitor","evidence_type":"registry-field","excerpt":"Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy","matched_text":"inhibitor","nct_id":"NCT03755739"}],"actions":["inhibitor"],"aliases":["Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy"],"intervention_id":"I-CTG-checkpoint-inhibitor-cpi-such-as-pembroliz-b7de134724","intervention_name":"Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2 / PHASE3","phases":["PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03755739","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"registered_name":"Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy","registry_intervention_type":"DRUG","source_record_index":75,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT03755739"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Chemoradiotherapy plus Bevacizumab"],"intervention_id":"I-CTG-chemoradiotherapy-plus-bevacizumab-4cc222d1f2","intervention_name":"Chemoradiotherapy plus Bevacizumab","intervention_type":"OTHER","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["FLUOROURACIL"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03085992","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Chemoradiotherapy plus Bevacizumab","registry_intervention_type":"OTHER","source_record_index":32,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03085992"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Chemotherapy"],"intervention_id":"I-CTG-chemotherapy-ec0f3b0bd1","intervention_name":"Chemotherapy","intervention_type":"multiple","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":3}],"modality_support":{"matched_cues":["Chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","DRUG"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT02831842","overall_status":"COMPLETED","phases":[],"registered_name":"Chemotherapy","registry_intervention_type":"DRUG","source_record_index":4,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT03563326","overall_status":"UNKNOWN","phases":["PHASE1"],"registered_name":"Chemotherapy","registry_intervention_type":"BIOLOGICAL","source_record_index":90,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT04868877","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Chemotherapy","registry_intervention_type":"DRUG","source_record_index":70,"source_ref":"ctg-page-003"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / UNKNOWN","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","UNKNOWN"],"study_count":3,"study_ids":["NCT02831842","NCT03563326","NCT04868877"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Chemotherapy Drugs"],"intervention_id":"I-CTG-chemotherapy-drugs-94ae93efe0","intervention_name":"Chemotherapy Drugs","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07594925","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Chemotherapy Drugs","registry_intervention_type":"DRUG","source_record_index":16,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07594925"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["chemotherapy in combination with trastuzumab for arm1"],"intervention_id":"I-CTG-chemotherapy-in-combination-with-trastuzum-1a4b4db3d3","intervention_name":"chemotherapy in combination with trastuzumab for arm1","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03185988","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"chemotherapy in combination with trastuzumab for arm1","registry_intervention_type":"DRUG","source_record_index":29,"source_ref":"ctg-page-001"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT03185988"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["chemotherapy in combination with trastuzumab for arm2"],"intervention_id":"I-CTG-chemotherapy-in-combination-with-trastuzum-18646cd401","intervention_name":"chemotherapy in combination with trastuzumab for arm2","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Irinotecan"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03185988","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"chemotherapy in combination with trastuzumab for arm2","registry_intervention_type":"DRUG","source_record_index":29,"source_ref":"ctg-page-001"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT03185988"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["chemotherapy in combination with trastuzumab for arm3"],"intervention_id":"I-CTG-chemotherapy-in-combination-with-trastuzum-b750fc0438","intervention_name":"chemotherapy in combination with trastuzumab for arm3","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Irinotecan"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT03185988","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"chemotherapy in combination with trastuzumab for arm3","registry_intervention_type":"DRUG","source_record_index":29,"source_ref":"ctg-page-001"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT03185988"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["chemotherapy in combination with trastuzumab for arm4"],"intervention_id":"I-CTG-chemotherapy-in-combination-with-trastuzum-0327251cbb","intervention_name":"chemotherapy in combination with trastuzumab for arm4","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Irinotecan"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT03185988","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"chemotherapy in combination with trastuzumab for arm4","registry_intervention_type":"DRUG","source_record_index":29,"source_ref":"ctg-page-001"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT03185988"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["chemotherapy plus bevacizumab"],"intervention_id":"I-CTG-chemotherapy-plus-bevacizumab-fa81e187f1","intervention_name":"chemotherapy plus bevacizumab","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02623621","overall_status":"COMPLETED","phases":[],"registered_name":"chemotherapy plus bevacizumab","registry_intervention_type":"DRUG","source_record_index":86,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02623621"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Chest x-ray"],"intervention_id":"I-CTG-chest-x-ray-3fa98eebe0","intervention_name":"Chest x-ray","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":8,"nct_id":"NCT03745326","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"Chest x-ray","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":63,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT03745326"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Chimeric antigen receptor T cell preparation targeting GCC"],"intervention_id":"I-CTG-chimeric-antigen-receptor-t-cell-preparati-2461b7b2f2","intervention_name":"Chimeric antigen receptor T cell preparation targeting GCC","intervention_type":"DRUG","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Chimeric antigen receptor T cell"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05875402","overall_status":"UNKNOWN","phases":["NA"],"registered_name":"Chimeric antigen receptor T cell preparation targeting GCC","registry_intervention_type":"DRUG","source_record_index":8,"source_ref":"ctg-page-004"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT05875402"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Chimeric antigen receptor T cell preparation targeting GCC","matched_alias":"GCC","nct_id":"NCT05875402","relation":"targeting GCC"},{"evidence_type":"registry-field","excerpt":"Chimeric antigen receptor T cell preparation targeting GCC","matched_alias":"GCC","nct_id":"NCT05875402","relation":"targeting GCC"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:GUCY2C","target_name":"guanylate cyclase 2C","target_symbol":"GUCY2C"}],"target_directness":"registry-explicit","target_ids":["symbol:GUCY2C"],"target_names":["guanylate cyclase 2C"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CHM-2101 CAR-T cells"],"intervention_id":"I-CTG-chm-2101-car-t-cells-1f528dedbe","intervention_name":"CHM-2101 CAR-T cells","intervention_type":"BIOLOGICAL","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR-T cells"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06055439","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"CHM-2101 CAR-T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":9,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06055439"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR)-positive T cells","matched_alias":"CDH17","nct_id":"NCT06055439","relation":"Chimeric Antigen Receptor"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CDH17","target_name":"cadherin-17","target_symbol":"CDH17"}],"target_directness":"registry-explicit","target_ids":["symbol:CDH17"],"target_names":["cadherin-17"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Chromoendoscopy"],"intervention_id":"I-CTG-chromoendoscopy-af0875c463","intervention_name":"Chromoendoscopy","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT04192929","overall_status":"WITHDRAWN","phases":["NA"],"registered_name":"Chromoendoscopy","registry_intervention_type":"OTHER","source_record_index":91,"source_ref":"ctg-page-005"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT04192929"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Cibisatamab"],"intervention_id":"I-CTG-cibisatamab-7c89498bdb","intervention_name":"Cibisatamab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT03866239","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Cibisatamab","registry_intervention_type":"DRUG","source_record_index":65,"source_ref":"ctg-page-002"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT03866239"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Cisplatin"],"intervention_id":"I-CTG-cisplatin-8114f85e2a","intervention_name":"Cisplatin","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":4}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":4,"registry_occurrences":[{"intervention_index":10,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Cisplatin","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"},{"intervention_index":14,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Cisplatin","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"},{"intervention_index":17,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Cisplatin","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"},{"intervention_index":8,"nct_id":"NCT05489211","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Cisplatin","registry_intervention_type":"DRUG","source_record_index":76,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":2,"study_ids":["NCT04999761","NCT05489211"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CJM112"],"intervention_id":"I-CTG-cjm112-5dfdfeda68","intervention_name":"CJM112","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT02900664","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"CJM112","registry_intervention_type":"BIOLOGICAL","source_record_index":26,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02900664"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Claudin18.2-targeted CAR-DCs"],"intervention_id":"I-CTG-claudin18-2-targeted-car-dcs-af64bdaa0d","intervention_name":"Claudin18.2-targeted CAR-DCs","intervention_type":"BIOLOGICAL","modality":"cellular-therapy","modality_distribution":[{"modality":"cellular-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["dendritic cells"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT06946615","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Claudin18.2-targeted CAR-DCs","registry_intervention_type":"BIOLOGICAL","source_record_index":78,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06946615"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Autologous dendritic cells (DCs) genetically modified to express a chimeric antigen receptor (CAR) targeting Claudin18.2.","matched_alias":"Claudin18.2","nct_id":"NCT06946615","relation":"targeting Claudin18.2"},{"evidence_type":"registry-field","excerpt":"Claudin18.2-targeted CAR-DCs","matched_alias":"Claudin18.2","nct_id":"NCT06946615","relation":"targeted"}],"target_entity_type":"cell-surface-proteoform","target_id":"proteoform:CLDN18.2","target_name":"claudin-18 isoform 2","target_symbol":"CLDN18"}],"target_directness":"registry-explicit","target_ids":["proteoform:CLDN18.2"],"target_names":["claudin-18 isoform 2"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Claudin18.2-targeted CAR-T Cells"],"intervention_id":"I-CTG-claudin18-2-targeted-car-t-cells-84d6f72ad0","intervention_name":"Claudin18.2-targeted CAR-T Cells","intervention_type":"BIOLOGICAL","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR-T Cells"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06946615","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Claudin18.2-targeted CAR-T Cells","registry_intervention_type":"BIOLOGICAL","source_record_index":78,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06946615"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Autologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting Claudin18.2.","matched_alias":"Claudin18.2","nct_id":"NCT06946615","relation":"targeting Claudin18.2"},{"evidence_type":"registry-field","excerpt":"Claudin18.2-targeted CAR-T Cells","matched_alias":"Claudin18.2","nct_id":"NCT06946615","relation":"targeted"}],"target_entity_type":"cell-surface-proteoform","target_id":"proteoform:CLDN18.2","target_name":"claudin-18 isoform 2","target_symbol":"CLDN18"}],"target_directness":"registry-explicit","target_ids":["proteoform:CLDN18.2"],"target_names":["claudin-18 isoform 2"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Clostridium butyricum"],"intervention_id":"I-CTG-clostridium-butyricum-c2370b6d03","intervention_name":"Clostridium butyricum","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT05914389","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Clostridium butyricum","registry_intervention_type":"DRUG","source_record_index":51,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05914389"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CM-24 (MK-6018)"],"intervention_id":"I-CTG-cm-24-mk-6018-f0ba3f9e9f","intervention_name":"CM-24 (MK-6018)","intervention_type":"BIOLOGICAL","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02346955","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"CM-24 (MK-6018)","registry_intervention_type":"BIOLOGICAL","source_record_index":92,"source_ref":"ctg-page-002"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT02346955"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CMAB009"],"intervention_id":"I-CTG-cmab009-ed1299fc41","intervention_name":"CMAB009","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03206151","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"CMAB009","registry_intervention_type":"DRUG","source_record_index":82,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03206151"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CNA3103: 1.5 x 10^8 cells"],"intervention_id":"I-CTG-cna3103-1-5-x-10-8-cells-77927f9de8","intervention_name":"CNA3103: 1.5 x 10^8 cells","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05759728","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"CNA3103: 1.5 x 10^8 cells","registry_intervention_type":"BIOLOGICAL","source_record_index":90,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05759728"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CNA3103: 1.5 x 10^9 cells"],"intervention_id":"I-CTG-cna3103-1-5-x-10-9-cells-7b8c8a35bf","intervention_name":"CNA3103: 1.5 x 10^9 cells","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT05759728","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"CNA3103: 1.5 x 10^9 cells","registry_intervention_type":"BIOLOGICAL","source_record_index":90,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05759728"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CNA3103: 2.5 x 10^7 cells"],"intervention_id":"I-CTG-cna3103-2-5-x-10-7-cells-39766e37d3","intervention_name":"CNA3103: 2.5 x 10^7 cells","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT05759728","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"CNA3103: 2.5 x 10^7 cells","registry_intervention_type":"BIOLOGICAL","source_record_index":90,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05759728"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CNA3103: 4.5 x 10^8 cells"],"intervention_id":"I-CTG-cna3103-4-5-x-10-8-cells-b238ca48c9","intervention_name":"CNA3103: 4.5 x 10^8 cells","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT05759728","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"CNA3103: 4.5 x 10^8 cells","registry_intervention_type":"BIOLOGICAL","source_record_index":90,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05759728"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CNA3103: 5 x 10^7 cells"],"intervention_id":"I-CTG-cna3103-5-x-10-7-cells-ed12107ac1","intervention_name":"CNA3103: 5 x 10^7 cells","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05759728","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"CNA3103: 5 x 10^7 cells","registry_intervention_type":"BIOLOGICAL","source_record_index":90,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05759728"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CNA3103: 6.75 × 10^8 cells"],"intervention_id":"I-CTG-cna3103-6-75-10-8-cells-4f68dfa5a1","intervention_name":"CNA3103: 6.75 × 10^8 cells","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT05759728","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"CNA3103: 6.75 × 10^8 cells","registry_intervention_type":"BIOLOGICAL","source_record_index":90,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05759728"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CNTO 328; Anti-interleukin-6 monoclonal antibody"],"intervention_id":"I-CTG-cnto-328-anti-interleukin-6-monoclonal-ant-18a7114fa4","intervention_name":"CNTO 328; Anti-interleukin-6 monoclonal antibody","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":7}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":7,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00841191","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"CNTO 328; Anti-interleukin-6 monoclonal antibody","registry_intervention_type":"DRUG","source_record_index":54,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT00841191","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"CNTO 328; Anti-interleukin-6 monoclonal antibody","registry_intervention_type":"DRUG","source_record_index":54,"source_ref":"ctg-page-005"},{"intervention_index":2,"nct_id":"NCT00841191","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"CNTO 328; Anti-interleukin-6 monoclonal antibody","registry_intervention_type":"DRUG","source_record_index":54,"source_ref":"ctg-page-005"},{"intervention_index":3,"nct_id":"NCT00841191","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"CNTO 328; Anti-interleukin-6 monoclonal antibody","registry_intervention_type":"DRUG","source_record_index":54,"source_ref":"ctg-page-005"},{"intervention_index":4,"nct_id":"NCT00841191","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"CNTO 328; Anti-interleukin-6 monoclonal antibody","registry_intervention_type":"DRUG","source_record_index":54,"source_ref":"ctg-page-005"},{"intervention_index":5,"nct_id":"NCT00841191","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"CNTO 328; Anti-interleukin-6 monoclonal antibody","registry_intervention_type":"DRUG","source_record_index":54,"source_ref":"ctg-page-005"},{"intervention_index":6,"nct_id":"NCT00841191","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"CNTO 328; Anti-interleukin-6 monoclonal antibody","registry_intervention_type":"DRUG","source_record_index":54,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00841191"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"CNTO 328; Anti-interleukin-6 monoclonal antibody","matched_alias":"interleukin-6","nct_id":"NCT00841191","relation":"Anti-interleukin-6"},{"evidence_type":"registry-field","excerpt":"CNTO 328; Anti-interleukin-6 monoclonal antibody","matched_alias":"interleukin-6","nct_id":"NCT00841191","relation":"Anti-interleukin-6"},{"evidence_type":"registry-field","excerpt":"CNTO 328; Anti-interleukin-6 monoclonal antibody","matched_alias":"interleukin-6","nct_id":"NCT00841191","relation":"Anti-interleukin-6"},{"evidence_type":"registry-field","excerpt":"CNTO 328; Anti-interleukin-6 monoclonal antibody","matched_alias":"interleukin-6","nct_id":"NCT00841191","relation":"Anti-interleukin-6"},{"evidence_type":"registry-field","excerpt":"CNTO 328; Anti-interleukin-6 monoclonal antibody","matched_alias":"interleukin-6","nct_id":"NCT00841191","relation":"Anti-interleukin-6"},{"evidence_type":"registry-field","excerpt":"CNTO 328; Anti-interleukin-6 monoclonal antibody","matched_alias":"interleukin-6","nct_id":"NCT00841191","relation":"Anti-interleukin-6"},{"evidence_type":"registry-field","excerpt":"CNTO 328; Anti-interleukin-6 monoclonal antibody","matched_alias":"interleukin-6","nct_id":"NCT00841191","relation":"Anti-interleukin-6"}],"target_entity_type":"secreted-ligand","target_id":"symbol:IL6","target_name":"interleukin-6","target_symbol":"IL6"}],"target_directness":"registry-explicit","target_ids":["symbol:IL6"],"target_names":["interleukin-6"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Cobimetinib"],"intervention_id":"I-CTG-cobimetinib-da77e494cc","intervention_name":"Cobimetinib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":8,"nct_id":"NCT02291289","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Cobimetinib","registry_intervention_type":"DRUG","source_record_index":28,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02291289"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Colectomy"],"intervention_id":"I-CTG-colectomy-8a2d7bf2fb","intervention_name":"Colectomy","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT05914389","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Colectomy","registry_intervention_type":"PROCEDURE","source_record_index":51,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05914389"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Colonoscopy"],"intervention_id":"I-CTG-colonoscopy-255c6f3995","intervention_name":"Colonoscopy","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT05419011","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Colonoscopy","registry_intervention_type":"PROCEDURE","source_record_index":85,"source_ref":"ctg-page-001"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT05419011"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Colonoscopy with Retroview scope combing forward and retroflexed withdrawal technique"],"intervention_id":"I-CTG-colonoscopy-with-retroview-scope-combing-f-e77e031f92","intervention_name":"Colonoscopy with Retroview scope combing forward and retroflexed withdrawal technique","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03901651","overall_status":"COMPLETED","phases":["NA"],"registered_name":"Colonoscopy with Retroview scope combing forward and retroflexed withdrawal technique","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":25,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03901651"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Colonoscopy with standard colonoscope and forward withdrawal technique"],"intervention_id":"I-CTG-colonoscopy-with-standard-colonoscope-and--f34c8cebcc","intervention_name":"Colonoscopy with standard colonoscope and forward withdrawal technique","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03901651","overall_status":"COMPLETED","phases":["NA"],"registered_name":"Colonoscopy with standard colonoscope and forward withdrawal technique","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":25,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03901651"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Colorectal cancer procedures"],"intervention_id":"I-CTG-colorectal-cancer-procedures-bfa4f087aa","intervention_name":"Colorectal cancer procedures","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06886022","overall_status":"ACTIVE_NOT_RECRUITING","phases":[],"registered_name":"Colorectal cancer procedures","registry_intervention_type":"PROCEDURE","source_record_index":36,"source_ref":"ctg-page-005"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT06886022"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Colorectal surgery (resection)"],"intervention_id":"I-CTG-colorectal-surgery-resection-805dd62c05","intervention_name":"Colorectal surgery (resection)","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02557061","overall_status":"COMPLETED","phases":["NA"],"registered_name":"Colorectal surgery (resection)","registry_intervention_type":"PROCEDURE","source_record_index":37,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02557061"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["COM701"],"intervention_id":"I-CTG-com701-eb74d629d9","intervention_name":"COM701","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03667716","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"COM701","registry_intervention_type":"DRUG","source_record_index":66,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03667716"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["COM701 with Opdivo (Nivolumab)."],"intervention_id":"I-CTG-com701-with-opdivo-nivolumab-e3d14f4c17","intervention_name":"COM701 with Opdivo (Nivolumab).","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03667716","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"COM701 with Opdivo (Nivolumab).","registry_intervention_type":"DRUG","source_record_index":66,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03667716"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Combination Therapy: PY314 + Pembrolizumab"],"intervention_id":"I-CTG-combination-therapy-py314-pembrolizumab-397f9f194b","intervention_name":"Combination Therapy: PY314 + Pembrolizumab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT04691375","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Combination Therapy: PY314 + Pembrolizumab","registry_intervention_type":"DRUG","source_record_index":4,"source_ref":"ctg-page-003"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT04691375"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Computed Tomography"],"intervention_id":"I-CTG-computed-tomography-d4953cd85e","intervention_name":"Computed Tomography","intervention_type":"PROCEDURE","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":16},{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["18F"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1 / PHASE1 / PHASE2","phases":["EARLY_PHASE1","PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":17,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT02298959","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"registered_name":"Computed Tomography","registry_intervention_type":"PROCEDURE","source_record_index":64,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT02314169","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Computed Tomography","registry_intervention_type":"PROCEDURE","source_record_index":61,"source_ref":"ctg-page-004"},{"intervention_index":2,"nct_id":"NCT02374931","overall_status":"TERMINATED","phases":["EARLY_PHASE1"],"registered_name":"Computed Tomography","registry_intervention_type":"PROCEDURE","source_record_index":63,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT02408861","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Computed Tomography","registry_intervention_type":"PROCEDURE","source_record_index":50,"source_ref":"ctg-page-003"},{"intervention_index":4,"nct_id":"NCT02600949","overall_status":"ENROLLING_BY_INVITATION","phases":["PHASE1"],"registered_name":"Computed Tomography","registry_intervention_type":"PROCEDURE","source_record_index":89,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT02834013","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Computed Tomography","registry_intervention_type":"PROCEDURE","source_record_index":44,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT02978625","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Computed Tomography","registry_intervention_type":"PROCEDURE","source_record_index":93,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT04147494","overall_status":"ACTIVE_NOT_RECRUITING","phases":["EARLY_PHASE1"],"registered_name":"Computed Tomography","registry_intervention_type":"PROCEDURE","source_record_index":41,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT04314401","overall_status":"ACTIVE_NOT_RECRUITING","phases":[],"registered_name":"Computed Tomography","registry_intervention_type":"PROCEDURE","source_record_index":47,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT04595747","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Computed Tomography","registry_intervention_type":"PROCEDURE","source_record_index":49,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT04751370","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Computed Tomography","registry_intervention_type":"PROCEDURE","source_record_index":31,"source_ref":"ctg-page-002"},{"intervention_index":3,"nct_id":"NCT05672316","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Computed Tomography","registry_intervention_type":"PROCEDURE","source_record_index":24,"source_ref":"ctg-page-001"},{"intervention_index":4,"nct_id":"NCT05803382","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Computed Tomography","registry_intervention_type":"PROCEDURE","source_record_index":53,"source_ref":"ctg-page-001"},{"intervention_index":3,"nct_id":"NCT06130826","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Computed Tomography","registry_intervention_type":"PROCEDURE","source_record_index":89,"source_ref":"ctg-page-004"},{"intervention_index":2,"nct_id":"NCT06307548","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Computed Tomography","registry_intervention_type":"PROCEDURE","source_record_index":91,"source_ref":"ctg-page-002"},{"intervention_index":3,"nct_id":"NCT06696768","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Computed Tomography","registry_intervention_type":"PROCEDURE","source_record_index":70,"source_ref":"ctg-page-002"},{"intervention_index":6,"nct_id":"NCT07405476","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Computed Tomography","registry_intervention_type":"PROCEDURE","source_record_index":97,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING / ENROLLING_BY_INVITATION / RECRUITING / TERMINATED","statuses":["ACTIVE_NOT_RECRUITING","ENROLLING_BY_INVITATION","RECRUITING","TERMINATED"],"study_count":17,"study_ids":["NCT02298959","NCT02314169","NCT02374931","NCT02408861","NCT02600949","NCT02834013","NCT02978625","NCT04147494","NCT04314401","NCT04595747","NCT04751370","NCT05672316","NCT05803382","NCT06130826","NCT06307548","NCT06696768","NCT07405476"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Computer-aided diagnosis (CADx) support tool"],"intervention_id":"I-CTG-computer-aided-diagnosis-cadx-support-tool-3c1ea5a6ea","intervention_name":"Computer-aided diagnosis (CADx) support tool","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06791395","overall_status":"COMPLETED","phases":[],"registered_name":"Computer-aided diagnosis (CADx) support tool","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":6,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT06791395"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Conatumumab"],"intervention_id":"I-CTG-conatumumab-1002c2336a","intervention_name":"Conatumumab","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT01327612","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Conatumumab","registry_intervention_type":"BIOLOGICAL","source_record_index":4,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01327612"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Confocal endomicroscopy"],"intervention_id":"I-CTG-confocal-endomicroscopy-6af8f1b27c","intervention_name":"Confocal endomicroscopy","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02284802","overall_status":"COMPLETED","phases":["NA"],"registered_name":"Confocal endomicroscopy","registry_intervention_type":"PROCEDURE","source_record_index":75,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02284802"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Confocal laser endomicroscopy (CLE)"],"intervention_id":"I-CTG-confocal-laser-endomicroscopy-cle-a7feb51e6c","intervention_name":"Confocal laser endomicroscopy (CLE)","intervention_type":"DEVICE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01214031","overall_status":"UNKNOWN","phases":["NA"],"registered_name":"Confocal laser endomicroscopy (CLE)","registry_intervention_type":"DEVICE","source_record_index":83,"source_ref":"ctg-page-001"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT01214031"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin"],"intervention_id":"I-CTG-continuous-hyperthermic-peritoneal-perfusi-7542d19b4a","intervention_name":"Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00004547","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin","registry_intervention_type":"PROCEDURE","source_record_index":96,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00004547"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Contrasting CT"],"intervention_id":"I-CTG-contrasting-ct-f6ec36a18e","intervention_name":"Contrasting CT","intervention_type":"RADIATION","modality":"radiation","modality_distribution":[{"modality":"radiation","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["RADIATION"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":6,"nct_id":"NCT02280070","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Contrasting CT","registry_intervention_type":"RADIATION","source_record_index":62,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02280070"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Control group"],"intervention_id":"I-CTG-control-group-bfb83ec17b","intervention_name":"Control group","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2 / PHASE3","phases":["PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07505472","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"registered_name":"Control group","registry_intervention_type":"DRUG","source_record_index":70,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07505472"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["conventional surgery"],"intervention_id":"I-CTG-conventional-surgery-983550c6c0","intervention_name":"conventional surgery","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT00003422","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"conventional surgery","registry_intervention_type":"PROCEDURE","source_record_index":51,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00003422"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Copper Cu 64 Anti-CEA Monoclonal Antibody M5A"],"intervention_id":"I-CTG-copper-cu-64-anti-cea-monoclonal-antibody--1c38eaff9c","intervention_name":"Copper Cu 64 Anti-CEA Monoclonal Antibody M5A","intervention_type":"BIOLOGICAL","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Monoclonal Antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1","phases":["EARLY_PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05245786","overall_status":"ACTIVE_NOT_RECRUITING","phases":["EARLY_PHASE1"],"registered_name":"Copper Cu 64 Anti-CEA Monoclonal Antibody M5A","registry_intervention_type":"BIOLOGICAL","source_record_index":2,"source_ref":"ctg-page-005"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT05245786"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Copper Cu 64 Anti-CEA Monoclonal Antibody M5A","matched_alias":"CEA","nct_id":"NCT05245786","relation":"Anti-CEA"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CEACAM5","target_name":"carcinoembryonic antigen-related cell adhesion molecule 5","target_symbol":"CEACAM5"}],"target_directness":"registry-explicit","target_ids":["symbol:CEACAM5"],"target_names":["carcinoembryonic antigen-related cell adhesion molecule 5"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CP-675,206"],"intervention_id":"I-CTG-cp-675-206-a32de41159","intervention_name":"CP-675,206","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00313794","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"CP-675,206","registry_intervention_type":"DRUG","source_record_index":11,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00313794"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CP-751, 871"],"intervention_id":"I-CTG-cp-751-871-7112346d32","intervention_name":"CP-751, 871","intervention_type":"BIOLOGICAL","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":2}],"modality_support":{"matched_cues":["Monoclonal Antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00560560","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"CP-751, 871","registry_intervention_type":"BIOLOGICAL","source_record_index":58,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00560560"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"CP-751, 871","rationale":"Exact intervention-name aliases for IGF1R-directed antibodies.","rule_id":"candidate-ganitumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:IGF1R","target_name":"insulin-like growth factor 1 receptor","target_symbol":"IGF1R"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:IGF1R"],"target_names":["insulin-like growth factor 1 receptor"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CPGJ602"],"intervention_id":"I-CTG-cpgj602-8f9c6c2f70","intervention_name":"CPGJ602","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03356158","overall_status":"UNKNOWN","phases":["PHASE1"],"registered_name":"CPGJ602","registry_intervention_type":"BIOLOGICAL","source_record_index":12,"source_ref":"ctg-page-004"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT03356158"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CPI-006"],"intervention_id":"I-CTG-cpi-006-7295548d5e","intervention_name":"CPI-006","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2},{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03454451","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"CPI-006","registry_intervention_type":"DRUG","source_record_index":81,"source_ref":"ctg-page-001"},{"intervention_index":3,"nct_id":"NCT03454451","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"CPI-006","registry_intervention_type":"DRUG","source_record_index":81,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03454451"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"CPI-006","rationale":"Exact intervention-name alias for the CD73-directed antibody.","rule_id":"candidate-cpi006","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:NT5E","target_name":"ecto-5-prime-nucleotidase","target_symbol":"NT5E"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:NT5E"],"target_names":["ecto-5-prime-nucleotidase"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CPI-006 + ciforadenant"],"intervention_id":"I-CTG-cpi-006-ciforadenant-c153076cc2","intervention_name":"CPI-006 + ciforadenant","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03454451","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"CPI-006 + ciforadenant","registry_intervention_type":"DRUG","source_record_index":81,"source_ref":"ctg-page-001"},{"intervention_index":4,"nct_id":"NCT03454451","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"CPI-006 + ciforadenant","registry_intervention_type":"DRUG","source_record_index":81,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03454451"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CPI-006 + pembrolizumab"],"intervention_id":"I-CTG-cpi-006-pembrolizumab-3ab6f2ce6c","intervention_name":"CPI-006 + pembrolizumab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT03454451","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"CPI-006 + pembrolizumab","registry_intervention_type":"DRUG","source_record_index":81,"source_ref":"ctg-page-001"},{"intervention_index":5,"nct_id":"NCT03454451","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"CPI-006 + pembrolizumab","registry_intervention_type":"DRUG","source_record_index":81,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03454451"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Creatinine clearance"],"intervention_id":"I-CTG-creatinine-clearance-18461fe2a0","intervention_name":"Creatinine clearance","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT02280070","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Creatinine clearance","registry_intervention_type":"OTHER","source_record_index":62,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02280070"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Crisaborole Ointment"],"intervention_id":"I-CTG-crisaborole-ointment-f6a3fcb92f","intervention_name":"Crisaborole Ointment","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06118047","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Crisaborole Ointment","registry_intervention_type":"DRUG","source_record_index":47,"source_ref":"ctg-page-001"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT06118047"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CT"],"intervention_id":"I-CTG-ct-f8dcb34308","intervention_name":"CT","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT03745326","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"CT","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":63,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT03745326"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CT scan"],"intervention_id":"I-CTG-ct-scan-25e54eb278","intervention_name":"CT scan","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT01851369","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"CT scan","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":99,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01851369"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CT-0508"],"intervention_id":"I-CTG-ct-0508-e0402d4074","intervention_name":"CT-0508","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04660929","overall_status":"UNKNOWN","phases":["PHASE1"],"registered_name":"CT-0508","registry_intervention_type":"BIOLOGICAL","source_record_index":24,"source_ref":"ctg-page-002"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT04660929"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"anti-HER2 CAR macrophages","matched_alias":"HER2","nct_id":"NCT04660929","relation":"anti-HER2"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:ERBB2","target_name":"receptor tyrosine-protein kinase erbB-2","target_symbol":"ERBB2"}],"target_directness":"registry-explicit","target_ids":["symbol:ERBB2"],"target_names":["receptor tyrosine-protein kinase erbB-2"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ctDNA methylation dynamic monitoring"],"intervention_id":"I-CTG-ctdna-methylation-dynamic-monitoring-e78a5899f0","intervention_name":"ctDNA methylation dynamic monitoring","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05904665","overall_status":"RECRUITING","phases":["NA"],"registered_name":"ctDNA methylation dynamic monitoring","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":5,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05904665"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ctDNA Mutation Analysis via ddPCR"],"intervention_id":"I-CTG-ctdna-mutation-analysis-via-ddpcr-158cc851ac","intervention_name":"ctDNA Mutation Analysis via ddPCR","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT07001085","overall_status":"RECRUITING","phases":["NA"],"registered_name":"ctDNA Mutation Analysis via ddPCR","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":34,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07001085"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ctDNA testing"],"intervention_id":"I-CTG-ctdna-testing-188082d0ed","intervention_name":"ctDNA testing","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT07058012","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"ctDNA testing","registry_intervention_type":"OTHER","source_record_index":40,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07058012"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Cu 64 anti-CEA monoclonal antibody M5A IV"],"intervention_id":"I-CTG-cu-64-anti-cea-monoclonal-antibody-m5a-iv-ffd848d4d4","intervention_name":"Cu 64 anti-CEA monoclonal antibody M5A IV","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT02293954","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"registered_name":"Cu 64 anti-CEA monoclonal antibody M5A IV","registry_intervention_type":"DRUG","source_record_index":92,"source_ref":"ctg-page-005"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT02293954"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Cu 64 anti-CEA monoclonal antibody M5A IV","matched_alias":"CEA","nct_id":"NCT02293954","relation":"anti-CEA"},{"evidence_type":"registry-field","excerpt":"Cu 64 anti-CEA monoclonal antibody M5A IV","matched_alias":"CEA","nct_id":"NCT02293954","relation":"anti-CEA"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CEACAM5","target_name":"carcinoembryonic antigen-related cell adhesion molecule 5","target_symbol":"CEACAM5"}],"target_directness":"registry-explicit","target_ids":["symbol:CEACAM5"],"target_names":["carcinoembryonic antigen-related cell adhesion molecule 5"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CV301"],"intervention_id":"I-CTG-cv301-53b7453e29","intervention_name":"CV301","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04491955","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"CV301","registry_intervention_type":"BIOLOGICAL","source_record_index":62,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT04491955"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["CYAD-101"],"intervention_id":"I-CTG-cyad-101-869368c463","intervention_name":"CYAD-101","intervention_type":"DRUG","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":2}],"modality_support":{"matched_cues":["Chimeric antigen Receptor T-cells"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03692429","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"CYAD-101","registry_intervention_type":"DRUG","source_record_index":79,"source_ref":"ctg-page-005"},{"intervention_index":0,"nct_id":"NCT04991948","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"CYAD-101","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":2,"study_ids":["NCT03692429","NCT04991948"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Cyclophosphamide"],"intervention_id":"I-CTG-cyclophosphamide-f8f5717419","intervention_name":"Cyclophosphamide","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":10}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":10,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02650635","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Cyclophosphamide","registry_intervention_type":"DRUG","source_record_index":79,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT02757391","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Cyclophosphamide","registry_intervention_type":"DRUG","source_record_index":42,"source_ref":"ctg-page-004"},{"intervention_index":4,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"Cyclophosphamide","registry_intervention_type":"DRUG","source_record_index":17,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT03190941","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Cyclophosphamide","registry_intervention_type":"DRUG","source_record_index":60,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT03745326","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"Cyclophosphamide","registry_intervention_type":"DRUG","source_record_index":63,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT05395052","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Cyclophosphamide","registry_intervention_type":"DRUG","source_record_index":52,"source_ref":"ctg-page-005"},{"intervention_index":2,"nct_id":"NCT05451849","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"Cyclophosphamide","registry_intervention_type":"DRUG","source_record_index":73,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT05492682","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Cyclophosphamide","registry_intervention_type":"DRUG","source_record_index":99,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT06530303","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Cyclophosphamide","registry_intervention_type":"DRUG","source_record_index":8,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT07411599","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Cyclophosphamide","registry_intervention_type":"DRUG","source_record_index":99,"source_ref":"ctg-page-003"}],"status":"RECRUITING / TERMINATED / WITHDRAWN","statuses":["RECRUITING","TERMINATED","WITHDRAWN"],"study_count":10,"study_ids":["NCT02650635","NCT02757391","NCT03169777","NCT03190941","NCT03745326","NCT05395052","NCT05451849","NCT05492682","NCT06530303","NCT07411599"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["DacogenTM (decitabine)"],"intervention_id":"I-CTG-dacogentm-decitabine-1b1d831e14","intervention_name":"DacogenTM (decitabine)","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00879385","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"DacogenTM (decitabine)","registry_intervention_type":"DRUG","source_record_index":33,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00879385"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Dalotuzumab 10 mg/kg"],"intervention_id":"I-CTG-dalotuzumab-10-mg-kg-73403e9c09","intervention_name":"Dalotuzumab 10 mg/kg","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00925015","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Dalotuzumab 10 mg/kg","registry_intervention_type":"BIOLOGICAL","source_record_index":38,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00925015"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Dalotuzumab 15/7.5 mg/kg"],"intervention_id":"I-CTG-dalotuzumab-15-7-5-mg-kg-cb2902ab21","intervention_name":"Dalotuzumab 15/7.5 mg/kg","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT00925015","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Dalotuzumab 15/7.5 mg/kg","registry_intervention_type":"BIOLOGICAL","source_record_index":38,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00925015"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Datopotamab deruxtecan (Dato-DXd)"],"intervention_id":"I-CTG-datopotamab-deruxtecan-dato-dxd-90cdcc43e0","intervention_name":"Datopotamab deruxtecan (Dato-DXd)","intervention_type":"DRUG","modality":"antibody-drug-conjugate","modality_distribution":[{"modality":"antibody-drug-conjugate","registry_occurrence_count":2}],"modality_support":{"matched_cues":["Antibody drug conjugate"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05489211","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Datopotamab deruxtecan (Dato-DXd)","registry_intervention_type":"DRUG","source_record_index":76,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05489211"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"datopotamab deruxtecan (Dato-DXd)","rationale":"Exact intervention-name aliases for the TROP2-directed antibody-drug conjugate.","rule_id":"candidate-datopotamab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:TACSTD2","target_name":"tumor-associated calcium signal transducer 2","target_symbol":"TACSTD2"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:TACSTD2"],"target_names":["tumor-associated calcium signal transducer 2"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["DDI Probe Cocktail"],"intervention_id":"I-CTG-ddi-probe-cocktail-1ab21be774","intervention_name":"DDI Probe Cocktail","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":8,"nct_id":"NCT05176483","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"DDI Probe Cocktail","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05176483"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["DEBIRI"],"intervention_id":"I-CTG-debiri-90728d2685","intervention_name":"DEBIRI","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Irinotecan"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02015754","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"DEBIRI","registry_intervention_type":"DRUG","source_record_index":28,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02015754"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Decitabine"],"intervention_id":"I-CTG-decitabine-44e1b32827","intervention_name":"Decitabine","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT07007767","overall_status":"NOT_YET_RECRUITING","phases":["PHASE2"],"registered_name":"Decitabine","registry_intervention_type":"DRUG","source_record_index":79,"source_ref":"ctg-page-002"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07007767"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"agonist","action_evidence":[{"action":"agonist","evidence_type":"registry-field","excerpt":"Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy.","matched_text":"agonist","nct_id":"NCT05651022"}],"actions":["agonist"],"aliases":["Decoy20"],"intervention_id":"I-CTG-decoy20-942a6c91bd","intervention_name":"Decoy20","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05651022","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Decoy20","registry_intervention_type":"DRUG","source_record_index":10,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT05651022"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Dendritic Cell Vaccine"],"intervention_id":"I-CTG-dendritic-cell-vaccine-40ced16617","intervention_name":"Dendritic Cell Vaccine","intervention_type":"DRUG","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01413295","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Dendritic Cell Vaccine","registry_intervention_type":"DRUG","source_record_index":21,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01413295"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Dendritic cells vaccine"],"intervention_id":"I-CTG-dendritic-cells-vaccine-e87c5fcd01","intervention_name":"Dendritic cells vaccine","intervention_type":"DRUG","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01348256","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Dendritic cells vaccine","registry_intervention_type":"DRUG","source_record_index":75,"source_ref":"ctg-page-002"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT01348256"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["denileukin diftitox"],"intervention_id":"I-CTG-denileukin-diftitox-1d79e88212","intervention_name":"denileukin diftitox","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00128622","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"denileukin diftitox","registry_intervention_type":"BIOLOGICAL","source_record_index":7,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00128622"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Digital Rectal Examination"],"intervention_id":"I-CTG-digital-rectal-examination-382bc63c95","intervention_name":"Digital Rectal Examination","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":10,"nct_id":"NCT07405476","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Digital Rectal Examination","registry_intervention_type":"PROCEDURE","source_record_index":97,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07405476"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Diphenhydramine hydrochloride (HCl)"],"intervention_id":"I-CTG-diphenhydramine-hydrochloride-hcl-c1cd720f4e","intervention_name":"Diphenhydramine hydrochloride (HCl)","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT00226941","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"Diphenhydramine hydrochloride (HCl)","registry_intervention_type":"DRUG","source_record_index":26,"source_ref":"ctg-page-002"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT00226941"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Diphtheria/Tetanus Vaccine"],"intervention_id":"I-CTG-diphtheria-tetanus-vaccine-155e5d9925","intervention_name":"Diphtheria/Tetanus Vaccine","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT01339000","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Diphtheria/Tetanus Vaccine","registry_intervention_type":"BIOLOGICAL","source_record_index":61,"source_ref":"ctg-page-001"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT01339000"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["DISP-10"],"intervention_id":"I-CTG-disp-10-89d47f9270","intervention_name":"DISP-10","intervention_type":"BIOLOGICAL","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07544589","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"DISP-10","registry_intervention_type":"BIOLOGICAL","source_record_index":26,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07544589"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Divarasib"],"intervention_id":"I-CTG-divarasib-396157f6b6","intervention_name":"Divarasib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":6,"nct_id":"NCT04929223","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Divarasib","registry_intervention_type":"DRUG","source_record_index":64,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT04929223"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Docetaxel"],"intervention_id":"I-CTG-docetaxel-1ad915ad9e","intervention_name":"Docetaxel","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":3}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT02740985","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Docetaxel","registry_intervention_type":"DRUG","source_record_index":72,"source_ref":"ctg-page-002"},{"intervention_index":7,"nct_id":"NCT05176483","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Docetaxel","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-001"},{"intervention_index":11,"nct_id":"NCT05719558","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Docetaxel","registry_intervention_type":"DRUG","source_record_index":80,"source_ref":"ctg-page-001"}],"status":"COMPLETED / RECRUITING","statuses":["COMPLETED","RECRUITING"],"study_count":3,"study_ids":["NCT02740985","NCT05176483","NCT05719558"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Docetaxel (Taxotere)"],"intervention_id":"I-CTG-docetaxel-taxotere-168b0a7cb0","intervention_name":"Docetaxel (Taxotere)","intervention_type":"COMBINATION_PRODUCT","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["COMBINATION_PRODUCT"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT05592626","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Docetaxel (Taxotere)","registry_intervention_type":"COMBINATION_PRODUCT","source_record_index":90,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05592626"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Dostarlimab"],"intervention_id":"I-CTG-dostarlimab-b72c71f530","intervention_name":"Dostarlimab","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["IgG4"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03250832","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Dostarlimab","registry_intervention_type":"DRUG","source_record_index":77,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03250832"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["DS-8201a"],"intervention_id":"I-CTG-ds-8201a-cf25a7a751","intervention_name":"DS-8201a","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03384940","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"DS-8201a","registry_intervention_type":"DRUG","source_record_index":58,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03384940"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["DS-8201a 5.4 mg/kg Q3W"],"intervention_id":"I-CTG-ds-8201a-5-4-mg-kg-q3w-e5805da10c","intervention_name":"DS-8201a 5.4 mg/kg Q3W","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04744831","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"DS-8201a 5.4 mg/kg Q3W","registry_intervention_type":"DRUG","source_record_index":76,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT04744831"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["DS-8201a 6.4 mg/kg Q3W"],"intervention_id":"I-CTG-ds-8201a-6-4-mg-kg-q3w-df2034b62f","intervention_name":"DS-8201a 6.4 mg/kg Q3W","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT04744831","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"DS-8201a 6.4 mg/kg Q3W","registry_intervention_type":"DRUG","source_record_index":76,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT04744831"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Dual-Target Antigen-Selected CAR-NK"],"intervention_id":"I-CTG-dual-target-antigen-selected-car-nk-c69960a6a1","intervention_name":"Dual-Target Antigen-Selected CAR-NK","intervention_type":"BIOLOGICAL","modality":"car-nk-cell-therapy","modality_distribution":[{"modality":"car-nk-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR-NK"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07410494","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Dual-Target Antigen-Selected CAR-NK","registry_intervention_type":"BIOLOGICAL","source_record_index":82,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07410494"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"binder; blocker","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"… human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. …","matched_text":"binds","nct_id":"NCT03851614"},{"action":"blocker","evidence_type":"registry-field","excerpt":"…clonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of…","matched_text":"blocks","nct_id":"NCT03851614"}],"actions":["binder","blocker"],"aliases":["Durvalumab"],"intervention_id":"I-CTG-durvalumab-a8c0108ba9","intervention_name":"Durvalumab","intervention_type":"multiple","modality":"antibody","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":4},{"modality":"antibody","registry_occurrence_count":2}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","DRUG"],"registry_occurrence_count":5,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT02503774","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Durvalumab","registry_intervention_type":"DRUG","source_record_index":23,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT02671435","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Durvalumab","registry_intervention_type":"DRUG","source_record_index":66,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT02740985","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Durvalumab","registry_intervention_type":"DRUG","source_record_index":72,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT03206073","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Durvalumab","registry_intervention_type":"DRUG","source_record_index":56,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT03851614","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Durvalumab","registry_intervention_type":"BIOLOGICAL","source_record_index":11,"source_ref":"ctg-page-005"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED"],"study_count":5,"study_ids":["NCT02503774","NCT02671435","NCT02740985","NCT03206073","NCT03851614"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"durvalumab","rationale":"Exact intervention-name aliases for PD-L1-directed antibodies.","rule_id":"candidate-pdl1-antibodies","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CD274","target_name":"programmed death-ligand 1","target_symbol":"CD274"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:CD274"],"target_names":["programmed death-ligand 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Dye-Based Chromoendoscopy"],"intervention_id":"I-CTG-dye-based-chromoendoscopy-dd57846283","intervention_name":"Dye-Based Chromoendoscopy","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07089771","overall_status":"NOT_YET_RECRUITING","phases":["NA"],"registered_name":"Dye-Based Chromoendoscopy","registry_intervention_type":"PROCEDURE","source_record_index":58,"source_ref":"ctg-page-003"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07089771"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["E7 TCR-T cells"],"intervention_id":"I-CTG-e7-tcr-t-cells-28141aa90b","intervention_name":"E7 TCR-T cells","intervention_type":"BIOLOGICAL","modality":"cellular-therapy","modality_distribution":[{"modality":"cellular-therapy","registry_occurrence_count":2}],"modality_support":{"matched_cues":["TCR-T"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05639972","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"E7 TCR-T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":22,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT05686226","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"E7 TCR-T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":38,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":2,"study_ids":["NCT05639972","NCT05686226"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["E7046"],"intervention_id":"I-CTG-e7046-9a933e04a4","intervention_name":"E7046","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03152370","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"E7046","registry_intervention_type":"DRUG","source_record_index":18,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03152370"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["EB-DUO-CAR-NK-CEA/GCC"],"intervention_id":"I-CTG-eb-duo-car-nk-cea-gcc-9ddb5588c2","intervention_name":"EB-DUO-CAR-NK-CEA/GCC","intervention_type":"BIOLOGICAL","modality":"car-nk-cell-therapy","modality_distribution":[{"modality":"car-nk-cell-therapy","registry_occurrence_count":2}],"modality_support":{"matched_cues":["CAR-NK"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07589517","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"EB-DUO-CAR-NK-CEA/GCC","registry_intervention_type":"BIOLOGICAL","source_record_index":33,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07589517"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"EB-DUO-CAR-NK-CEA/GCC","rationale":"Exact registered dual-target CAR-NK product names encode CEA and GCC as the two targets.","rule_id":"candidate-eb-duo-car-nk","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CEACAM5","target_name":"carcinoembryonic antigen-related cell adhesion molecule 5","target_symbol":"CEACAM5"},{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"EB-DUO-CAR-NK-CEA/GCC","rationale":"Exact registered dual-target CAR-NK product names encode CEA and GCC as the two targets.","rule_id":"candidate-eb-duo-car-nk","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:GUCY2C","target_name":"guanylate cyclase 2C","target_symbol":"GUCY2C"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:CEACAM5","symbol:GUCY2C"],"target_names":["carcinoembryonic antigen-related cell adhesion molecule 5","guanylate cyclase 2C"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["EB-DUO-CAR-NK-CEA/GCC (IV)"],"intervention_id":"I-CTG-eb-duo-car-nk-cea-gcc-iv-ea153d70da","intervention_name":"EB-DUO-CAR-NK-CEA/GCC (IV)","intervention_type":"BIOLOGICAL","modality":"car-nk-cell-therapy","modality_distribution":[{"modality":"car-nk-cell-therapy","registry_occurrence_count":2}],"modality_support":{"matched_cues":["CAR-NK"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07462650","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"EB-DUO-CAR-NK-CEA/GCC (IV)","registry_intervention_type":"BIOLOGICAL","source_record_index":35,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07462650"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"EB-DUO-CAR-NK-CEA/GCC (IV)","rationale":"Exact registered dual-target CAR-NK product names encode CEA and GCC as the two targets.","rule_id":"candidate-eb-duo-car-nk","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CEACAM5","target_name":"carcinoembryonic antigen-related cell adhesion molecule 5","target_symbol":"CEACAM5"},{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"EB-DUO-CAR-NK-CEA/GCC (IV)","rationale":"Exact registered dual-target CAR-NK product names encode CEA and GCC as the two targets.","rule_id":"candidate-eb-duo-car-nk","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:GUCY2C","target_name":"guanylate cyclase 2C","target_symbol":"GUCY2C"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:CEACAM5","symbol:GUCY2C"],"target_names":["carcinoembryonic antigen-related cell adhesion molecule 5","guanylate cyclase 2C"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["EB-SELECT Single-Target CAR-NK Cells"],"intervention_id":"I-CTG-eb-select-single-target-car-nk-cells-f1020c8ad8","intervention_name":"EB-SELECT Single-Target CAR-NK Cells","intervention_type":"BIOLOGICAL","modality":"car-nk-cell-therapy","modality_distribution":[{"modality":"car-nk-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR-NK"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07410494","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"EB-SELECT Single-Target CAR-NK Cells","registry_intervention_type":"BIOLOGICAL","source_record_index":82,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07410494"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Echocardiography Test"],"intervention_id":"I-CTG-echocardiography-test-b5bb6dc083","intervention_name":"Echocardiography Test","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":3}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT02834013","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Echocardiography Test","registry_intervention_type":"PROCEDURE","source_record_index":44,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT06136897","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Echocardiography Test","registry_intervention_type":"PROCEDURE","source_record_index":41,"source_ref":"ctg-page-004"},{"intervention_index":3,"nct_id":"NCT07405476","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Echocardiography Test","registry_intervention_type":"PROCEDURE","source_record_index":97,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING / RECRUITING","statuses":["ACTIVE_NOT_RECRUITING","RECRUITING"],"study_count":3,"study_ids":["NCT02834013","NCT06136897","NCT07405476"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Educational Intervention"],"intervention_id":"I-CTG-educational-intervention-90963afc6d","intervention_name":"Educational Intervention","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06995924","overall_status":"RECRUITING","phases":["NA"],"registered_name":"Educational Intervention","registry_intervention_type":"OTHER","source_record_index":29,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06995924"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["EGF816"],"intervention_id":"I-CTG-egf816-65942cfc88","intervention_name":"EGF816","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT02900664","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"EGF816","registry_intervention_type":"DRUG","source_record_index":26,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02900664"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["EKG"],"intervention_id":"I-CTG-ekg-1518c8fdc6","intervention_name":"EKG","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT03745326","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"EKG","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":63,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT03745326"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Electronic Health Record Review"],"intervention_id":"I-CTG-electronic-health-record-review-58bf833df3","intervention_name":"Electronic Health Record Review","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA / PHASE2","phases":["NA","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT06995924","overall_status":"RECRUITING","phases":["NA"],"registered_name":"Electronic Health Record Review","registry_intervention_type":"OTHER","source_record_index":29,"source_ref":"ctg-page-003"},{"intervention_index":11,"nct_id":"NCT07405476","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Electronic Health Record Review","registry_intervention_type":"OTHER","source_record_index":97,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":2,"study_ids":["NCT06995924","NCT07405476"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ELI-002 7P"],"intervention_id":"I-CTG-eli-002-7p-1fc1f11779","intervention_name":"ELI-002 7P","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05726864","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"ELI-002 7P","registry_intervention_type":"DRUG","source_record_index":76,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT05726864"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Emavusertib"],"intervention_id":"I-CTG-emavusertib-198f10d92d","intervention_name":"Emavusertib","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT06696768","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Emavusertib","registry_intervention_type":"BIOLOGICAL","source_record_index":70,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06696768"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["EMB-01"],"intervention_id":"I-CTG-emb-01-c55ad0eb9b","intervention_name":"EMB-01","intervention_type":"DRUG","modality":"bispecific-antibody","modality_distribution":[{"modality":"bispecific-antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["bispecific"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07649655","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1"],"registered_name":"EMB-01","registry_intervention_type":"DRUG","source_record_index":52,"source_ref":"ctg-page-004"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07649655"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["EMI-137"],"intervention_id":"I-CTG-emi-137-5c73a8f0cd","intervention_name":"EMI-137","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03360461","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"EMI-137","registry_intervention_type":"DRUG","source_record_index":1,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03360461"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["encorafenib"],"intervention_id":"I-CTG-encorafenib-66cf055d05","intervention_name":"encorafenib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT04800822","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"encorafenib","registry_intervention_type":"DRUG","source_record_index":15,"source_ref":"ctg-page-002"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT04800822"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["endocytoscopy"],"intervention_id":"I-CTG-endocytoscopy-a0b76fa672","intervention_name":"endocytoscopy","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06324097","overall_status":"COMPLETED","phases":[],"registered_name":"endocytoscopy","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":68,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT06324097"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Endoscope"],"intervention_id":"I-CTG-endoscope-8590d2a265","intervention_name":"Endoscope","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07024225","overall_status":"RECRUITING","phases":[],"registered_name":"Endoscope","registry_intervention_type":"PROCEDURE","source_record_index":60,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07024225"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Endoscopic Procedure"],"intervention_id":"I-CTG-endoscopic-procedure-8af6485519","intervention_name":"Endoscopic Procedure","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT07405476","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Endoscopic Procedure","registry_intervention_type":"PROCEDURE","source_record_index":97,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07405476"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Endoscopy"],"intervention_id":"I-CTG-endoscopy-14a417830e","intervention_name":"Endoscopy","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":9,"nct_id":"NCT02280070","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Endoscopy","registry_intervention_type":"OTHER","source_record_index":62,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02280070"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Enzalutamide"],"intervention_id":"I-CTG-enzalutamide-02d130d71a","intervention_name":"Enzalutamide","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":3}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT02740985","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Enzalutamide","registry_intervention_type":"DRUG","source_record_index":72,"source_ref":"ctg-page-002"},{"intervention_index":4,"nct_id":"NCT05551117","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Enzalutamide","registry_intervention_type":"DRUG","source_record_index":69,"source_ref":"ctg-page-001"},{"intervention_index":4,"nct_id":"NCT07277270","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Enzalutamide","registry_intervention_type":"DRUG","source_record_index":23,"source_ref":"ctg-page-002"}],"status":"COMPLETED / RECRUITING / TERMINATED","statuses":["COMPLETED","RECRUITING","TERMINATED"],"study_count":3,"study_ids":["NCT02740985","NCT05551117","NCT07277270"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["EO2040"],"intervention_id":"I-CTG-eo2040-1f62e48b14","intervention_name":"EO2040","intervention_type":"DRUG","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05350501","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"EO2040","registry_intervention_type":"DRUG","source_record_index":33,"source_ref":"ctg-page-001"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT05350501"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["EPCAM CAR-T"],"intervention_id":"I-CTG-epcam-car-t-6e829ef49b","intervention_name":"EPCAM CAR-T","intervention_type":"DRUG","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR-T"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05028933","overall_status":"UNKNOWN","phases":["PHASE1"],"registered_name":"EPCAM CAR-T","registry_intervention_type":"DRUG","source_record_index":49,"source_ref":"ctg-page-005"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT05028933"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Pretreatment with fludarabine and cyclophosphamide EpCAM CAR-T Cells infusion","matched_alias":"EpCAM","nct_id":"NCT05028933","relation":"CAR"},{"evidence_type":"registry-field","excerpt":"EPCAM CAR-T","matched_alias":"EPCAM","nct_id":"NCT05028933","relation":"CAR"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:EPCAM","target_name":"epithelial cell adhesion molecule","target_symbol":"EPCAM"}],"target_directness":"registry-explicit","target_ids":["symbol:EPCAM"],"target_names":["epithelial cell adhesion molecule"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["epidural"],"intervention_id":"I-CTG-epidural-864413e5bb","intervention_name":"epidural","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00747292","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"epidural","registry_intervention_type":"PROCEDURE","source_record_index":64,"source_ref":"ctg-page-005"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT00747292"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Erlotinib"],"intervention_id":"I-CTG-erlotinib-fa6bba6f28","intervention_name":"Erlotinib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00784667","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Erlotinib","registry_intervention_type":"DRUG","source_record_index":63,"source_ref":"ctg-page-002"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT00784667"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["erlotinib hydrochloride"],"intervention_id":"I-CTG-erlotinib-hydrochloride-25091918cd","intervention_name":"erlotinib hydrochloride","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00397384","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"erlotinib hydrochloride","registry_intervention_type":"DRUG","source_record_index":98,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT00940316","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"erlotinib hydrochloride","registry_intervention_type":"DRUG","source_record_index":51,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":2,"study_ids":["NCT00397384","NCT00940316"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ETBX-011"],"intervention_id":"I-CTG-etbx-011-51ede04218","intervention_name":"ETBX-011","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":14,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"ETBX-011","registry_intervention_type":"BIOLOGICAL","source_record_index":17,"source_ref":"ctg-page-001"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT03169777"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ETBX-021"],"intervention_id":"I-CTG-etbx-021-adeeb90c9f","intervention_name":"ETBX-021","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":15,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"ETBX-021","registry_intervention_type":"BIOLOGICAL","source_record_index":17,"source_ref":"ctg-page-001"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT03169777"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ETBX-051"],"intervention_id":"I-CTG-etbx-051-c8adc785a4","intervention_name":"ETBX-051","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":16,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"ETBX-051","registry_intervention_type":"BIOLOGICAL","source_record_index":17,"source_ref":"ctg-page-001"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT03169777"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ETBX-061"],"intervention_id":"I-CTG-etbx-061-20b1a51bf2","intervention_name":"ETBX-061","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":17,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"ETBX-061","registry_intervention_type":"BIOLOGICAL","source_record_index":17,"source_ref":"ctg-page-001"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT03169777"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"antagonist","action_evidence":[{"action":"antagonist","evidence_type":"registry-field","excerpt":"Etrumadenant is a dual adenosine receptor (A2aR and A2bR) antagonist","matched_text":"antagonist","nct_id":"NCT04660812"}],"actions":["antagonist"],"aliases":["Etrumadenant"],"intervention_id":"I-CTG-etrumadenant-9cc45271d9","intervention_name":"Etrumadenant","intervention_type":"DRUG","modality":"small-molecule","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1},{"modality":"small-molecule","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT04660812","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Etrumadenant","registry_intervention_type":"DRUG","source_record_index":78,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT04660812"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Etrumadenant is a dual adenosine receptor (A2aR and A2bR) antagonist","matched_alias":"A2aR","nct_id":"NCT04660812","relation":"co-listed-target"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"etrumadenant","rationale":"Exact intervention-name alias for the dual adenosine A2A/A2B receptor antagonist.","rule_id":"candidate-etrumadenant","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:ADORA2A","target_name":"adenosine A2A receptor","target_symbol":"ADORA2A"},{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Etrumadenant is a dual adenosine receptor (A2aR and A2bR) antagonist","matched_alias":"A2bR","nct_id":"NCT04660812","relation":"antagonist"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"etrumadenant","rationale":"Exact intervention-name alias for the dual adenosine A2A/A2B receptor antagonist.","rule_id":"candidate-etrumadenant","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:ADORA2B","target_name":"adenosine A2B receptor","target_symbol":"ADORA2B"}],"target_directness":"registry-explicit","target_ids":["symbol:ADORA2A","symbol:ADORA2B"],"target_names":["adenosine A2A receptor","adenosine A2B receptor"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Experimental Group"],"intervention_id":"I-CTG-experimental-group-ee3e8ab9d9","intervention_name":"Experimental Group","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2 / PHASE3","phases":["PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07505472","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"registered_name":"Experimental Group","registry_intervention_type":"DRUG","source_record_index":70,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07505472"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Experimental: COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab"],"intervention_id":"I-CTG-experimental-colonyvaq-crc-mfolfox6-or-cap-5487896cc8","intervention_name":"Experimental: COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1","phases":["EARLY_PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07328087","overall_status":"RECRUITING","phases":["EARLY_PHASE1"],"registered_name":"Experimental: COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab","registry_intervention_type":"BIOLOGICAL","source_record_index":96,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07328087"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Extension HER-2 vaccine trial at OBD"],"intervention_id":"I-CTG-extension-her-2-vaccine-trial-at-obd-755266448d","intervention_name":"Extension HER-2 vaccine trial at OBD","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT01376505","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Extension HER-2 vaccine trial at OBD","registry_intervention_type":"BIOLOGICAL","source_record_index":18,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01376505"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["F-18 16 Alpha-Fluoroestradiol"],"intervention_id":"I-CTG-f-18-16-alpha-fluoroestradiol-131fc1e46a","intervention_name":"F-18 16 Alpha-Fluoroestradiol","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["18F"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1","phases":["EARLY_PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02374931","overall_status":"TERMINATED","phases":["EARLY_PHASE1"],"registered_name":"F-18 16 Alpha-Fluoroestradiol","registry_intervention_type":"DRUG","source_record_index":63,"source_ref":"ctg-page-003"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT02374931"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Faecal Immunochemical Test"],"intervention_id":"I-CTG-faecal-immunochemical-test-5870f968de","intervention_name":"Faecal Immunochemical Test","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04034953","overall_status":"UNKNOWN","phases":["NA"],"registered_name":"Faecal Immunochemical Test","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":90,"source_ref":"ctg-page-002"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT04034953"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Fam-Trastuzumab Deruxtecan-Nxki"],"intervention_id":"I-CTG-fam-trastuzumab-deruxtecan-nxki-f9be2eb3a8","intervention_name":"Fam-Trastuzumab Deruxtecan-Nxki","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05868226","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Fam-Trastuzumab Deruxtecan-Nxki","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05868226"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FAST LACO-Stim CDH17 CAR-T"],"intervention_id":"I-CTG-fast-laco-stim-cdh17-car-t-41ef783a2e","intervention_name":"FAST LACO-Stim CDH17 CAR-T","intervention_type":"BIOLOGICAL","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR-T"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1","phases":["EARLY_PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT06937567","overall_status":"RECRUITING","phases":["EARLY_PHASE1"],"registered_name":"FAST LACO-Stim CDH17 CAR-T","registry_intervention_type":"BIOLOGICAL","source_record_index":88,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06937567"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"The initial dose of LACO-Stim CDH17 CAR-T cell therapy in this clinical study was set at 3.0×104/kg and the maximum dose was set at 1.0×105/kg. Subjects will be treated with Fludarabine and Cyclophosphamide based lymphod…","matched_alias":"CDH17","nct_id":"NCT06937567","relation":"CAR"},{"evidence_type":"registry-field","excerpt":"FAST LACO-Stim CDH17 CAR-T","matched_alias":"CDH17","nct_id":"NCT06937567","relation":"CAR"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CDH17","target_name":"cadherin-17","target_symbol":"CDH17"}],"target_directness":"registry-explicit","target_ids":["symbol:CDH17"],"target_names":["cadherin-17"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FATE-NK100"],"intervention_id":"I-CTG-fate-nk100-41bd5322f7","intervention_name":"FATE-NK100","intervention_type":"DRUG","modality":"cellular-therapy","modality_distribution":[{"modality":"cellular-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["NK cell"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03319459","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"FATE-NK100","registry_intervention_type":"DRUG","source_record_index":56,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03319459"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["favezelimab/pembrolizumab"],"intervention_id":"I-CTG-favezelimab-pembrolizumab-4da1038787","intervention_name":"favezelimab/pembrolizumab","intervention_type":"BIOLOGICAL","modality":"bispecific-antibody","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2},{"modality":"bispecific-antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05064059","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"favezelimab/pembrolizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":27,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT05600309","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"favezelimab/pembrolizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":30,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":2,"study_ids":["NCT05064059","NCT05600309"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"favezelimab/pembrolizumab","rationale":"Exact registered combination name for LAG3- and PD-1-directed antibodies.","rule_id":"candidate-favezelimab-pembrolizumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:LAG3","target_name":"lymphocyte activation gene 3 protein","target_symbol":"LAG3"},{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"favezelimab/pembrolizumab","rationale":"Exact registered combination name for LAG3- and PD-1-directed antibodies.","rule_id":"candidate-favezelimab-pembrolizumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:LAG3","symbol:PDCD1"],"target_names":["lymphocyte activation gene 3 protein","programmed cell death protein 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Flow cytometry"],"intervention_id":"I-CTG-flow-cytometry-0e267cdbea","intervention_name":"Flow cytometry","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT07586293","overall_status":"NOT_YET_RECRUITING","phases":[],"registered_name":"Flow cytometry","registry_intervention_type":"OTHER","source_record_index":95,"source_ref":"ctg-page-001"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07586293"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab"],"intervention_id":"I-CTG-flox-5-fluorouracil-and-folinic-acid-and-o-3b6c9dadca","intervention_name":"FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["fluorouracil"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT00145314","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00145314"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FLOX (5-fluorouracil/folinic acid/oxaliplatin)"],"intervention_id":"I-CTG-flox-5-fluorouracil-folinic-acid-oxaliplat-d728562dd9","intervention_name":"FLOX (5-fluorouracil/folinic acid/oxaliplatin)","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["fluorouracil"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00145314","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"FLOX (5-fluorouracil/folinic acid/oxaliplatin)","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00145314"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab"],"intervention_id":"I-CTG-flox-5-fluorouracil-folinic-acid-oxaliplat-a4c08af5e7","intervention_name":"FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["fluorouracil"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00145314","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00145314"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Fludarabine"],"intervention_id":"I-CTG-fludarabine-cb9905f3e0","intervention_name":"Fludarabine","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":6}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":6,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03190941","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Fludarabine","registry_intervention_type":"DRUG","source_record_index":60,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT03745326","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"Fludarabine","registry_intervention_type":"DRUG","source_record_index":63,"source_ref":"ctg-page-004"},{"intervention_index":2,"nct_id":"NCT05395052","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Fludarabine","registry_intervention_type":"DRUG","source_record_index":52,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT05451849","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"Fludarabine","registry_intervention_type":"DRUG","source_record_index":73,"source_ref":"ctg-page-005"},{"intervention_index":2,"nct_id":"NCT06530303","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Fludarabine","registry_intervention_type":"DRUG","source_record_index":8,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT07411599","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Fludarabine","registry_intervention_type":"DRUG","source_record_index":99,"source_ref":"ctg-page-003"}],"status":"RECRUITING / TERMINATED","statuses":["RECRUITING","TERMINATED"],"study_count":6,"study_ids":["NCT03190941","NCT03745326","NCT05395052","NCT05451849","NCT06530303","NCT07411599"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Fluorescence-Guided Surgery"],"intervention_id":"I-CTG-fluorescence-guided-surgery-00a8f26f44","intervention_name":"Fluorescence-Guided Surgery","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT06307548","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Fluorescence-Guided Surgery","registry_intervention_type":"PROCEDURE","source_record_index":91,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06307548"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Fluoropyrimidine (5-FU/LV or capecitabine)"],"intervention_id":"I-CTG-fluoropyrimidine-5-fu-lv-or-capecitabine-d8b0b970a1","intervention_name":"Fluoropyrimidine (5-FU/LV or capecitabine)","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["capecitabine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT02291289","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Fluoropyrimidine (5-FU/LV or capecitabine)","registry_intervention_type":"DRUG","source_record_index":28,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02291289"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["fluorouracil","Fluorouracil"],"intervention_id":"I-CTG-fluorouracil-9095bd0841","intervention_name":"fluorouracil","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":16}],"modality_support":{"matched_cues":["fluorouracil","Fluorouracil"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3","phases":["PHASE1","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":16,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00003422","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"fluorouracil","registry_intervention_type":"DRUG","source_record_index":51,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT00020917","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"fluorouracil","registry_intervention_type":"DRUG","source_record_index":94,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT00647530","overall_status":"UNKNOWN","phases":["PHASE2","PHASE3"],"registered_name":"fluorouracil","registry_intervention_type":"DRUG","source_record_index":48,"source_ref":"ctg-page-001"},{"intervention_index":5,"nct_id":"NCT01167725","overall_status":"TERMINATED","phases":["PHASE3"],"registered_name":"fluorouracil","registry_intervention_type":"DRUG","source_record_index":35,"source_ref":"ctg-page-004"},{"intervention_index":2,"nct_id":"NCT01205022","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"fluorouracil","registry_intervention_type":"DRUG","source_record_index":39,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT02508077","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Fluorouracil","registry_intervention_type":"DRUG","source_record_index":53,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT02688712","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Fluorouracil","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-003"},{"intervention_index":6,"nct_id":"NCT03715933","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Fluorouracil","registry_intervention_type":"DRUG","source_record_index":9,"source_ref":"ctg-page-005"},{"intervention_index":9,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Fluorouracil","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"},{"intervention_index":12,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Fluorouracil","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"},{"intervention_index":4,"nct_id":"NCT05719558","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Fluorouracil","registry_intervention_type":"DRUG","source_record_index":80,"source_ref":"ctg-page-001"},{"intervention_index":3,"nct_id":"NCT06490536","overall_status":"RECRUITING","phases":["PHASE3"],"registered_name":"Fluorouracil","registry_intervention_type":"DRUG","source_record_index":6,"source_ref":"ctg-page-002"},{"intervention_index":3,"nct_id":"NCT06654037","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Fluorouracil","registry_intervention_type":"DRUG","source_record_index":55,"source_ref":"ctg-page-004"},{"intervention_index":5,"nct_id":"NCT06696768","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Fluorouracil","registry_intervention_type":"DRUG","source_record_index":70,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT07277270","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Fluorouracil","registry_intervention_type":"DRUG","source_record_index":23,"source_ref":"ctg-page-002"},{"intervention_index":3,"nct_id":"NCT07318805","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Fluorouracil","registry_intervention_type":"DRUG","source_record_index":61,"source_ref":"ctg-page-003"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / RECRUITING / TERMINATED / UNKNOWN","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","RECRUITING","TERMINATED","UNKNOWN"],"study_count":15,"study_ids":["NCT00003422","NCT00020917","NCT00647530","NCT01167725","NCT01205022","NCT02508077","NCT02688712","NCT03715933","NCT04999761","NCT05719558","NCT06490536","NCT06654037","NCT06696768","NCT07277270","NCT07318805"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Fluorouracil (5-FU)"],"intervention_id":"I-CTG-fluorouracil-5-fu-e06666de0c","intervention_name":"Fluorouracil (5-FU)","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Fluorouracil"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT02083653","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Fluorouracil (5-FU)","registry_intervention_type":"DRUG","source_record_index":76,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02083653"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FOLFIRI"],"intervention_id":"I-CTG-folfiri-35fc3df147","intervention_name":"FOLFIRI","intervention_type":"multiple","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":12}],"modality_support":{"matched_cues":["fluorouracil","FOLFIRI","Irinotecan","irinotecan"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3","phases":["PHASE1","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG","OTHER"],"registry_occurrence_count":12,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT00101894","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"FOLFIRI","registry_intervention_type":"DRUG","source_record_index":13,"source_ref":"ctg-page-002"},{"intervention_index":4,"nct_id":"NCT00636610","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"FOLFIRI","registry_intervention_type":"DRUG","source_record_index":44,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT00719199","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"FOLFIRI","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT00813605","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"FOLFIRI","registry_intervention_type":"OTHER","source_record_index":41,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT02563002","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"FOLFIRI","registry_intervention_type":"DRUG","source_record_index":90,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT02568046","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"FOLFIRI","registry_intervention_type":"DRUG","source_record_index":40,"source_ref":"ctg-page-002"},{"intervention_index":3,"nct_id":"NCT03082209","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"FOLFIRI","registry_intervention_type":"DRUG","source_record_index":70,"source_ref":"ctg-page-004"},{"intervention_index":3,"nct_id":"NCT03250832","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"FOLFIRI","registry_intervention_type":"DRUG","source_record_index":77,"source_ref":"ctg-page-005"},{"intervention_index":2,"nct_id":"NCT03692429","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"FOLFIRI","registry_intervention_type":"DRUG","source_record_index":79,"source_ref":"ctg-page-005"},{"intervention_index":4,"nct_id":"NCT04485013","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"FOLFIRI","registry_intervention_type":"DRUG","source_record_index":46,"source_ref":"ctg-page-004"},{"intervention_index":8,"nct_id":"NCT04929223","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"FOLFIRI","registry_intervention_type":"DRUG","source_record_index":64,"source_ref":"ctg-page-003"},{"intervention_index":4,"nct_id":"NCT07649655","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1"],"registered_name":"FOLFIRI","registry_intervention_type":"DRUG","source_record_index":52,"source_ref":"ctg-page-004"}],"status":"COMPLETED / NOT_YET_RECRUITING / RECRUITING / TERMINATED","statuses":["COMPLETED","NOT_YET_RECRUITING","RECRUITING","TERMINATED"],"study_count":12,"study_ids":["NCT00101894","NCT00636610","NCT00719199","NCT00813605","NCT02563002","NCT02568046","NCT03082209","NCT03250832","NCT03692429","NCT04485013","NCT04929223","NCT07649655"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)"],"intervention_id":"I-CTG-folfiri-5-fluorouracil-folinic-acid-irinot-2b114c7db7","intervention_name":"FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Fluorouracil"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00154102","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)","registry_intervention_type":"DRUG","source_record_index":11,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00154102"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FOLFIRI + Cetuximab"],"intervention_id":"I-CTG-folfiri-cetuximab-860059a0ea","intervention_name":"FOLFIRI + Cetuximab","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1},{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["FOLFIRI","monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE4","phases":["PHASE4"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01315990","overall_status":"UNKNOWN","phases":["PHASE4"],"registered_name":"FOLFIRI + Cetuximab","registry_intervention_type":"DRUG","source_record_index":57,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT01943786","overall_status":"UNKNOWN","phases":[],"registered_name":"FOLFIRI + Cetuximab","registry_intervention_type":"DRUG","source_record_index":17,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":2,"study_ids":["NCT01315990","NCT01943786"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FOLFIRI Protocol"],"intervention_id":"I-CTG-folfiri-protocol-7d8f4e05f8","intervention_name":"FOLFIRI Protocol","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":3}],"modality_support":{"matched_cues":["fluorouracil","Irinotecan"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03186326","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"FOLFIRI Protocol","registry_intervention_type":"DRUG","source_record_index":60,"source_ref":"ctg-page-005"},{"intervention_index":3,"nct_id":"NCT04587128","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"FOLFIRI Protocol","registry_intervention_type":"DRUG","source_record_index":81,"source_ref":"ctg-page-005"},{"intervention_index":7,"nct_id":"NCT06047379","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"FOLFIRI Protocol","registry_intervention_type":"DRUG","source_record_index":79,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / RECRUITING","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","RECRUITING"],"study_count":3,"study_ids":["NCT03186326","NCT04587128","NCT06047379"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FOLFIRI regimen"],"intervention_id":"I-CTG-folfiri-regimen-c607e2b8f0","intervention_name":"FOLFIRI regimen","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["FOLFIRI"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT01167725","overall_status":"TERMINATED","phases":["PHASE3"],"registered_name":"FOLFIRI regimen","registry_intervention_type":"DRUG","source_record_index":35,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT01167725"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Folfiri/Cetuximab"],"intervention_id":"I-CTG-folfiri-cetuximab-4796e99102","intervention_name":"Folfiri/Cetuximab","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["fluorouracil"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03874026","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Folfiri/Cetuximab","registry_intervention_type":"DRUG","source_record_index":37,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT03874026"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FOLFOX"],"intervention_id":"I-CTG-folfox-d34f6ef74e","intervention_name":"FOLFOX","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":3}],"modality_support":{"matched_cues":["fluorouracil","oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03692429","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"FOLFOX","registry_intervention_type":"DRUG","source_record_index":79,"source_ref":"ctg-page-005"},{"intervention_index":7,"nct_id":"NCT04929223","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"FOLFOX","registry_intervention_type":"DRUG","source_record_index":64,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT04991948","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"FOLFOX","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":3,"study_ids":["NCT03692429","NCT04929223","NCT04991948"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FOLFOX 6"],"intervention_id":"I-CTG-folfox-6-e0fad68f21","intervention_name":"FOLFOX 6","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["fluorouracil"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00387387","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"FOLFOX 6","registry_intervention_type":"DRUG","source_record_index":59,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00387387"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FOLFOX induction regimen"],"intervention_id":"I-CTG-folfox-induction-regimen-9bade73465","intervention_name":"FOLFOX induction regimen","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["FOLFOX"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT02291289","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"FOLFOX induction regimen","registry_intervention_type":"DRUG","source_record_index":28,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02291289"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FOLFOX regimen"],"intervention_id":"I-CTG-folfox-regimen-ea3401d06d","intervention_name":"FOLFOX regimen","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":4}],"modality_support":{"matched_cues":["FOLFOX","oxaliplatin","Oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2 / PHASE3","phases":["PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":4,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT01167725","overall_status":"TERMINATED","phases":["PHASE3"],"registered_name":"FOLFOX regimen","registry_intervention_type":"DRUG","source_record_index":35,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT03186326","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"FOLFOX regimen","registry_intervention_type":"DRUG","source_record_index":60,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT06003998","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"FOLFOX regimen","registry_intervention_type":"DRUG","source_record_index":6,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT06509880","overall_status":"COMPLETED","phases":["PHASE2","PHASE3"],"registered_name":"FOLFOX regimen","registry_intervention_type":"DRUG","source_record_index":30,"source_ref":"ctg-page-002"}],"status":"COMPLETED / TERMINATED / UNKNOWN","statuses":["COMPLETED","TERMINATED","UNKNOWN"],"study_count":4,"study_ids":["NCT01167725","NCT03186326","NCT06003998","NCT06509880"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FOLFOX-4"],"intervention_id":"I-CTG-folfox-4-d040833f0b","intervention_name":"FOLFOX-4","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00101894","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"FOLFOX-4","registry_intervention_type":"DRUG","source_record_index":13,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00101894"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FOLFOXIRI plus Bevacizumab"],"intervention_id":"I-CTG-folfoxiri-plus-bevacizumab-364286467b","intervention_name":"FOLFOXIRI plus Bevacizumab","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["FLUOROURACIL"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03085992","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"FOLFOXIRI plus Bevacizumab","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03085992"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Folic acid"],"intervention_id":"I-CTG-folic-acid-501412629a","intervention_name":"Folic acid","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT05720559","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Folic acid","registry_intervention_type":"DRUG","source_record_index":49,"source_ref":"ctg-page-003"},{"intervention_index":5,"nct_id":"NCT05774964","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Folic acid","registry_intervention_type":"DRUG","source_record_index":8,"source_ref":"ctg-page-005"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":2,"study_ids":["NCT05720559","NCT05774964"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Folinic Acid","Folinic acid"],"intervention_id":"I-CTG-folinic-acid-555688dff7","intervention_name":"Folinic acid","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":3},{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["fluorouracil"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2 / PHASE3","phases":["PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":4,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT01442935","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Folinic Acid","registry_intervention_type":"DRUG","source_record_index":96,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT03206151","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"Folinic acid","registry_intervention_type":"DRUG","source_record_index":82,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT03751176","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Folinic acid","registry_intervention_type":"DRUG","source_record_index":2,"source_ref":"ctg-page-004"},{"intervention_index":2,"nct_id":"NCT06490536","overall_status":"RECRUITING","phases":["PHASE3"],"registered_name":"Folinic acid","registry_intervention_type":"DRUG","source_record_index":6,"source_ref":"ctg-page-002"}],"status":"COMPLETED / RECRUITING / UNKNOWN","statuses":["COMPLETED","RECRUITING","UNKNOWN"],"study_count":4,"study_ids":["NCT01442935","NCT03206151","NCT03751176","NCT06490536"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["folinic acid/5-FU/oxaliplatin (mFOLFOX-6)"],"intervention_id":"I-CTG-folinic-acid-5-fu-oxaliplatin-mfolfox-6-f63a4d8e1f","intervention_name":"folinic acid/5-FU/oxaliplatin (mFOLFOX-6)","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT03152370","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"folinic acid/5-FU/oxaliplatin (mFOLFOX-6)","registry_intervention_type":"DRUG","source_record_index":18,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03152370"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FoundationOne®Liquid CDx"],"intervention_id":"I-CTG-foundationoneliquid-cdx-f5f2d66cf0","intervention_name":"FoundationOne®Liquid CDx","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":9,"nct_id":"NCT04929223","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"FoundationOne®Liquid CDx","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":64,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT04929223"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FPI-2053"],"intervention_id":"I-CTG-fpi-2053-a6fb70a89b","intervention_name":"FPI-2053","intervention_type":"DRUG","modality":"bispecific-antibody","modality_distribution":[{"modality":"bispecific-antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["bispecific"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06147037","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"registered_name":"FPI-2053","registry_intervention_type":"DRUG","source_record_index":24,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT06147037"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"inhibitor","action_evidence":[{"action":"inhibitor","evidence_type":"registry-field","excerpt":"highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3","matched_text":"inhibitor","nct_id":"NCT06856837"}],"actions":["inhibitor"],"aliases":["Fruquintinib"],"intervention_id":"I-CTG-fruquintinib-990786ee64","intervention_name":"Fruquintinib","intervention_type":"multiple","modality":"small-molecule","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":3},{"modality":"small-molecule","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["COMBINATION_PRODUCT","DRUG"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05565417","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Fruquintinib","registry_intervention_type":"COMBINATION_PRODUCT","source_record_index":62,"source_ref":"ctg-page-005"},{"intervention_index":0,"nct_id":"NCT06856837","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Fruquintinib","registry_intervention_type":"DRUG","source_record_index":31,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT07591597","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Fruquintinib","registry_intervention_type":"DRUG","source_record_index":0,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING / NOT_YET_RECRUITING / RECRUITING","statuses":["ACTIVE_NOT_RECRUITING","NOT_YET_RECRUITING","RECRUITING"],"study_count":3,"study_ids":["NCT05565417","NCT06856837","NCT07591597"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3","matched_alias":"vascular endothelial growth factor receptors","nct_id":"NCT06856837","relation":"inhibitor of vascular endothelial growth factor receptors"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"fruquintinib","rationale":"Exact intervention-name alias for the VEGFR-directed small-molecule inhibitor.","rule_id":"candidate-fruquintinib","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein-family","target_id":"protein-family:VEGFR","target_name":"vascular endothelial growth factor receptor family","target_symbol":"VEGFR"}],"target_directness":"registry-explicit","target_ids":["protein-family:VEGFR"],"target_names":["vascular endothelial growth factor receptor family"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Fruquintinib combined with anti-PD-1 antibodies"],"intervention_id":"I-CTG-fruquintinib-combined-with-anti-pd-1-antib-d7689fe1ff","intervention_name":"Fruquintinib combined with anti-PD-1 antibodies","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["anti-PD-1 antibodies"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06011330","overall_status":"COMPLETED","phases":[],"registered_name":"Fruquintinib combined with anti-PD-1 antibodies","registry_intervention_type":"DRUG","source_record_index":18,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT06011330"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Fruquintinib (3-5mg once daily for 21 days on/7 days off) anti-PD-1 antibodies (including sintilimab, toripalimab, pembrolizumab, tislelizumab, and nivolumab).","matched_alias":"PD-1","nct_id":"NCT06011330","relation":"anti-PD-1"},{"evidence_type":"registry-field","excerpt":"Fruquintinib combined with anti-PD-1 antibodies","matched_alias":"PD-1","nct_id":"NCT06011330","relation":"anti-PD-1"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"registry-explicit","target_ids":["symbol:PDCD1"],"target_names":["programmed cell death protein 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["FT536"],"intervention_id":"I-CTG-ft536-68cc3bb06f","intervention_name":"FT536","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05395052","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"FT536","registry_intervention_type":"DRUG","source_record_index":52,"source_ref":"ctg-page-005"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT05395052"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["fulvestrant","Fulvestrant"],"intervention_id":"I-CTG-fulvestrant-45c4801d03","intervention_name":"fulvestrant","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":3}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":6,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"fulvestrant","registry_intervention_type":"DRUG","source_record_index":17,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT04579380","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"fulvestrant","registry_intervention_type":"DRUG","source_record_index":45,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT07318805","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Fulvestrant","registry_intervention_type":"DRUG","source_record_index":61,"source_ref":"ctg-page-003"}],"status":"ACTIVE_NOT_RECRUITING / RECRUITING / WITHDRAWN","statuses":["ACTIVE_NOT_RECRUITING","RECRUITING","WITHDRAWN"],"study_count":3,"study_ids":["NCT03169777","NCT04579380","NCT07318805"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Futuximab"],"intervention_id":"I-CTG-futuximab-083f8ace97","intervention_name":"Futuximab","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["mAb"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03549338","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Futuximab","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-005"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT03549338"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["G17DT-Irinotecan"],"intervention_id":"I-CTG-g17dt-irinotecan-112db7bbf1","intervention_name":"G17DT-Irinotecan","intervention_type":"BIOLOGICAL","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Irinotecan"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02118064","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"G17DT-Irinotecan","registry_intervention_type":"BIOLOGICAL","source_record_index":20,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02118064"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Ga-68-FAPI-46"],"intervention_id":"I-CTG-ga-68-fapi-46-53a9f71020","intervention_name":"Ga-68-FAPI-46","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06769828","overall_status":"RECRUITING","phases":["NA"],"registered_name":"Ga-68-FAPI-46","registry_intervention_type":"DRUG","source_record_index":55,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06769828"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Gallium Ga 68 FAPi-46"],"intervention_id":"I-CTG-gallium-ga-68-fapi-46-15339208a2","intervention_name":"Gallium Ga 68 FAPi-46","intervention_type":"RADIATION","modality":"radiation","modality_distribution":[{"modality":"radiation","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1","phases":["EARLY_PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["RADIATION"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT04147494","overall_status":"ACTIVE_NOT_RECRUITING","phases":["EARLY_PHASE1"],"registered_name":"Gallium Ga 68 FAPi-46","registry_intervention_type":"RADIATION","source_record_index":41,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT04147494"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Gallium Ga 68-labeled PSMA-11"],"intervention_id":"I-CTG-gallium-ga-68-labeled-psma-11-9bb7e663d2","intervention_name":"Gallium Ga 68-labeled PSMA-11","intervention_type":"RADIATION","modality":"radiation","modality_distribution":[{"modality":"radiation","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1","phases":["EARLY_PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["RADIATION"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT04147494","overall_status":"ACTIVE_NOT_RECRUITING","phases":["EARLY_PHASE1"],"registered_name":"Gallium Ga 68-labeled PSMA-11","registry_intervention_type":"RADIATION","source_record_index":41,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT04147494"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"inhibitor","action_evidence":[{"action":"inhibitor","evidence_type":"registry-field","excerpt":"Gamma-Secretase Inhibitor RO4929097","matched_text":"Inhibitor","nct_id":"NCT01198535"}],"actions":["inhibitor"],"aliases":["Gamma-Secretase Inhibitor RO4929097"],"intervention_id":"I-CTG-gamma-secretase-inhibitor-ro4929097-1775af3aa6","intervention_name":"Gamma-Secretase Inhibitor RO4929097","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT01198535","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Gamma-Secretase Inhibitor RO4929097","registry_intervention_type":"DRUG","source_record_index":11,"source_ref":"ctg-page-003"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT01198535"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Ganitumab"],"intervention_id":"I-CTG-ganitumab-5365bed8a8","intervention_name":"Ganitumab","intervention_type":"BIOLOGICAL","modality":"antibody","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2},{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00891930","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Ganitumab","registry_intervention_type":"BIOLOGICAL","source_record_index":53,"source_ref":"ctg-page-005"},{"intervention_index":2,"nct_id":"NCT01327612","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Ganitumab","registry_intervention_type":"BIOLOGICAL","source_record_index":4,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":2,"study_ids":["NCT00891930","NCT01327612"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"ganitumab","rationale":"Exact intervention-name aliases for IGF1R-directed antibodies.","rule_id":"candidate-ganitumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:IGF1R","target_name":"insulin-like growth factor 1 receptor","target_symbol":"IGF1R"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:IGF1R"],"target_names":["insulin-like growth factor 1 receptor"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Gardasil"],"intervention_id":"I-CTG-gardasil-16ee4fb02f","intervention_name":"Gardasil","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00666107","overall_status":"UNKNOWN","phases":["NA"],"registered_name":"Gardasil","registry_intervention_type":"BIOLOGICAL","source_record_index":29,"source_ref":"ctg-page-004"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT00666107"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Gemcitabine"],"intervention_id":"I-CTG-gemcitabine-cb0f740757","intervention_name":"Gemcitabine","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":3},{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":4,"registry_occurrences":[{"intervention_index":7,"nct_id":"NCT03607643","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"Gemcitabine","registry_intervention_type":"DRUG","source_record_index":59,"source_ref":"ctg-page-003"},{"intervention_index":18,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Gemcitabine","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"},{"intervention_index":20,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Gemcitabine","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"},{"intervention_index":3,"nct_id":"NCT07020221","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Gemcitabine","registry_intervention_type":"DRUG","source_record_index":57,"source_ref":"ctg-page-002"}],"status":"RECRUITING / UNKNOWN","statuses":["RECRUITING","UNKNOWN"],"study_count":3,"study_ids":["NCT03607643","NCT04999761","NCT07020221"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Gemcitabine + Nab-paclitaxel"],"intervention_id":"I-CTG-gemcitabine-nab-paclitaxel-7dd4208c30","intervention_name":"Gemcitabine + Nab-paclitaxel","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT07020221","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Gemcitabine + Nab-paclitaxel","registry_intervention_type":"DRUG","source_record_index":57,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07020221"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Gene Modified T Cells"],"intervention_id":"I-CTG-gene-modified-t-cells-fc791108b3","intervention_name":"Gene Modified T Cells","intervention_type":"multiple","modality":"cellular-therapy","modality_distribution":[{"modality":"cellular-therapy","registry_occurrence_count":2}],"modality_support":{"matched_cues":["Gene Modified T Cells"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","GENETIC"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00673322","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Gene Modified T Cells","registry_intervention_type":"BIOLOGICAL","source_record_index":7,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT01723306","overall_status":"SUSPENDED","phases":["PHASE2"],"registered_name":"Gene Modified T Cells","registry_intervention_type":"GENETIC","source_record_index":15,"source_ref":"ctg-page-003"}],"status":"SUSPENDED / TERMINATED","statuses":["SUSPENDED","TERMINATED"],"study_count":2,"study_ids":["NCT00673322","NCT01723306"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["GI-4000"],"intervention_id":"I-CTG-gi-4000-8114732f91","intervention_name":"GI-4000","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":18,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"GI-4000","registry_intervention_type":"BIOLOGICAL","source_record_index":17,"source_ref":"ctg-page-001"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT03169777"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["GI-6207"],"intervention_id":"I-CTG-gi-6207-a3bf2bdcf9","intervention_name":"GI-6207","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":19,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"GI-6207","registry_intervention_type":"BIOLOGICAL","source_record_index":17,"source_ref":"ctg-page-001"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT03169777"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["GI-6301"],"intervention_id":"I-CTG-gi-6301-7ace324b92","intervention_name":"GI-6301","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":20,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"GI-6301","registry_intervention_type":"BIOLOGICAL","source_record_index":17,"source_ref":"ctg-page-001"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT03169777"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Glycosylated Recombinant Human Interleukin-7"],"intervention_id":"I-CTG-glycosylated-recombinant-human-interleukin-22e6df37bf","intervention_name":"Glycosylated Recombinant Human Interleukin-7","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01339000","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Glycosylated Recombinant Human Interleukin-7","registry_intervention_type":"DRUG","source_record_index":61,"source_ref":"ctg-page-001"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT01339000"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["GM-CT-01 plus 5-Fluorouracil"],"intervention_id":"I-CTG-gm-ct-01-plus-5-fluorouracil-d4bb5b655a","intervention_name":"GM-CT-01 plus 5-Fluorouracil","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Fluorouracil"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00110721","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"GM-CT-01 plus 5-Fluorouracil","registry_intervention_type":"DRUG","source_record_index":63,"source_ref":"ctg-page-001"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT00110721"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["GM102"],"intervention_id":"I-CTG-gm102-28e316180e","intervention_name":"GM102","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03799731","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"GM102","registry_intervention_type":"DRUG","source_record_index":87,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03799731"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["GM102 expansion"],"intervention_id":"I-CTG-gm102-expansion-a5fb9bace4","intervention_name":"GM102 expansion","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT03799731","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"GM102 expansion","registry_intervention_type":"DRUG","source_record_index":87,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03799731"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["GSK5764227"],"intervention_id":"I-CTG-gsk5764227-624456bca2","intervention_name":"GSK5764227","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07277270","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"GSK5764227","registry_intervention_type":"DRUG","source_record_index":23,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07277270"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["haNK"],"intervention_id":"I-CTG-hank-0a99b793f4","intervention_name":"haNK","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":21,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"haNK","registry_intervention_type":"BIOLOGICAL","source_record_index":17,"source_ref":"ctg-page-001"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT03169777"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["HBs antibody and HBc antibody"],"intervention_id":"I-CTG-hbs-antibody-and-hbc-antibody-f4b0725ed8","intervention_name":"HBs antibody and HBc antibody","intervention_type":"OTHER","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["antibody and HBc antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":10,"nct_id":"NCT02280070","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"HBs antibody and HBc antibody","registry_intervention_type":"OTHER","source_record_index":62,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02280070"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["HBs antigen and HCV antibody"],"intervention_id":"I-CTG-hbs-antigen-and-hcv-antibody-c0e3aee1da","intervention_name":"HBs antigen and HCV antibody","intervention_type":"OTHER","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["antigen and HCV antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":8,"nct_id":"NCT02280070","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"HBs antigen and HCV antibody","registry_intervention_type":"OTHER","source_record_index":62,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02280070"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["HD Colon"],"intervention_id":"I-CTG-hd-colon-d1daf5e764","intervention_name":"HD Colon","intervention_type":"DEVICE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT01617278","overall_status":"COMPLETED","phases":["NA"],"registered_name":"HD Colon","registry_intervention_type":"DEVICE","source_record_index":39,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT02016326","overall_status":"UNKNOWN","phases":["NA"],"registered_name":"HD Colon","registry_intervention_type":"DEVICE","source_record_index":10,"source_ref":"ctg-page-005"}],"status":"COMPLETED / UNKNOWN","statuses":["COMPLETED","UNKNOWN"],"study_count":2,"study_ids":["NCT01617278","NCT02016326"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Hepatitis A Vaccine"],"intervention_id":"I-CTG-hepatitis-a-vaccine-9cc9cd5d2c","intervention_name":"Hepatitis A Vaccine","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT01339000","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Hepatitis A Vaccine","registry_intervention_type":"BIOLOGICAL","source_record_index":61,"source_ref":"ctg-page-001"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT01339000"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Hepatitis B Vaccine"],"intervention_id":"I-CTG-hepatitis-b-vaccine-04776562f0","intervention_name":"Hepatitis B Vaccine","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT01339000","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Hepatitis B Vaccine","registry_intervention_type":"BIOLOGICAL","source_record_index":61,"source_ref":"ctg-page-001"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT01339000"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["HER-2 vaccine"],"intervention_id":"I-CTG-her-2-vaccine-0f2c831000","intervention_name":"HER-2 vaccine","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01376505","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"HER-2 vaccine","registry_intervention_type":"BIOLOGICAL","source_record_index":18,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01376505"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["High definition white light endoscopy"],"intervention_id":"I-CTG-high-definition-white-light-endoscopy-6d4580e861","intervention_name":"High definition white light endoscopy","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT04192929","overall_status":"WITHDRAWN","phases":["NA"],"registered_name":"High definition white light endoscopy","registry_intervention_type":"OTHER","source_record_index":91,"source_ref":"ctg-page-005"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT04192929"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["High Definition White Light Endosocopy"],"intervention_id":"I-CTG-high-definition-white-light-endosocopy-14d56656d6","intervention_name":"High Definition White Light Endosocopy","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07474844","overall_status":"WITHDRAWN","phases":["NA"],"registered_name":"High Definition White Light Endosocopy","registry_intervention_type":"OTHER","source_record_index":0,"source_ref":"ctg-page-004"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT07474844"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["HIPEC"],"intervention_id":"I-CTG-hipec-cefb483ae4","intervention_name":"HIPEC","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03422432","overall_status":"COMPLETED","phases":["NA"],"registered_name":"HIPEC","registry_intervention_type":"PROCEDURE","source_record_index":17,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03422432"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["HMBD-001"],"intervention_id":"I-CTG-hmbd-001-a5fb342724","intervention_name":"HMBD-001","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05057013","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"HMBD-001","registry_intervention_type":"DRUG","source_record_index":99,"source_ref":"ctg-page-001"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT05057013"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["HMBD-001 and enzalutamide"],"intervention_id":"I-CTG-hmbd-001-and-enzalutamide-acde4f5f43","intervention_name":"HMBD-001 and enzalutamide","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05057013","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"HMBD-001 and enzalutamide","registry_intervention_type":"DRUG","source_record_index":99,"source_ref":"ctg-page-001"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT05057013"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["huA33"],"intervention_id":"I-CTG-hua33-7320a578ae","intervention_name":"huA33","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT00199797","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"huA33","registry_intervention_type":"DRUG","source_record_index":34,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00199797"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Huaier granule"],"intervention_id":"I-CTG-huaier-granule-22f248c6e6","intervention_name":"Huaier granule","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE4","phases":["PHASE4"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06665334","overall_status":"NOT_YET_RECRUITING","phases":["PHASE4"],"registered_name":"Huaier granule","registry_intervention_type":"DRUG","source_record_index":18,"source_ref":"ctg-page-003"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT06665334"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["HuC242-DM4"],"intervention_id":"I-CTG-huc242-dm4-fbf428acab","intervention_name":"HuC242-DM4","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00352131","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"HuC242-DM4","registry_intervention_type":"DRUG","source_record_index":87,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00352131"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["I-scan 1","I-Scan 1"],"intervention_id":"I-CTG-i-scan-1-767b38fc5b","intervention_name":"I-Scan 1","intervention_type":"DEVICE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01617278","overall_status":"COMPLETED","phases":["NA"],"registered_name":"I-Scan 1","registry_intervention_type":"DEVICE","source_record_index":39,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT02016326","overall_status":"UNKNOWN","phases":["NA"],"registered_name":"I-scan 1","registry_intervention_type":"DEVICE","source_record_index":10,"source_ref":"ctg-page-005"}],"status":"COMPLETED / UNKNOWN","statuses":["COMPLETED","UNKNOWN"],"study_count":2,"study_ids":["NCT01617278","NCT02016326"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["I-Scan 2"],"intervention_id":"I-CTG-i-scan-2-85eb2b3764","intervention_name":"I-Scan 2","intervention_type":"DEVICE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT01617278","overall_status":"COMPLETED","phases":["NA"],"registered_name":"I-Scan 2","registry_intervention_type":"DEVICE","source_record_index":39,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT02016326","overall_status":"UNKNOWN","phases":["NA"],"registered_name":"I-Scan 2","registry_intervention_type":"DEVICE","source_record_index":10,"source_ref":"ctg-page-005"}],"status":"COMPLETED / UNKNOWN","statuses":["COMPLETED","UNKNOWN"],"study_count":2,"study_ids":["NCT01617278","NCT02016326"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["i-scan CE, SE, TE mode"],"intervention_id":"I-CTG-i-scan-ce-se-te-mode-64102b4db8","intervention_name":"i-scan CE, SE, TE mode","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01417611","overall_status":"COMPLETED","phases":["NA"],"registered_name":"i-scan CE, SE, TE mode","registry_intervention_type":"PROCEDURE","source_record_index":6,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01417611"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"cytotoxic-payload-delivery","action_evidence":[{"action":"cytotoxic-payload-delivery","evidence_type":"registry-field","excerpt":"Recombinant anti-EGFR(Epidermal growth factor receptor) and c-Met antibodies-dual-payload conjugate for injection","matched_text":"dual-payload conjugate","nct_id":"NCT07589205"}],"actions":["cytotoxic-payload-delivery"],"aliases":["IBI3028"],"intervention_id":"I-CTG-ibi3028-ff981e0ea3","intervention_name":"IBI3028","intervention_type":"DRUG","modality":"antibody-drug-conjugate","modality_distribution":[{"modality":"antibody-drug-conjugate","registry_occurrence_count":1}],"modality_support":{"matched_cues":["dual-payload conjugate"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07589205","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Drug: IBI3028","registry_intervention_type":"DRUG","source_record_index":0,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07589205"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Recombinant anti-EGFR(Epidermal growth factor receptor) and c-Met antibodies-dual-payload conjugate for injection","matched_alias":"EGFR","nct_id":"NCT07589205","relation":"anti-EGFR"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:EGFR","target_name":"epidermal growth factor receptor","target_symbol":"EGFR"},{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Recombinant anti-EGFR(Epidermal growth factor receptor) and c-Met antibodies-dual-payload conjugate for injection","matched_alias":"c-Met","nct_id":"NCT07589205","relation":"antibodies"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:MET","target_name":"hepatocyte growth factor receptor","target_symbol":"MET"}],"target_directness":"registry-explicit","target_ids":["symbol:EGFR","symbol:MET"],"target_names":["epidermal growth factor receptor","hepatocyte growth factor receptor"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ICG"],"intervention_id":"I-CTG-icg-183a746658","intervention_name":"ICG","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05517681","overall_status":"COMPLETED","phases":["NA"],"registered_name":"ICG","registry_intervention_type":"DRUG","source_record_index":3,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT05517681"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"cytotoxic-payload-delivery","action_evidence":[{"action":"cytotoxic-payload-delivery","evidence_type":"registry-field","excerpt":"IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody","matched_text":"antibody drug conjugate","nct_id":"NCT07738939"}],"actions":["cytotoxic-payload-delivery"],"aliases":["IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody"],"intervention_id":"I-CTG-iks04-antibody-drug-conjugate-adc-isumab04-99f7e1dc77","intervention_name":"IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody","intervention_type":"DRUG","modality":"antibody-drug-conjugate","modality_distribution":[{"modality":"antibody-drug-conjugate","registry_occurrence_count":1}],"modality_support":{"matched_cues":["antibody drug conjugate"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07738939","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1"],"registered_name":"IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody","registry_intervention_type":"DRUG","source_record_index":59,"source_ref":"ctg-page-001"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07738939"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["IL-2"],"intervention_id":"I-CTG-il-2-2f861543e7","intervention_name":"IL-2","intervention_type":"multiple","modality":"antibody","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2},{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["mAb"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","DRUG"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT03970382","overall_status":"SUSPENDED","phases":["PHASE1"],"registered_name":"IL-2","registry_intervention_type":"BIOLOGICAL","source_record_index":81,"source_ref":"ctg-page-003"},{"intervention_index":3,"nct_id":"NCT05395052","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"IL-2","registry_intervention_type":"DRUG","source_record_index":52,"source_ref":"ctg-page-005"},{"intervention_index":11,"nct_id":"NCT05395052","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"IL-2","registry_intervention_type":"DRUG","source_record_index":52,"source_ref":"ctg-page-005"}],"status":"SUSPENDED / TERMINATED","statuses":["SUSPENDED","TERMINATED"],"study_count":2,"study_ids":["NCT03970382","NCT05395052"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["IL2"],"intervention_id":"I-CTG-il2-839489f4fd","intervention_name":"IL2","intervention_type":"DRUG","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT02919644","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"IL2","registry_intervention_type":"DRUG","source_record_index":83,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT02919644"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["IM96 CAR-T cells"],"intervention_id":"I-CTG-im96-car-t-cells-111524d9e1","intervention_name":"IM96 CAR-T cells","intervention_type":"DRUG","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR-T cells"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1","phases":["EARLY_PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05287165","overall_status":"UNKNOWN","phases":["EARLY_PHASE1"],"registered_name":"IM96 CAR-T cells","registry_intervention_type":"DRUG","source_record_index":62,"source_ref":"ctg-page-001"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT05287165"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"treatment with anti-GUCY2C chimeric antigen receptor T-cell infusion","matched_alias":"GUCY2C","nct_id":"NCT05287165","relation":"anti-GUCY2C"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:GUCY2C","target_name":"guanylate cyclase 2C","target_symbol":"GUCY2C"}],"target_directness":"registry-explicit","target_ids":["symbol:GUCY2C"],"target_names":["guanylate cyclase 2C"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Imaging study"],"intervention_id":"I-CTG-imaging-study-ce73d4d01a","intervention_name":"Imaging study","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00828620","overall_status":"TERMINATED","phases":[],"registered_name":"Imaging study","registry_intervention_type":"OTHER","source_record_index":27,"source_ref":"ctg-page-002"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT00828620"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Imaging Technique"],"intervention_id":"I-CTG-imaging-technique-b81c2ffbd9","intervention_name":"Imaging Technique","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1","phases":["EARLY_PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05245786","overall_status":"ACTIVE_NOT_RECRUITING","phases":["EARLY_PHASE1"],"registered_name":"Imaging Technique","registry_intervention_type":"PROCEDURE","source_record_index":2,"source_ref":"ctg-page-005"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT05245786"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Imatinib mesylate and panitumumab"],"intervention_id":"I-CTG-imatinib-mesylate-and-panitumumab-19db40f9ca","intervention_name":"Imatinib mesylate and panitumumab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00867334","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Imatinib mesylate and panitumumab","registry_intervention_type":"DRUG","source_record_index":40,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00867334"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["IMC-A12"],"intervention_id":"I-CTG-imc-a12-68ed666b05","intervention_name":"IMC-A12","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00503685","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"IMC-A12","registry_intervention_type":"BIOLOGICAL","source_record_index":73,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00503685"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["IMC-A12 (cixutumumab)"],"intervention_id":"I-CTG-imc-a12-cixutumumab-14d748b189","intervention_name":"IMC-A12 (cixutumumab)","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT00845039","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"IMC-A12 (cixutumumab)","registry_intervention_type":"BIOLOGICAL","source_record_index":78,"source_ref":"ctg-page-002"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT00845039"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Imiquimod"],"intervention_id":"I-CTG-imiquimod-ab6fc72dae","intervention_name":"Imiquimod","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02600949","overall_status":"ENROLLING_BY_INVITATION","phases":["PHASE1"],"registered_name":"Imiquimod","registry_intervention_type":"DRUG","source_record_index":89,"source_ref":"ctg-page-001"}],"status":"ENROLLING_BY_INVITATION","statuses":["ENROLLING_BY_INVITATION"],"study_count":1,"study_ids":["NCT02600949"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Immunohistochemistry"],"intervention_id":"I-CTG-immunohistochemistry-e5a00a7d8d","intervention_name":"Immunohistochemistry","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03986541","overall_status":"COMPLETED","phases":[],"registered_name":"Immunohistochemistry","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":30,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03986541"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Immunohistochemistry or immunofluorescence"],"intervention_id":"I-CTG-immunohistochemistry-or-immunofluorescence-4e7605b331","intervention_name":"Immunohistochemistry or immunofluorescence","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07586293","overall_status":"NOT_YET_RECRUITING","phases":[],"registered_name":"Immunohistochemistry or immunofluorescence","registry_intervention_type":"OTHER","source_record_index":95,"source_ref":"ctg-page-001"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07586293"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Immunotherapeutic Agents"],"intervention_id":"I-CTG-immunotherapeutic-agents-d86db01d18","intervention_name":"Immunotherapeutic Agents","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03695835","overall_status":"COMPLETED","phases":[],"registered_name":"Immunotherapeutic Agents","registry_intervention_type":"DRUG","source_record_index":92,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03695835"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Immunotherapy"],"intervention_id":"I-CTG-immunotherapy-f3bf3779cf","intervention_name":"Immunotherapy","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04612309","overall_status":"ACTIVE_NOT_RECRUITING","phases":[],"registered_name":"Immunotherapy","registry_intervention_type":"DRUG","source_record_index":14,"source_ref":"ctg-page-003"},{"intervention_index":4,"nct_id":"NCT06130826","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Immunotherapy","registry_intervention_type":"DRUG","source_record_index":89,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING / RECRUITING","statuses":["ACTIVE_NOT_RECRUITING","RECRUITING"],"study_count":2,"study_ids":["NCT04612309","NCT06130826"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["IMO-2055"],"intervention_id":"I-CTG-imo-2055-35cf7400a8","intervention_name":"IMO-2055","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00719199","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"IMO-2055","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT00719199"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Impact of Gender on Davinci rectal surgery"],"intervention_id":"I-CTG-impact-of-gender-on-davinci-rectal-surgery-4282ba07bc","intervention_name":"Impact of Gender on Davinci rectal surgery","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06391060","overall_status":"COMPLETED","phases":[],"registered_name":"Impact of Gender on Davinci rectal surgery","registry_intervention_type":"PROCEDURE","source_record_index":48,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT06391060"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["IMT-009"],"intervention_id":"I-CTG-imt-009-1ad49d3434","intervention_name":"IMT-009","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05565417","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"IMT-009","registry_intervention_type":"DRUG","source_record_index":62,"source_ref":"ctg-page-005"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT05565417"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Inavolisib"],"intervention_id":"I-CTG-inavolisib-3eae227893","intervention_name":"Inavolisib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04929223","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Inavolisib","registry_intervention_type":"DRUG","source_record_index":64,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT04929223"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"agonist","action_evidence":[{"action":"agonist","evidence_type":"registry-field","excerpt":"Tetravalent DR5 Agonist Antibody","matched_text":"Agonist","nct_id":"NCT03715933"}],"actions":["agonist"],"aliases":["INBRX-109"],"intervention_id":"I-CTG-inbrx-109-fb6bab3c3e","intervention_name":"INBRX-109","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03715933","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"INBRX-109","registry_intervention_type":"DRUG","source_record_index":9,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT03715933"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Tetravalent DR5 Agonist Antibody","matched_alias":"DR5","nct_id":"NCT03715933","relation":"Agonist"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:TNFRSF10B","target_name":"tumor necrosis factor receptor superfamily member 10B","target_symbol":"TNFRSF10B"}],"target_directness":"registry-explicit","target_ids":["symbol:TNFRSF10B"],"target_names":["tumor necrosis factor receptor superfamily member 10B"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["INCAGN01876"],"intervention_id":"I-CTG-incagn01876-21ea5e3fa0","intervention_name":"INCAGN01876","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03126110","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"INCAGN01876","registry_intervention_type":"DRUG","source_record_index":89,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03126110"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Indium labeled IMP-205xm734"],"intervention_id":"I-CTG-indium-labeled-imp-205xm734-fdb1ad65c0","intervention_name":"Indium labeled IMP-205xm734","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00185081","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Indium labeled IMP-205xm734","registry_intervention_type":"DRUG","source_record_index":22,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00185081"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["INT230-6"],"intervention_id":"I-CTG-int230-6-3bc32b436c","intervention_name":"INT230-6","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03058289","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"INT230-6","registry_intervention_type":"DRUG","source_record_index":58,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03058289"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Interleukin-2"],"intervention_id":"I-CTG-interleukin-2-531a829bc6","intervention_name":"Interleukin-2","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT06530303","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Interleukin-2","registry_intervention_type":"DRUG","source_record_index":8,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06530303"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Internet-Based Intervention"],"intervention_id":"I-CTG-internet-based-intervention-a8c0566a46","intervention_name":"Internet-Based Intervention","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT06995924","overall_status":"RECRUITING","phases":["NA"],"registered_name":"Internet-Based Intervention","registry_intervention_type":"OTHER","source_record_index":29,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06995924"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Intraperitoneal infusion of FAST CEA-targeted CAR-T"],"intervention_id":"I-CTG-intraperitoneal-infusion-of-fast-cea-targe-5d1a5c7453","intervention_name":"Intraperitoneal infusion of FAST CEA-targeted CAR-T","intervention_type":"BIOLOGICAL","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR-T"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06821048","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Intraperitoneal infusion of FAST CEA-targeted CAR-T","registry_intervention_type":"BIOLOGICAL","source_record_index":44,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06821048"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Intraperitoneal infusion of FAST CEA-targeted CAR-T (PTC13); Subjects will be treated with Fludarabine and Cyclophosphamide based lymphodepleting chemotherapy before CAR-T cell infusion.","matched_alias":"CEA","nct_id":"NCT06821048","relation":"targeted"},{"evidence_type":"registry-field","excerpt":"Intraperitoneal infusion of FAST CEA-targeted CAR-T","matched_alias":"CEA","nct_id":"NCT06821048","relation":"targeted"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CEACAM5","target_name":"carcinoembryonic antigen-related cell adhesion molecule 5","target_symbol":"CEACAM5"}],"target_directness":"registry-explicit","target_ids":["symbol:CEACAM5"],"target_names":["carcinoembryonic antigen-related cell adhesion molecule 5"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["investigator choice re-challenge with anti EGFR Rx"],"intervention_id":"I-CTG-investigator-choice-re-challenge-with-anti-9694a696df","intervention_name":"investigator choice re-challenge with anti EGFR Rx","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["anti EGFR antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04775862","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"investigator choice re-challenge with anti EGFR Rx","registry_intervention_type":"DRUG","source_record_index":7,"source_ref":"ctg-page-001"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT04775862"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"…tatus will be examined. If RAS is wildtype, then the investigator will decide whether to re-challenge with an anti EGFR antibody , or give SOC third line chemotherapy (Regorafenib or TAS-102).","matched_alias":"EGFR","nct_id":"NCT04775862","relation":"anti EGFR"},{"evidence_type":"registry-field","excerpt":"investigator choice re-challenge with anti EGFR Rx","matched_alias":"EGFR","nct_id":"NCT04775862","relation":"anti EGFR"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:EGFR","target_name":"epidermal growth factor receptor","target_symbol":"EGFR"}],"target_directness":"registry-explicit","target_ids":["symbol:EGFR"],"target_names":["epidermal growth factor receptor"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["iodine I 123 anti-CEA recombinant diabody T84.66"],"intervention_id":"I-CTG-iodine-i-123-anti-cea-recombinant-diabody--bd95c1eb88","intervention_name":"iodine I 123 anti-CEA recombinant diabody T84.66","intervention_type":"RADIATION","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["iodine I 123"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["RADIATION"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT00647153","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"iodine I 123 anti-CEA recombinant diabody T84.66","registry_intervention_type":"RADIATION","source_record_index":12,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00647153"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"iodine I 123 anti-CEA recombinant diabody T84.66","matched_alias":"CEA","nct_id":"NCT00647153","relation":"anti-CEA"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CEACAM5","target_name":"carcinoembryonic antigen-related cell adhesion molecule 5","target_symbol":"CEACAM5"}],"target_directness":"registry-explicit","target_ids":["symbol:CEACAM5"],"target_names":["carcinoembryonic antigen-related cell adhesion molecule 5"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Iodine I 124 Monoclonal Antibody M5A"],"intervention_id":"I-CTG-iodine-i-124-monoclonal-antibody-m5a-3d0b190b93","intervention_name":"Iodine I 124 Monoclonal Antibody M5A","intervention_type":"BIOLOGICAL","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Iodine I 124"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03993327","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Iodine I 124 Monoclonal Antibody M5A","registry_intervention_type":"BIOLOGICAL","source_record_index":55,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03993327"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Iodine-124 labeled humanized A33 (antibody)"],"intervention_id":"I-CTG-iodine-124-labeled-humanized-a33-antibody-e8caa6e23e","intervention_name":"Iodine-124 labeled humanized A33 (antibody)","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Iodine-124"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00199862","overall_status":"COMPLETED","phases":["NA"],"registered_name":"Iodine-124 labeled humanized A33 (antibody)","registry_intervention_type":"DRUG","source_record_index":3,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00199862"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Iodine-124 labeled humanized A33 (antibody)","matched_alias":"A33","nct_id":"NCT00199862","relation":"antibody"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:GPA33","target_name":"cell surface A33 antigen","target_symbol":"GPA33"}],"target_directness":"registry-explicit","target_ids":["symbol:GPA33"],"target_names":["cell surface A33 antigen"]},{"action":"binder; blocker","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"…imumab is a fully humanized monoclonal anti-CTLA-4 antibody that acts as an antineoplastic ICI by selectively binding to cytotoxic T-lymphocyte-associated antigen 4, a molecule located on the surface of cytotoxic T-cells, suppr…","matched_text":"binding","nct_id":"NCT05732389"},{"action":"blocker","evidence_type":"registry-field","excerpt":"…n 4, a molecule located on the surface of cytotoxic T-cells, suppressing the immune response (17). Ipilimumab blocks CTLA-4, leading to a continuously active immune response in malignant cells.","matched_text":"blocks","nct_id":"NCT05732389"}],"actions":["binder","blocker"],"aliases":["Ipilimumab","ipilimumab"],"intervention_id":"I-CTG-ipilimumab-b766c43ce0","intervention_name":"Ipilimumab","intervention_type":"multiple","modality":"antibody","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":13},{"modality":"antibody","registry_occurrence_count":3}],"modality_support":{"matched_cues":["anti-CTLA-4 antibody","monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3","phases":["PHASE1","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","DRUG"],"registry_occurrence_count":15,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01769222","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Ipilimumab","registry_intervention_type":"BIOLOGICAL","source_record_index":38,"source_ref":"ctg-page-004"},{"intervention_index":2,"nct_id":"NCT02314169","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Ipilimumab","registry_intervention_type":"BIOLOGICAL","source_record_index":61,"source_ref":"ctg-page-004"},{"intervention_index":3,"nct_id":"NCT02408861","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Ipilimumab","registry_intervention_type":"BIOLOGICAL","source_record_index":50,"source_ref":"ctg-page-003"},{"intervention_index":3,"nct_id":"NCT02834013","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Ipilimumab","registry_intervention_type":"BIOLOGICAL","source_record_index":44,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT03126110","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Ipilimumab","registry_intervention_type":"DRUG","source_record_index":89,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT03271047","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"ipilimumab","registry_intervention_type":"DRUG","source_record_index":77,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT03373188","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Ipilimumab","registry_intervention_type":"BIOLOGICAL","source_record_index":14,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT04362839","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Ipilimumab","registry_intervention_type":"BIOLOGICAL","source_record_index":11,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT04500548","overall_status":"WITHDRAWN","phases":["PHASE1"],"registered_name":"Ipilimumab","registry_intervention_type":"BIOLOGICAL","source_record_index":51,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT04751370","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Ipilimumab","registry_intervention_type":"BIOLOGICAL","source_record_index":31,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT05176483","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Ipilimumab","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT05310643","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Ipilimumab","registry_intervention_type":"DRUG","source_record_index":24,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT05732389","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Ipilimumab","registry_intervention_type":"DRUG","source_record_index":84,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT06047379","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Ipilimumab","registry_intervention_type":"DRUG","source_record_index":79,"source_ref":"ctg-page-004"},{"intervention_index":7,"nct_id":"NCT06490536","overall_status":"RECRUITING","phases":["PHASE3"],"registered_name":"Ipilimumab","registry_intervention_type":"DRUG","source_record_index":6,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / RECRUITING / TERMINATED / WITHDRAWN","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","RECRUITING","TERMINATED","WITHDRAWN"],"study_count":15,"study_ids":["NCT01769222","NCT02314169","NCT02408861","NCT02834013","NCT03126110","NCT03271047","NCT03373188","NCT04362839","NCT04500548","NCT04751370","NCT05176483","NCT05310643","NCT05732389","NCT06047379","NCT06490536"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Ipilimumab is a fully humanized monoclonal anti-CTLA-4 antibody that acts as an antineoplastic ICI by selectively binding to cytotoxic T-lymphocyte-associated antigen 4, a molecule located on the surface of cytotoxic T-c…","matched_alias":"CTLA-4","nct_id":"NCT05732389","relation":"anti-CTLA-4"},{"evidence_type":"registry-field","excerpt":"… under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy c…","matched_alias":"CTLA-4","nct_id":"NCT06047379","relation":"targeting CTLA-4"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"ipilimumab","rationale":"Exact intervention-name alias for the CTLA-4-directed antibody.","rule_id":"candidate-ipilimumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CTLA4","target_name":"cytotoxic T-lymphocyte protein 4","target_symbol":"CTLA4"}],"target_directness":"registry-explicit","target_ids":["symbol:CTLA4"],"target_names":["cytotoxic T-lymphocyte protein 4"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Irinotecan","irinotecan"],"intervention_id":"I-CTG-irinotecan-3298e18a64","intervention_name":"Irinotecan","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":23}],"modality_support":{"matched_cues":["fluorouracil","Irinotecan","irinotecan","oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3 / PHASE4","phases":["PHASE1","PHASE2","PHASE3","PHASE4"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":23,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00063141","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":74,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT00063141","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":74,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT00436072","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":31,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT00845039","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":78,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT00891930","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":53,"source_ref":"ctg-page-005"},{"intervention_index":2,"nct_id":"NCT00925015","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":38,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT01225744","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-004"},{"intervention_index":3,"nct_id":"NCT01442935","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":96,"source_ref":"ctg-page-002"},{"intervention_index":4,"nct_id":"NCT01442935","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":96,"source_ref":"ctg-page-002"},{"intervention_index":5,"nct_id":"NCT01588990","overall_status":"COMPLETED","phases":["PHASE4"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":13,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT01925274","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"irinotecan","registry_intervention_type":"DRUG","source_record_index":52,"source_ref":"ctg-page-003"},{"intervention_index":3,"nct_id":"NCT01925274","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":52,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT03206151","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":82,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT03380689","overall_status":"WITHDRAWN","phases":["PHASE1"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":95,"source_ref":"ctg-page-003"},{"intervention_index":6,"nct_id":"NCT03607643","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":59,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT03715933","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":9,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT03751176","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":2,"source_ref":"ctg-page-004"},{"intervention_index":2,"nct_id":"NCT04587128","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":81,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT05278728","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":34,"source_ref":"ctg-page-004"},{"intervention_index":5,"nct_id":"NCT05719558","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":80,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT06003998","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":6,"source_ref":"ctg-page-003"},{"intervention_index":5,"nct_id":"NCT06490536","overall_status":"RECRUITING","phases":["PHASE3"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":6,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT07649655","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1"],"registered_name":"Irinotecan","registry_intervention_type":"DRUG","source_record_index":52,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / NOT_YET_RECRUITING / RECRUITING / TERMINATED / UNKNOWN / WITHDRAWN","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","NOT_YET_RECRUITING","RECRUITING","TERMINATED","UNKNOWN","WITHDRAWN"],"study_count":20,"study_ids":["NCT00063141","NCT00436072","NCT00845039","NCT00891930","NCT00925015","NCT01225744","NCT01442935","NCT01588990","NCT01925274","NCT03206151","NCT03380689","NCT03607643","NCT03715933","NCT03751176","NCT04587128","NCT05278728","NCT05719558","NCT06003998","NCT06490536","NCT07649655"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Irinotecan (Camptosar)"],"intervention_id":"I-CTG-irinotecan-camptosar-ed020bb67e","intervention_name":"Irinotecan (Camptosar)","intervention_type":"COMBINATION_PRODUCT","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Irinotecan"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["COMBINATION_PRODUCT"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05592626","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Irinotecan (Camptosar)","registry_intervention_type":"COMBINATION_PRODUCT","source_record_index":90,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05592626"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Irinotecan Hydrochloride","irinotecan hydrochloride"],"intervention_id":"I-CTG-irinotecan-hydrochloride-cd73034bfe","intervention_name":"irinotecan hydrochloride","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":7}],"modality_support":{"matched_cues":["Irinotecan","irinotecan"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3","phases":["PHASE1","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":7,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00005076","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"irinotecan hydrochloride","registry_intervention_type":"DRUG","source_record_index":83,"source_ref":"ctg-page-005"},{"intervention_index":2,"nct_id":"NCT00020917","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"irinotecan hydrochloride","registry_intervention_type":"DRUG","source_record_index":94,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT00940316","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"irinotecan hydrochloride","registry_intervention_type":"DRUG","source_record_index":51,"source_ref":"ctg-page-005"},{"intervention_index":6,"nct_id":"NCT01167725","overall_status":"TERMINATED","phases":["PHASE3"],"registered_name":"irinotecan hydrochloride","registry_intervention_type":"DRUG","source_record_index":35,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT01205022","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"irinotecan hydrochloride","registry_intervention_type":"DRUG","source_record_index":39,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT02164916","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"irinotecan hydrochloride","registry_intervention_type":"DRUG","source_record_index":72,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT02508077","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Irinotecan Hydrochloride","registry_intervention_type":"DRUG","source_record_index":53,"source_ref":"ctg-page-003"}],"status":"COMPLETED / TERMINATED","statuses":["COMPLETED","TERMINATED"],"study_count":7,"study_ids":["NCT00005076","NCT00020917","NCT00940316","NCT01167725","NCT01205022","NCT02164916","NCT02508077"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Itraconazole"],"intervention_id":"I-CTG-itraconazole-25098b221a","intervention_name":"Itraconazole","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT06400472","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Itraconazole","registry_intervention_type":"DRUG","source_record_index":48,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06400472"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["IX001 TCR-T cells"],"intervention_id":"I-CTG-ix001-tcr-t-cells-520199426c","intervention_name":"IX001 TCR-T cells","intervention_type":"BIOLOGICAL","modality":"cellular-therapy","modality_distribution":[{"modality":"cellular-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["TCR-T"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06487377","overall_status":"WITHDRAWN","phases":["PHASE1"],"registered_name":"IX001 TCR-T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":2,"source_ref":"ctg-page-002"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT06487377"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["JAB-3312"],"intervention_id":"I-CTG-jab-3312-c22867e75e","intervention_name":"JAB-3312","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04045496","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"JAB-3312","registry_intervention_type":"DRUG","source_record_index":52,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT04121286","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"JAB-3312","registry_intervention_type":"DRUG","source_record_index":0,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":2,"study_ids":["NCT04045496","NCT04121286"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["JNJ-78306358"],"intervention_id":"I-CTG-jnj-78306358-208bd1f312","intervention_name":"JNJ-78306358","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04991740","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"JNJ-78306358","registry_intervention_type":"DRUG","source_record_index":91,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT04991740"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["JS207"],"intervention_id":"I-CTG-js207-13bb7c5a22","intervention_name":"JS207","intervention_type":"DRUG","modality":"bispecific-antibody","modality_distribution":[{"modality":"bispecific-antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Bispecific"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT07503756","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"JS207","registry_intervention_type":"DRUG","source_record_index":49,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07503756"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Bispecific antibody targeting PD-1 and VEGF","matched_alias":"PD-1","nct_id":"NCT07503756","relation":"targeting PD-1"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"registry-explicit","target_ids":["symbol:PDCD1"],"target_names":["programmed cell death protein 1"]},{"action":"cytotoxic-payload-delivery","action_evidence":[{"action":"cytotoxic-payload-delivery","evidence_type":"registry-field","excerpt":"Bispecific antibody-drug conjugate targeting EGFR and HER3","matched_text":"antibody-drug conjugate","nct_id":"NCT07503756"}],"actions":["cytotoxic-payload-delivery"],"aliases":["JS212"],"intervention_id":"I-CTG-js212-0f8ea7a70b","intervention_name":"JS212","intervention_type":"DRUG","modality":"bispecific-antibody-drug-conjugate","modality_distribution":[{"modality":"bispecific-antibody-drug-conjugate","registry_occurrence_count":1}],"modality_support":{"matched_cues":["antibody-drug conjugate","Bispecific"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07503756","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"JS212","registry_intervention_type":"DRUG","source_record_index":49,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07503756"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Bispecific antibody-drug conjugate targeting EGFR and HER3","matched_alias":"EGFR","nct_id":"NCT07503756","relation":"targeting EGFR"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:EGFR","target_name":"epidermal growth factor receptor","target_symbol":"EGFR"},{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Bispecific antibody-drug conjugate targeting EGFR and HER3","matched_alias":"HER3","nct_id":"NCT07503756","relation":"co-listed-target"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:ERBB3","target_name":"receptor tyrosine-protein kinase erbB-3","target_symbol":"ERBB3"}],"target_directness":"registry-explicit","target_ids":["symbol:EGFR","symbol:ERBB3"],"target_names":["epidermal growth factor receptor","receptor tyrosine-protein kinase erbB-3"]},{"action":"binder; blocker","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"KEYTRUDA binds to the PD - 1 receptor, blocking both immune-suppressing ligands, PD L1 and PD L2, from interacting with PD - 1 to help restore T-cell response and immune response.","matched_text":"binds","nct_id":"NCT06400160"},{"action":"blocker","evidence_type":"registry-field","excerpt":"KEYTRUDA binds to the PD - 1 receptor, blocking both immune-suppressing ligands, PD L1 and PD L2, from interacting with PD - 1 to help restore T-cell response and immune response.","matched_text":"blocking","nct_id":"NCT06400160"}],"actions":["binder","blocker"],"aliases":["Keytruda"],"intervention_id":"I-CTG-keytruda-8266394dac","intervention_name":"Keytruda","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1},{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT06400160","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Keytruda","registry_intervention_type":"DRUG","source_record_index":27,"source_ref":"ctg-page-005"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT06400160"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"Keytruda","rationale":"Exact intervention-name alias for the PD-1-directed antibody.","rule_id":"candidate-pembrolizumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:PDCD1"],"target_names":["programmed cell death protein 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["KL-140"],"intervention_id":"I-CTG-kl-140-f567d37d02","intervention_name":"KL-140","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03426371","overall_status":"TERMINATED","phases":["PHASE3"],"registered_name":"KL-140","registry_intervention_type":"DRUG","source_record_index":31,"source_ref":"ctg-page-003"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT03426371"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["KRAS BRAF mutant Sintilimab + regafinil"],"intervention_id":"I-CTG-kras-braf-mutant-sintilimab-regafinil-1470da0aa8","intervention_name":"KRAS BRAF mutant Sintilimab + regafinil","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT04745130","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"KRAS BRAF mutant Sintilimab + regafinil","registry_intervention_type":"DRUG","source_record_index":94,"source_ref":"ctg-page-001"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT04745130"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["KT032(anti-MSLN chimeric antigen receptor autologous T cell injection)"],"intervention_id":"I-CTG-kt032-anti-msln-chimeric-antigen-receptor--6cffa98224","intervention_name":"KT032(anti-MSLN chimeric antigen receptor autologous T cell injection)","intervention_type":"BIOLOGICAL","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chimeric antigen receptor autologous T cell"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1","phases":["EARLY_PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07420010","overall_status":"NOT_YET_RECRUITING","phases":["EARLY_PHASE1"],"registered_name":"KT032(anti-MSLN chimeric antigen receptor autologous T cell injection)","registry_intervention_type":"BIOLOGICAL","source_record_index":82,"source_ref":"ctg-page-003"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07420010"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Lymphodepletion conditioning is required prior to administration of anti-MSLN chimeric antigen receptor autologous T cell injection (KT032). KT032 is administered via intraperitoneal injection (10-30 ml cell injection so…","matched_alias":"MSLN","nct_id":"NCT07420010","relation":"anti-MSLN"},{"evidence_type":"registry-field","excerpt":"KT032(anti-MSLN chimeric antigen receptor autologous T cell injection)","matched_alias":"MSLN","nct_id":"NCT07420010","relation":"anti-MSLN"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:MSLN","target_name":"mesothelin","target_symbol":"MSLN"}],"target_directness":"registry-explicit","target_ids":["symbol:MSLN"],"target_names":["mesothelin"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["l-LV"],"intervention_id":"I-CTG-l-lv-732e59f83b","intervention_name":"l-LV","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":14,"nct_id":"NCT02280070","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"l-LV","registry_intervention_type":"DRUG","source_record_index":62,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02280070"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["L-OHP (130mg/m2)"],"intervention_id":"I-CTG-l-ohp-130mg-m2-eefa83ccf2","intervention_name":"L-OHP (130mg/m2)","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":12,"nct_id":"NCT02280070","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"L-OHP (130mg/m2)","registry_intervention_type":"DRUG","source_record_index":62,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02280070"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["L-OHP (85 mg/m2)"],"intervention_id":"I-CTG-l-ohp-85-mg-m2-4da8ea34dd","intervention_name":"L-OHP (85 mg/m2)","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":13,"nct_id":"NCT02280070","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"L-OHP (85 mg/m2)","registry_intervention_type":"DRUG","source_record_index":62,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02280070"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Labetuzumab Govitecan (LG)"],"intervention_id":"I-CTG-labetuzumab-govitecan-lg-76b9d44000","intervention_name":"Labetuzumab Govitecan (LG)","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01605318","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"Labetuzumab Govitecan (LG)","registry_intervention_type":"DRUG","source_record_index":45,"source_ref":"ctg-page-003"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT01605318"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["laboratory biomarker analysis","Laboratory Biomarker Analysis"],"intervention_id":"I-CTG-laboratory-biomarker-analysis-5dff388dd6","intervention_name":"Laboratory Biomarker Analysis","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":13}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1 / NA / PHASE1 / PHASE2","phases":["EARLY_PHASE1","NA","PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":13,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT00397384","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"laboratory biomarker analysis","registry_intervention_type":"OTHER","source_record_index":98,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT01198535","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Laboratory Biomarker Analysis","registry_intervention_type":"OTHER","source_record_index":11,"source_ref":"ctg-page-003"},{"intervention_index":5,"nct_id":"NCT01205022","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"laboratory biomarker analysis","registry_intervention_type":"OTHER","source_record_index":39,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT01254617","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Laboratory Biomarker Analysis","registry_intervention_type":"OTHER","source_record_index":41,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT01696994","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"registered_name":"Laboratory Biomarker Analysis","registry_intervention_type":"OTHER","source_record_index":28,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT02293954","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"registered_name":"laboratory biomarker analysis","registry_intervention_type":"OTHER","source_record_index":92,"source_ref":"ctg-page-005"},{"intervention_index":3,"nct_id":"NCT02374931","overall_status":"TERMINATED","phases":["EARLY_PHASE1"],"registered_name":"Laboratory Biomarker Analysis","registry_intervention_type":"OTHER","source_record_index":63,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT02432963","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"registered_name":"Laboratory Biomarker Analysis","registry_intervention_type":"OTHER","source_record_index":85,"source_ref":"ctg-page-005"},{"intervention_index":2,"nct_id":"NCT02508077","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Laboratory Biomarker Analysis","registry_intervention_type":"OTHER","source_record_index":53,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT02650635","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Laboratory Biomarker Analysis","registry_intervention_type":"OTHER","source_record_index":79,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT02713373","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Laboratory Biomarker Analysis","registry_intervention_type":"OTHER","source_record_index":80,"source_ref":"ctg-page-002"},{"intervention_index":3,"nct_id":"NCT02757391","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Laboratory Biomarker Analysis","registry_intervention_type":"OTHER","source_record_index":42,"source_ref":"ctg-page-004"},{"intervention_index":3,"nct_id":"NCT02978625","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Laboratory Biomarker Analysis","registry_intervention_type":"OTHER","source_record_index":93,"source_ref":"ctg-page-003"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / TERMINATED","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","TERMINATED"],"study_count":13,"study_ids":["NCT00397384","NCT01198535","NCT01205022","NCT01254617","NCT01696994","NCT02293954","NCT02374931","NCT02432963","NCT02508077","NCT02650635","NCT02713373","NCT02757391","NCT02978625"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Laboratory test"],"intervention_id":"I-CTG-laboratory-test-905b6fc4d1","intervention_name":"Laboratory test","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02280070","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Laboratory test","registry_intervention_type":"OTHER","source_record_index":62,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02280070"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["LB-100"],"intervention_id":"I-CTG-lb-100-99b29ca4a0","intervention_name":"LB-100","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06012734","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"LB-100","registry_intervention_type":"DRUG","source_record_index":7,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06012734"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["LC Bead M1"],"intervention_id":"I-CTG-lc-bead-m1-cae64da0e3","intervention_name":"LC Bead M1","intervention_type":"DEVICE","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["irinotecan"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT02015754","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"LC Bead M1","registry_intervention_type":"DEVICE","source_record_index":28,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02015754"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Lenalidomide"],"intervention_id":"I-CTG-lenalidomide-5f0194b3aa","intervention_name":"Lenalidomide","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT01254617","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Lenalidomide","registry_intervention_type":"DRUG","source_record_index":41,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01254617"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Lenvatinib"],"intervention_id":"I-CTG-lenvatinib-949cb28155","intervention_name":"Lenvatinib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03797326","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Lenvatinib","registry_intervention_type":"DRUG","source_record_index":73,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03797326"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["leucovorin","Leucovorin"],"intervention_id":"I-CTG-leucovorin-477cf9e8e1","intervention_name":"leucovorin","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":8},{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":3}],"modality_support":{"matched_cues":["chemotherapy","oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3 / PHASE4","phases":["PHASE1","PHASE2","PHASE3","PHASE4"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":11,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT00061815","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"leucovorin","registry_intervention_type":"DRUG","source_record_index":25,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT00199797","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Leucovorin","registry_intervention_type":"DRUG","source_record_index":34,"source_ref":"ctg-page-001"},{"intervention_index":3,"nct_id":"NCT00803647","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"leucovorin","registry_intervention_type":"DRUG","source_record_index":43,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT01522612","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"leucovorin","registry_intervention_type":"DRUG","source_record_index":20,"source_ref":"ctg-page-005"},{"intervention_index":3,"nct_id":"NCT01588990","overall_status":"COMPLETED","phases":["PHASE4"],"registered_name":"Leucovorin","registry_intervention_type":"DRUG","source_record_index":13,"source_ref":"ctg-page-003"},{"intervention_index":7,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"leucovorin","registry_intervention_type":"DRUG","source_record_index":17,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT03607643","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"Leucovorin","registry_intervention_type":"DRUG","source_record_index":59,"source_ref":"ctg-page-003"},{"intervention_index":5,"nct_id":"NCT03715933","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Leucovorin","registry_intervention_type":"DRUG","source_record_index":9,"source_ref":"ctg-page-005"},{"intervention_index":3,"nct_id":"NCT05719558","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Leucovorin","registry_intervention_type":"DRUG","source_record_index":80,"source_ref":"ctg-page-001"},{"intervention_index":3,"nct_id":"NCT07277270","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"leucovorin","registry_intervention_type":"DRUG","source_record_index":23,"source_ref":"ctg-page-002"},{"intervention_index":5,"nct_id":"NCT07318805","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Leucovorin","registry_intervention_type":"DRUG","source_record_index":61,"source_ref":"ctg-page-003"}],"status":"COMPLETED / RECRUITING / TERMINATED / UNKNOWN / WITHDRAWN","statuses":["COMPLETED","RECRUITING","TERMINATED","UNKNOWN","WITHDRAWN"],"study_count":11,"study_ids":["NCT00061815","NCT00199797","NCT00803647","NCT01522612","NCT01588990","NCT03169777","NCT03607643","NCT03715933","NCT05719558","NCT07277270","NCT07318805"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Leucovorin Calcium","leucovorin calcium"],"intervention_id":"I-CTG-leucovorin-calcium-12cd7dfb0d","intervention_name":"Leucovorin Calcium","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":6}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3","phases":["PHASE1","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":6,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00003422","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"leucovorin calcium","registry_intervention_type":"DRUG","source_record_index":51,"source_ref":"ctg-page-003"},{"intervention_index":3,"nct_id":"NCT00020917","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"leucovorin calcium","registry_intervention_type":"DRUG","source_record_index":94,"source_ref":"ctg-page-003"},{"intervention_index":7,"nct_id":"NCT01167725","overall_status":"TERMINATED","phases":["PHASE3"],"registered_name":"leucovorin calcium","registry_intervention_type":"DRUG","source_record_index":35,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT01205022","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"leucovorin calcium","registry_intervention_type":"DRUG","source_record_index":39,"source_ref":"ctg-page-004"},{"intervention_index":3,"nct_id":"NCT02508077","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Leucovorin Calcium","registry_intervention_type":"DRUG","source_record_index":53,"source_ref":"ctg-page-003"},{"intervention_index":6,"nct_id":"NCT06696768","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Leucovorin Calcium","registry_intervention_type":"DRUG","source_record_index":70,"source_ref":"ctg-page-002"}],"status":"COMPLETED / RECRUITING / TERMINATED","statuses":["COMPLETED","RECRUITING","TERMINATED"],"study_count":6,"study_ids":["NCT00003422","NCT00020917","NCT01167725","NCT01205022","NCT02508077","NCT06696768"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["LGX818"],"intervention_id":"I-CTG-lgx818-7201f7370f","intervention_name":"LGX818","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01719380","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"LGX818","registry_intervention_type":"DRUG","source_record_index":16,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01719380"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Lomotil"],"intervention_id":"I-CTG-lomotil-2f49e64322","intervention_name":"Lomotil","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT01851369","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Lomotil","registry_intervention_type":"OTHER","source_record_index":99,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01851369"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Long Course Chemoradiotherapy (LCRT)"],"intervention_id":"I-CTG-long-course-chemoradiotherapy-lcrt-8ef4c30b58","intervention_name":"Long Course Chemoradiotherapy (LCRT)","intervention_type":"RADIATION","modality":"radiation","modality_distribution":[{"modality":"radiation","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["RADIATION"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03152370","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Long Course Chemoradiotherapy (LCRT)","registry_intervention_type":"RADIATION","source_record_index":18,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03152370"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations"],"intervention_id":"I-CTG-long-course-radiotherapy-capecitabine-pd-1-717aefe155","intervention_name":"long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations","intervention_type":"COMBINATION_PRODUCT","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["COMBINATION_PRODUCT"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04911517","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations","registry_intervention_type":"COMBINATION_PRODUCT","source_record_index":9,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT04911517"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer","matched_alias":"PD-1","nct_id":"NCT04911517","relation":"monoclonal antibody"},{"evidence_type":"registry-field","excerpt":"long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations","matched_alias":"PD-1","nct_id":"NCT04911517","relation":"monoclonal antibody"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"registry-explicit","target_ids":["symbol:PDCD1"],"target_names":["programmed cell death protein 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Long Range NGS HLA typing"],"intervention_id":"I-CTG-long-range-ngs-hla-typing-81c163d1b8","intervention_name":"Long Range NGS HLA typing","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT04981119","overall_status":"RECRUITING","phases":[],"registered_name":"Long Range NGS HLA typing","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":63,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT04981119"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Lorigerlimab"],"intervention_id":"I-CTG-lorigerlimab-bce46b3b96","intervention_name":"Lorigerlimab","intervention_type":"BIOLOGICAL","modality":"bispecific-antibody","modality_distribution":[{"modality":"bispecific-antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Bispecific"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03761017","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Lorigerlimab","registry_intervention_type":"BIOLOGICAL","source_record_index":78,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03761017"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["lorlatinib"],"intervention_id":"I-CTG-lorlatinib-dd395f4ea5","intervention_name":"lorlatinib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT04800822","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"lorlatinib","registry_intervention_type":"DRUG","source_record_index":15,"source_ref":"ctg-page-002"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT04800822"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Lovaza"],"intervention_id":"I-CTG-lovaza-27b865bab7","intervention_name":"Lovaza","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":10,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"Lovaza","registry_intervention_type":"DRUG","source_record_index":17,"source_ref":"ctg-page-001"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT03169777"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Low dose [177Lu]Lu-A9-0631"],"intervention_id":"I-CTG-low-dose-177lu-lu-a9-0631-59fb059ef2","intervention_name":"Low dose [177Lu]Lu-A9-0631","intervention_type":"DIAGNOSTIC_TEST","modality":"radioligand-therapy","modality_distribution":[{"modality":"radioligand-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["177Lu"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07661641","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Low dose [177Lu]Lu-A9-0631","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":18,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07661641"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["LY2157299"],"intervention_id":"I-CTG-ly2157299-6d0eb5d7f4","intervention_name":"LY2157299","intervention_type":"DRUG","modality":"small-molecule","modality_distribution":[{"modality":"small-molecule","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Small molecule"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02688712","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"LY2157299","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-003"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT02688712"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["LY4257496"],"intervention_id":"I-CTG-ly4257496-f47e0b6be4","intervention_name":"LY4257496","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07114601","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"LY4257496","registry_intervention_type":"DRUG","source_record_index":2,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07114601"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["LY4257529"],"intervention_id":"I-CTG-ly4257529-a6560d255b","intervention_name":"LY4257529","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT07114601","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"LY4257529","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":2,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07114601"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Lycopene"],"intervention_id":"I-CTG-lycopene-8fe10f92e2","intervention_name":"Lycopene","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03167268","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Lycopene","registry_intervention_type":"DRUG","source_record_index":13,"source_ref":"ctg-page-001"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT03167268"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["LYL273"],"intervention_id":"I-CTG-lyl273-4b65a0f719","intervention_name":"LYL273","intervention_type":"DRUG","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR) transduced autologous T cells"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05319314","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"LYL273","registry_intervention_type":"DRUG","source_record_index":36,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05319314"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Lymphodepletion"],"intervention_id":"I-CTG-lymphodepletion-d9aa4bb4f0","intervention_name":"Lymphodepletion","intervention_type":"DRUG","modality":"car-nk-cell-therapy","modality_distribution":[{"modality":"car-nk-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR-NK"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07589517","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Lymphodepletion","registry_intervention_type":"DRUG","source_record_index":33,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07589517"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["m-FOLFOX-6 regimen"],"intervention_id":"I-CTG-m-folfox-6-regimen-e461ed5c58","intervention_name":"m-FOLFOX-6 regimen","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT04660812","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"m-FOLFOX-6 regimen","registry_intervention_type":"DRUG","source_record_index":78,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT04660812"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Magnesium glycinate"],"intervention_id":"I-CTG-magnesium-glycinate-357334ce51","intervention_name":"Magnesium glycinate","intervention_type":"DIETARY_SUPPLEMENT","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIETARY_SUPPLEMENT"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01105169","overall_status":"COMPLETED","phases":["NA"],"registered_name":"Magnesium glycinate","registry_intervention_type":"DIETARY_SUPPLEMENT","source_record_index":7,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01105169"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Magnesium-rich mineral water (Rozana)"],"intervention_id":"I-CTG-magnesium-rich-mineral-water-rozana-b593c89603","intervention_name":"Magnesium-rich mineral water (Rozana)","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03146338","overall_status":"UNKNOWN","phases":["NA"],"registered_name":"Magnesium-rich mineral water (Rozana)","registry_intervention_type":"OTHER","source_record_index":72,"source_ref":"ctg-page-005"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT03146338"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Magnetic Resonance Elastography"],"intervention_id":"I-CTG-magnetic-resonance-elastography-c2f988514f","intervention_name":"Magnetic Resonance Elastography","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT02298959","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"registered_name":"Magnetic Resonance Elastography","registry_intervention_type":"PROCEDURE","source_record_index":64,"source_ref":"ctg-page-001"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT02298959"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Magnetic Resonance Imaging"],"intervention_id":"I-CTG-magnetic-resonance-imaging-8db75186a3","intervention_name":"Magnetic Resonance Imaging","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":11}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":11,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT02314169","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Magnetic Resonance Imaging","registry_intervention_type":"PROCEDURE","source_record_index":61,"source_ref":"ctg-page-004"},{"intervention_index":5,"nct_id":"NCT02600949","overall_status":"ENROLLING_BY_INVITATION","phases":["PHASE1"],"registered_name":"Magnetic Resonance Imaging","registry_intervention_type":"PROCEDURE","source_record_index":89,"source_ref":"ctg-page-001"},{"intervention_index":4,"nct_id":"NCT02834013","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Magnetic Resonance Imaging","registry_intervention_type":"PROCEDURE","source_record_index":44,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT04314401","overall_status":"ACTIVE_NOT_RECRUITING","phases":[],"registered_name":"Magnetic Resonance Imaging","registry_intervention_type":"PROCEDURE","source_record_index":47,"source_ref":"ctg-page-002"},{"intervention_index":3,"nct_id":"NCT04595747","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Magnetic Resonance Imaging","registry_intervention_type":"PROCEDURE","source_record_index":49,"source_ref":"ctg-page-004"},{"intervention_index":2,"nct_id":"NCT04751370","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Magnetic Resonance Imaging","registry_intervention_type":"PROCEDURE","source_record_index":31,"source_ref":"ctg-page-002"},{"intervention_index":5,"nct_id":"NCT05803382","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Magnetic Resonance Imaging","registry_intervention_type":"PROCEDURE","source_record_index":53,"source_ref":"ctg-page-001"},{"intervention_index":5,"nct_id":"NCT06130826","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Magnetic Resonance Imaging","registry_intervention_type":"PROCEDURE","source_record_index":89,"source_ref":"ctg-page-004"},{"intervention_index":4,"nct_id":"NCT06307548","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Magnetic Resonance Imaging","registry_intervention_type":"PROCEDURE","source_record_index":91,"source_ref":"ctg-page-002"},{"intervention_index":7,"nct_id":"NCT06696768","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Magnetic Resonance Imaging","registry_intervention_type":"PROCEDURE","source_record_index":70,"source_ref":"ctg-page-002"},{"intervention_index":7,"nct_id":"NCT07405476","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Magnetic Resonance Imaging","registry_intervention_type":"PROCEDURE","source_record_index":97,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING / ENROLLING_BY_INVITATION / RECRUITING","statuses":["ACTIVE_NOT_RECRUITING","ENROLLING_BY_INVITATION","RECRUITING"],"study_count":11,"study_ids":["NCT02314169","NCT02600949","NCT02834013","NCT04314401","NCT04595747","NCT04751370","NCT05803382","NCT06130826","NCT06307548","NCT06696768","NCT07405476"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["magnetic resonance imaging with positron emission tomography scanning"],"intervention_id":"I-CTG-magnetic-resonance-imaging-with-positron-e-a3601d6508","intervention_name":"magnetic resonance imaging with positron emission tomography scanning","intervention_type":"DEVICE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01557881","overall_status":"TERMINATED","phases":["NA"],"registered_name":"magnetic resonance imaging with positron emission tomography scanning","registry_intervention_type":"DEVICE","source_record_index":5,"source_ref":"ctg-page-005"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT01557881"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Mammogram"],"intervention_id":"I-CTG-mammogram-670591afa3","intervention_name":"Mammogram","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT04034953","overall_status":"UNKNOWN","phases":["NA"],"registered_name":"Mammogram","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":90,"source_ref":"ctg-page-002"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT04034953"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["MCLA-129"],"intervention_id":"I-CTG-mcla-129-5e5c8330bb","intervention_name":"MCLA-129","intervention_type":"DRUG","modality":"bispecific-antibody","modality_distribution":[{"modality":"bispecific-antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["bispecific"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04868877","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"MCLA-129","registry_intervention_type":"DRUG","source_record_index":70,"source_ref":"ctg-page-003"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT04868877"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["MDX-1106"],"intervention_id":"I-CTG-mdx-1106-4f4f9f6015","intervention_name":"MDX-1106","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00441337","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"MDX-1106","registry_intervention_type":"BIOLOGICAL","source_record_index":8,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00441337"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["MDX2001"],"intervention_id":"I-CTG-mdx2001-28c05f2fd6","intervention_name":"MDX2001","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06239194","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"MDX2001","registry_intervention_type":"DRUG","source_record_index":83,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06239194"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Medical Chart Review"],"intervention_id":"I-CTG-medical-chart-review-5ba239bed0","intervention_name":"Medical Chart Review","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT04314401","overall_status":"ACTIVE_NOT_RECRUITING","phases":[],"registered_name":"Medical Chart Review","registry_intervention_type":"OTHER","source_record_index":47,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT04314401"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Medical history and physical examination"],"intervention_id":"I-CTG-medical-history-and-physical-examination-a10d3d3eb0","intervention_name":"Medical history and physical examination","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT02280070","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Medical history and physical examination","registry_intervention_type":"OTHER","source_record_index":62,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02280070"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["MelCancerVac"],"intervention_id":"I-CTG-melcancervac-62927713d3","intervention_name":"MelCancerVac","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00311272","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"MelCancerVac","registry_intervention_type":"BIOLOGICAL","source_record_index":12,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00311272"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Metformin"],"intervention_id":"I-CTG-metformin-c18f8cceb7","intervention_name":"Metformin","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03800602","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Metformin","registry_intervention_type":"DRUG","source_record_index":76,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03800602"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Metoclopramide"],"intervention_id":"I-CTG-metoclopramide-8ddbc3c706","intervention_name":"Metoclopramide","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT01851369","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Metoclopramide","registry_intervention_type":"OTHER","source_record_index":99,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01851369"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Metronidazole"],"intervention_id":"I-CTG-metronidazole-524a0b3040","intervention_name":"Metronidazole","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT05720559","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Metronidazole","registry_intervention_type":"DRUG","source_record_index":49,"source_ref":"ctg-page-003"},{"intervention_index":3,"nct_id":"NCT05774964","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Metronidazole","registry_intervention_type":"DRUG","source_record_index":8,"source_ref":"ctg-page-005"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":2,"study_ids":["NCT05720559","NCT05774964"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["mFOLFOX6"],"intervention_id":"I-CTG-mfolfox6-4bcab81a9c","intervention_name":"mFOLFOX6","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":3},{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":["fluorouracil"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3","phases":["PHASE1","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":5,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT00819780","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"mFOLFOX6","registry_intervention_type":"DRUG","source_record_index":46,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT02563002","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"mFOLFOX6","registry_intervention_type":"DRUG","source_record_index":90,"source_ref":"ctg-page-004"},{"intervention_index":3,"nct_id":"NCT02671435","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"mFOLFOX6","registry_intervention_type":"DRUG","source_record_index":66,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT03250832","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"mFOLFOX6","registry_intervention_type":"DRUG","source_record_index":77,"source_ref":"ctg-page-005"},{"intervention_index":3,"nct_id":"NCT07649655","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1"],"registered_name":"mFOLFOX6","registry_intervention_type":"DRUG","source_record_index":52,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / NOT_YET_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","NOT_YET_RECRUITING"],"study_count":5,"study_ids":["NCT00819780","NCT02563002","NCT02671435","NCT03250832","NCT07649655"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["mitomycin C"],"intervention_id":"I-CTG-mitomycin-c-1fbfe1c12b","intervention_name":"mitomycin C","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":8,"nct_id":"NCT01167725","overall_status":"TERMINATED","phases":["PHASE3"],"registered_name":"mitomycin C","registry_intervention_type":"DRUG","source_record_index":35,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT01167725"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["MK-0646"],"intervention_id":"I-CTG-mk-0646-4fd2f3ddeb","intervention_name":"MK-0646","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Fluorouracil"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01175291","overall_status":"WITHDRAWN","phases":["PHASE2"],"registered_name":"MK-0646","registry_intervention_type":"DRUG","source_record_index":47,"source_ref":"ctg-page-005"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT01175291"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["MK-1697"],"intervention_id":"I-CTG-mk-1697-c2f0cfd65b","intervention_name":"MK-1697","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03515824","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"MK-1697","registry_intervention_type":"BIOLOGICAL","source_record_index":66,"source_ref":"ctg-page-005"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT03515824"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Modified FOLFOX"],"intervention_id":"I-CTG-modified-folfox-8e88d4b748","intervention_name":"Modified FOLFOX","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["fluorouracil"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT00636610","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Modified FOLFOX","registry_intervention_type":"DRUG","source_record_index":44,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00636610"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Modified FOLFOX6"],"intervention_id":"I-CTG-modified-folfox6-c371e07b89","intervention_name":"Modified FOLFOX6","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["fluorouracil"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01327612","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Modified FOLFOX6","registry_intervention_type":"DRUG","source_record_index":4,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01327612"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Modified Vaccinia Virus Ankara Vaccine Expressing p53"],"intervention_id":"I-CTG-modified-vaccinia-virus-ankara-vaccine-exp-01c7ba8124","intervention_name":"Modified Vaccinia Virus Ankara Vaccine Expressing p53","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT02432963","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"registered_name":"Modified Vaccinia Virus Ankara Vaccine Expressing p53","registry_intervention_type":"BIOLOGICAL","source_record_index":85,"source_ref":"ctg-page-005"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT02432963"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Modotuximab"],"intervention_id":"I-CTG-modotuximab-e59aed6c41","intervention_name":"Modotuximab","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["mAb"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT03549338","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Modotuximab","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-005"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT03549338"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Monalizumab"],"intervention_id":"I-CTG-monalizumab-b20b5f3a0f","intervention_name":"Monalizumab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02671435","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Monalizumab","registry_intervention_type":"DRUG","source_record_index":66,"source_ref":"ctg-page-001"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT02671435"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Monalizumab/MEDI5257"],"intervention_id":"I-CTG-monalizumab-medi5257-aa7dcbff79","intervention_name":"Monalizumab/MEDI5257","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06152523","overall_status":"WITHDRAWN","phases":["PHASE2"],"registered_name":"Monalizumab/MEDI5257","registry_intervention_type":"DRUG","source_record_index":43,"source_ref":"ctg-page-004"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT06152523"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["MRI"],"intervention_id":"I-CTG-mri-86b3733153","intervention_name":"MRI","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":6,"nct_id":"NCT03745326","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"MRI","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":63,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT03745326"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["MRI scan"],"intervention_id":"I-CTG-mri-scan-8b04e2b9bb","intervention_name":"MRI scan","intervention_type":"DEVICE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05524012","overall_status":"ACTIVE_NOT_RECRUITING","phases":[],"registered_name":"MRI scan","registry_intervention_type":"DEVICE","source_record_index":54,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT05524012"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["MSB0011359C"],"intervention_id":"I-CTG-msb0011359c-a7e415b949","intervention_name":"MSB0011359C","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT04491955","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"MSB0011359C","registry_intervention_type":"DRUG","source_record_index":62,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT04491955"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["MT-304"],"intervention_id":"I-CTG-mt-304-191b938129","intervention_name":"MT-304","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07334119","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"MT-304","registry_intervention_type":"DRUG","source_record_index":77,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07334119"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["MT-304 + Nivolumab"],"intervention_id":"I-CTG-mt-304-nivolumab-6d974fa050","intervention_name":"MT-304 + Nivolumab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07334119","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"MT-304 + Nivolumab","registry_intervention_type":"DRUG","source_record_index":77,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07334119"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Multi-mode tumor treatment system"],"intervention_id":"I-CTG-multi-mode-tumor-treatment-system-db11679dc4","intervention_name":"Multi-mode tumor treatment system","intervention_type":"DEVICE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA / PHASE2","phases":["NA","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06588569","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"registered_name":"Multi-mode tumor treatment system","registry_intervention_type":"DEVICE","source_record_index":47,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT06590259","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Multi-mode tumor treatment system","registry_intervention_type":"DEVICE","source_record_index":59,"source_ref":"ctg-page-005"}],"status":"ACTIVE_NOT_RECRUITING / RECRUITING","statuses":["ACTIVE_NOT_RECRUITING","RECRUITING"],"study_count":2,"study_ids":["NCT06588569","NCT06590259"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Multigated Acquisition Scan"],"intervention_id":"I-CTG-multigated-acquisition-scan-9e1daf79ee","intervention_name":"Multigated Acquisition Scan","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT07405476","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Multigated Acquisition Scan","registry_intervention_type":"PROCEDURE","source_record_index":97,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07405476"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Multimodal Deep Learning Model Analysis"],"intervention_id":"I-CTG-multimodal-deep-learning-model-analysis-86746ee930","intervention_name":"Multimodal Deep Learning Model Analysis","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07399236","overall_status":"RECRUITING","phases":[],"registered_name":"Multimodal Deep Learning Model Analysis","registry_intervention_type":"OTHER","source_record_index":21,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07399236"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["MVT-5873"],"intervention_id":"I-CTG-mvt-5873-fbf4e8bac1","intervention_name":"MVT-5873","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03801915","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"MVT-5873","registry_intervention_type":"DRUG","source_record_index":77,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03801915"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["N-803"],"intervention_id":"I-CTG-n-803-891d9321ab","intervention_name":"N-803","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT04491955","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"N-803","registry_intervention_type":"DRUG","source_record_index":62,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT04491955"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["nab paclitaxel"],"intervention_id":"I-CTG-nab-paclitaxel-78f836ff99","intervention_name":"nab paclitaxel","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":8,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"nab paclitaxel","registry_intervention_type":"DRUG","source_record_index":17,"source_ref":"ctg-page-001"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT03169777"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["nab-Paclitaxel"],"intervention_id":"I-CTG-nab-paclitaxel-876379c6c9","intervention_name":"nab-Paclitaxel","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":16,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"nab-Paclitaxel","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"},{"intervention_index":19,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"nab-Paclitaxel","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT04999761"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Nanrilkefusp Alfa","Nanrilkefusp alfa"],"intervention_id":"I-CTG-nanrilkefusp-alfa-b7922c4227","intervention_name":"Nanrilkefusp alfa","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04234113","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Nanrilkefusp alfa","registry_intervention_type":"DRUG","source_record_index":74,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT05256381","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Nanrilkefusp Alfa","registry_intervention_type":"DRUG","source_record_index":25,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":2,"study_ids":["NCT04234113","NCT05256381"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Narrow band imaging"],"intervention_id":"I-CTG-narrow-band-imaging-5c2930fe9c","intervention_name":"Narrow band imaging","intervention_type":"DEVICE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04192929","overall_status":"WITHDRAWN","phases":["NA"],"registered_name":"Narrow band imaging","registry_intervention_type":"DEVICE","source_record_index":91,"source_ref":"ctg-page-005"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT04192929"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Natural Killer (NK) Cells"],"intervention_id":"I-CTG-natural-killer-nk-cells-025ec9bc0f","intervention_name":"Natural Killer (NK) Cells","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02890758","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Natural Killer (NK) Cells","registry_intervention_type":"BIOLOGICAL","source_record_index":85,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02890758"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["NBI Function"],"intervention_id":"I-CTG-nbi-function-4db99cb116","intervention_name":"NBI Function","intervention_type":"multiple","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE","PROCEDURE"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02009774","overall_status":"COMPLETED","phases":[],"registered_name":"NBI Function","registry_intervention_type":"PROCEDURE","source_record_index":67,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT03679429","overall_status":"UNKNOWN","phases":[],"registered_name":"NBI Function","registry_intervention_type":"DEVICE","source_record_index":3,"source_ref":"ctg-page-004"}],"status":"COMPLETED / UNKNOWN","statuses":["COMPLETED","UNKNOWN"],"study_count":2,"study_ids":["NCT02009774","NCT03679429"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["NEO212 Oral Capsule"],"intervention_id":"I-CTG-neo212-oral-capsule-cedf19c5ce","intervention_name":"NEO212 Oral Capsule","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06047379","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"NEO212 Oral Capsule","registry_intervention_type":"DRUG","source_record_index":79,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06047379"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["neoadjuvant therapy"],"intervention_id":"I-CTG-neoadjuvant-therapy-49585eb21a","intervention_name":"neoadjuvant therapy","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT00003422","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"neoadjuvant therapy","registry_intervention_type":"PROCEDURE","source_record_index":51,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00003422"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["NeoTCR-P1 adoptive cell therapy"],"intervention_id":"I-CTG-neotcr-p1-adoptive-cell-therapy-7c65a49604","intervention_name":"NeoTCR-P1 adoptive cell therapy","intervention_type":"BIOLOGICAL","modality":"cellular-therapy","modality_distribution":[{"modality":"cellular-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["adoptive cell therap"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03970382","overall_status":"SUSPENDED","phases":["PHASE1"],"registered_name":"NeoTCR-P1 adoptive cell therapy","registry_intervention_type":"BIOLOGICAL","source_record_index":81,"source_ref":"ctg-page-003"}],"status":"SUSPENDED","statuses":["SUSPENDED"],"study_count":1,"study_ids":["NCT03970382"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Nexavar"],"intervention_id":"I-CTG-nexavar-22e25f1d4c","intervention_name":"Nexavar","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT01507740","overall_status":"TERMINATED","phases":[],"registered_name":"Nexavar","registry_intervention_type":"DRUG","source_record_index":28,"source_ref":"ctg-page-002"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT01507740"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Next Generation Sequencing (NGS)"],"intervention_id":"I-CTG-next-generation-sequencing-ngs-fe6f9c3d40","intervention_name":"Next Generation Sequencing (NGS)","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT04981119","overall_status":"RECRUITING","phases":[],"registered_name":"Next Generation Sequencing (NGS)","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":63,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT04981119"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["NHS-IL12"],"intervention_id":"I-CTG-nhs-il12-c6e5b8268b","intervention_name":"NHS-IL12","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT04491955","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"NHS-IL12","registry_intervention_type":"DRUG","source_record_index":62,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT04491955"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Nimotuzumab"],"intervention_id":"I-CTG-nimotuzumab-9d33f20df6","intervention_name":"Nimotuzumab","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1},{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05278728","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Nimotuzumab","registry_intervention_type":"DRUG","source_record_index":34,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT05278728"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"nimotuzumab","rationale":"Exact intervention-name alias for the EGFR-directed antibody.","rule_id":"candidate-nimotuzumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:EGFR","target_name":"epidermal growth factor receptor","target_symbol":"EGFR"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:EGFR"],"target_names":["epidermal growth factor receptor"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Nimotuzumab and chemotherapy"],"intervention_id":"I-CTG-nimotuzumab-and-chemotherapy-70271ffbe9","intervention_name":"Nimotuzumab and chemotherapy","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Irinotecan"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00972465","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Nimotuzumab and chemotherapy","registry_intervention_type":"DRUG","source_record_index":21,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT00972465"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Nintedanib"],"intervention_id":"I-CTG-nintedanib-45ffbcd092","intervention_name":"Nintedanib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02835833","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Nintedanib","registry_intervention_type":"DRUG","source_record_index":1,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02835833"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"binder; blocker; inhibitor","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"…he programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab binds specifically to the human PD-1 receptor and inhibits the interaction of PD-1 with its ligands, programmed dea…","matched_text":"binds","nct_id":"NCT04963283"},{"action":"binder","evidence_type":"registry-field","excerpt":"…is an inhibitory receptor expressed on the surface of T-cells, B cells, macrophages, and NK cells. Endogenous binding of PD-1 with one of its two ligands PD-L1 and PD-L2 results in production of an inhibitory signal which resul…","matched_text":"binding","nct_id":"NCT05732389"},{"action":"blocker","evidence_type":"registry-field","excerpt":"…totoxic activity. This results in significant dampening of the immune response. Nivolumab acts to selectively block the receptor activation of PD-L1 and PD-L2, resulting in a release of PD-1 mediated inhibition of the immune …","matched_text":"block","nct_id":"NCT05732389"},{"action":"inhibitor","evidence_type":"registry-field","excerpt":"…ation 279 (CD279) cell surface membrane receptor. Nivolumab binds specifically to the human PD-1 receptor and inhibits the interaction of PD-1 with its ligands, programmed death ligands-1 (PD-L1) and 2 (PD-L2), which promotes im…","matched_text":"inhibits","nct_id":"NCT04963283"},{"action":"inhibitor","evidence_type":"registry-field","excerpt":"Nivolumab is a highly selective fully humanized, IgG4 monoclonal antibody inhibitor of programmed death-1 (PD-1) (17). PD-1 is an inhibitory receptor expressed on the surface of T-cells, B cells, macrophages, and NK cell…","matched_text":"inhibitor","nct_id":"NCT05732389"}],"actions":["binder","blocker","inhibitor"],"aliases":["Nivolumab","nivolumab"],"intervention_id":"I-CTG-nivolumab-af64a27aa2","intervention_name":"nivolumab","intervention_type":"multiple","modality":"antibody","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":19},{"modality":"antibody","registry_occurrence_count":6}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3","phases":["PHASE1","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","COMBINATION_PRODUCT","DRUG"],"registry_occurrence_count":24,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT02314169","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Nivolumab","registry_intervention_type":"BIOLOGICAL","source_record_index":61,"source_ref":"ctg-page-004"},{"intervention_index":4,"nct_id":"NCT02408861","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Nivolumab","registry_intervention_type":"BIOLOGICAL","source_record_index":50,"source_ref":"ctg-page-003"},{"intervention_index":5,"nct_id":"NCT02834013","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Nivolumab","registry_intervention_type":"BIOLOGICAL","source_record_index":44,"source_ref":"ctg-page-003"},{"intervention_index":3,"nct_id":"NCT02848443","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Nivolumab","registry_intervention_type":"DRUG","source_record_index":40,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT02860546","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"nivolumab","registry_intervention_type":"DRUG","source_record_index":65,"source_ref":"ctg-page-005"},{"intervention_index":4,"nct_id":"NCT02978625","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Nivolumab","registry_intervention_type":"BIOLOGICAL","source_record_index":93,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT03126110","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Nivolumab","registry_intervention_type":"DRUG","source_record_index":89,"source_ref":"ctg-page-002"},{"intervention_index":9,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"nivolumab","registry_intervention_type":"BIOLOGICAL","source_record_index":17,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT03271047","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"nivolumab","registry_intervention_type":"DRUG","source_record_index":77,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT03373188","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Nivolumab","registry_intervention_type":"BIOLOGICAL","source_record_index":14,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT03800602","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Nivolumab","registry_intervention_type":"BIOLOGICAL","source_record_index":76,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT03970382","overall_status":"SUSPENDED","phases":["PHASE1"],"registered_name":"nivolumab","registry_intervention_type":"BIOLOGICAL","source_record_index":81,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT04362839","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Nivolumab","registry_intervention_type":"BIOLOGICAL","source_record_index":11,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT04500548","overall_status":"WITHDRAWN","phases":["PHASE1"],"registered_name":"Nivolumab","registry_intervention_type":"BIOLOGICAL","source_record_index":51,"source_ref":"ctg-page-004"},{"intervention_index":3,"nct_id":"NCT04751370","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Nivolumab","registry_intervention_type":"BIOLOGICAL","source_record_index":31,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT04963283","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Nivolumab","registry_intervention_type":"DRUG","source_record_index":19,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT05176483","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Nivolumab","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-001"},{"intervention_index":3,"nct_id":"NCT05176483","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Nivolumab","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-001"},{"intervention_index":4,"nct_id":"NCT05176483","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Nivolumab","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT05310643","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Nivolumab","registry_intervention_type":"DRUG","source_record_index":24,"source_ref":"ctg-page-003"},{"intervention_index":6,"nct_id":"NCT05395052","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Nivolumab","registry_intervention_type":"COMBINATION_PRODUCT","source_record_index":52,"source_ref":"ctg-page-005"},{"intervention_index":0,"nct_id":"NCT05732389","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Nivolumab","registry_intervention_type":"DRUG","source_record_index":84,"source_ref":"ctg-page-005"},{"intervention_index":3,"nct_id":"NCT06047379","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Nivolumab","registry_intervention_type":"DRUG","source_record_index":79,"source_ref":"ctg-page-004"},{"intervention_index":6,"nct_id":"NCT06490536","overall_status":"RECRUITING","phases":["PHASE3"],"registered_name":"Nivolumab","registry_intervention_type":"DRUG","source_record_index":6,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / RECRUITING / SUSPENDED / TERMINATED / WITHDRAWN","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","RECRUITING","SUSPENDED","TERMINATED","WITHDRAWN"],"study_count":22,"study_ids":["NCT02314169","NCT02408861","NCT02834013","NCT02848443","NCT02860546","NCT02978625","NCT03126110","NCT03169777","NCT03271047","NCT03373188","NCT03800602","NCT03970382","NCT04362839","NCT04500548","NCT04751370","NCT04963283","NCT05176483","NCT05310643","NCT05395052","NCT05732389","NCT06047379","NCT06490536"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Human anti-programmed cell death protein 1 (PD-1) IgG4 kappa monoclonal antibody","matched_alias":"programmed cell death protein 1","nct_id":"NCT03169777","relation":"anti-programmed cell death protein 1"},{"evidence_type":"registry-field","excerpt":"Nivolumab is a human IgG4 anti-PD-1 monoclonal antibody","matched_alias":"PD-1","nct_id":"NCT03970382","relation":"anti-PD-1"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"nivolumab","rationale":"Exact intervention-name alias for the PD-1-directed antibody.","rule_id":"candidate-nivolumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"registry-explicit","target_ids":["symbol:PDCD1"],"target_names":["programmed cell death protein 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Nivolumab + Relatlimab"],"intervention_id":"I-CTG-nivolumab-relatlimab-c697e48401","intervention_name":"Nivolumab + Relatlimab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT05176483","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Nivolumab + Relatlimab","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05176483"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["NK Cells"],"intervention_id":"I-CTG-nk-cells-0545a45d30","intervention_name":"NK Cells","intervention_type":"DRUG","modality":"cellular-therapy","modality_distribution":[{"modality":"cellular-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["NK Cells"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT07411599","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"NK Cells","registry_intervention_type":"DRUG","source_record_index":99,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07411599"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["NKG2D CAR-NK"],"intervention_id":"I-CTG-nkg2d-car-nk-f396e4aac1","intervention_name":"NKG2D CAR-NK","intervention_type":"DRUG","modality":"car-nk-cell-therapy","modality_distribution":[{"modality":"car-nk-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR-NK"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05213195","overall_status":"UNKNOWN","phases":["PHASE1"],"registered_name":"NKG2D CAR-NK","registry_intervention_type":"DRUG","source_record_index":84,"source_ref":"ctg-page-004"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT05213195"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"NKG2D CAR-NK infusion through peritoneal in stage 1 and later combined with intra venous in stage 2.","matched_alias":"NKG2D","nct_id":"NCT05213195","relation":"CAR"},{"evidence_type":"registry-field","excerpt":"NKG2D CAR-NK","matched_alias":"NKG2D","nct_id":"NCT05213195","relation":"CAR"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:KLRK1","target_name":"NKG2-D type II integral membrane protein","target_symbol":"KLRK1"}],"target_directness":"registry-explicit","target_ids":["symbol:KLRK1"],"target_names":["NKG2-D type II integral membrane protein"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Nogapendekin Alfa"],"intervention_id":"I-CTG-nogapendekin-alfa-ebbb83472c","intervention_name":"Nogapendekin Alfa","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT05419011","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Nogapendekin Alfa","registry_intervention_type":"DRUG","source_record_index":85,"source_ref":"ctg-page-001"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT05419011"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Non interventional study"],"intervention_id":"I-CTG-non-interventional-study-32c67f44dd","intervention_name":"Non interventional study","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02980146","overall_status":"COMPLETED","phases":[],"registered_name":"Non interventional study","registry_intervention_type":"OTHER","source_record_index":88,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02980146"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["non-ICG"],"intervention_id":"I-CTG-non-icg-1c4db64104","intervention_name":"non-ICG","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05517681","overall_status":"COMPLETED","phases":["NA"],"registered_name":"non-ICG","registry_intervention_type":"OTHER","source_record_index":3,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT05517681"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["NPC-1C/NEO-102"],"intervention_id":"I-CTG-npc-1c-neo-102-6e847a3366","intervention_name":"NPC-1C/NEO-102","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01040000","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"NPC-1C/NEO-102","registry_intervention_type":"DRUG","source_record_index":36,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01040000"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["NPX267"],"intervention_id":"I-CTG-npx267-9503d7abf9","intervention_name":"NPX267","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05958199","overall_status":"SUSPENDED","phases":["PHASE1"],"registered_name":"NPX267","registry_intervention_type":"DRUG","source_record_index":4,"source_ref":"ctg-page-002"}],"status":"SUSPENDED","statuses":["SUSPENDED"],"study_count":1,"study_ids":["NCT05958199"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["NV1020"],"intervention_id":"I-CTG-nv1020-10d6ab1e16","intervention_name":"NV1020","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00149396","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"NV1020","registry_intervention_type":"DRUG","source_record_index":38,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00149396"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["OB-002"],"intervention_id":"I-CTG-ob-002-f64eed50f8","intervention_name":"OB-002","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05940844","overall_status":"WITHDRAWN","phases":["PHASE1"],"registered_name":"OB-002","registry_intervention_type":"DRUG","source_record_index":37,"source_ref":"ctg-page-002"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT05940844"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Obinutuzumab"],"intervention_id":"I-CTG-obinutuzumab-27a705e961","intervention_name":"Obinutuzumab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03866239","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Obinutuzumab","registry_intervention_type":"DRUG","source_record_index":65,"source_ref":"ctg-page-002"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT03866239"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"binder; inhibitor","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"…; the trapped PARP1- or PARP2-DNA complex is cytotoxic and produces clinical response. Although olaparib also binds to PARP3, recent investigations have suggested PARP-3 inhibition does not contribute towards anti-cancer acti…","matched_text":"binds","nct_id":"NCT03851614"},{"action":"inhibitor","evidence_type":"registry-field","excerpt":"Olaparib (AZD2281) is a potent oral poly Poly (ADP-ribose) Polymerase (PARP) enzyme inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combinat…","matched_text":"inhibitor","nct_id":"NCT03851614"}],"actions":["binder","inhibitor"],"aliases":["Olaparib"],"intervention_id":"I-CTG-olaparib-a02f1e209b","intervention_name":"Olaparib","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03851614","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Olaparib","registry_intervention_type":"DRUG","source_record_index":11,"source_ref":"ctg-page-005"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT03851614"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Oleclumab"],"intervention_id":"I-CTG-oleclumab-ad0acf4f20","intervention_name":"Oleclumab","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2},{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02503774","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Oleclumab","registry_intervention_type":"DRUG","source_record_index":23,"source_ref":"ctg-page-003"},{"intervention_index":4,"nct_id":"NCT02740985","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Oleclumab","registry_intervention_type":"DRUG","source_record_index":72,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":2,"study_ids":["NCT02503774","NCT02740985"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"oleclumab","rationale":"Exact intervention-name alias for the CD73-directed antibody.","rule_id":"candidate-oleclumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:NT5E","target_name":"ecto-5-prime-nucleotidase","target_symbol":"NT5E"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:NT5E"],"target_names":["ecto-5-prime-nucleotidase"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["On-Treatment Biopsy"],"intervention_id":"I-CTG-on-treatment-biopsy-2778688f6b","intervention_name":"On-Treatment Biopsy","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT06784947","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"On-Treatment Biopsy","registry_intervention_type":"PROCEDURE","source_record_index":9,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT06784947"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ONCR-177"],"intervention_id":"I-CTG-oncr-177-b2c5097c90","intervention_name":"ONCR-177","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04348916","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"ONCR-177","registry_intervention_type":"BIOLOGICAL","source_record_index":25,"source_ref":"ctg-page-001"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT04348916"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Optical coherence tomography probe"],"intervention_id":"I-CTG-optical-coherence-tomography-probe-bcc09f15e0","intervention_name":"Optical coherence tomography probe","intervention_type":"DEVICE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05179837","overall_status":"TERMINATED","phases":["NA"],"registered_name":"Optical coherence tomography probe","registry_intervention_type":"DEVICE","source_record_index":34,"source_ref":"ctg-page-005"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT05179837"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"molecular-imaging","action_evidence":[{"action":"molecular-imaging","evidence_type":"registry-field","excerpt":"… a suitable area of tissue is identified by the clinician during a patient's colonoscopy (e.g., a polyp), the imaging probe is inserted into the colonoscope so that it can view the tissue. Optical spectral reflectance and autofluores…","matched_text":"imaging probe","nct_id":"NCT03139942"}],"actions":["molecular-imaging"],"aliases":["Optical spectral reflectance and autofluorescence imaging"],"intervention_id":"I-CTG-optical-spectral-reflectance-and-autofluor-d48d84bdf6","intervention_name":"Optical spectral reflectance and autofluorescence imaging","intervention_type":"DEVICE","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["imaging probe"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03139942","overall_status":"COMPLETED","phases":["NA"],"registered_name":"Optical spectral reflectance and autofluorescence imaging","registry_intervention_type":"DEVICE","source_record_index":48,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03139942"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Osimertinib"],"intervention_id":"I-CTG-osimertinib-83b1b6c8b8","intervention_name":"Osimertinib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT04868877","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Osimertinib","registry_intervention_type":"DRUG","source_record_index":70,"source_ref":"ctg-page-003"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT04868877"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["oxaliplatin","Oxaliplatin"],"intervention_id":"I-CTG-oxaliplatin-217ec63088","intervention_name":"oxaliplatin","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":26}],"modality_support":{"matched_cues":["fluorouracil","oxaliplatin","Oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3 / PHASE4","phases":["PHASE1","PHASE2","PHASE3","PHASE4"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":26,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00061815","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"oxaliplatin","registry_intervention_type":"DRUG","source_record_index":25,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT00125034","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":98,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT00199797","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":34,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT00226941","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":26,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT00444678","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":21,"source_ref":"ctg-page-001"},{"intervention_index":3,"nct_id":"NCT00647530","overall_status":"UNKNOWN","phases":["PHASE2","PHASE3"],"registered_name":"oxaliplatin","registry_intervention_type":"DRUG","source_record_index":48,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT00803647","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"oxaliplatin","registry_intervention_type":"DRUG","source_record_index":43,"source_ref":"ctg-page-001"},{"intervention_index":9,"nct_id":"NCT01167725","overall_status":"TERMINATED","phases":["PHASE3"],"registered_name":"oxaliplatin","registry_intervention_type":"DRUG","source_record_index":35,"source_ref":"ctg-page-004"},{"intervention_index":2,"nct_id":"NCT01225744","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT01442935","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":96,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT01588990","overall_status":"COMPLETED","phases":["PHASE4"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":13,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT01955629","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":16,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT02848443","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":40,"source_ref":"ctg-page-001"},{"intervention_index":11,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"oxaliplatin","registry_intervention_type":"DRUG","source_record_index":17,"source_ref":"ctg-page-001"},{"intervention_index":4,"nct_id":"NCT03607643","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":59,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT04262687","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":65,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT05307198","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":95,"source_ref":"ctg-page-004"},{"intervention_index":2,"nct_id":"NCT05719558","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":80,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT05720559","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":49,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT05774964","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":8,"source_ref":"ctg-page-005"},{"intervention_index":3,"nct_id":"NCT05794750","overall_status":"NOT_YET_RECRUITING","phases":["PHASE2"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":19,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT05914389","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":51,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT06490536","overall_status":"RECRUITING","phases":["PHASE3"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":6,"source_ref":"ctg-page-002"},{"intervention_index":8,"nct_id":"NCT06696768","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":70,"source_ref":"ctg-page-002"},{"intervention_index":4,"nct_id":"NCT07318805","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":61,"source_ref":"ctg-page-003"},{"intervention_index":3,"nct_id":"NCT07503756","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Oxaliplatin","registry_intervention_type":"DRUG","source_record_index":49,"source_ref":"ctg-page-001"}],"status":"COMPLETED / NOT_YET_RECRUITING / RECRUITING / TERMINATED / UNKNOWN / WITHDRAWN","statuses":["COMPLETED","NOT_YET_RECRUITING","RECRUITING","TERMINATED","UNKNOWN","WITHDRAWN"],"study_count":26,"study_ids":["NCT00061815","NCT00125034","NCT00199797","NCT00226941","NCT00444678","NCT00647530","NCT00803647","NCT01167725","NCT01225744","NCT01442935","NCT01588990","NCT01955629","NCT02848443","NCT03169777","NCT03607643","NCT04262687","NCT05307198","NCT05719558","NCT05720559","NCT05774964","NCT05794750","NCT05914389","NCT06490536","NCT06696768","NCT07318805","NCT07503756"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid"],"intervention_id":"I-CTG-oxaliplatin-eloxatin-fluorouracil-folinic--25baf1aa13","intervention_name":"Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Fluorouracil"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00660582","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid","registry_intervention_type":"DRUG","source_record_index":3,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00660582"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Oxaliplatin, Capecitabine"],"intervention_id":"I-CTG-oxaliplatin-capecitabine-ff0e23ed84","intervention_name":"Oxaliplatin, Capecitabine","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00950820","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Oxaliplatin, Capecitabine","registry_intervention_type":"DRUG","source_record_index":17,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT00950820"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Oxaliplatin, Capecitabine, Panitumumab"],"intervention_id":"I-CTG-oxaliplatin-capecitabine-panitumumab-7f1f26bbad","intervention_name":"Oxaliplatin, Capecitabine, Panitumumab","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00950820","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Oxaliplatin, Capecitabine, Panitumumab","registry_intervention_type":"DRUG","source_record_index":17,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT00950820"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Pabolizumab+ bevacizumab and CapeOX (bevacizumab + oxaliplatin + capecitabine)"],"intervention_id":"I-CTG-pabolizumab-bevacizumab-and-capeox-bevaciz-9c1b6a42fb","intervention_name":"Pabolizumab+ bevacizumab and CapeOX (bevacizumab + oxaliplatin + capecitabine)","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE4","phases":["PHASE4"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06550453","overall_status":"UNKNOWN","phases":["PHASE4"],"registered_name":"Pabolizumab+ bevacizumab and CapeOX (bevacizumab + oxaliplatin + capecitabine)","registry_intervention_type":"DRUG","source_record_index":82,"source_ref":"ctg-page-004"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT06550453"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Paclitaxel"],"intervention_id":"I-CTG-paclitaxel-2662a98344","intervention_name":"Paclitaxel","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1},{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1 / PHASE1 / PHASE2","phases":["EARLY_PHASE1","PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT04906382","overall_status":"TERMINATED","phases":["EARLY_PHASE1"],"registered_name":"Paclitaxel","registry_intervention_type":"DRUG","source_record_index":84,"source_ref":"ctg-page-002"},{"intervention_index":6,"nct_id":"NCT06047379","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Paclitaxel","registry_intervention_type":"DRUG","source_record_index":79,"source_ref":"ctg-page-004"}],"status":"RECRUITING / TERMINATED","statuses":["RECRUITING","TERMINATED"],"study_count":2,"study_ids":["NCT04906382","NCT06047379"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Palbociclib"],"intervention_id":"I-CTG-palbociclib-f8ab549720","intervention_name":"Palbociclib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1","phases":["EARLY_PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT04870034","overall_status":"WITHDRAWN","phases":["EARLY_PHASE1"],"registered_name":"Palbociclib","registry_intervention_type":"DRUG","source_record_index":1,"source_ref":"ctg-page-003"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT04870034"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["pancreatectomy or hepatectomy"],"intervention_id":"I-CTG-pancreatectomy-or-hepatectomy-c32742d453","intervention_name":"pancreatectomy or hepatectomy","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03801915","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"pancreatectomy or hepatectomy","registry_intervention_type":"PROCEDURE","source_record_index":77,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03801915"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"antagonist; inhibitor","action_evidence":[{"action":"antagonist","evidence_type":"registry-field","excerpt":"Panitumumab is a fully human immunoglobulin G (IgG)2 monoclonal antibody antagonist directed against human Epidermal Growth Factor receptor (EGFr).","matched_text":"antagonist","nct_id":"NCT00819780"},{"action":"inhibitor","evidence_type":"registry-field","excerpt":"Epidermal growth factor receptor inhibitor, anti-neoplastic","matched_text":"inhibitor","nct_id":"NCT04587128"}],"actions":["antagonist","inhibitor"],"aliases":["panitumumab","Panitumumab"],"intervention_id":"I-CTG-panitumumab-b41fb4011c","intervention_name":"panitumumab","intervention_type":"multiple","modality":"antibody","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":12},{"modality":"antibody","registry_occurrence_count":2},{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy","monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2 / PHASE3","phases":["PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","DRUG"],"registry_occurrence_count":14,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00113763","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"Panitumumab","registry_intervention_type":"DRUG","source_record_index":1,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT00647530","overall_status":"UNKNOWN","phases":["PHASE2","PHASE3"],"registered_name":"panitumumab","registry_intervention_type":"BIOLOGICAL","source_record_index":48,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT00819780","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Panitumumab","registry_intervention_type":"DRUG","source_record_index":46,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT00842257","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"panitumumab","registry_intervention_type":"DRUG","source_record_index":12,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT00891930","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Panitumumab","registry_intervention_type":"BIOLOGICAL","source_record_index":53,"source_ref":"ctg-page-005"},{"intervention_index":0,"nct_id":"NCT00940316","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"panitumumab","registry_intervention_type":"BIOLOGICAL","source_record_index":51,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT02399943","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Panitumumab","registry_intervention_type":"DRUG","source_record_index":86,"source_ref":"ctg-page-004"},{"intervention_index":4,"nct_id":"NCT02508077","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Panitumumab","registry_intervention_type":"BIOLOGICAL","source_record_index":53,"source_ref":"ctg-page-003"},{"intervention_index":3,"nct_id":"NCT03186326","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Panitumumab","registry_intervention_type":"DRUG","source_record_index":60,"source_ref":"ctg-page-005"},{"intervention_index":0,"nct_id":"NCT03311750","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Panitumumab","registry_intervention_type":"DRUG","source_record_index":26,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT03751176","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Panitumumab","registry_intervention_type":"DRUG","source_record_index":2,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT04587128","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Panitumumab","registry_intervention_type":"DRUG","source_record_index":81,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT05694936","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Panitumumab","registry_intervention_type":"DRUG","source_record_index":66,"source_ref":"ctg-page-003"},{"intervention_index":10,"nct_id":"NCT06490536","overall_status":"RECRUITING","phases":["PHASE3"],"registered_name":"Panitumumab","registry_intervention_type":"DRUG","source_record_index":6,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / RECRUITING / TERMINATED / UNKNOWN","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","RECRUITING","TERMINATED","UNKNOWN"],"study_count":14,"study_ids":["NCT00113763","NCT00647530","NCT00819780","NCT00842257","NCT00891930","NCT00940316","NCT02399943","NCT02508077","NCT03186326","NCT03311750","NCT03751176","NCT04587128","NCT05694936","NCT06490536"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Epidermal growth factor receptor inhibitor, anti-neoplastic","matched_alias":"Epidermal growth factor receptor","nct_id":"NCT04587128","relation":"inhibitor"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"panitumumab","rationale":"Exact intervention-name alias for the EGFR-directed antibody.","rule_id":"candidate-panitumumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:EGFR","target_name":"epidermal growth factor receptor","target_symbol":"EGFR"}],"target_directness":"registry-explicit","target_ids":["symbol:EGFR"],"target_names":["epidermal growth factor receptor"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Panitumumab (Part 1a only)"],"intervention_id":"I-CTG-panitumumab-part-1a-only-fa5aed2249","intervention_name":"Panitumumab (Part 1a only)","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT00101894","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Panitumumab (Part 1a only)","registry_intervention_type":"BIOLOGICAL","source_record_index":13,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00101894"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Panitumumab + FOLFOX (DP)"],"intervention_id":"I-CTG-panitumumab-folfox-dp-a74d96e257","intervention_name":"Panitumumab + FOLFOX (DP)","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["FOLFOX"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01288339","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Panitumumab + FOLFOX (DP)","registry_intervention_type":"DRUG","source_record_index":64,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01288339"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Panitumumab + FOLFOX (no-DP)"],"intervention_id":"I-CTG-panitumumab-folfox-no-dp-c31419ac32","intervention_name":"Panitumumab + FOLFOX (no-DP)","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["FOLFOX"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT01288339","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Panitumumab + FOLFOX (no-DP)","registry_intervention_type":"DRUG","source_record_index":64,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01288339"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Panitumumab 20 milligram/ML"],"intervention_id":"I-CTG-panitumumab-20-milligram-ml-b5aa88c37a","intervention_name":"Panitumumab 20 milligram/ML","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05007132","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Panitumumab 20 milligram/ML","registry_intervention_type":"BIOLOGICAL","source_record_index":86,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05007132"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by"],"intervention_id":"I-CTG-panitumumab-with-capecitabine-and-oxalipla-75b2d60e4a","intervention_name":"Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00346099","overall_status":"WITHDRAWN","phases":["PHASE2"],"registered_name":"Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by","registry_intervention_type":"DRUG","source_record_index":33,"source_ref":"ctg-page-004"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT00346099"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Panitumumab with capecitabine and radiation"],"intervention_id":"I-CTG-panitumumab-with-capecitabine-and-radiatio-3c589bacfc","intervention_name":"Panitumumab with capecitabine and radiation","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["capecitabine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00346099","overall_status":"WITHDRAWN","phases":["PHASE2"],"registered_name":"Panitumumab with capecitabine and radiation","registry_intervention_type":"DRUG","source_record_index":33,"source_ref":"ctg-page-004"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT00346099"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["PANVAC-F"],"intervention_id":"I-CTG-panvac-f-cda251040f","intervention_name":"PANVAC-F","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00088413","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"PANVAC-F","registry_intervention_type":"BIOLOGICAL","source_record_index":68,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00088413"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["PANVAC-V"],"intervention_id":"I-CTG-panvac-v-abadae5abc","intervention_name":"PANVAC-V","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00088413","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"PANVAC-V","registry_intervention_type":"BIOLOGICAL","source_record_index":68,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00088413"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Paracentesis"],"intervention_id":"I-CTG-paracentesis-716ce570e3","intervention_name":"Paracentesis","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT04314401","overall_status":"ACTIVE_NOT_RECRUITING","phases":[],"registered_name":"Paracentesis","registry_intervention_type":"PROCEDURE","source_record_index":47,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT04314401"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Part 1 TPST-1120"],"intervention_id":"I-CTG-part-1-tpst-1120-6adb3ad37b","intervention_name":"Part 1 TPST-1120","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03829436","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Part 1 TPST-1120","registry_intervention_type":"DRUG","source_record_index":77,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03829436"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Part 2 TPST-1120 + nivolumab"],"intervention_id":"I-CTG-part-2-tpst-1120-nivolumab-eed7a87307","intervention_name":"Part 2 TPST-1120 + nivolumab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03829436","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Part 2 TPST-1120 + nivolumab","registry_intervention_type":"DRUG","source_record_index":77,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03829436"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Part 3 TPST-1120"],"intervention_id":"I-CTG-part-3-tpst-1120-12beb5165a","intervention_name":"Part 3 TPST-1120","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT03829436","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Part 3 TPST-1120","registry_intervention_type":"DRUG","source_record_index":77,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03829436"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Part 4 TPST-1120 + nivolumab"],"intervention_id":"I-CTG-part-4-tpst-1120-nivolumab-b109e23900","intervention_name":"Part 4 TPST-1120 + nivolumab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT03829436","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Part 4 TPST-1120 + nivolumab","registry_intervention_type":"DRUG","source_record_index":77,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03829436"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Patient Control Analgesia (PCA) Morphine"],"intervention_id":"I-CTG-patient-control-analgesia-pca-morphine-86f8799359","intervention_name":"Patient Control Analgesia (PCA) Morphine","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT01477190","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Patient Control Analgesia (PCA) Morphine","registry_intervention_type":"DRUG","source_record_index":37,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01477190"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Patient Navigation"],"intervention_id":"I-CTG-patient-navigation-a0550250d8","intervention_name":"Patient Navigation","intervention_type":"BEHAVIORAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BEHAVIORAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT06995924","overall_status":"RECRUITING","phases":["NA"],"registered_name":"Patient Navigation","registry_intervention_type":"BEHAVIORAL","source_record_index":29,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06995924"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Patient Observation"],"intervention_id":"I-CTG-patient-observation-007d5aee2e","intervention_name":"Patient Observation","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT07405476","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Patient Observation","registry_intervention_type":"OTHER","source_record_index":97,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07405476"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Patritumab Deruxtecan"],"intervention_id":"I-CTG-patritumab-deruxtecan-266372e24a","intervention_name":"Patritumab Deruxtecan","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04479436","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Patritumab Deruxtecan","registry_intervention_type":"DRUG","source_record_index":87,"source_ref":"ctg-page-003"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT04479436"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"inhibitor","action_evidence":[{"action":"inhibitor","evidence_type":"registry-field","excerpt":"Pazopanib is an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases","matched_text":"inhibitor","nct_id":"NCT00387387"}],"actions":["inhibitor"],"aliases":["Pazopanib"],"intervention_id":"I-CTG-pazopanib-fc47d3a172","intervention_name":"Pazopanib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00387387","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Pazopanib","registry_intervention_type":"DRUG","source_record_index":59,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00387387"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["PB101"],"intervention_id":"I-CTG-pb101-433455a932","intervention_name":"PB101","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06075849","overall_status":"UNKNOWN","phases":["PHASE1"],"registered_name":"PB101","registry_intervention_type":"DRUG","source_record_index":36,"source_ref":"ctg-page-001"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT06075849"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["PCA"],"intervention_id":"I-CTG-pca-4dda90e8db","intervention_name":"PCA","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00747292","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"PCA","registry_intervention_type":"PROCEDURE","source_record_index":64,"source_ref":"ctg-page-005"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT00747292"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["PDR001"],"intervention_id":"I-CTG-pdr001-ece896f523","intervention_name":"PDR001","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02900664","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"PDR001","registry_intervention_type":"BIOLOGICAL","source_record_index":26,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02900664"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Pegfilgrastim"],"intervention_id":"I-CTG-pegfilgrastim-f08268964f","intervention_name":"Pegfilgrastim","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT02650635","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Pegfilgrastim","registry_intervention_type":"BIOLOGICAL","source_record_index":79,"source_ref":"ctg-page-003"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT02650635"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"binder; inhibitor","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"…somal doxorubicin (PLD) is doxorubicin hydrochloride (HCl), an anthracycline topoisomerase inhibitor that can bind DNA and inhibit nucleic acid synthesis. PLD is doxorubicin HCL encapsulated in liposomes formulated with surf…","matched_text":"bind","nct_id":"NCT04244552"},{"action":"inhibitor","evidence_type":"registry-field","excerpt":"Pegylated liposomal doxorubicin (PLD) is doxorubicin hydrochloride (HCl), an anthracycline topoisomerase inhibitor that can bind DNA and inhibit nucleic acid synthesis. PLD is doxorubicin HCL encapsulated in liposomes formul…","matched_text":"inhibitor","nct_id":"NCT04244552"}],"actions":["binder","inhibitor"],"aliases":["Pegylated liposomal doxorubicin (PLD)"],"intervention_id":"I-CTG-pegylated-liposomal-doxorubicin-pld-be373b3834","intervention_name":"Pegylated liposomal doxorubicin (PLD)","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT04244552","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Pegylated liposomal doxorubicin (PLD)","registry_intervention_type":"DRUG","source_record_index":70,"source_ref":"ctg-page-005"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT04244552"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"binder; inhibitor","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"Pembrolizumab (Keytruda®) is a humanized immunoglobulin G4 monoclonal antibody with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death li…","matched_text":"binding","nct_id":"NCT04244552"},{"action":"inhibitor","evidence_type":"registry-field","excerpt":"Pembrolizumab, an immune checkpoint inhibitor, concomitantly with standard CRT in patients with locally advanced T3/4 anal cancer.","matched_text":"inhibitor","nct_id":"NCT04046133"},{"action":"inhibitor","evidence_type":"registry-field","excerpt":"… G4 monoclonal antibody with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).","matched_text":"inhibiting","nct_id":"NCT04244552"}],"actions":["binder","inhibitor"],"aliases":["Pembrolizumab","pembrolizumab"],"intervention_id":"I-CTG-pembrolizumab-d8acadde7d","intervention_name":"pembrolizumab","intervention_type":"multiple","modality":"antibody","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":17},{"modality":"antibody","registry_occurrence_count":7}],"modality_support":{"matched_cues":["anti-PD antibody","monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3","phases":["PHASE1","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","COMBINATION_PRODUCT","DRUG"],"registry_occurrence_count":23,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT02298959","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"registered_name":"Pembrolizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":64,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT02432963","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"registered_name":"Pembrolizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":85,"source_ref":"ctg-page-005"},{"intervention_index":2,"nct_id":"NCT02563002","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"Pembrolizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":90,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT02600949","overall_status":"ENROLLING_BY_INVITATION","phases":["PHASE1"],"registered_name":"Pembrolizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":89,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT02713373","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Pembrolizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":80,"source_ref":"ctg-page-002"},{"intervention_index":4,"nct_id":"NCT02757391","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Pembrolizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":42,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT03797326","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Pembrolizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":73,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT04046133","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"registered_name":"Pembrolizumab","registry_intervention_type":"DRUG","source_record_index":69,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT04234113","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Pembrolizumab","registry_intervention_type":"DRUG","source_record_index":74,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT04244552","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Pembrolizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":70,"source_ref":"ctg-page-005"},{"intervention_index":3,"nct_id":"NCT04262687","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Pembrolizumab","registry_intervention_type":"DRUG","source_record_index":65,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT04348916","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"pembrolizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":25,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT04485013","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"pembrolizumab","registry_intervention_type":"DRUG","source_record_index":46,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT04660929","overall_status":"UNKNOWN","phases":["PHASE1"],"registered_name":"Pembrolizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":24,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT04991948","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Pembrolizumab","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT05256381","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Pembrolizumab","registry_intervention_type":"DRUG","source_record_index":25,"source_ref":"ctg-page-004"},{"intervention_index":5,"nct_id":"NCT05395052","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Pembrolizumab","registry_intervention_type":"COMBINATION_PRODUCT","source_record_index":52,"source_ref":"ctg-page-005"},{"intervention_index":2,"nct_id":"NCT05492682","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Pembrolizumab","registry_intervention_type":"DRUG","source_record_index":99,"source_ref":"ctg-page-002"},{"intervention_index":7,"nct_id":"NCT05719558","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Pembrolizumab","registry_intervention_type":"DRUG","source_record_index":80,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT06047379","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Pembrolizumab","registry_intervention_type":"DRUG","source_record_index":79,"source_ref":"ctg-page-004"},{"intervention_index":4,"nct_id":"NCT06400472","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"pembrolizumab","registry_intervention_type":"DRUG","source_record_index":48,"source_ref":"ctg-page-002"},{"intervention_index":4,"nct_id":"NCT06530303","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Pembrolizumab","registry_intervention_type":"DRUG","source_record_index":8,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT07591597","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Pembrolizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":0,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / ENROLLING_BY_INVITATION / NOT_YET_RECRUITING / RECRUITING / TERMINATED / UNKNOWN","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","ENROLLING_BY_INVITATION","NOT_YET_RECRUITING","RECRUITING","TERMINATED","UNKNOWN"],"study_count":23,"study_ids":["NCT02298959","NCT02432963","NCT02563002","NCT02600949","NCT02713373","NCT02757391","NCT03797326","NCT04046133","NCT04234113","NCT04244552","NCT04262687","NCT04348916","NCT04485013","NCT04660929","NCT04991948","NCT05256381","NCT05395052","NCT05492682","NCT05719558","NCT06047379","NCT06400472","NCT06530303","NCT07591597"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Anti-PD-1 monoclonal antibody","matched_alias":"PD-1","nct_id":"NCT04348916","relation":"Anti-PD-1"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"pembrolizumab","rationale":"Exact intervention-name alias for the PD-1-directed antibody.","rule_id":"candidate-pembrolizumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"registry-explicit","target_ids":["symbol:PDCD1"],"target_names":["programmed cell death protein 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Pembrolizumab (MK-3475)"],"intervention_id":"I-CTG-pembrolizumab-mk-3475-ef646ad129","intervention_name":"Pembrolizumab (MK-3475)","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT02346955","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Pembrolizumab (MK-3475)","registry_intervention_type":"BIOLOGICAL","source_record_index":92,"source_ref":"ctg-page-002"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT02346955"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["pemetrexed","Pemetrexed"],"intervention_id":"I-CTG-pemetrexed-e1d4553852","intervention_name":"Pemetrexed","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1},{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT03715933","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"pemetrexed","registry_intervention_type":"DRUG","source_record_index":9,"source_ref":"ctg-page-005"},{"intervention_index":8,"nct_id":"NCT05719558","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Pemetrexed","registry_intervention_type":"DRUG","source_record_index":80,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":2,"study_ids":["NCT03715933","NCT05719558"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Penpulimab injection"],"intervention_id":"I-CTG-penpulimab-injection-7da2c3d9ca","intervention_name":"Penpulimab injection","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT06010901","overall_status":"UNKNOWN","phases":["PHASE1"],"registered_name":"Penpulimab injection","registry_intervention_type":"DRUG","source_record_index":19,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT06010901"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["PeptiCRAd-1"],"intervention_id":"I-CTG-pepticrad-1-a6c55038c8","intervention_name":"PeptiCRAd-1","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05492682","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"PeptiCRAd-1","registry_intervention_type":"DRUG","source_record_index":99,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05492682"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Performance status"],"intervention_id":"I-CTG-performance-status-d6ee286977","intervention_name":"Performance status","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT02280070","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Performance status","registry_intervention_type":"OTHER","source_record_index":62,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02280070"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Pertuzumab"],"intervention_id":"I-CTG-pertuzumab-fc1d976b9c","intervention_name":"Pertuzumab","intervention_type":"multiple","modality":"antibody","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":4},{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2 / PHASE3","phases":["PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","DRUG"],"registry_occurrence_count":4,"registry_occurrences":[{"intervention_index":7,"nct_id":"NCT02291289","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Pertuzumab","registry_intervention_type":"DRUG","source_record_index":28,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT05786716","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"registered_name":"Pertuzumab","registry_intervention_type":"DRUG","source_record_index":20,"source_ref":"ctg-page-003"},{"intervention_index":3,"nct_id":"NCT06136897","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Pertuzumab","registry_intervention_type":"BIOLOGICAL","source_record_index":41,"source_ref":"ctg-page-004"},{"intervention_index":9,"nct_id":"NCT06490536","overall_status":"RECRUITING","phases":["PHASE3"],"registered_name":"Pertuzumab","registry_intervention_type":"DRUG","source_record_index":6,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / RECRUITING","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","RECRUITING"],"study_count":4,"study_ids":["NCT02291289","NCT05786716","NCT06136897","NCT06490536"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"pertuzumab","rationale":"Exact intervention-name alias for the HER2-directed antibody.","rule_id":"candidate-pertuzumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:ERBB2","target_name":"receptor tyrosine-protein kinase erbB-2","target_symbol":"ERBB2"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:ERBB2"],"target_names":["receptor tyrosine-protein kinase erbB-2"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["PET"],"intervention_id":"I-CTG-pet-bbba57318f","intervention_name":"PET","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":7,"nct_id":"NCT03745326","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"PET","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":63,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT03745326"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Pexa-Vec"],"intervention_id":"I-CTG-pexa-vec-4e9eb29c59","intervention_name":"Pexa-Vec","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT03206073","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Pexa-Vec","registry_intervention_type":"BIOLOGICAL","source_record_index":56,"source_ref":"ctg-page-004"},{"intervention_index":3,"nct_id":"NCT03206073","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Pexa-Vec","registry_intervention_type":"BIOLOGICAL","source_record_index":56,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03206073"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["PF-05212384"],"intervention_id":"I-CTG-pf-05212384-24958d3455","intervention_name":"PF-05212384","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01925274","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"PF-05212384","registry_intervention_type":"DRUG","source_record_index":52,"source_ref":"ctg-page-003"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT01925274"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["PF-07284892"],"intervention_id":"I-CTG-pf-07284892-c7dd60dbfd","intervention_name":"PF-07284892","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04800822","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"PF-07284892","registry_intervention_type":"DRUG","source_record_index":15,"source_ref":"ctg-page-002"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT04800822"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["PF-07329640"],"intervention_id":"I-CTG-pf-07329640-371a79391a","intervention_name":"PF-07329640","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06448364","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"PF-07329640","registry_intervention_type":"BIOLOGICAL","source_record_index":54,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT06448364"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["PF-07826390"],"intervention_id":"I-CTG-pf-07826390-8e559facb7","intervention_name":"PF-07826390","intervention_type":"DRUG","modality":"bispecific-antibody","modality_distribution":[{"modality":"bispecific-antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["bispecific"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06546553","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"PF-07826390","registry_intervention_type":"DRUG","source_record_index":67,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT06546553"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["PF-08032562"],"intervention_id":"I-CTG-pf-08032562-669c79729c","intervention_name":"PF-08032562","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07318805","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"PF-08032562","registry_intervention_type":"DRUG","source_record_index":61,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07318805"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["pharmacological study","Pharmacological Study"],"intervention_id":"I-CTG-pharmacological-study-61a08d0ad1","intervention_name":"pharmacological study","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":4}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA / PHASE1","phases":["NA","PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":4,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00647153","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"pharmacological study","registry_intervention_type":"OTHER","source_record_index":12,"source_ref":"ctg-page-002"},{"intervention_index":3,"nct_id":"NCT01198535","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Pharmacological Study","registry_intervention_type":"OTHER","source_record_index":11,"source_ref":"ctg-page-003"},{"intervention_index":3,"nct_id":"NCT02293954","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"registered_name":"pharmacological study","registry_intervention_type":"OTHER","source_record_index":92,"source_ref":"ctg-page-005"},{"intervention_index":3,"nct_id":"NCT02650635","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Pharmacological Study","registry_intervention_type":"OTHER","source_record_index":79,"source_ref":"ctg-page-003"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / TERMINATED","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","TERMINATED"],"study_count":4,"study_ids":["NCT00647153","NCT01198535","NCT02293954","NCT02650635"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"cytotoxic-payload-delivery","action_evidence":[{"action":"cytotoxic-payload-delivery","evidence_type":"registry-field","excerpt":"PHN-010 is an ADC","matched_text":"ADC","nct_id":"NCT06457997"}],"actions":["cytotoxic-payload-delivery"],"aliases":["PHN-010"],"intervention_id":"I-CTG-phn-010-a2f9d1e170","intervention_name":"PHN-010","intervention_type":"DRUG","modality":"antibody-drug-conjugate","modality_distribution":[{"modality":"antibody-drug-conjugate","registry_occurrence_count":1}],"modality_support":{"matched_cues":["ADC"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06457997","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"PHN-010","registry_intervention_type":"DRUG","source_record_index":29,"source_ref":"ctg-page-005"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT06457997"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Photodynamic Therapy"],"intervention_id":"I-CTG-photodynamic-therapy-c27ebbabef","intervention_name":"Photodynamic Therapy","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT06307548","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Photodynamic Therapy","registry_intervention_type":"DRUG","source_record_index":91,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06307548"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Photography"],"intervention_id":"I-CTG-photography-25f3aeb51f","intervention_name":"Photography","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":9,"nct_id":"NCT03745326","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"Photography","registry_intervention_type":"OTHER","source_record_index":63,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT03745326"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Placebo"],"intervention_id":"I-CTG-placebo-9c3b89ebaf","intervention_name":"Placebo","intervention_type":"multiple","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":5},{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":2}],"modality_support":{"matched_cues":["Fluorouracil","Oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA / PHASE2 / PHASE3","phases":["NA","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","DIETARY_SUPPLEMENT","DRUG","OTHER"],"registry_occurrence_count":7,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT00813605","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Placebo","registry_intervention_type":"OTHER","source_record_index":41,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT01105169","overall_status":"COMPLETED","phases":["NA"],"registered_name":"Placebo","registry_intervention_type":"DIETARY_SUPPLEMENT","source_record_index":7,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT01175291","overall_status":"WITHDRAWN","phases":["PHASE2"],"registered_name":"Placebo","registry_intervention_type":"DRUG","source_record_index":47,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT03167268","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Placebo","registry_intervention_type":"OTHER","source_record_index":13,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT03426371","overall_status":"TERMINATED","phases":["PHASE3"],"registered_name":"Placebo","registry_intervention_type":"DRUG","source_record_index":31,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT06465914","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"registered_name":"Placebo","registry_intervention_type":"BIOLOGICAL","source_record_index":50,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT06509880","overall_status":"COMPLETED","phases":["PHASE2","PHASE3"],"registered_name":"Placebo","registry_intervention_type":"OTHER","source_record_index":30,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / TERMINATED / UNKNOWN / WITHDRAWN","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","TERMINATED","UNKNOWN","WITHDRAWN"],"study_count":7,"study_ids":["NCT00813605","NCT01105169","NCT01175291","NCT03167268","NCT03426371","NCT06465914","NCT06509880"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Placebo Administration"],"intervention_id":"I-CTG-placebo-administration-51232b6d97","intervention_name":"Placebo Administration","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT05419011","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Placebo Administration","registry_intervention_type":"DRUG","source_record_index":85,"source_ref":"ctg-page-001"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT05419011"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Placebo to vismodegib"],"intervention_id":"I-CTG-placebo-to-vismodegib-54ef69d1df","intervention_name":"Placebo to vismodegib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00636610","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Placebo to vismodegib","registry_intervention_type":"DRUG","source_record_index":44,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00636610"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Plasma circulating DNA analysis"],"intervention_id":"I-CTG-plasma-circulating-dna-analysis-6a080be6a4","intervention_name":"Plasma circulating DNA analysis","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03750175","overall_status":"COMPLETED","phases":[],"registered_name":"Plasma circulating DNA analysis","registry_intervention_type":"OTHER","source_record_index":51,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03750175"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Plerixafor"],"intervention_id":"I-CTG-plerixafor-0e8302753d","intervention_name":"Plerixafor","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03277209","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Plerixafor","registry_intervention_type":"DRUG","source_record_index":94,"source_ref":"ctg-page-002"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT03277209"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Pneumococcal Vaccine"],"intervention_id":"I-CTG-pneumococcal-vaccine-3a286e3cff","intervention_name":"Pneumococcal Vaccine","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT01339000","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Pneumococcal Vaccine","registry_intervention_type":"BIOLOGICAL","source_record_index":61,"source_ref":"ctg-page-001"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT01339000"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Polio Vaccine"],"intervention_id":"I-CTG-polio-vaccine-8bd23171cc","intervention_name":"Polio Vaccine","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT01339000","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Polio Vaccine","registry_intervention_type":"BIOLOGICAL","source_record_index":61,"source_ref":"ctg-page-001"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT01339000"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["PolyPEPI1018"],"intervention_id":"I-CTG-polypepi1018-d64b014978","intervention_name":"PolyPEPI1018","intervention_type":"DRUG","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05243862","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"PolyPEPI1018","registry_intervention_type":"DRUG","source_record_index":54,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT05243862"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Positron Emission Mammography"],"intervention_id":"I-CTG-positron-emission-mammography-0118d1dc52","intervention_name":"Positron Emission Mammography","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT02978625","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Positron Emission Mammography","registry_intervention_type":"PROCEDURE","source_record_index":93,"source_ref":"ctg-page-003"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT02978625"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["positron emission tomography","Positron Emission Tomography"],"intervention_id":"I-CTG-positron-emission-tomography-ffd4d5b3e4","intervention_name":"Positron Emission Tomography","intervention_type":"PROCEDURE","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":9},{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":["18F"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1 / NA / PHASE1 / PHASE2","phases":["EARLY_PHASE1","NA","PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":10,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT02293954","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"registered_name":"positron emission tomography","registry_intervention_type":"PROCEDURE","source_record_index":92,"source_ref":"ctg-page-005"},{"intervention_index":1,"nct_id":"NCT02374931","overall_status":"TERMINATED","phases":["EARLY_PHASE1"],"registered_name":"Positron Emission Tomography","registry_intervention_type":"PROCEDURE","source_record_index":63,"source_ref":"ctg-page-003"},{"intervention_index":5,"nct_id":"NCT02408861","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Positron Emission Tomography","registry_intervention_type":"PROCEDURE","source_record_index":50,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT03993327","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Positron Emission Tomography","registry_intervention_type":"PROCEDURE","source_record_index":55,"source_ref":"ctg-page-003"},{"intervention_index":3,"nct_id":"NCT04147494","overall_status":"ACTIVE_NOT_RECRUITING","phases":["EARLY_PHASE1"],"registered_name":"Positron Emission Tomography","registry_intervention_type":"PROCEDURE","source_record_index":41,"source_ref":"ctg-page-002"},{"intervention_index":5,"nct_id":"NCT04314401","overall_status":"ACTIVE_NOT_RECRUITING","phases":[],"registered_name":"Positron Emission Tomography","registry_intervention_type":"PROCEDURE","source_record_index":47,"source_ref":"ctg-page-002"},{"intervention_index":4,"nct_id":"NCT04595747","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Positron Emission Tomography","registry_intervention_type":"PROCEDURE","source_record_index":49,"source_ref":"ctg-page-004"},{"intervention_index":6,"nct_id":"NCT05803382","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Positron Emission Tomography","registry_intervention_type":"PROCEDURE","source_record_index":53,"source_ref":"ctg-page-001"},{"intervention_index":6,"nct_id":"NCT06130826","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Positron Emission Tomography","registry_intervention_type":"PROCEDURE","source_record_index":89,"source_ref":"ctg-page-004"},{"intervention_index":9,"nct_id":"NCT06696768","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Positron Emission Tomography","registry_intervention_type":"PROCEDURE","source_record_index":70,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / RECRUITING / TERMINATED","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","RECRUITING","TERMINATED"],"study_count":10,"study_ids":["NCT02293954","NCT02374931","NCT02408861","NCT03993327","NCT04147494","NCT04314401","NCT04595747","NCT05803382","NCT06130826","NCT06696768"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Postoperative dwell with paclitaxel and 5-FU"],"intervention_id":"I-CTG-postoperative-dwell-with-paclitaxel-and-5--cbaf1635c9","intervention_name":"Postoperative dwell with paclitaxel and 5-FU","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT00004547","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Postoperative dwell with paclitaxel and 5-FU","registry_intervention_type":"DRUG","source_record_index":96,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00004547"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Pre-Treatment Biopsy"],"intervention_id":"I-CTG-pre-treatment-biopsy-a90e655b1d","intervention_name":"Pre-Treatment Biopsy","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06784947","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Pre-Treatment Biopsy","registry_intervention_type":"PROCEDURE","source_record_index":9,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT06784947"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Prednisone"],"intervention_id":"I-CTG-prednisone-4995a7ba74","intervention_name":"Prednisone","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":6,"nct_id":"NCT05176483","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Prednisone","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05176483"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Prednisone/ prednisolone"],"intervention_id":"I-CTG-prednisone-prednisolone-ab44bed919","intervention_name":"Prednisone/ prednisolone","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":7,"nct_id":"NCT05489211","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Prednisone/ prednisolone","registry_intervention_type":"DRUG","source_record_index":76,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05489211"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Prochlorperazine"],"intervention_id":"I-CTG-prochlorperazine-c8ee5fcc08","intervention_name":"Prochlorperazine","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT01851369","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Prochlorperazine","registry_intervention_type":"OTHER","source_record_index":99,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01851369"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Prostate-Specific Antigen Test"],"intervention_id":"I-CTG-prostate-specific-antigen-test-69e1daab23","intervention_name":"Prostate-Specific Antigen Test","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT04034953","overall_status":"UNKNOWN","phases":["NA"],"registered_name":"Prostate-Specific Antigen Test","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":90,"source_ref":"ctg-page-002"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT04034953"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Proton-decoupled 31P MRS at 1.5T"],"intervention_id":"I-CTG-proton-decoupled-31p-mrs-at-1-5t-d78a91489f","intervention_name":"Proton-decoupled 31P MRS at 1.5T","intervention_type":"DEVICE","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["IGG"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00581815","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Proton-decoupled 31P MRS at 1.5T","registry_intervention_type":"DEVICE","source_record_index":74,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00581815"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["PY314"],"intervention_id":"I-CTG-py314-c569282056","intervention_name":"PY314","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04691375","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"PY314","registry_intervention_type":"DRUG","source_record_index":4,"source_ref":"ctg-page-003"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT04691375"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["QL1706 Drug: mFOLFOX6 Radiation: Short-Course Radiotherapy (SCRT)"],"intervention_id":"I-CTG-ql1706-drug-mfolfox6-radiation-short-cours-52e0d55470","intervention_name":"QL1706 Drug: mFOLFOX6 Radiation: Short-Course Radiotherapy (SCRT)","intervention_type":"DRUG","modality":"bispecific-antibody","modality_distribution":[{"modality":"bispecific-antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["bifunctional MabPair"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07175636","overall_status":"NOT_YET_RECRUITING","phases":["PHASE2"],"registered_name":"Drug: QL1706 Drug: mFOLFOX6 Radiation: Short-Course Radiotherapy (SCRT)","registry_intervention_type":"DRUG","source_record_index":10,"source_ref":"ctg-page-001"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07175636"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["quality-of-life assessment"],"intervention_id":"I-CTG-quality-of-life-assessment-28a9608bcf","intervention_name":"quality-of-life assessment","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00079066","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"quality-of-life assessment","registry_intervention_type":"PROCEDURE","source_record_index":83,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00079066"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Questionnaire"],"intervention_id":"I-CTG-questionnaire-ba8850dcf4","intervention_name":"Questionnaire","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07339904","overall_status":"RECRUITING","phases":["NA"],"registered_name":"Questionnaire","registry_intervention_type":"OTHER","source_record_index":91,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07339904"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Questionnaire Administration"],"intervention_id":"I-CTG-questionnaire-administration-f956df30f2","intervention_name":"Questionnaire Administration","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":6,"nct_id":"NCT05419011","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Questionnaire Administration","registry_intervention_type":"OTHER","source_record_index":85,"source_ref":"ctg-page-001"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT05419011"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["radiation therapy","Radiation therapy","Radiation Therapy"],"intervention_id":"I-CTG-radiation-therapy-0a178cc5e4","intervention_name":"Radiation Therapy","intervention_type":"RADIATION","modality":"radiation","modality_distribution":[{"modality":"radiation","registry_occurrence_count":3}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3","phases":["PHASE1","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["RADIATION"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT00003422","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"radiation therapy","registry_intervention_type":"RADIATION","source_record_index":51,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT01769222","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Radiation therapy","registry_intervention_type":"RADIATION","source_record_index":38,"source_ref":"ctg-page-004"},{"intervention_index":4,"nct_id":"NCT04751370","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Radiation Therapy","registry_intervention_type":"RADIATION","source_record_index":31,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / TERMINATED","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","TERMINATED"],"study_count":3,"study_ids":["NCT00003422","NCT01769222","NCT04751370"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Radiofrequency ablation therapeutic apparatus"],"intervention_id":"I-CTG-radiofrequency-ablation-therapeutic-appara-a642dca4d5","intervention_name":"Radiofrequency ablation therapeutic apparatus","intervention_type":"DEVICE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT06588569","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"registered_name":"Radiofrequency ablation therapeutic apparatus","registry_intervention_type":"DEVICE","source_record_index":47,"source_ref":"ctg-page-003"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT06588569"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Radiologic Examination"],"intervention_id":"I-CTG-radiologic-examination-9a6ce96111","intervention_name":"Radiologic Examination","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT06136897","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Radiologic Examination","registry_intervention_type":"PROCEDURE","source_record_index":41,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT06136897"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Radiologic Imaging Procedure"],"intervention_id":"I-CTG-radiologic-imaging-procedure-34b1192459","intervention_name":"Radiologic Imaging Procedure","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT06654037","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Radiologic Imaging Procedure","registry_intervention_type":"PROCEDURE","source_record_index":55,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06654037"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["radionuclide imaging"],"intervention_id":"I-CTG-radionuclide-imaging-4ddc489e17","intervention_name":"radionuclide imaging","intervention_type":"PROCEDURE","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"molecular-imaging-agent","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02293954","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"registered_name":"radionuclide imaging","registry_intervention_type":"PROCEDURE","source_record_index":92,"source_ref":"ctg-page-005"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT02293954"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Given copper Cu 64 anti-CEA monoclonal antibody M5A IV","matched_alias":"CEA","nct_id":"NCT02293954","relation":"anti-CEA"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CEACAM5","target_name":"carcinoembryonic antigen-related cell adhesion molecule 5","target_symbol":"CEACAM5"}],"target_directness":"registry-explicit","target_ids":["symbol:CEACAM5"],"target_names":["carcinoembryonic antigen-related cell adhesion molecule 5"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Radiotherapy","radiotherapy"],"intervention_id":"I-CTG-radiotherapy-7f9e778d18","intervention_name":"Radiotherapy","intervention_type":"RADIATION","modality":"radiation","modality_distribution":[{"modality":"radiation","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["RADIATION"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT00226941","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"Radiotherapy","registry_intervention_type":"RADIATION","source_record_index":26,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT07594925","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"radiotherapy","registry_intervention_type":"RADIATION","source_record_index":16,"source_ref":"ctg-page-004"}],"status":"RECRUITING / TERMINATED","statuses":["RECRUITING","TERMINATED"],"study_count":2,"study_ids":["NCT00226941","NCT07594925"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Raman spectroscopy (SPECTRA IMDx)"],"intervention_id":"I-CTG-raman-spectroscopy-spectra-imdx-952b1686c5","intervention_name":"Raman spectroscopy (SPECTRA IMDx)","intervention_type":"DEVICE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04888299","overall_status":"UNKNOWN","phases":["NA"],"registered_name":"Raman spectroscopy (SPECTRA IMDx)","registry_intervention_type":"DEVICE","source_record_index":73,"source_ref":"ctg-page-001"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT04888299"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Ramucirumab"],"intervention_id":"I-CTG-ramucirumab-3e3bf3aa35","intervention_name":"Ramucirumab","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2},{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":6,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Ramucirumab","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"},{"intervention_index":10,"nct_id":"NCT05719558","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Ramucirumab","registry_intervention_type":"DRUG","source_record_index":80,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":2,"study_ids":["NCT04999761","NCT05719558"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"ramucirumab","rationale":"Exact intervention-name aliases for the VEGFR2-directed antibody.","rule_id":"candidate-ramucirumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:KDR","target_name":"vascular endothelial growth factor receptor 2","target_symbol":"KDR"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:KDR"],"target_names":["vascular endothelial growth factor receptor 2"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Ramucirumab Injection"],"intervention_id":"I-CTG-ramucirumab-injection-5636405d75","intervention_name":"Ramucirumab Injection","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05800418","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Ramucirumab Injection","registry_intervention_type":"DRUG","source_record_index":39,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT05800418"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"antagonist; binder; blocker; inhibitor","action_evidence":[{"action":"antagonist","evidence_type":"registry-field","excerpt":"… Lilly Co., the bran name is Cyramza. Ramucirumab is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds to VEGF receptor 2 and blocks VEGFR ligand, VEGF-A, VEGF-C, and VEGF-D binding to the…","matched_text":"antagonist","nct_id":"NCT05800418"},{"action":"binder","evidence_type":"registry-field","excerpt":"…Cyramza. Ramucirumab is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds to VEGF receptor 2 and blocks VEGFR ligand, VEGF-A, VEGF-C, and VEGF-D binding to the receptor. As a result, …","matched_text":"binds","nct_id":"NCT05800418"},{"action":"blocker","evidence_type":"registry-field","excerpt":"…cular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds to VEGF receptor 2 and blocks VEGFR ligand, VEGF-A, VEGF-C, and VEGF-D binding to the receptor. As a result, Ramucirumab inhibits ligand-st…","matched_text":"blocks","nct_id":"NCT05800418"},{"action":"inhibitor","evidence_type":"registry-field","excerpt":"…eptor 2 and blocks VEGFR ligand, VEGF-A, VEGF-C, and VEGF-D binding to the receptor. As a result, Ramucirumab inhibits ligand-stimulated VEGF receptor 2 activation, thereby inhibiting ligand-induced proliferation, and human endo…","matched_text":"inhibits","nct_id":"NCT05800418"}],"actions":["antagonist","binder","blocker","inhibitor"],"aliases":["Ramucirumab Injection [Cyramza]"],"intervention_id":"I-CTG-ramucirumab-injection-cyramza-f05ac3bf5c","intervention_name":"Ramucirumab Injection [Cyramza]","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":2}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05800418","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Ramucirumab Injection [Cyramza]","registry_intervention_type":"DRUG","source_record_index":39,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT05800418"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"…d by Eli Lilly Co., the bran name is Cyramza. Ramucirumab is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds to VEGF receptor 2 and blocks VEGFR ligand, VEGF-A, VEGF-C, and VEGF-D binding to the…","matched_alias":"VEGFR2","nct_id":"NCT05800418","relation":"antagonist"},{"evidence_type":"registry-field","excerpt":"…Cyramza. Ramucirumab is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds to VEGF receptor 2 and blocks VEGFR ligand, VEGF-A, VEGF-C, and VEGF-D binding to the receptor. As a result, Ramucirumab inhibit…","matched_alias":"VEGF receptor 2","nct_id":"NCT05800418","relation":"binds to VEGF receptor 2"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"Ramucirumab Injection [Cyramza]","rationale":"Exact intervention-name aliases for the VEGFR2-directed antibody.","rule_id":"candidate-ramucirumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:KDR","target_name":"vascular endothelial growth factor receptor 2","target_symbol":"KDR"}],"target_directness":"registry-explicit","target_ids":["symbol:KDR"],"target_names":["vascular endothelial growth factor receptor 2"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Recombinant Anti-EGFr Antibody"],"intervention_id":"I-CTG-recombinant-anti-egfr-antibody-95e6a19c1f","intervention_name":"Recombinant Anti-EGFr Antibody","intervention_type":"BIOLOGICAL","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Anti-EGFr Antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03017807","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Recombinant Anti-EGFr Antibody","registry_intervention_type":"BIOLOGICAL","source_record_index":56,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03017807"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Recombinant Anti-EGFr Antibody","matched_alias":"EGFr","nct_id":"NCT03017807","relation":"Anti-EGFr"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:EGFR","target_name":"epidermal growth factor receptor","target_symbol":"EGFR"}],"target_directness":"registry-explicit","target_ids":["symbol:EGFR"],"target_names":["epidermal growth factor receptor"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["recombinant fowlpox-CEA(6D)/TRICOM vaccine"],"intervention_id":"I-CTG-recombinant-fowlpox-cea-6d-tricom-vaccine-65049cf12c","intervention_name":"recombinant fowlpox-CEA(6D)/TRICOM vaccine","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00128622","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"recombinant fowlpox-CEA(6D)/TRICOM vaccine","registry_intervention_type":"BIOLOGICAL","source_record_index":7,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00128622"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Recombinant Fowlpox-GM-CSF"],"intervention_id":"I-CTG-recombinant-fowlpox-gm-csf-b0118f1760","intervention_name":"Recombinant Fowlpox-GM-CSF","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT00081848","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Recombinant Fowlpox-GM-CSF","registry_intervention_type":"DRUG","source_record_index":14,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00081848"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Recombinant full human Anti-EGFR Monoclonal Antibody"],"intervention_id":"I-CTG-recombinant-full-human-anti-egfr-monoclona-465bb5f843","intervention_name":"Recombinant full human Anti-EGFR Monoclonal Antibody","intervention_type":"BIOLOGICAL","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Monoclonal Antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02211443","overall_status":"UNKNOWN","phases":["PHASE1"],"registered_name":"Recombinant full human Anti-EGFR Monoclonal Antibody","registry_intervention_type":"BIOLOGICAL","source_record_index":5,"source_ref":"ctg-page-002"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02211443"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Recombinant full human Anti-EGFR Monoclonal Antibody","matched_alias":"EGFR","nct_id":"NCT02211443","relation":"Anti-EGFR"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:EGFR","target_name":"epidermal growth factor receptor","target_symbol":"EGFR"}],"target_directness":"registry-explicit","target_ids":["symbol:EGFR"],"target_names":["epidermal growth factor receptor"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)"],"intervention_id":"I-CTG-recombinant-nonavalent-types-6-11-16-18-31-5a6e71a614","intervention_name":"Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":2}],"modality_support":{"matched_cues":["Vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05680454","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)","registry_intervention_type":"BIOLOGICAL","source_record_index":17,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT05694728","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)","registry_intervention_type":"BIOLOGICAL","source_record_index":92,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":2,"study_ids":["NCT05680454","NCT05694728"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine"],"intervention_id":"I-CTG-recombinant-nonavalent-human-papillomaviru-da7b49af2c","intervention_name":"Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05680454","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine","registry_intervention_type":"BIOLOGICAL","source_record_index":17,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT05680454"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)"],"intervention_id":"I-CTG-recombinant-quadrivalent-human-papillomavi-36bae07401","intervention_name":"Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05694728","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)","registry_intervention_type":"BIOLOGICAL","source_record_index":92,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT05694728"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Rectectomy"],"intervention_id":"I-CTG-rectectomy-87902c3df2","intervention_name":"Rectectomy","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05307198","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Rectectomy","registry_intervention_type":"PROCEDURE","source_record_index":95,"source_ref":"ctg-page-004"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT05307198"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"inhibitor","action_evidence":[{"action":"inhibitor","evidence_type":"registry-field","excerpt":"Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogen…","matched_text":"inhibitor","nct_id":"NCT06047379"}],"actions":["inhibitor"],"aliases":["regorafenib","Regorafenib"],"intervention_id":"I-CTG-regorafenib-9aec6927fe","intervention_name":"Regorafenib","intervention_type":"DRUG","modality":"small-molecule","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":4},{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1},{"modality":"small-molecule","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy","kinase inhibitor"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3","phases":["PHASE1","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":6,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT04362839","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Regorafenib","registry_intervention_type":"DRUG","source_record_index":11,"source_ref":"ctg-page-002"},{"intervention_index":5,"nct_id":"NCT04660812","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Regorafenib","registry_intervention_type":"DRUG","source_record_index":78,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT05064059","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"regorafenib","registry_intervention_type":"DRUG","source_record_index":27,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT05600309","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"regorafenib","registry_intervention_type":"DRUG","source_record_index":30,"source_ref":"ctg-page-005"},{"intervention_index":4,"nct_id":"NCT05672316","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Regorafenib","registry_intervention_type":"DRUG","source_record_index":24,"source_ref":"ctg-page-001"},{"intervention_index":4,"nct_id":"NCT06047379","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Regorafenib","registry_intervention_type":"DRUG","source_record_index":79,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / RECRUITING","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","RECRUITING"],"study_count":6,"study_ids":["NCT04362839","NCT04660812","NCT05064059","NCT05600309","NCT05672316","NCT06047379"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"…c, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition","matched_alias":"VEGFR2","nct_id":"NCT06047379","relation":"targeted VEGFR2"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:KDR","target_name":"vascular endothelial growth factor receptor 2","target_symbol":"KDR"}],"target_directness":"registry-explicit","target_ids":["symbol:KDR"],"target_names":["vascular endothelial growth factor receptor 2"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Regorafenib (BAY 73-4506)"],"intervention_id":"I-CTG-regorafenib-bay-73-4506-e8f7d047b9","intervention_name":"Regorafenib (BAY 73-4506)","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06887218","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Regorafenib (BAY 73-4506)","registry_intervention_type":"DRUG","source_record_index":29,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06887218"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["regorafenib plus anti-PD-1 antibodies"],"intervention_id":"I-CTG-regorafenib-plus-anti-pd-1-antibodies-89d65224dd","intervention_name":"regorafenib plus anti-PD-1 antibodies","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["anti-PD-1 antibodies"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05942768","overall_status":"COMPLETED","phases":[],"registered_name":"regorafenib plus anti-PD-1 antibodies","registry_intervention_type":"DRUG","source_record_index":69,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT05942768"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"…of the 5 anti-PD-1 antibodies (i.e., nivolumab, pembrolizumab, camrelizumab, sintilimab, or toripalimab). The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 m…","matched_alias":"PD-1","nct_id":"NCT05942768","relation":"anti-PD-1"},{"evidence_type":"registry-field","excerpt":"regorafenib plus anti-PD-1 antibodies","matched_alias":"PD-1","nct_id":"NCT05942768","relation":"anti-PD-1"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"registry-explicit","target_ids":["symbol:PDCD1"],"target_names":["programmed cell death protein 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Resection"],"intervention_id":"I-CTG-resection-704a490aaa","intervention_name":"Resection","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07405476","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Resection","registry_intervention_type":"PROCEDURE","source_record_index":97,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07405476"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Resection surgery"],"intervention_id":"I-CTG-resection-surgery-b8514ede44","intervention_name":"Resection surgery","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT06395337","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"Resection surgery","registry_intervention_type":"PROCEDURE","source_record_index":4,"source_ref":"ctg-page-004"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT06395337"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["RetroviewTM colonoscope"],"intervention_id":"I-CTG-retroviewtm-colonoscope-d6b6d7ed2c","intervention_name":"RetroviewTM colonoscope","intervention_type":"DEVICE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03155165","overall_status":"COMPLETED","phases":[],"registered_name":"RetroviewTM colonoscope","registry_intervention_type":"DEVICE","source_record_index":91,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03155165"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["rF-CEA(6D)/TRICOM"],"intervention_id":"I-CTG-rf-cea-6d-tricom-d76022ee81","intervention_name":"rF-CEA(6D)/TRICOM","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00081848","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"rF-CEA(6D)/TRICOM","registry_intervention_type":"DRUG","source_record_index":14,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00081848"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Rilvegostomig"],"intervention_id":"I-CTG-rilvegostomig-51ddc4cd03","intervention_name":"Rilvegostomig","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":6,"nct_id":"NCT05489211","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Rilvegostomig","registry_intervention_type":"DRUG","source_record_index":76,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05489211"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Rituximab"],"intervention_id":"I-CTG-rituximab-2e49eb3c34","intervention_name":"Rituximab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00001805","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Rituximab","registry_intervention_type":"DRUG","source_record_index":54,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00001805"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["RO7515629"],"intervention_id":"I-CTG-ro7515629-a1f49e9aff","intervention_name":"RO7515629","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05769959","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"RO7515629","registry_intervention_type":"DRUG","source_record_index":25,"source_ref":"ctg-page-005"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT05769959"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Rogaratinib"],"intervention_id":"I-CTG-rogaratinib-f1e5447552","intervention_name":"Rogaratinib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT04595747","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Rogaratinib","registry_intervention_type":"DRUG","source_record_index":49,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT04595747"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM"],"intervention_id":"I-CTG-rv-cea-6d-tricom-rf-cea-6d-tricom-6ecc12eb4e","intervention_name":"rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00081848","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM","registry_intervention_type":"DRUG","source_record_index":14,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00081848"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["S-1"],"intervention_id":"I-CTG-s-1-6a840baf5d","intervention_name":"S-1","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":11,"nct_id":"NCT02280070","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"S-1","registry_intervention_type":"DRUG","source_record_index":62,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT03380689","overall_status":"WITHDRAWN","phases":["PHASE1"],"registered_name":"S-1","registry_intervention_type":"DRUG","source_record_index":95,"source_ref":"ctg-page-003"}],"status":"UNKNOWN / WITHDRAWN","statuses":["UNKNOWN","WITHDRAWN"],"study_count":2,"study_ids":["NCT02280070","NCT03380689"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["S-1, Bevacizumab"],"intervention_id":"I-CTG-s-1-bevacizumab-b11d2b44f6","intervention_name":"S-1, Bevacizumab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00569699","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"S-1, Bevacizumab","registry_intervention_type":"DRUG","source_record_index":97,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00569699"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["S-1, Irinotecan, Bevacizumab"],"intervention_id":"I-CTG-s-1-irinotecan-bevacizumab-ed76068ac9","intervention_name":"S-1, Irinotecan, Bevacizumab","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":2}],"modality_support":{"matched_cues":["Irinotecan"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00569335","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"S-1, Irinotecan, Bevacizumab","registry_intervention_type":"DRUG","source_record_index":95,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT00569790","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"S-1, Irinotecan, Bevacizumab","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":2,"study_ids":["NCT00569335","NCT00569790"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["S-531011"],"intervention_id":"I-CTG-s-531011-71168055f0","intervention_name":"S-531011","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07591597","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"S-531011","registry_intervention_type":"BIOLOGICAL","source_record_index":0,"source_ref":"ctg-page-002"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07591597"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["S1"],"intervention_id":"I-CTG-s1-e8bc163c82","intervention_name":"S1","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05720559","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"S1","registry_intervention_type":"DRUG","source_record_index":49,"source_ref":"ctg-page-003"},{"intervention_index":1,"nct_id":"NCT05774964","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"S1","registry_intervention_type":"DRUG","source_record_index":8,"source_ref":"ctg-page-005"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":2,"study_ids":["NCT05720559","NCT05774964"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Sampling"],"intervention_id":"I-CTG-sampling-52630e4131","intervention_name":"Sampling","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06435689","overall_status":"NOT_YET_RECRUITING","phases":[],"registered_name":"Sampling","registry_intervention_type":"OTHER","source_record_index":67,"source_ref":"ctg-page-001"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT06435689"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Sargramostim (GM-CSF, Leukine)"],"intervention_id":"I-CTG-sargramostim-gm-csf-leukine-d29647800f","intervention_name":"Sargramostim (GM-CSF, Leukine)","intervention_type":"DRUG","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["vaccination"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT00088413","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Sargramostim (GM-CSF, Leukine)","registry_intervention_type":"DRUG","source_record_index":68,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00088413"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["sasanlimab"],"intervention_id":"I-CTG-sasanlimab-dd86800660","intervention_name":"sasanlimab","intervention_type":"BIOLOGICAL","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":3}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT06448364","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"sasanlimab","registry_intervention_type":"BIOLOGICAL","source_record_index":54,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT06546553","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"sasanlimab","registry_intervention_type":"BIOLOGICAL","source_record_index":67,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":2,"study_ids":["NCT06448364","NCT06546553"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"sasanlimab","rationale":"Exact intervention-name aliases for PD-1-directed antibodies.","rule_id":"candidate-other-pd1-antibodies","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:PDCD1"],"target_names":["programmed cell death protein 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Screening Questionnaire Administration"],"intervention_id":"I-CTG-screening-questionnaire-administration-0a65b6feb4","intervention_name":"Screening Questionnaire Administration","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT01696994","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"registered_name":"Screening Questionnaire Administration","registry_intervention_type":"OTHER","source_record_index":28,"source_ref":"ctg-page-003"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT01696994"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Serum metabolomic analysis or ELISA"],"intervention_id":"I-CTG-serum-metabolomic-analysis-or-elisa-71fe764949","intervention_name":"Serum metabolomic analysis or ELISA","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07586293","overall_status":"NOT_YET_RECRUITING","phases":[],"registered_name":"Serum metabolomic analysis or ELISA","registry_intervention_type":"OTHER","source_record_index":95,"source_ref":"ctg-page-001"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07586293"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"molecular-imaging","action_evidence":[{"action":"molecular-imaging","evidence_type":"registry-field","excerpt":"A fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent.","matched_text":"imaging agent","nct_id":"NCT03659448"}],"actions":["molecular-imaging"],"aliases":["SGM-101"],"intervention_id":"I-CTG-sgm-101-3d31779152","intervention_name":"SGM-101","intervention_type":"DRUG","modality":"molecular-imaging-agent","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":4},{"modality":"molecular-imaging-agent","registry_occurrence_count":2}],"modality_support":{"matched_cues":["imaging agent"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3","phases":["PHASE1","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":5,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02973672","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"SGM-101","registry_intervention_type":"DRUG","source_record_index":69,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT03659448","overall_status":"RECRUITING","phases":["PHASE3"],"registered_name":"SGM-101","registry_intervention_type":"DRUG","source_record_index":79,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT04642924","overall_status":"UNKNOWN","phases":["PHASE2","PHASE3"],"registered_name":"SGM-101","registry_intervention_type":"DRUG","source_record_index":10,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT04737213","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"SGM-101","registry_intervention_type":"DRUG","source_record_index":45,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT04755920","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"SGM-101","registry_intervention_type":"DRUG","source_record_index":73,"source_ref":"ctg-page-002"}],"status":"COMPLETED / RECRUITING / UNKNOWN","statuses":["COMPLETED","RECRUITING","UNKNOWN"],"study_count":5,"study_ids":["NCT02973672","NCT03659448","NCT04642924","NCT04737213","NCT04755920"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"A fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent.","matched_alias":"carcinoembryonic antigen","nct_id":"NCT03659448","relation":"anti-carcinoembryonic antigen"},{"evidence_type":"registry-field","excerpt":"A fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent.","matched_alias":"CEA","nct_id":"NCT03659448","relation":"monoclonal antibody"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"SGM-101","rationale":"Exact intervention-name alias for the CEA-directed fluorescent antibody conjugate.","rule_id":"candidate-sgm101","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CEACAM5","target_name":"carcinoembryonic antigen-related cell adhesion molecule 5","target_symbol":"CEACAM5"}],"target_directness":"registry-explicit","target_ids":["symbol:CEACAM5"],"target_names":["carcinoembryonic antigen-related cell adhesion molecule 5"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Short Course Radiotherapy (SCRT)"],"intervention_id":"I-CTG-short-course-radiotherapy-scrt-0d75e0f8f8","intervention_name":"Short Course Radiotherapy (SCRT)","intervention_type":"RADIATION","modality":"radiation","modality_distribution":[{"modality":"radiation","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["RADIATION"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT03152370","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Short Course Radiotherapy (SCRT)","registry_intervention_type":"RADIATION","source_record_index":18,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03152370"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Sigmoidoscopy"],"intervention_id":"I-CTG-sigmoidoscopy-4dbc0d4ee1","intervention_name":"Sigmoidoscopy","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT04751370","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Sigmoidoscopy","registry_intervention_type":"PROCEDURE","source_record_index":31,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT04751370"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["single photon emission computed tomography"],"intervention_id":"I-CTG-single-photon-emission-computed-tomography-fa3b449559","intervention_name":"single photon emission computed tomography","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00647153","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"single photon emission computed tomography","registry_intervention_type":"PROCEDURE","source_record_index":12,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00647153"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["sintilimab","Sintilimab"],"intervention_id":"I-CTG-sintilimab-77dca9d617","intervention_name":"sintilimab","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":2},{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy","monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07007767","overall_status":"NOT_YET_RECRUITING","phases":["PHASE2"],"registered_name":"sintilimab","registry_intervention_type":"DRUG","source_record_index":79,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT07594925","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Sintilimab","registry_intervention_type":"DRUG","source_record_index":16,"source_ref":"ctg-page-004"}],"status":"NOT_YET_RECRUITING / RECRUITING","statuses":["NOT_YET_RECRUITING","RECRUITING"],"study_count":2,"study_ids":["NCT07007767","NCT07594925"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Sintilimab (anti-PD-1 monoclonal antibody) Specification: 100 mg/10 mL (10 mg/mL concentrated solution) Administration: Dose: 200 mg (fixed dose) Route: Intravenous (IV) infusion over 30-60 minutes Schedule: Day 1 of eac…","matched_alias":"PD-1","nct_id":"NCT07007767","relation":"anti-PD-1"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"sintilimab","rationale":"Exact intervention-name aliases for PD-1-directed antibodies.","rule_id":"candidate-other-pd1-antibodies","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"registry-explicit","target_ids":["symbol:PDCD1"],"target_names":["programmed cell death protein 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine"],"intervention_id":"I-CTG-sintilimab-ibi308-bevacizumab-oxaliplatin--9f8d711e91","intervention_name":"Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04194359","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine","registry_intervention_type":"DRUG","source_record_index":96,"source_ref":"ctg-page-004"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT04194359"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Humanized PD-1 antibody (Sintilimab, IBI308)+bevacizumab+oxaliplatin+capecitabine","matched_alias":"PD-1","nct_id":"NCT04194359","relation":"antibody"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"registry-explicit","target_ids":["symbol:PDCD1"],"target_names":["programmed cell death protein 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)"],"intervention_id":"I-CTG-sintilimab-cetuximab-chemotherapy-mfolfox6-6f8c632ed7","intervention_name":"Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":2}],"modality_support":{"matched_cues":["Chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06776757","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)","registry_intervention_type":"DRUG","source_record_index":93,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT06776757","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)","registry_intervention_type":"DRUG","source_record_index":93,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06776757"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"inhibitor","action_evidence":[{"action":"inhibitor","evidence_type":"registry-field","excerpt":"Systemic therapy including PD-1 inhibitor starts on the 7th day after ablation (sintilimab 200 mg IV D1 + mFOLFOX6 or FOLFIRI + bevacizumab or cetuximab (determined according to the subject's first-line chemotherapy regi…","matched_text":"inhibitor","nct_id":"NCT06590259"}],"actions":["inhibitor"],"aliases":["Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab"],"intervention_id":"I-CTG-sintilimab-mfolfox6-or-folfiri-bevacizumab-6e665e903a","intervention_name":"Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT06590259","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab","registry_intervention_type":"DRUG","source_record_index":59,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06590259"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Systemic therapy including PD-1 inhibitor starts on the 7th day after ablation (sintilimab 200 mg IV D1 + mFOLFOX6 or FOLFIRI + bevacizumab or cetuximab (determined according to the subject's first-line chemotherapy regi…","matched_alias":"PD-1","nct_id":"NCT06590259","relation":"inhibitor"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"registry-explicit","target_ids":["symbol:PDCD1"],"target_names":["programmed cell death protein 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Sintilimab,regofinib,cetuximab"],"intervention_id":"I-CTG-sintilimab-regofinib-cetuximab-4ca21f4c71","intervention_name":"Sintilimab,regofinib,cetuximab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04745130","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Sintilimab,regofinib,cetuximab","registry_intervention_type":"DRUG","source_record_index":94,"source_ref":"ctg-page-001"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT04745130"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["SIR-Sphere"],"intervention_id":"I-CTG-sir-sphere-80cf50063d","intervention_name":"SIR-Sphere","intervention_type":"DEVICE","modality":"radioligand-therapy","modality_distribution":[{"modality":"radioligand-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Yttrium-90"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT02602327","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"SIR-Sphere","registry_intervention_type":"DEVICE","source_record_index":98,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02602327"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Sir-Spheres"],"intervention_id":"I-CTG-sir-spheres-bd0d6f6e70","intervention_name":"Sir-Spheres","intervention_type":"DEVICE","modality":"radioligand-therapy","modality_distribution":[{"modality":"radioligand-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["yttrium-90"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT02416466","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Sir-Spheres","registry_intervention_type":"DEVICE","source_record_index":55,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02416466"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["SNB-101"],"intervention_id":"I-CTG-snb-101-9f3414b5ea","intervention_name":"SNB-101","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04640480","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"SNB-101","registry_intervention_type":"DRUG","source_record_index":44,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT04640480"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["SNK01"],"intervention_id":"I-CTG-snk01-622d96f88e","intervention_name":"SNK01","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04464967","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"SNK01","registry_intervention_type":"BIOLOGICAL","source_record_index":52,"source_ref":"ctg-page-002"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT04464967"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["SOC (anti-PD-1 + platinum -based chemo)"],"intervention_id":"I-CTG-soc-anti-pd-1-platinum-based-chemo-fa3d4d0cf3","intervention_name":"SOC (anti-PD-1 + platinum -based chemo)","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT06546553","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"SOC (anti-PD-1 + platinum -based chemo)","registry_intervention_type":"OTHER","source_record_index":67,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT06546553"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Standard of Care (anti-PD-1 + platinum -based chemo)","matched_alias":"PD-1","nct_id":"NCT06546553","relation":"anti-PD-1"},{"evidence_type":"registry-field","excerpt":"SOC (anti-PD-1 + platinum -based chemo)","matched_alias":"PD-1","nct_id":"NCT06546553","relation":"anti-PD-1"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"registry-explicit","target_ids":["symbol:PDCD1"],"target_names":["programmed cell death protein 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Sodium Valproate"],"intervention_id":"I-CTG-sodium-valproate-ad466db77f","intervention_name":"Sodium Valproate","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05694936","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Sodium Valproate","registry_intervention_type":"DRUG","source_record_index":66,"source_ref":"ctg-page-003"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT05694936"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Sofe-M"],"intervention_id":"I-CTG-sofe-m-d6f06a2647","intervention_name":"Sofe-M","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06400472","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Sofe-M","registry_intervention_type":"DRUG","source_record_index":48,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06400472"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Sotigalimab"],"intervention_id":"I-CTG-sotigalimab-44c2a2ac30","intervention_name":"Sotigalimab","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT02600949","overall_status":"ENROLLING_BY_INVITATION","phases":["PHASE1"],"registered_name":"Sotigalimab","registry_intervention_type":"BIOLOGICAL","source_record_index":89,"source_ref":"ctg-page-001"}],"status":"ENROLLING_BY_INVITATION","statuses":["ENROLLING_BY_INVITATION"],"study_count":1,"study_ids":["NCT02600949"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["SPECT/CT scan"],"intervention_id":"I-CTG-spect-ct-scan-f23d165d06","intervention_name":"SPECT/CT scan","intervention_type":"RADIATION","modality":"radiation","modality_distribution":[{"modality":"radiation","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["RADIATION"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT06395337","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"SPECT/CT scan","registry_intervention_type":"RADIATION","source_record_index":4,"source_ref":"ctg-page-004"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT06395337"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Spinal"],"intervention_id":"I-CTG-spinal-6676403310","intervention_name":"Spinal","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT00747292","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"Spinal","registry_intervention_type":"PROCEDURE","source_record_index":64,"source_ref":"ctg-page-005"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT00747292"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Spinal analgesia"],"intervention_id":"I-CTG-spinal-analgesia-c430588c7a","intervention_name":"Spinal analgesia","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01477190","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Spinal analgesia","registry_intervention_type":"DRUG","source_record_index":37,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01477190"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["SPLIT Abs"],"intervention_id":"I-CTG-split-abs-568a6369c5","intervention_name":"SPLIT Abs","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07416552","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"SPLIT Abs","registry_intervention_type":"DRUG","source_record_index":2,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07416552"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Standard of Care"],"intervention_id":"I-CTG-standard-of-care-2154d8c49a","intervention_name":"Standard of Care","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT05608044","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Standard of Care","registry_intervention_type":"DRUG","source_record_index":45,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT05608044"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Standard of Care Anticancer Therapies"],"intervention_id":"I-CTG-standard-of-care-anticancer-therapies-ca35c42b0d","intervention_name":"Standard of Care Anticancer Therapies","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Capecitabine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07114601","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Standard of Care Anticancer Therapies","registry_intervention_type":"DRUG","source_record_index":2,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07114601"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Standard-of-care treatment with panitumumab"],"intervention_id":"I-CTG-standard-of-care-treatment-with-panitumuma-dd47c9ecad","intervention_name":"Standard-of-care treatment with panitumumab","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1},{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00867334","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Standard-of-care treatment with panitumumab","registry_intervention_type":"DRUG","source_record_index":40,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00867334"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"Standard-of-care treatment with panitumumab","rationale":"Exact registered intervention name explicitly identifies panitumumab.","rule_id":"candidate-standard-panitumumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:EGFR","target_name":"epidermal growth factor receptor","target_symbol":"EGFR"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:EGFR"],"target_names":["epidermal growth factor receptor"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["STAR0602"],"intervention_id":"I-CTG-star0602-0e31bea916","intervention_name":"STAR0602","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05592626","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"STAR0602","registry_intervention_type":"DRUG","source_record_index":90,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05592626"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Stereotactic Body Radiation Therapy"],"intervention_id":"I-CTG-stereotactic-body-radiation-therapy-50b9b943a9","intervention_name":"Stereotactic Body Radiation Therapy","intervention_type":"RADIATION","modality":"radiation","modality_distribution":[{"modality":"radiation","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["RADIATION"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":12,"nct_id":"NCT03169777","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"Stereotactic Body Radiation Therapy","registry_intervention_type":"RADIATION","source_record_index":17,"source_ref":"ctg-page-001"},{"intervention_index":7,"nct_id":"NCT06130826","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Stereotactic Body Radiation Therapy","registry_intervention_type":"RADIATION","source_record_index":89,"source_ref":"ctg-page-004"}],"status":"RECRUITING / WITHDRAWN","statuses":["RECRUITING","WITHDRAWN"],"study_count":2,"study_ids":["NCT03169777","NCT06130826"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["stereotactic body radiation treatment (SBRT)"],"intervention_id":"I-CTG-stereotactic-body-radiation-treatment-sbrt-f2d353b710","intervention_name":"stereotactic body radiation treatment (SBRT)","intervention_type":"RADIATION","modality":"radiation","modality_distribution":[{"modality":"radiation","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["RADIATION"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05775146","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"stereotactic body radiation treatment (SBRT)","registry_intervention_type":"RADIATION","source_record_index":56,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05775146"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["sunitinib added to FOLFIRI"],"intervention_id":"I-CTG-sunitinib-added-to-folfiri-740e02fad6","intervention_name":"sunitinib added to FOLFIRI","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["FOLFIRI"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00806663","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"sunitinib added to FOLFIRI","registry_intervention_type":"DRUG","source_record_index":35,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00806663"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Suntent"],"intervention_id":"I-CTG-suntent-c1d3a1ed5b","intervention_name":"Suntent","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT01507740","overall_status":"TERMINATED","phases":[],"registered_name":"Suntent","registry_intervention_type":"DRUG","source_record_index":28,"source_ref":"ctg-page-002"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT01507740"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Supportive treatment"],"intervention_id":"I-CTG-supportive-treatment-374c0d91c4","intervention_name":"Supportive treatment","intervention_type":"OTHER","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT01413295","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Supportive treatment","registry_intervention_type":"OTHER","source_record_index":21,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01413295"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Surgery"],"intervention_id":"I-CTG-surgery-fc00eb484b","intervention_name":"Surgery","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00004547","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Surgery","registry_intervention_type":"PROCEDURE","source_record_index":96,"source_ref":"ctg-page-001"},{"intervention_index":3,"nct_id":"NCT03373188","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Surgery","registry_intervention_type":"PROCEDURE","source_record_index":14,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":2,"study_ids":["NCT00004547","NCT03373188"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Surgery and Radiation Therapy"],"intervention_id":"I-CTG-surgery-and-radiation-therapy-1f3ec33ef0","intervention_name":"Surgery and Radiation Therapy","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00725400","overall_status":"WITHDRAWN","phases":["PHASE2"],"registered_name":"Surgery and Radiation Therapy","registry_intervention_type":"PROCEDURE","source_record_index":97,"source_ref":"ctg-page-003"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT00725400"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Surgical Procedure"],"intervention_id":"I-CTG-surgical-procedure-4c06a922cd","intervention_name":"Surgical Procedure","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":6,"nct_id":"NCT06307548","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Surgical Procedure","registry_intervention_type":"PROCEDURE","source_record_index":91,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06307548"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["surveillance program after completion of primary treatment"],"intervention_id":"I-CTG-surveillance-program-after-completion-of-p-5da708d826","intervention_name":"surveillance program after completion of primary treatment","intervention_type":"OTHER","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02409472","overall_status":"COMPLETED","phases":["NA"],"registered_name":"surveillance program after completion of primary treatment","registry_intervention_type":"OTHER","source_record_index":74,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02409472"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Survey Administration"],"intervention_id":"I-CTG-survey-administration-bb8be55b97","intervention_name":"Survey Administration","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT06995924","overall_status":"RECRUITING","phases":["NA"],"registered_name":"Survey Administration","registry_intervention_type":"OTHER","source_record_index":29,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06995924"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["SY-5609"],"intervention_id":"I-CTG-sy-5609-026f831140","intervention_name":"SY-5609","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT04929223","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"SY-5609","registry_intervention_type":"DRUG","source_record_index":64,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT04929223"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"binder","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"Sym004 is a 1:1 mixture of 2 monoclonal antibodies (mAbs), which bind specifically to 2 non-overlapping epitopes of the epidermal growth factor receptor (EGFR).","matched_text":"bind","nct_id":"NCT02568046"},{"action":"binder","evidence_type":"registry-field","excerpt":"Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).","matched_text":"bind","nct_id":"NCT02965417"},{"action":"binder","evidence_type":"registry-field","excerpt":"Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.","matched_text":"bind","nct_id":"NCT03549338"}],"actions":["binder"],"aliases":["Sym004"],"intervention_id":"I-CTG-sym004-e0e4b03009","intervention_name":"Sym004","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":2},{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":["monoclonal antibodies"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02568046","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"Sym004","registry_intervention_type":"DRUG","source_record_index":40,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT02965417","overall_status":"WITHDRAWN","phases":["PHASE2"],"registered_name":"Sym004","registry_intervention_type":"DRUG","source_record_index":22,"source_ref":"ctg-page-003"},{"intervention_index":0,"nct_id":"NCT03549338","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Sym004","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-005"}],"status":"TERMINATED / WITHDRAWN","statuses":["TERMINATED","WITHDRAWN"],"study_count":3,"study_ids":["NCT02568046","NCT02965417","NCT03549338"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Sym004 (12 mg/kg)"],"intervention_id":"I-CTG-sym004-12-mg-kg-421e2d5840","intervention_name":"Sym004 (12 mg/kg)","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02083653","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Sym004 (12 mg/kg)","registry_intervention_type":"DRUG","source_record_index":76,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02083653"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Sym004 (9/6 mg/kg)"],"intervention_id":"I-CTG-sym004-9-6-mg-kg-06c895353e","intervention_name":"Sym004 (9/6 mg/kg)","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT02083653","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Sym004 (9/6 mg/kg)","registry_intervention_type":"DRUG","source_record_index":76,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02083653"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["SYN004"],"intervention_id":"I-CTG-syn004-98f543afc6","intervention_name":"SYN004","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02391727","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"SYN004","registry_intervention_type":"BIOLOGICAL","source_record_index":44,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02391727"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Synthetic Tumor-Associated Peptide Vaccine Therapy"],"intervention_id":"I-CTG-synthetic-tumor-associated-peptide-vaccine-c83b521589","intervention_name":"Synthetic Tumor-Associated Peptide Vaccine Therapy","intervention_type":"BIOLOGICAL","modality":"vaccine","modality_distribution":[{"modality":"vaccine","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Vaccine"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT02600949","overall_status":"ENROLLING_BY_INVITATION","phases":["PHASE1"],"registered_name":"Synthetic Tumor-Associated Peptide Vaccine Therapy","registry_intervention_type":"BIOLOGICAL","source_record_index":89,"source_ref":"ctg-page-001"}],"status":"ENROLLING_BY_INVITATION","statuses":["ENROLLING_BY_INVITATION"],"study_count":1,"study_ids":["NCT02600949"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["TAA06 injection"],"intervention_id":"I-CTG-taa06-injection-bab9f355e9","intervention_name":"TAA06 injection","intervention_type":"BIOLOGICAL","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR-T"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05190185","overall_status":"UNKNOWN","phases":["PHASE1"],"registered_name":"TAA06 injection","registry_intervention_type":"BIOLOGICAL","source_record_index":42,"source_ref":"ctg-page-002"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT05190185"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["TACE"],"intervention_id":"I-CTG-tace-1c10c95381","intervention_name":"TACE","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT02015754","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"TACE","registry_intervention_type":"PROCEDURE","source_record_index":28,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02015754"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Tailored surgery"],"intervention_id":"I-CTG-tailored-surgery-c768a57377","intervention_name":"Tailored surgery","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05164315","overall_status":"TERMINATED","phases":["NA"],"registered_name":"Tailored surgery","registry_intervention_type":"PROCEDURE","source_record_index":97,"source_ref":"ctg-page-001"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT05164315"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Talimogene Laherparepvec"],"intervention_id":"I-CTG-talimogene-laherparepvec-7f8686419b","intervention_name":"Talimogene Laherparepvec","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":6,"nct_id":"NCT02978625","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Talimogene Laherparepvec","registry_intervention_type":"BIOLOGICAL","source_record_index":93,"source_ref":"ctg-page-003"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT02978625"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Tas-102","TAS-102"],"intervention_id":"I-CTG-tas-102-0cc3712f32","intervention_name":"TAS-102","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":7}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3","phases":["PHASE1","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":7,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02602327","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Tas-102","registry_intervention_type":"DRUG","source_record_index":98,"source_ref":"ctg-page-004"},{"intervention_index":0,"nct_id":"NCT02860546","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"TAS-102","registry_intervention_type":"DRUG","source_record_index":65,"source_ref":"ctg-page-005"},{"intervention_index":5,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"TAS-102","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"},{"intervention_index":7,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"TAS-102","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT05064059","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"TAS-102","registry_intervention_type":"DRUG","source_record_index":27,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT05600309","overall_status":"COMPLETED","phases":["PHASE3"],"registered_name":"TAS-102","registry_intervention_type":"DRUG","source_record_index":30,"source_ref":"ctg-page-005"},{"intervention_index":2,"nct_id":"NCT07649655","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1"],"registered_name":"TAS-102","registry_intervention_type":"DRUG","source_record_index":52,"source_ref":"ctg-page-004"}],"status":"COMPLETED / NOT_YET_RECRUITING / RECRUITING","statuses":["COMPLETED","NOT_YET_RECRUITING","RECRUITING"],"study_count":6,"study_ids":["NCT02602327","NCT02860546","NCT04999761","NCT05064059","NCT05600309","NCT07649655"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["TAS-115"],"intervention_id":"I-CTG-tas-115-4a45b73319","intervention_name":"TAS-115","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"TAS-115","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT04999761"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["TAS-116"],"intervention_id":"I-CTG-tas-116-d30001104c","intervention_name":"TAS-116","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"TAS-116","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT04999761"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["TAS-120"],"intervention_id":"I-CTG-tas-120-05739c5158","intervention_name":"TAS-120","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT04999761","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"TAS-120","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT04999761"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"binder","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"…ith a specific targeting of M2 macrophages and an apoptosis-inducing peptide (dKLA). As a transporter, the M2 binding peptide acts as a drug conjugate, explicitly binding to M2 macrophages and inducing cell penetration. In the …","matched_text":"binding","nct_id":"NCT06400160"}],"actions":["binder"],"aliases":["TB511"],"intervention_id":"I-CTG-tb511-1f505b7653","intervention_name":"TB511","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06400160","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"TB511","registry_intervention_type":"DRUG","source_record_index":27,"source_ref":"ctg-page-005"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT06400160"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["TC-510"],"intervention_id":"I-CTG-tc-510-9b1833ab76","intervention_name":"TC-510","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05451849","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"TC-510","registry_intervention_type":"BIOLOGICAL","source_record_index":73,"source_ref":"ctg-page-005"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT05451849"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Temozolomide"],"intervention_id":"I-CTG-temozolomide-fb2da10619","intervention_name":"Temozolomide","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":3}],"modality_support":{"matched_cues":["Chemotherapy","chemotherapy","irinotecan"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3","phases":["PHASE1","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":8,"nct_id":"NCT03607643","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"registered_name":"Temozolomide","registry_intervention_type":"DRUG","source_record_index":59,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT03715933","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Temozolomide","registry_intervention_type":"DRUG","source_record_index":9,"source_ref":"ctg-page-005"},{"intervention_index":4,"nct_id":"NCT06490536","overall_status":"RECRUITING","phases":["PHASE3"],"registered_name":"Temozolomide","registry_intervention_type":"DRUG","source_record_index":6,"source_ref":"ctg-page-002"}],"status":"RECRUITING / UNKNOWN","statuses":["RECRUITING","UNKNOWN"],"study_count":3,"study_ids":["NCT03607643","NCT03715933","NCT06490536"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Tepotinib"],"intervention_id":"I-CTG-tepotinib-3d05149ad4","intervention_name":"Tepotinib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04515394","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"Tepotinib","registry_intervention_type":"DRUG","source_record_index":16,"source_ref":"ctg-page-005"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT04515394"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Texture and Color Enhancement Imaging (TXI) and Red Dichromatic Imaging (RDI)"],"intervention_id":"I-CTG-texture-and-color-enhancement-imaging-txi--eb14ffad61","intervention_name":"Texture and Color Enhancement Imaging (TXI) and Red Dichromatic Imaging (RDI)","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07474844","overall_status":"WITHDRAWN","phases":["NA"],"registered_name":"Texture and Color Enhancement Imaging (TXI) and Red Dichromatic Imaging (RDI)","registry_intervention_type":"OTHER","source_record_index":0,"source_ref":"ctg-page-004"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT07474844"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["TF2/IMP288"],"intervention_id":"I-CTG-tf2-imp288-e51344a77e","intervention_name":"TF2/IMP288","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01273402","overall_status":"WITHDRAWN","phases":["PHASE1"],"registered_name":"TF2/IMP288","registry_intervention_type":"DRUG","source_record_index":62,"source_ref":"ctg-page-002"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT01273402"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["The P1 Check-Cap capsule"],"intervention_id":"I-CTG-the-p1-check-cap-capsule-c18b3f27b1","intervention_name":"The P1 Check-Cap capsule","intervention_type":"DEVICE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DEVICE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01458925","overall_status":"TERMINATED","phases":["NA"],"registered_name":"The P1 Check-Cap capsule","registry_intervention_type":"DEVICE","source_record_index":43,"source_ref":"ctg-page-005"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT01458925"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["therapeutic autologous dendritic cells"],"intervention_id":"I-CTG-therapeutic-autologous-dendritic-cells-5fb7aea80f","intervention_name":"therapeutic autologous dendritic cells","intervention_type":"BIOLOGICAL","modality":"cellular-therapy","modality_distribution":[{"modality":"cellular-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["dendritic cells"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT00128622","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"therapeutic autologous dendritic cells","registry_intervention_type":"BIOLOGICAL","source_record_index":7,"source_ref":"ctg-page-002"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00128622"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["therapeutic autologous lymphocytes"],"intervention_id":"I-CTG-therapeutic-autologous-lymphocytes-df7f58a66d","intervention_name":"therapeutic autologous lymphocytes","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00004178","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"therapeutic autologous lymphocytes","registry_intervention_type":"BIOLOGICAL","source_record_index":46,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00004178"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["therapeutic conventional surgery","Therapeutic Conventional Surgery"],"intervention_id":"I-CTG-therapeutic-conventional-surgery-338b35cbac","intervention_name":"Therapeutic Conventional Surgery","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1 / PHASE3","phases":["EARLY_PHASE1","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":10,"nct_id":"NCT01167725","overall_status":"TERMINATED","phases":["PHASE3"],"registered_name":"therapeutic conventional surgery","registry_intervention_type":"PROCEDURE","source_record_index":35,"source_ref":"ctg-page-004"},{"intervention_index":2,"nct_id":"NCT04870034","overall_status":"WITHDRAWN","phases":["EARLY_PHASE1"],"registered_name":"Therapeutic Conventional Surgery","registry_intervention_type":"PROCEDURE","source_record_index":1,"source_ref":"ctg-page-003"}],"status":"TERMINATED / WITHDRAWN","statuses":["TERMINATED","WITHDRAWN"],"study_count":2,"study_ids":["NCT01167725","NCT04870034"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"inhibitor","action_evidence":[{"action":"inhibitor","evidence_type":"registry-field","excerpt":"Tiragolumab is a human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) dom…","matched_text":"inhibitory","nct_id":"NCT06784947"}],"actions":["inhibitor"],"aliases":["Tiragolumab"],"intervention_id":"I-CTG-tiragolumab-dd38477944","intervention_name":"Tiragolumab","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":2},{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT04929223","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Tiragolumab","registry_intervention_type":"DRUG","source_record_index":64,"source_ref":"ctg-page-003"},{"intervention_index":2,"nct_id":"NCT06784947","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Tiragolumab","registry_intervention_type":"DRUG","source_record_index":9,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING / RECRUITING","statuses":["ACTIVE_NOT_RECRUITING","RECRUITING"],"study_count":2,"study_ids":["NCT04929223","NCT06784947"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"tiragolumab","rationale":"Exact intervention-name alias for the TIGIT-directed antibody.","rule_id":"candidate-tiragolumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:TIGIT","target_name":"T-cell immunoreceptor with Ig and ITIM domains","target_symbol":"TIGIT"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:TIGIT"],"target_names":["T-cell immunoreceptor with Ig and ITIM domains"]},{"action":"inhibitor","action_evidence":[{"action":"inhibitor","evidence_type":"registry-field","excerpt":"Tislelizumab is a PD-1 inhibitor.","matched_text":"inhibitor","nct_id":"NCT05651022"}],"actions":["inhibitor"],"aliases":["Tislelizumab"],"intervention_id":"I-CTG-tislelizumab-45f8cec74e","intervention_name":"Tislelizumab","intervention_type":"multiple","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":2},{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1 / PHASE1 / PHASE2","phases":["EARLY_PHASE1","PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","DRUG"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT04906382","overall_status":"TERMINATED","phases":["EARLY_PHASE1"],"registered_name":"Tislelizumab","registry_intervention_type":"BIOLOGICAL","source_record_index":84,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT05651022","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Tislelizumab","registry_intervention_type":"DRUG","source_record_index":10,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT06856837","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Tislelizumab","registry_intervention_type":"DRUG","source_record_index":31,"source_ref":"ctg-page-005"}],"status":"ACTIVE_NOT_RECRUITING / RECRUITING / TERMINATED","statuses":["ACTIVE_NOT_RECRUITING","RECRUITING","TERMINATED"],"study_count":3,"study_ids":["NCT04906382","NCT05651022","NCT06856837"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Tislelizumab is a PD-1 inhibitor.","matched_alias":"PD-1","nct_id":"NCT05651022","relation":"inhibitor"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"tislelizumab","rationale":"Exact intervention-name aliases for PD-1-directed antibodies.","rule_id":"candidate-other-pd1-antibodies","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"registry-explicit","target_ids":["symbol:PDCD1"],"target_names":["programmed cell death protein 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["tissue biopsy"],"intervention_id":"I-CTG-tissue-biopsy-4563eb941c","intervention_name":"tissue biopsy","intervention_type":"OTHER","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["OTHER"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06946745","overall_status":"RECRUITING","phases":[],"registered_name":"tissue biopsy","registry_intervention_type":"OTHER","source_record_index":88,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06946745"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"agonist","action_evidence":[{"action":"agonist","evidence_type":"registry-field","excerpt":"TLR8 Agonist VTX-2337","matched_text":"Agonist","nct_id":"NCT02650635"}],"actions":["agonist"],"aliases":["TLR8 Agonist VTX-2337"],"intervention_id":"I-CTG-tlr8-agonist-vtx-2337-94adde9273","intervention_name":"TLR8 Agonist VTX-2337","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT02650635","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"TLR8 Agonist VTX-2337","registry_intervention_type":"DRUG","source_record_index":79,"source_ref":"ctg-page-003"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT02650635"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["TME surgery"],"intervention_id":"I-CTG-tme-surgery-574b272c1c","intervention_name":"TME surgery","intervention_type":"PROCEDURE","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05794750","overall_status":"NOT_YET_RECRUITING","phases":["PHASE2"],"registered_name":"TME surgery","registry_intervention_type":"PROCEDURE","source_record_index":19,"source_ref":"ctg-page-001"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT05794750"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["TMT212"],"intervention_id":"I-CTG-tmt212-c2703c9f1c","intervention_name":"TMT212","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT02900664","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"TMT212","registry_intervention_type":"DRUG","source_record_index":26,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02900664"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Tocilizumab","tocilizumab"],"intervention_id":"I-CTG-tocilizumab-85bf04378e","intervention_name":"Tocilizumab","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2},{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT03866239","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Tocilizumab","registry_intervention_type":"DRUG","source_record_index":65,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT05769959","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"tocilizumab","registry_intervention_type":"DRUG","source_record_index":25,"source_ref":"ctg-page-005"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":2,"study_ids":["NCT03866239","NCT05769959"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"tocilizumab","rationale":"Exact intervention-name alias for the IL-6 receptor-directed antibody.","rule_id":"candidate-tocilizumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:IL6R","target_name":"interleukin-6 receptor subunit alpha","target_symbol":"IL6R"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:IL6R"],"target_names":["interleukin-6 receptor subunit alpha"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Total Mesorectal Excision"],"intervention_id":"I-CTG-total-mesorectal-excision-05ac87e6b3","intervention_name":"Total Mesorectal Excision","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":6,"nct_id":"NCT04751370","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Total Mesorectal Excision","registry_intervention_type":"PROCEDURE","source_record_index":31,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT04751370"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Total mesorectal excision (TME)"],"intervention_id":"I-CTG-total-mesorectal-excision-tme-cfef43fa3a","intervention_name":"Total mesorectal excision (TME)","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05164315","overall_status":"TERMINATED","phases":["NA"],"registered_name":"Total mesorectal excision (TME)","registry_intervention_type":"PROCEDURE","source_record_index":97,"source_ref":"ctg-page-001"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT05164315"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"cytotoxic-payload-delivery","action_evidence":[{"action":"cytotoxic-payload-delivery","evidence_type":"registry-field","excerpt":"TQB2101 for injection is a receptor tyrosine kinase-like orphan receptor-1 antibody drug conjugate.","matched_text":"antibody drug conjugate","nct_id":"NCT06948539"}],"actions":["cytotoxic-payload-delivery"],"aliases":["TQB2101 for injection"],"intervention_id":"I-CTG-tqb2101-for-injection-9460dec982","intervention_name":"TQB2101 for injection","intervention_type":"DRUG","modality":"antibody-drug-conjugate","modality_distribution":[{"modality":"antibody-drug-conjugate","registry_occurrence_count":1}],"modality_support":{"matched_cues":["antibody drug conjugate"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06948539","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1"],"registered_name":"TQB2101 for injection","registry_intervention_type":"DRUG","source_record_index":68,"source_ref":"ctg-page-004"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT06948539"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"cytotoxic-payload-delivery","action_evidence":[{"action":"cytotoxic-payload-delivery","evidence_type":"registry-field","excerpt":"TQB2102 Injection is a next-generation HER2 Antibody-Drug Conjugate (ADC) drug.","matched_text":"Antibody-Drug Conjugate","nct_id":"NCT07483684"}],"actions":["cytotoxic-payload-delivery"],"aliases":["TQB2102 Injection"],"intervention_id":"I-CTG-tqb2102-injection-fe523b8bde","intervention_name":"TQB2102 Injection","intervention_type":"DRUG","modality":"antibody-drug-conjugate","modality_distribution":[{"modality":"antibody-drug-conjugate","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Antibody-Drug Conjugate"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07483684","overall_status":"NOT_YET_RECRUITING","phases":["PHASE3"],"registered_name":"TQB2102 Injection","registry_intervention_type":"DRUG","source_record_index":68,"source_ref":"ctg-page-003"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07483684"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"TQB2102 Injection is a next-generation HER2 Antibody-Drug Conjugate (ADC) drug.","matched_alias":"HER2","nct_id":"NCT07483684","relation":"Antibody"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:ERBB2","target_name":"receptor tyrosine-protein kinase erbB-2","target_symbol":"ERBB2"}],"target_directness":"registry-explicit","target_ids":["symbol:ERBB2"],"target_names":["receptor tyrosine-protein kinase erbB-2"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["TQB2618 injection"],"intervention_id":"I-CTG-tqb2618-injection-1e9a8d0d95","intervention_name":"TQB2618 injection","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06010901","overall_status":"UNKNOWN","phases":["PHASE1"],"registered_name":"TQB2618 injection","registry_intervention_type":"DRUG","source_record_index":19,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT06010901"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"TQB2618 is a monoclonal antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) receptor.","matched_alias":"T cell immunoglobulin and mucin domain-3","nct_id":"NCT06010901","relation":"targeting T cell immunoglobulin and mucin domain-3"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:HAVCR2","target_name":"T-cell immunoglobulin and mucin-domain containing-3","target_symbol":"HAVCR2"}],"target_directness":"registry-explicit","target_ids":["symbol:HAVCR2"],"target_names":["T-cell immunoglobulin and mucin-domain containing-3"]},{"action":"binder; blocker","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"…body, subtype Immunoglobulin G1 (IgG1). TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour growth and progression. At the same …","matched_text":"binding","nct_id":"NCT07044908"},{"action":"blocker","evidence_type":"registry-field","excerpt":"TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype Immunoglobulin G1 (IgG1). TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus pr…","matched_text":"blocks","nct_id":"NCT07044908"}],"actions":["binder","blocker"],"aliases":["TQB2922 injection ± TAS-102 tablets"],"intervention_id":"I-CTG-tqb2922-injection-tas-102-tablets-39aec93b5f","intervention_name":"TQB2922 injection ± TAS-102 tablets","intervention_type":"DRUG","modality":"bispecific-antibody","modality_distribution":[{"modality":"bispecific-antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["bispecific"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07044908","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"TQB2922 injection ± TAS-102 tablets","registry_intervention_type":"DRUG","source_record_index":65,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07044908"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype Immunoglobulin G1 (IgG1). TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus pr…","matched_alias":"EGFR","nct_id":"NCT07044908","relation":"anti-EGFR"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:EGFR","target_name":"epidermal growth factor receptor","target_symbol":"EGFR"},{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype Immunoglobulin G1 (IgG1). TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus pr…","matched_alias":"c-Met","nct_id":"NCT07044908","relation":"bispecific antibody"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:MET","target_name":"hepatocyte growth factor receptor","target_symbol":"MET"}],"target_directness":"registry-explicit","target_ids":["symbol:EGFR","symbol:MET"],"target_names":["epidermal growth factor receptor","hepatocyte growth factor receptor"]},{"action":"binder; blocker","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"…-Met bispecific antibody, subtype IgG1. TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour growth and progression. At the same …","matched_text":"binding","nct_id":"NCT07044908"},{"action":"blocker","evidence_type":"registry-field","excerpt":"TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype IgG1. TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour grow…","matched_text":"blocks","nct_id":"NCT07044908"}],"actions":["binder","blocker"],"aliases":["TQB2922 injection+TAS-102 tablets ± Bevacizumab"],"intervention_id":"I-CTG-tqb2922-injection-tas-102-tablets-bevacizu-862724615d","intervention_name":"TQB2922 injection+TAS-102 tablets ± Bevacizumab","intervention_type":"DRUG","modality":"bispecific-antibody","modality_distribution":[{"modality":"bispecific-antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["bispecific"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07044908","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"TQB2922 injection+TAS-102 tablets ± Bevacizumab","registry_intervention_type":"DRUG","source_record_index":65,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07044908"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype IgG1. TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour grow…","matched_alias":"EGFR","nct_id":"NCT07044908","relation":"anti-EGFR"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:EGFR","target_name":"epidermal growth factor receptor","target_symbol":"EGFR"},{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype IgG1. TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour grow…","matched_alias":"c-Met","nct_id":"NCT07044908","relation":"bispecific antibody"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:MET","target_name":"hepatocyte growth factor receptor","target_symbol":"MET"}],"target_directness":"registry-explicit","target_ids":["symbol:EGFR","symbol:MET"],"target_names":["epidermal growth factor receptor","hepatocyte growth factor receptor"]},{"action":"binder","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting Extracellular Domain 2 (ECD2) and Extracellular Domain 4 (ECD4), two non-overlappi…","matched_text":"binding","nct_id":"NCT07653685"}],"actions":["binder"],"aliases":["TQB2930 injection + Oxaliplatin injection + Capecitabine tablets"],"intervention_id":"I-CTG-tqb2930-injection-oxaliplatin-injection-ca-64a50abf1a","intervention_name":"TQB2930 injection + Oxaliplatin injection + Capecitabine tablets","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07653685","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"TQB2930 injection + Oxaliplatin injection + Capecitabine tablets","registry_intervention_type":"DRUG","source_record_index":68,"source_ref":"ctg-page-005"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07653685"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting Extracellular Domain 2 (ECD2) and Extracellular Domain 4 (ECD4), two non-overlappi…","matched_alias":"HER2","nct_id":"NCT07653685","relation":"binding to HER2"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:ERBB2","target_name":"receptor tyrosine-protein kinase erbB-2","target_symbol":"ERBB2"}],"target_directness":"registry-explicit","target_ids":["symbol:ERBB2"],"target_names":["receptor tyrosine-protein kinase erbB-2"]},{"action":"binder","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more ef…","matched_text":"binding","nct_id":"NCT07653685"}],"actions":["binder"],"aliases":["TQB2930 injection + Oxaliplatin injection + Capecitabine tablets + Bevacizumab injection"],"intervention_id":"I-CTG-tqb2930-injection-oxaliplatin-injection-ca-f14a3dfa1c","intervention_name":"TQB2930 injection + Oxaliplatin injection + Capecitabine tablets + Bevacizumab injection","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Oxaliplatin"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07653685","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"TQB2930 injection + Oxaliplatin injection + Capecitabine tablets + Bevacizumab injection","registry_intervention_type":"DRUG","source_record_index":68,"source_ref":"ctg-page-005"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07653685"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more ef…","matched_alias":"HER2","nct_id":"NCT07653685","relation":"binding to HER2"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:ERBB2","target_name":"receptor tyrosine-protein kinase erbB-2","target_symbol":"ERBB2"}],"target_directness":"registry-explicit","target_ids":["symbol:ERBB2"],"target_names":["receptor tyrosine-protein kinase erbB-2"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Trametinib"],"intervention_id":"I-CTG-trametinib-fd739ca975","intervention_name":"Trametinib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02399943","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Trametinib","registry_intervention_type":"DRUG","source_record_index":86,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02399943"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"inhibitor","action_evidence":[{"action":"inhibitor","evidence_type":"registry-field","excerpt":"HER2/neu receptor inhibitor","matched_text":"inhibitor","nct_id":"NCT03319459"}],"actions":["inhibitor"],"aliases":["trastuzumab","Trastuzumab"],"intervention_id":"I-CTG-trastuzumab-672bb991dc","intervention_name":"trastuzumab","intervention_type":"multiple","modality":"antibody","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":7},{"modality":"antibody","registry_occurrence_count":3}],"modality_support":{"matched_cues":["Monoclonal antibody","monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2 / PHASE3","phases":["PHASE1","PHASE2","PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","COMBINATION_PRODUCT","DRUG"],"registry_occurrence_count":9,"registry_occurrences":[{"intervention_index":6,"nct_id":"NCT02291289","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Trastuzumab","registry_intervention_type":"DRUG","source_record_index":28,"source_ref":"ctg-page-005"},{"intervention_index":2,"nct_id":"NCT03319459","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Trastuzumab","registry_intervention_type":"DRUG","source_record_index":56,"source_ref":"ctg-page-001"},{"intervention_index":1,"nct_id":"NCT04464967","overall_status":"WITHDRAWN","phases":["PHASE1","PHASE2"],"registered_name":"Trastuzumab","registry_intervention_type":"DRUG","source_record_index":52,"source_ref":"ctg-page-002"},{"intervention_index":1,"nct_id":"NCT04579380","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"trastuzumab","registry_intervention_type":"DRUG","source_record_index":45,"source_ref":"ctg-page-001"},{"intervention_index":0,"nct_id":"NCT05356897","overall_status":"WITHDRAWN","phases":["PHASE2"],"registered_name":"Trastuzumab","registry_intervention_type":"BIOLOGICAL","source_record_index":12,"source_ref":"ctg-page-003"},{"intervention_index":8,"nct_id":"NCT05395052","overall_status":"TERMINATED","phases":["PHASE1"],"registered_name":"Trastuzumab","registry_intervention_type":"COMBINATION_PRODUCT","source_record_index":52,"source_ref":"ctg-page-005"},{"intervention_index":0,"nct_id":"NCT05786716","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"registered_name":"Trastuzumab","registry_intervention_type":"DRUG","source_record_index":20,"source_ref":"ctg-page-003"},{"intervention_index":5,"nct_id":"NCT06136897","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Trastuzumab","registry_intervention_type":"BIOLOGICAL","source_record_index":41,"source_ref":"ctg-page-004"},{"intervention_index":8,"nct_id":"NCT06490536","overall_status":"RECRUITING","phases":["PHASE3"],"registered_name":"Trastuzumab","registry_intervention_type":"DRUG","source_record_index":6,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING / COMPLETED / RECRUITING / TERMINATED / WITHDRAWN","statuses":["ACTIVE_NOT_RECRUITING","COMPLETED","RECRUITING","TERMINATED","WITHDRAWN"],"study_count":9,"study_ids":["NCT02291289","NCT03319459","NCT04464967","NCT04579380","NCT05356897","NCT05395052","NCT05786716","NCT06136897","NCT06490536"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"HER2/neu receptor inhibitor","matched_alias":"HER2/neu","nct_id":"NCT03319459","relation":"receptor inhibitor"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"trastuzumab","rationale":"Exact intervention-name alias for the HER2-directed antibody.","rule_id":"candidate-trastuzumab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:ERBB2","target_name":"receptor tyrosine-protein kinase erbB-2","target_symbol":"ERBB2"}],"target_directness":"registry-explicit","target_ids":["symbol:ERBB2"],"target_names":["receptor tyrosine-protein kinase erbB-2"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Trastuzumab-Deruxtecan (T-DXd)"],"intervention_id":"I-CTG-trastuzumab-deruxtecan-t-dxd-094319d6cd","intervention_name":"Trastuzumab-Deruxtecan (T-DXd)","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07407465","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Trastuzumab-Deruxtecan (T-DXd)","registry_intervention_type":"DRUG","source_record_index":86,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07407465"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["TRC102"],"intervention_id":"I-CTG-trc102-33d32944bb","intervention_name":"TRC102","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT01851369","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"TRC102","registry_intervention_type":"DRUG","source_record_index":99,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01851369"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Tremelimumab"],"intervention_id":"I-CTG-tremelimumab-b96a065b39","intervention_name":"Tremelimumab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03206073","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Tremelimumab","registry_intervention_type":"DRUG","source_record_index":56,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03206073"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["TRICOM-CEA(6D)"],"intervention_id":"I-CTG-tricom-cea-6d-a240edb949","intervention_name":"TRICOM-CEA(6D)","intervention_type":"BIOLOGICAL","modality":"cellular-therapy","modality_distribution":[{"modality":"cellular-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["dendritic cells"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00027534","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"TRICOM-CEA(6D)","registry_intervention_type":"BIOLOGICAL","source_record_index":42,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00027534"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Trifluridine + Tipiracil"],"intervention_id":"I-CTG-trifluridine-tipiracil-bc0eab59a7","intervention_name":"Trifluridine + Tipiracil","intervention_type":"DRUG","modality":"conventional-cytotoxic-regimen","modality_distribution":[{"modality":"conventional-cytotoxic-regimen","registry_occurrence_count":1}],"modality_support":{"matched_cues":["chemotherapy"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":8,"nct_id":"NCT03715933","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Trifluridine + Tipiracil","registry_intervention_type":"DRUG","source_record_index":9,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT03715933"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"blocker; inhibitor","action_evidence":[{"action":"blocker","evidence_type":"registry-field","excerpt":"…ine bioavailability by inhibiting its degradation. Fruquintinib Tablets: Oral small-molecule VEGFR inhibitor; blocks VEGFR 1/2/3 signaling to inhibit tumor angiogenesis, cutting off tumor nutrient and oxygen supply. Regorafeni…","matched_text":"blocks","nct_id":"NCT07483684"},{"action":"inhibitor","evidence_type":"registry-field","excerpt":"TAS-102 Tablets: Antimetabolite antitumor drug; trifluridine inhibits DNA synthesis by incorporating into tumor cell DNA, while tipiracil increases trifluridine bioavailability by inhibiting its degradation. Fruquintinib…","matched_text":"inhibits","nct_id":"NCT07483684"}],"actions":["blocker","inhibitor"],"aliases":["Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets"],"intervention_id":"I-CTG-trifluridine-tipiracil-tas-102-tablets-fru-6a185e2f56","intervention_name":"Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets","intervention_type":"DRUG","modality":"small-molecule","modality_distribution":[{"modality":"small-molecule","registry_occurrence_count":1}],"modality_support":{"matched_cues":["small-molecule"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07483684","overall_status":"NOT_YET_RECRUITING","phases":["PHASE3"],"registered_name":"Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets","registry_intervention_type":"DRUG","source_record_index":68,"source_ref":"ctg-page-003"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07483684"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"…creases trifluridine bioavailability by inhibiting its degradation. Fruquintinib Tablets: Oral small-molecule VEGFR inhibitor; blocks VEGFR 1/2/3 signaling to inhibit tumor angiogenesis, cutting off tumor nutrient and oxygen supply. Re…","matched_alias":"VEGFR","nct_id":"NCT07483684","relation":"inhibitor"}],"target_entity_type":"cell-surface-protein-family","target_id":"protein-family:VEGFR","target_name":"vascular endothelial growth factor receptor family","target_symbol":"VEGFR"}],"target_directness":"registry-explicit","target_ids":["protein-family:VEGFR"],"target_names":["vascular endothelial growth factor receptor family"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Trifluridine and Tipiracil Hydrochloride"],"intervention_id":"I-CTG-trifluridine-and-tipiracil-hydrochloride-54105ecac7","intervention_name":"Trifluridine and Tipiracil Hydrochloride","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05356897","overall_status":"WITHDRAWN","phases":["PHASE2"],"registered_name":"Trifluridine and Tipiracil Hydrochloride","registry_intervention_type":"DRUG","source_record_index":12,"source_ref":"ctg-page-003"}],"status":"WITHDRAWN","statuses":["WITHDRAWN"],"study_count":1,"study_ids":["NCT05356897"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Trifluridine-Tipiracil","Trifluridine-tipiracil"],"intervention_id":"I-CTG-trifluridine-tipiracil-0ce439aa95","intervention_name":"Trifluridine-Tipiracil","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":6,"nct_id":"NCT05719558","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Trifluridine-Tipiracil","registry_intervention_type":"DRUG","source_record_index":80,"source_ref":"ctg-page-001"},{"intervention_index":3,"nct_id":"NCT06887218","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Trifluridine-tipiracil","registry_intervention_type":"DRUG","source_record_index":29,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":2,"study_ids":["NCT05719558","NCT06887218"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Trifluridine/tipiracil","Trifluridine/Tipiracil"],"intervention_id":"I-CTG-trifluridine-tipiracil-0032e66d66","intervention_name":"Trifluridine/Tipiracil","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03799731","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Trifluridine/Tipiracil","registry_intervention_type":"DRUG","source_record_index":87,"source_ref":"ctg-page-002"},{"intervention_index":2,"nct_id":"NCT06856837","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Trifluridine/tipiracil","registry_intervention_type":"DRUG","source_record_index":31,"source_ref":"ctg-page-005"}],"status":"COMPLETED / RECRUITING","statuses":["COMPLETED","RECRUITING"],"study_count":2,"study_ids":["NCT03799731","NCT06856837"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Trifluridine/tipiracil (TAS-102) combined with bevacizumab and ptemizumab"],"intervention_id":"I-CTG-trifluridine-tipiracil-tas-102-combined-wi-6cfdffa038","intervention_name":"Trifluridine/tipiracil (TAS-102) combined with bevacizumab and ptemizumab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06882915","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1"],"registered_name":"Trifluridine/tipiracil (TAS-102) combined with bevacizumab and ptemizumab","registry_intervention_type":"DRUG","source_record_index":60,"source_ref":"ctg-page-003"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT06882915"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Trifluridine/tipiracil + bevacizumab"],"intervention_id":"I-CTG-trifluridine-tipiracil-bevacizumab-deb2085f44","intervention_name":"Trifluridine/tipiracil + bevacizumab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT06992648","overall_status":"RECRUITING","phases":["PHASE3"],"registered_name":"Trifluridine/tipiracil + bevacizumab","registry_intervention_type":"DRUG","source_record_index":94,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06992648"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Trifluridine/Tipiracil + Regorafenib"],"intervention_id":"I-CTG-trifluridine-tipiracil-regorafenib-1dbf1c0555","intervention_name":"Trifluridine/Tipiracil + Regorafenib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06992648","overall_status":"RECRUITING","phases":["PHASE3"],"registered_name":"Trifluridine/Tipiracil + Regorafenib","registry_intervention_type":"DRUG","source_record_index":94,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06992648"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Trifluridine/Tipiracil Hydrochloride"],"intervention_id":"I-CTG-trifluridine-tipiracil-hydrochloride-7dd4f1b568","intervention_name":"Trifluridine/Tipiracil Hydrochloride","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT05007132","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Trifluridine/Tipiracil Hydrochloride","registry_intervention_type":"DRUG","source_record_index":86,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05007132"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Trifluridine/tipiracil hydrochloride (S 95005)"],"intervention_id":"I-CTG-trifluridine-tipiracil-hydrochloride-s-950-acc4c34069","intervention_name":"Trifluridine/tipiracil hydrochloride (S 95005)","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02848443","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Trifluridine/tipiracil hydrochloride (S 95005)","registry_intervention_type":"DRUG","source_record_index":40,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT02848443"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Tripleitriumab"],"intervention_id":"I-CTG-tripleitriumab-75cead04cb","intervention_name":"Tripleitriumab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT04527068","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Tripleitriumab","registry_intervention_type":"DRUG","source_record_index":75,"source_ref":"ctg-page-004"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT04527068"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["TSR-033"],"intervention_id":"I-CTG-tsr-033-9cd9a29917","intervention_name":"TSR-033","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03250832","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"TSR-033","registry_intervention_type":"DRUG","source_record_index":77,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03250832"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["TTX-080"],"intervention_id":"I-CTG-ttx-080-be60161d02","intervention_name":"TTX-080","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":3},{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04485013","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"TTX-080","registry_intervention_type":"DRUG","source_record_index":46,"source_ref":"ctg-page-004"},{"intervention_index":1,"nct_id":"NCT04485013","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"TTX-080","registry_intervention_type":"DRUG","source_record_index":46,"source_ref":"ctg-page-004"},{"intervention_index":6,"nct_id":"NCT04485013","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"TTX-080","registry_intervention_type":"DRUG","source_record_index":46,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT04485013"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"TTX-080","rationale":"Exact intervention-name alias for the HLA-G-directed antibody.","rule_id":"candidate-ttx080","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:HLA-G","target_name":"HLA class I histocompatibility antigen, alpha chain G","target_symbol":"HLA-G"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:HLA-G"],"target_names":["HLA class I histocompatibility antigen, alpha chain G"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["TTX-MC138"],"intervention_id":"I-CTG-ttx-mc138-2165742de0","intervention_name":"TTX-MC138","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT05868226","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"TTX-MC138","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05868226"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Tucatinib","tucatinib"],"intervention_id":"I-CTG-tucatinib-096d38d2ad","intervention_name":"tucatinib","intervention_type":"DRUG","modality":"small-molecule","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":3},{"modality":"small-molecule","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04579380","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"tucatinib","registry_intervention_type":"DRUG","source_record_index":45,"source_ref":"ctg-page-001"},{"intervention_index":2,"nct_id":"NCT05356897","overall_status":"WITHDRAWN","phases":["PHASE2"],"registered_name":"Tucatinib","registry_intervention_type":"DRUG","source_record_index":12,"source_ref":"ctg-page-003"},{"intervention_index":3,"nct_id":"NCT05868226","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Tucatinib","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-002"}],"status":"ACTIVE_NOT_RECRUITING / RECRUITING / WITHDRAWN","statuses":["ACTIVE_NOT_RECRUITING","RECRUITING","WITHDRAWN"],"study_count":3,"study_ids":["NCT04579380","NCT05356897","NCT05868226"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"tucatinib","rationale":"Exact intervention-name alias for the HER2-directed kinase inhibitor.","rule_id":"candidate-tucatinib","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:ERBB2","target_name":"receptor tyrosine-protein kinase erbB-2","target_symbol":"ERBB2"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:ERBB2"],"target_names":["receptor tyrosine-protein kinase erbB-2"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Tumor Infiltrating Lymphocytes (TIL)"],"intervention_id":"I-CTG-tumor-infiltrating-lymphocytes-til-8887df852c","intervention_name":"Tumor Infiltrating Lymphocytes (TIL)","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06530303","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Tumor Infiltrating Lymphocytes (TIL)","registry_intervention_type":"BIOLOGICAL","source_record_index":8,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06530303"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Tumor specific mesorectal excision"],"intervention_id":"I-CTG-tumor-specific-mesorectal-excision-a965cbf0f1","intervention_name":"Tumor specific mesorectal excision","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT02688712","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"registered_name":"Tumor specific mesorectal excision","registry_intervention_type":"PROCEDURE","source_record_index":71,"source_ref":"ctg-page-003"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT02688712"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Tumor Tissue Collection and NGS"],"intervention_id":"I-CTG-tumor-tissue-collection-and-ngs-d22cb69308","intervention_name":"Tumor Tissue Collection and NGS","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07001085","overall_status":"RECRUITING","phases":["NA"],"registered_name":"Tumor Tissue Collection and NGS","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":34,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07001085"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Tumor tissue sampling for organoid development"],"intervention_id":"I-CTG-tumor-tissue-sampling-for-organoid-develop-e81a9022da","intervention_name":"Tumor tissue sampling for organoid development","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05401318","overall_status":"RECRUITING","phases":[],"registered_name":"Tumor tissue sampling for organoid development","registry_intervention_type":"PROCEDURE","source_record_index":93,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05401318"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["UCB4594"],"intervention_id":"I-CTG-ucb4594-3b78bd6490","intervention_name":"UCB4594","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT06380816","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"UCB4594","registry_intervention_type":"DRUG","source_record_index":78,"source_ref":"ctg-page-005"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06380816"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["UFT"],"intervention_id":"I-CTG-uft-94cca6fdcf","intervention_name":"UFT","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT01225744","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"UFT","registry_intervention_type":"DRUG","source_record_index":32,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01225744"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Ultrasound Imaging"],"intervention_id":"I-CTG-ultrasound-imaging-8ed1941328","intervention_name":"Ultrasound Imaging","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT01696994","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"registered_name":"Ultrasound Imaging","registry_intervention_type":"PROCEDURE","source_record_index":28,"source_ref":"ctg-page-003"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT01696994"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"binder","action_evidence":[{"action":"binder","evidence_type":"registry-field","excerpt":"…urvival. DRUG DESCRIPTION Vectibix® (panitumumab) is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). Panitumumab has an approximate molecular w…","matched_text":"binds","nct_id":"NCT00879385"}],"actions":["binder"],"aliases":["Vectibix® (panitumumab)"],"intervention_id":"I-CTG-vectibix-panitumumab-33e4583e2c","intervention_name":"Vectibix® (panitumumab)","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT00879385","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Vectibix® (panitumumab)","registry_intervention_type":"DRUG","source_record_index":33,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00879385"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["vemurafenib","Vemurafenib"],"intervention_id":"I-CTG-vemurafenib-a383bf2e3e","intervention_name":"vemurafenib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT02164916","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"vemurafenib","registry_intervention_type":"DRUG","source_record_index":72,"source_ref":"ctg-page-001"},{"intervention_index":4,"nct_id":"NCT02291289","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Vemurafenib","registry_intervention_type":"DRUG","source_record_index":28,"source_ref":"ctg-page-005"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":2,"study_ids":["NCT02164916","NCT02291289"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Venetoclax"],"intervention_id":"I-CTG-venetoclax-87ebc9d39b","intervention_name":"Venetoclax","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03082209","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Venetoclax","registry_intervention_type":"DRUG","source_record_index":70,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03082209"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["virtual chromo-endoscopy using FICE Fujifilm Technology"],"intervention_id":"I-CTG-virtual-chromo-endoscopy-using-fice-fujifi-7ac4ba6b09","intervention_name":"virtual chromo-endoscopy using FICE Fujifilm Technology","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT02263144","overall_status":"UNKNOWN","phases":[],"registered_name":"virtual chromo-endoscopy using FICE Fujifilm Technology","registry_intervention_type":"PROCEDURE","source_record_index":93,"source_ref":"ctg-page-004"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT02263144"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Virtual Chromoendoscopy"],"intervention_id":"I-CTG-virtual-chromoendoscopy-5711d066c1","intervention_name":"Virtual Chromoendoscopy","intervention_type":"PROCEDURE","modality":"procedure-or-device","modality_distribution":[{"modality":"procedure-or-device","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"NA","phases":["NA"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07089771","overall_status":"NOT_YET_RECRUITING","phases":["NA"],"registered_name":"Virtual Chromoendoscopy","registry_intervention_type":"PROCEDURE","source_record_index":58,"source_ref":"ctg-page-003"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07089771"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Vismodegib 150 mg"],"intervention_id":"I-CTG-vismodegib-150-mg-0d5cf702a9","intervention_name":"Vismodegib 150 mg","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00636610","overall_status":"COMPLETED","phases":["PHASE2"],"registered_name":"Vismodegib 150 mg","registry_intervention_type":"DRUG","source_record_index":44,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00636610"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Vitamin A"],"intervention_id":"I-CTG-vitamin-a-2b6a15c1b9","intervention_name":"Vitamin A","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":2}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":2,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT05720559","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Vitamin A","registry_intervention_type":"DRUG","source_record_index":49,"source_ref":"ctg-page-003"},{"intervention_index":4,"nct_id":"NCT05774964","overall_status":"UNKNOWN","phases":["PHASE2"],"registered_name":"Vitamin A","registry_intervention_type":"DRUG","source_record_index":8,"source_ref":"ctg-page-005"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":2,"study_ids":["NCT05720559","NCT05774964"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["vobramitamab duocarmazine"],"intervention_id":"I-CTG-vobramitamab-duocarmazine-50a4e37d35","intervention_name":"vobramitamab duocarmazine","intervention_type":"BIOLOGICAL","modality":"antibody-drug-conjugate","modality_distribution":[{"modality":"antibody-drug-conjugate","registry_occurrence_count":1},{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT05551117","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"vobramitamab duocarmazine","registry_intervention_type":"BIOLOGICAL","source_record_index":69,"source_ref":"ctg-page-001"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT05551117"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"vobramitamab duocarmazine","rationale":"Exact intervention-name aliases for the B7-H3-directed antibody-drug conjugate.","rule_id":"candidate-vobramitamab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CD276","target_name":"CD276 antigen","target_symbol":"CD276"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:CD276"],"target_names":["CD276 antigen"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["vobramitamab duocarmazine 2.0 mg (Arm A)"],"intervention_id":"I-CTG-vobramitamab-duocarmazine-2-0-mg-arm-a-070889dad2","intervention_name":"vobramitamab duocarmazine 2.0 mg (Arm A)","intervention_type":"BIOLOGICAL","modality":"antibody-drug-conjugate","modality_distribution":[{"modality":"antibody-drug-conjugate","registry_occurrence_count":1},{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05551117","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"vobramitamab duocarmazine 2.0 mg (Arm A)","registry_intervention_type":"BIOLOGICAL","source_record_index":69,"source_ref":"ctg-page-001"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT05551117"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"vobramitamab duocarmazine 2.0 mg (Arm A)","rationale":"Exact intervention-name aliases for the B7-H3-directed antibody-drug conjugate.","rule_id":"candidate-vobramitamab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CD276","target_name":"CD276 antigen","target_symbol":"CD276"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:CD276"],"target_names":["CD276 antigen"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["vobramitamab duocarmazine 2.7 mg (Arm B)"],"intervention_id":"I-CTG-vobramitamab-duocarmazine-2-7-mg-arm-b-61467fa51b","intervention_name":"vobramitamab duocarmazine 2.7 mg (Arm B)","intervention_type":"BIOLOGICAL","modality":"antibody-drug-conjugate","modality_distribution":[{"modality":"antibody-drug-conjugate","registry_occurrence_count":1},{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05551117","overall_status":"TERMINATED","phases":["PHASE2"],"registered_name":"vobramitamab duocarmazine 2.7 mg (Arm B)","registry_intervention_type":"BIOLOGICAL","source_record_index":69,"source_ref":"ctg-page-001"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT05551117"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"vobramitamab duocarmazine 2.7 mg (Arm B)","rationale":"Exact intervention-name aliases for the B7-H3-directed antibody-drug conjugate.","rule_id":"candidate-vobramitamab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CD276","target_name":"CD276 antigen","target_symbol":"CD276"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:CD276"],"target_names":["CD276 antigen"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["vofatamab"],"intervention_id":"I-CTG-vofatamab-eb0c930491","intervention_name":"vofatamab","intervention_type":"BIOLOGICAL","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT05363605","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"vofatamab","registry_intervention_type":"BIOLOGICAL","source_record_index":87,"source_ref":"ctg-page-004"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT05363605"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Vofatamab is a Fibroblast Growth Factor Receptor 3 (FGFR3)-targeting human monoclonal antibody without a radioisotope. In Phase 1, the dose depends on cohort assignment. In Phase 2, if pre-dosing with vofatamab is indica…","matched_alias":"FGFR3","nct_id":"NCT05363605","relation":"targeting"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:FGFR3","target_name":"fibroblast growth factor receptor 3","target_symbol":"FGFR3"}],"target_directness":"registry-explicit","target_ids":["symbol:FGFR3"],"target_names":["fibroblast growth factor receptor 3"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Volrustomig"],"intervention_id":"I-CTG-volrustomig-94a09116dd","intervention_name":"Volrustomig","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE2","phases":["PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT05489211","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Volrustomig","registry_intervention_type":"DRUG","source_record_index":76,"source_ref":"ctg-page-003"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05489211"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":"inhibitor","action_evidence":[{"action":"inhibitor","evidence_type":"registry-field","excerpt":"VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D (ON/OFF) inhibitor.","matched_text":"inhibitor","nct_id":"NCT07020221"}],"actions":["inhibitor"],"aliases":["VS-7375"],"intervention_id":"I-CTG-vs-7375-6fa272ceb8","intervention_name":"VS-7375","intervention_type":"DRUG","modality":"small-molecule","modality_distribution":[{"modality":"small-molecule","registry_occurrence_count":1}],"modality_support":{"matched_cues":["small molecule"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07020221","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"VS-7375","registry_intervention_type":"DRUG","source_record_index":57,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT07020221"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["XELOX intensive treatment group"],"intervention_id":"I-CTG-xelox-intensive-treatment-group-cee89b6967","intervention_name":"XELOX intensive treatment group","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE3","phases":["PHASE3"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT06609551","overall_status":"RECRUITING","phases":["PHASE3"],"registered_name":"XELOX intensive treatment group","registry_intervention_type":"DRUG","source_record_index":19,"source_ref":"ctg-page-002"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT06609551"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["XmAb®23104"],"intervention_id":"I-CTG-xmab23104-e90fd3738f","intervention_name":"XmAb®23104","intervention_type":"BIOLOGICAL","modality":"bispecific-antibody","modality_distribution":[{"modality":"bispecific-antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["bispecific"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT03752398","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"XmAb®23104","registry_intervention_type":"BIOLOGICAL","source_record_index":85,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03752398"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["xT-Onco with HLA-LOH Assay"],"intervention_id":"I-CTG-xt-onco-with-hla-loh-assay-c4c1cf9999","intervention_name":"xT-Onco with HLA-LOH Assay","intervention_type":"DIAGNOSTIC_TEST","modality":"diagnostic-test","modality_distribution":[{"modality":"diagnostic-test","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DIAGNOSTIC_TEST"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT05736731","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"xT-Onco with HLA-LOH Assay","registry_intervention_type":"DIAGNOSTIC_TEST","source_record_index":10,"source_ref":"ctg-page-004"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT05736731"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Yervoy® (ipilimumab)"],"intervention_id":"I-CTG-yervoy-ipilimumab-11ea2964c9","intervention_name":"Yervoy® (ipilimumab)","intervention_type":"BIOLOGICAL","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT03752398","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"Yervoy® (ipilimumab)","registry_intervention_type":"BIOLOGICAL","source_record_index":85,"source_ref":"ctg-page-003"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT03752398"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["YMN-A02 1000μg"],"intervention_id":"I-CTG-ymn-a02-1000-g-8bb463fc63","intervention_name":"YMN-A02 1000μg","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":3,"nct_id":"NCT07610707","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1"],"registered_name":"YMN-A02 1000μg","registry_intervention_type":"BIOLOGICAL","source_record_index":80,"source_ref":"ctg-page-004"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07610707"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["YMN-A02 100μg"],"intervention_id":"I-CTG-ymn-a02-100-g-c78b72bc51","intervention_name":"YMN-A02 100μg","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07610707","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1"],"registered_name":"YMN-A02 100μg","registry_intervention_type":"BIOLOGICAL","source_record_index":80,"source_ref":"ctg-page-004"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07610707"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["YMN-A02 250μg"],"intervention_id":"I-CTG-ymn-a02-250-g-d0918ed5ef","intervention_name":"YMN-A02 250μg","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":1,"nct_id":"NCT07610707","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1"],"registered_name":"YMN-A02 250μg","registry_intervention_type":"BIOLOGICAL","source_record_index":80,"source_ref":"ctg-page-004"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07610707"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["YMN-A02 500μg"],"intervention_id":"I-CTG-ymn-a02-500-g-75e7f8f1cb","intervention_name":"YMN-A02 500μg","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT07610707","overall_status":"NOT_YET_RECRUITING","phases":["PHASE1"],"registered_name":"YMN-A02 500μg","registry_intervention_type":"BIOLOGICAL","source_record_index":80,"source_ref":"ctg-page-004"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07610707"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A"],"intervention_id":"I-CTG-yttrium-y-90-dota-anti-cea-monoclonal-anti-961f658b9c","intervention_name":"yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A","intervention_type":"RADIATION","modality":"radioligand-therapy","modality_distribution":[{"modality":"radioligand-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["yttrium Y 90"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["RADIATION"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":4,"nct_id":"NCT01205022","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A","registry_intervention_type":"RADIATION","source_record_index":39,"source_ref":"ctg-page-004"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT01205022"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A","matched_alias":"CEA","nct_id":"NCT01205022","relation":"anti-CEA"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:CEACAM5","target_name":"carcinoembryonic antigen-related cell adhesion molecule 5","target_symbol":"CEACAM5"}],"target_directness":"registry-explicit","target_ids":["symbol:CEACAM5"],"target_names":["carcinoembryonic antigen-related cell adhesion molecule 5"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Yttrium-90 Radioembolization with standard systemic therapy"],"intervention_id":"I-CTG-yttrium-90-radioembolization-with-standard-aaed2e60d5","intervention_name":"Yttrium-90 Radioembolization with standard systemic therapy","intervention_type":"PROCEDURE","modality":"radioligand-therapy","modality_distribution":[{"modality":"radioligand-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["Yttrium-90"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":null,"phases":[],"record_origin":"clinicaltrials-gov","registry_intervention_types":["PROCEDURE"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT07406126","overall_status":"NOT_YET_RECRUITING","phases":[],"registered_name":"Yttrium-90 Radioembolization with standard systemic therapy","registry_intervention_type":"PROCEDURE","source_record_index":87,"source_ref":"ctg-page-005"}],"status":"NOT_YET_RECRUITING","statuses":["NOT_YET_RECRUITING"],"study_count":1,"study_ids":["NCT07406126"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Zalutumumab"],"intervention_id":"I-CTG-zalutumumab-086552ae75","intervention_name":"Zalutumumab","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00677924","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"registered_name":"Zalutumumab","registry_intervention_type":"DRUG","source_record_index":41,"source_ref":"ctg-page-005"}],"status":"TERMINATED","statuses":["TERMINATED"],"study_count":1,"study_ids":["NCT00677924"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Zanidatamab"],"intervention_id":"I-CTG-zanidatamab-ab22a9e067","intervention_name":"Zanidatamab","intervention_type":"multiple","modality":"bispecific-antibody","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":3},{"modality":"bispecific-antibody","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL","DRUG"],"registry_occurrence_count":3,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT05868226","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"registered_name":"Zanidatamab","registry_intervention_type":"DRUG","source_record_index":50,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT06695845","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Zanidatamab","registry_intervention_type":"DRUG","source_record_index":81,"source_ref":"ctg-page-002"},{"intervention_index":0,"nct_id":"NCT07405476","overall_status":"RECRUITING","phases":["PHASE2"],"registered_name":"Zanidatamab","registry_intervention_type":"BIOLOGICAL","source_record_index":97,"source_ref":"ctg-page-004"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":3,"study_ids":["NCT05868226","NCT06695845","NCT07405476"],"target_assignments":[{"directness":"curated-candidate-alias","evidence":[{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"zanidatamab","rationale":"Exact intervention-name alias for the HER2-directed bispecific antibody.","rule_id":"candidate-zanidatamab","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:ERBB2","target_name":"receptor tyrosine-protein kinase erbB-2","target_symbol":"ERBB2"}],"target_directness":"curated-candidate-alias","target_ids":["symbol:ERBB2"],"target_names":["receptor tyrosine-protein kinase erbB-2"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Zanzalintinib"],"intervention_id":"I-CTG-zanzalintinib-6d6ea5e2a7","intervention_name":"Zanzalintinib","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT05176483","overall_status":"RECRUITING","phases":["PHASE1"],"registered_name":"Zanzalintinib","registry_intervention_type":"DRUG","source_record_index":71,"source_ref":"ctg-page-001"}],"status":"RECRUITING","statuses":["RECRUITING"],"study_count":1,"study_ids":["NCT05176483"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["ZD6474"],"intervention_id":"I-CTG-zd6474-67e2d836a2","intervention_name":"ZD6474","intervention_type":"DRUG","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT00436072","overall_status":"COMPLETED","phases":["PHASE1"],"registered_name":"ZD6474","registry_intervention_type":"DRUG","source_record_index":31,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT00436072"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Zimberelimab"],"intervention_id":"I-CTG-zimberelimab-7422e0c132","intervention_name":"Zimberelimab","intervention_type":"DRUG","modality":"antibody","modality_distribution":[{"modality":"antibody","registry_occurrence_count":2}],"modality_support":{"matched_cues":["monoclonal antibody"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1 / PHASE2","phases":["PHASE1","PHASE2"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["DRUG"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":2,"nct_id":"NCT04660812","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"registered_name":"Zimberelimab","registry_intervention_type":"DRUG","source_record_index":78,"source_ref":"ctg-page-001"}],"status":"COMPLETED","statuses":["COMPLETED"],"study_count":1,"study_ids":["NCT04660812"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"Zimberelimab is a fully human anti-PD-1 monoclonal antibody","matched_alias":"PD-1","nct_id":"NCT04660812","relation":"anti-PD-1"},{"evidence_type":"curated-candidate-alias","match_scope":"exact-normalized-intervention-name","matched_alias":"zimberelimab","rationale":"Exact intervention-name aliases for PD-1-directed antibodies.","rule_id":"candidate-other-pd1-antibodies","rule_set_sha256":"83c4d111655bd5180d7a19bc584bc8ac8a5e10ec05245e2f5e0bae0e6df3ce7b"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:PDCD1","target_name":"programmed cell death protein 1","target_symbol":"PDCD1"}],"target_directness":"registry-explicit","target_ids":["symbol:PDCD1"],"target_names":["programmed cell death protein 1"]},{"action":null,"action_evidence":[],"actions":[],"aliases":["Ziv-Aflibercept"],"intervention_id":"I-CTG-ziv-aflibercept-cb86c45d5b","intervention_name":"Ziv-Aflibercept","intervention_type":"BIOLOGICAL","modality":"other-or-unclear","modality_distribution":[{"modality":"other-or-unclear","registry_occurrence_count":1}],"modality_support":{"matched_cues":[],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"PHASE1","phases":["PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":5,"nct_id":"NCT02298959","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"registered_name":"Ziv-Aflibercept","registry_intervention_type":"BIOLOGICAL","source_record_index":64,"source_ref":"ctg-page-001"}],"status":"ACTIVE_NOT_RECRUITING","statuses":["ACTIVE_NOT_RECRUITING"],"study_count":1,"study_ids":["NCT02298959"],"target_assignments":[],"target_directness":"unassigned","target_ids":[],"target_names":[]},{"action":null,"action_evidence":[],"actions":[],"aliases":["αPD1-MSLN-CAR T cells"],"intervention_id":"I-CTG-pd1-msln-car-t-cells-2d2d907322","intervention_name":"αPD1-MSLN-CAR T cells","intervention_type":"BIOLOGICAL","modality":"car-t-cell-therapy","modality_distribution":[{"modality":"car-t-cell-therapy","registry_occurrence_count":1}],"modality_support":{"matched_cues":["CAR T cells"],"method":"deterministic-registry-field-classifier/v0.1"},"phase":"EARLY_PHASE1","phases":["EARLY_PHASE1"],"record_origin":"clinicaltrials-gov","registry_intervention_types":["BIOLOGICAL"],"registry_occurrence_count":1,"registry_occurrences":[{"intervention_index":0,"nct_id":"NCT04503980","overall_status":"UNKNOWN","phases":["EARLY_PHASE1"],"registered_name":"αPD1-MSLN-CAR T cells","registry_intervention_type":"BIOLOGICAL","source_record_index":74,"source_ref":"ctg-page-003"}],"status":"UNKNOWN","statuses":["UNKNOWN"],"study_count":1,"study_ids":["NCT04503980"],"target_assignments":[{"directness":"registry-explicit","evidence":[{"evidence_type":"registry-field","excerpt":"…s will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of αPD1-MSLN-CAR T cells. During αPD1-MSLN-CAR T cells production, subjects will receive cyclophosphamide for the purpose of l…","matched_alias":"MSLN","nct_id":"NCT04503980","relation":"CAR"},{"evidence_type":"registry-field","excerpt":"αPD1-MSLN-CAR T cells","matched_alias":"MSLN","nct_id":"NCT04503980","relation":"CAR"}],"target_entity_type":"cell-surface-protein","target_id":"symbol:MSLN","target_name":"mesothelin","target_symbol":"MSLN"}],"target_directness":"registry-explicit","target_ids":["symbol:MSLN"],"target_names":["mesothelin"]}],"schema_version":"codex-surface-intervention-collection/v0.1"}